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Abstract
Fetal gene therapy may treat genetic diseases before significant organ damage, target 
stem cell populations and avoid immune sensitisation. Candidate diseases include cystic 
fibrosis, haemophilia and lysosomal storage disorders. This thesis developed 
ultrasound-guided delivery of viral vectors to the sheep fetus for treatment o f these 
diseases.
For haemophilia B treatment we delivered adenovirus vectors containing the p- 
galactosidase reporter gene (adlacZ) or the human factor IX gene (adhFIX) by 
ultrasound guidance to the early gestation sheep fetus, when it is considered to be pre- 
immune. Intraperitoneal injection allowed the earliest time point for gene delivery, 
achieved the highest hFIX levels and the most localised p-galactosidase expression. 
Therapeutic hFIX levels were detected after intramuscular and intra-amniotic delivery 
suggesting that these are potentially alternative sites for therapeutic gene expression.
For each route examined, no humoral immune response was observed to the transgene, 
although antibodies to the adenovirus vector were identified. We achieved intravascular 
delivery via umbilical vein injection; therapeutic hFIX levels were detected.
We developed ultrasound-guided transthoracic injection o f the mid-gestation fetal 
trachea for cystic fibrosis treatment, p-galactosidase expression, measured by ELISA, 
was low after delivery o f adlacZ vector alone, but increased 10 fold when the vector 
was complexed with DEAE dextran. Pretreatment o f the fetal airways with sodium 
caprate increased expression by 90 fold; the effect o f the two agents was synergistic. 
Perflubron instillation following vector injection redistributed transgene expression 
from the large to the small airways. We developed ultrasound-guided fetal intragastric 
injection and achieved widespread transgene expression throughout the gastrointestinal 
epithelia after adlacZ vector delivery.
For brain manifestation o f lysosomal storage disorders we injected adlacZ vectors to the 
fetal ventricles under ultrasound guidance. Transduction o f the choroid plexus was seen. 
Future application o f integrating vectors such as lentivirus may allow for long term 
therapeutic correction and induce immune tolerance to the transgene.
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Glossary of Terms
AC abdominal circumference
adlacZ adenovirus vector containing the p-galactosidase transgene
adhFIX adenovirus vector containing the human factor IX transgene
adhCFTR adenovirus vector containing the human CFTR transgene
P-gal p-galactosidase
BAL bronchoalveolar lavage
BPD biparietal diameter
BrDU 5-bromo2’-deoxy-uridine
BSA bovine serum albumin
CsCl caesium chloride
CFTR cystic fibrosis transmembrane regulator
CMV cytomegalovirus
D-Mem Dulbecco’s Modified eagle media
DMSO dimethylsulfoxide
DOGS dioctadecylamidoglycyl spermine
DTT dithiothreitol
EDTA ethylenediaminetetraacetic acid
EIAV equine immune anaemia virus
FCS fetal calf serum
FL femur length
HE intrahepatic
HIV human immune deficiency virus
hFIX human factor IX clotting factor
IA intra-amniotic
IC intracardiac
IM intramuscular
IP intraperitoneal
IT intratracheal
LMP low melting point
MLV Moloney Leukemia Virus
NaCl sodium chloride
Na caprate or C 10 sodium caprate
OSL occipito-snout length
4
p particles
PBS physiological buffered saline
pen/strep pen ic i 11 in/ streptomy c in
pfu particle forming units
RSV Rous sarcoma virus
SD standard deviation
SDS sodium dodecyl sulphate
Sendai lacZ Sendai vector containing the p-galactosidase transgene
TE buffer tris-EDTA buffer
Tris tris (hydroxymethyl) methylamine
UA umbilical artery
UV umbilical vein
VSV-G Varicella zoster virus protein G
Xgal 5-bromo-4-chloro-3-indolyl-p-D-galactoside
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A. INTRODUCTION
A. Introduction
A 1 The rationale for prenatal gene therapy
Fetal somatic gene therapy has the potential to treat inherited genetic diseases in utero 
before significant organ damage has occurred. Rapidly expanding stem cell populations 
may be targeted and the introduction o f transgenes to the fetus during development o f 
the immune system could result in immune tolerance and facilitate repeat treatment 
postnatally. Finally, fetal gene therapy would give a third option to parents following 
prenatal diagnosis o f inherited disease, where currently termination o f pregnancy or 
acceptance o f an affected child have been the only choices. Genetic diseases such as 
cystic fibrosis (CF) and haemophilia B which are life threatening, and for which there 
are no currently acceptable treatments available are suggested targets for this therapy.
A 2 Candidate diseases for in utero gene therapy
A 2.1 Cystic fibrosis, a common systemic genetic disease 
A 2.1.1 Cystic fibrosis pathology and genetics
Cystic fibrosis appears to be an ideal candidate for treatment with in utero gene transfer. 
The Cystic Fibrosis Transmembrane Regulator (CFTR) gene encoding the CFTR 
protein is mutated in this disease resulting in abnormal electrolyte transport in airway, 
sweat ductal, intestinal and pancreatic ductal epithelia. CFTR is an integral membrane 
component o f the apical portion o f many epithelial cells (Crawford I et al., 1991). It 
functions as a transmembrane chloride channel regulated by cyclic adenosine 3’,5’- 
monophosphate (cAMP) and controls other ion channels such as the epithelial Na+ 
channel (Stutts MJ et al., 1995). Compared with other secretory epithelia, CFTR is 
expressed only in very small amounts in normal or CF airway epithelia (Trapnell BC et 
al., 1991). In vitro studies where normal and CF airway cells were mixed, suggest that 
only 6-10% of cells expressing normal CFTR are required to correct the ion transport 
defect in all cells o f an epithelial monolayer (Johnson LG et al., 1992).
The predominant site o f CFTR expression in the non-CF human bronchus is the 
submucosal glands, in particular the ducts and serous tubules (Figure A 1) In CF lung 
there is a similar distribution o f mutated CFTR expression as in the non-CF lung, with 
increased expression in the collecting ducts (Engelhardt JF et al., 1992). This is 
important for attempts to target gene transfer to the most suitable site in the airways for
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treatment o f CF.
In the human fetal lung CFJR  distribution follows a cephalocaudal pattern of 
maturation and differentiation (Gaillard D et al., 1994) being present in the trachea at 7 
weeks gestation, in glandular buds and ducts o f the trachea and lower epithelial airways 
between 12-15 weeks gestation, and in the apical domain o f tracheal and bronchial 
ciliated cells from 25 weeks gestation onwards. CFTR is also expressed in other tissues 
throughout normal human fetal development, in the yolk sac during embryogenesis, and 
in the epithelia o f the pancreatic ducts, the small intestine, the genital ducts and 
particularly the airways during fetal life (Trezise AE et al., 1993).
mucins airway
ciliated epithelial 
ceilmucin secreting 
cell
serous cell
submucosal gland
Figure A 1: The variety of CFTR-expressing cellular targets for gene therapy  of 
the CF airway.
Submucosal glands are found beneath the airway and express abundant CFTR protein in serous cells in 
the base o f  the glands. CFTR is also highly expressed in a non-ciliated cell in gland ducts and surface 
airway epithelia. Ciliated cells o f  the surface airway epithelia express low levels o f  CFTR. Cell types that 
express the highest levels o f  CFTR are shaded in purple. Adapted from (Driskell RA and Engelhardt J,
2003).
The expression profile o f CFTR in the fetal lung suggests a crucial role for this protein 
in lung epithelial maturation. In the fetal sheep lung, high CFTR expression is observed 
during the pseudoglandular phase when the bronchial tree and acini form, but this falls
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during the later canalicular phase (Broackes-Carter FC et al., 2002). One study 
delivering an adenovirus vector containing the CFTR gene to the amniotic fluid of 
normal or CFTR knockout fetal mice suggested that the CFTR gene may have an 
important physiological role in normal fetal development (Larson JE et al., 2000a). 
Survival o f the homozygote normal mice was much lower than expected, and 
histological analysis o f the lungs showed accelerated secretory cell proliferation and 
differentiation. Whether this is due to overexpression o f the CFTR gene during lung 
development however, is unclear.
A 2.1.2 Cystic fibrosis pathology begins in utero
There is evidence that the cystic fibrosis disease process begins during fetal 
development since by the mid-trimester, pancreatic ducts may be blocked by mucin 
secretion (Boue A et al., 1986) and a pro-inflammatory state exists in fetal CF airways 
with infiltration o f fetal CF trachea and lung by numerous mast cells and macrophages 
in mid to late gestation (Hubeau C et al., 2001). Thus correction o f the underlying CF 
defect during fetal life may present advantages over adult treatment.
A 2.1.3 Results of adult gene therapy treatment for cystic fibrosis are 
disappointing
Phase 1 adult gene therapy trials directed towards pulmonary disease in CF show 
equivocal results and highlight the problems of applying this therapy in adults (Bigger B 
and Coutelle C, 2001). The lungs may be severely damaged or obstructed even in young 
adult patients due to recurrent bacterial infections and a build up o f thick, sticky mucus. 
Immune responses to the vector, particularly in the case o f adenovirus vectors, limit the 
dose that may be safely administered, and reduce the duration o f expression. There is 
also a lack o f targeting to the epithelial stem cells. Thus most groups working on fetal 
gene delivery in animal models have suggested research towards treatment o f this 
disease.
The major difficulties with the adult gene therapy trials have been to measure the 
efficiency o f gene transfer and to quantify transgene expression using an appropriate 
clinical endpoint. Measurement o f the potential difference (PD) across the epithelial 
surface has been used to demonstrate functional correction in clinical trials although 
measurements in vivo in the lower airways are difficult to perform. The research has 
therefore been targeted to the nose although it is unclear how far results in the nasal 
epithelia can be extrapolated to the pulmonary epithelia.
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Most trials have used adenovirus vectors. When applied to the nasal epithelium, 
transient correction o f the chloride transport defect was seen in some studies (Zabner J 
et al., 1993,Hay JG et al., 1995) although others have failed to show any such correction 
(Knowles MR et al., 1995). Even when less immunogenic second and third generation 
vectors were used, the patients mounted a local and systemic immune response. 
Instillation to the airway epithelium had similar results (Zuckerman JB et al., 1999). 
Adeno-associated virus has been used as an alternative vector. Application to the 
maxillary sinus gave transient correction to the PD and resulted in a 25% reduction in 
the incidence o f recurrent sinusitis, a common complaint o f CF patients (Wagner JA et 
al., 1999). These encouraging results unfortunately could not be repeated in the lungs 
after nebulized delivery (Flotte TR et al., 2003). Non-viral gene delivery systems have 
also been studied. Application o f DNA/liposome formulations partially and transiently 
corrected the PD in the nasal epithlium. In contrast to findings from adenovirus trials, 
minimal immune responses were elicited and repeat administration was both safe and 
successful (Hyde SC et al., 2000).
A 2.2 Haemophilia B, a model for many inborn errors of metabolism 
A 2.2.1 Haemophilia B pathology and genetics
Haemophilia B is another disease that would be particularly suitable for gene therapy in 
utero. This X-linked hereditary haemorrhagic disorder occurs in lin 25000 males and is 
caused by the absence or dysfunction o f factor IX (FIX) clotting factor which is 
involved in the intrinsic pathway o f the coagulation cascade (Figure A 2) (Furie B et 
al., 1994). This results in recurrent haemorrhage into muscles and joints with 
subsequent arthiritis, and cerebrovascular accidents.
Current treatment o f haemophilia B uses replacement therapy with human Factor IX 
(hFIX). Extensive experience with protein concentrates over the last 25 years has shown 
that maintenance o f factor IX levels above 1% o f normal adult human levels (50 ng/ml) 
in patients with severe haemophilia significantly reduces the frequency o f spontaneous 
bleeding into joints and soft tissues, and reduces the risk o f fatal intracranial bleeding 
(Lofqvist T et al., 1997).
However, a number o f patients develop antibodies to therapy leading to ineffective 
treatment and occasional anaphylaxis, and induction o f immune tolerance to the 
replacement hFIX is only partly successful (Lusher JM, 2000). Indeed, the 
complications o f haemophilia treatment have in some cases been far worse than the
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disease itself, increasing the morbidity and mortality o f  patients (Soucie JM et al.,
2000). Restoration o f the functional hFIX gene by in utero gene transfer could provide 
long-term treatment using a single injection, avoid immune-sensitisation and also 
prevent any haemorrhagic complications that could occur at the time o f delivery.
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Figure A 2: The coagulation cascade.
Coagulation is initiated via the extrinsic pathway. Broken endothelium in a blood vessel allow s factor VII 
present in the blood to recognize and bind to tissue factor (TF, factor III) that is present on the surface o f  
fibroblasts and smooth m uscle cells o f  the vessel wall. This produces the factor VIEtissue factor activated 
com plex (TF:VIIa) which activates factor IX. A cascade quickly develops, culm inating in the production 
o f  a fibrin clot. Small amounts o f  thrombin generated by the extrinsic pathway amplify the coagulation  
process by activating the intrinsic pathway via factors XI and VIII,  which generates large amounts o f  
thrombin.
A 2.2.2 Adult gene therapy studies in animal models of haemophilia 
show promising results
Since the hFIX coagulation factor is required in the blood and can be secreted 
functionally from a variety o f tissues, the actual site o f production is not so important as 
long as therapeutic plasma levels are realized. Adult gene therapy strategies have 
therefore concentrated on application to the muscle or the liver.
Successful delivery and expression o f FIX has been achieved in adult animal models of 
haemophilia B following portal intravascular administration o f adenovirus (Kay MA et 
al., 1994) and retrovirus vectors (Kay MA et al., 1993). Sustained FIX expression was
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also observed after intramuscular injection of adult haemophiliac dogs with adeno- 
associated viral (AAV) vectors expressing canine FIX (Chao H et al., 1999,Herzog RW 
et al., 1999,Herzog RW et al., 1999,Chao H et al., 1999) and after intravascular 
injection o f adult haemophiliac mice with AAV vectors expressing hFIX (Snyder RO et 
al., 1999). These results culminated in the first clinical trial in humans that resulted in 
low level hFIX expression (Kay MA et al., 2000) although it was prematurely 
terminated because o f evidence o f liver toxicity in some patients (Kaiser J, 2004). 
Successful delivery and expression o f therapeutic hFIX without formation o f antibodies 
has been achieved following administration o f retrovirus vectors in neonatal animal 
models (Xu L et al., 2003). Prenatal gene therapy could be applied to the fetus via a 
number o f routes including muscle, peritoneal, hepatic, intravascular or skin 
application.
A 2.2.3 Therapeutic correction of haemophilia B has been achieved in 
preliminary in utero gene therapy animal studies
Therapeutic levels o f hFIX have been achieved after in utero application o f adenovirus 
vectors to fetal mice via intra-amniotic (Schneider H et al., 1999), intramuscular or 
intraperitoneal injection (Schneider H et al., 2002). The transient nature o f hFIX 
expression observed after intra-amniotic delivery was thought to be due to a number of 
factors including shedding of the transduced keratinocytes and the humoral immune 
response to the transgene and/or vector. Intravascular delivery of adenovirus hFIX 
vectors to fetal mice has resulted in long-term tolerance o f hFIX into adulthood on 
repeated applications o f purified proteins (Waddington SN et al., 2003b). Recently our 
group has demonstrated that in utero application can provide long-term postnatal 
correction o f  the haemophiliac phenotype in FIX deficient mice (Waddington SN et al., 
2004b). This provides proof o f principle that gene therapy applicaton in utero may 
allow induction o f immune tolerance.
A 2.3 Mucopolysaccharidosis type VII, a congenital lysosomal 
storage disorder affecting the central nervous system
A 2.3.1 Mucopolysaccharidosis type VII pathology and genetics
The lysosomal storage disorders (LSDs) are a group o f congenital deficiencies o f one or 
more lysosomal enzymes. In mucopolysaccharidosis type VII (MPS type VII), a 
deficiency o f p-glucuronidase activity leads to accumulation o f undegraded
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glycosaminoglycans in lysosomes. Clinically, patients develop hepatosplenomegaly, 
mental and growth retardation, hearing and vision defects, skeletal deformities and die 
o f cardiac failure. Many of the LSDs present already during fetal life with hydrops 
fetalis and prenatal diagnosis can be performed by detection o f p-glucuronidase 
deficiency in chorionic villi or fetal blood (Geipel A et al., 2002). Although individually 
rare, as a group the LSDs occur in approximately 1 in 7500 live births and are one o f the 
more prevalent groups o f inherited diseases in humans (Wraith JE, 2002).
Treatments are currently limited to enzyme replacement therapy and bone marrow 
transplantation. For non-neuropathic forms o f LSDs such as type 1 Gaucher disease, 
enzyme replacement therapy has been shown to be effective (Weinreb NJ et al., 2002). 
However, the short half-life o f lysosomal enzymes in the circulation means that patients 
need biweekly parenteral administration that increases the risk of an immune response 
to the infused enzyme, particular in patients with null mutations. In addition, 
systemically administered enzyme is unable to cross the blood-brain barrier and is 
therefore ineffective for those LSDs that have central nervous system disease 
manifestation such as MPS type VII. In utero haematopoietic stem cell transplantation 
has been attempted but was not effective at preventing neurological deterioration. This 
might be due to poor engraftment o f donor cells, but more probably, is because of a 
failure o f cross-correction in some LSDs, whereby the corrective enzyme produced by 
the transplanted cells fails to reach the lysosomes o f deficient cells (Martino S et al., 
2002).
The LSDs are considered to be good candidates for gene therapy since they are well- 
characterized single gene disorders. Localised gene transfer to an organ such as the liver 
may provide therapeutic levels o f enzymes in the circulation for correction o f non- 
neurological manifestations, since a proportion o f newly synthesized lysosomal 
enzymes are secreted into the systemic circulation and are recaptured by distant cells. 
Based on the observed enzyme levels in patients with mild late-onset disease, the 
amount o f enzyme needed to correct the deficiency may only be 1-10% of normal levels 
(Cheng SH and Smith AE, 2003). As discussed previously however, direct gene 
delivery to affected neural cells is thought to be necessary to treat central nervous 
system manifestations and this will require a strategy that can bypass the blood-brain 
barrier and deliver sufficient enzyme to the brain.
30
A. INTRODUCTION
A 2.3.2 Studies of gene transfer to the central nervous system show 
promising results. a
Several studies have shown encouraging results, particularly in neonatal animal models 
o f LSDs. The cells o f the CNS are relatively quiescent, even in the fetus, and this 
precludes the use o f vectors that require cell division for transduction. The age o f the 
animal and the site o f injection determine the efficacy o f treatment. Intravenous 
injection o f adenovirus vectors encoding p- glucuronidase into neonatal MPS type VII 
mice is more efficacious at preventing CNS manifestations than treatment o f adult mice 
(Kamata Y et al., 2003). This is probably due to the relative immaturity o f the blood 
brain barrier which is not fully intact until 1 0 -1 4  days o f life in rodents (Stewart PH 
and Hayakawa EM, 1987). Gene transfer was low level however, even when AAV 
vectors were applied (Daly TM et al., 1999).
Injection o f the brain parenchyma with recombinant AAV2 (Frisella WA et al., 2001) or 
feline immunodeficiency virus vectors (Brooks Al et al., 2002) encoding p- 
glucuronidase improved cognitive function in neonatal and adult MPS type VII mice. 
Enzyme expression was concentrated at the sites o f injection but cellular pathology was 
reduced in all areas of the brain, suggesting that enzymes secreted from transduced cells 
were taken up by uninfected cells. Delivery o f AAV2 vector into the lateral ventricles of 
normal or MPS type VII mice resulted in more widespread but low level gene transfer 
to the central nervous system (Passini MA and Wolfe JH, 2001) although this could be 
improved by application o f AAV1 vectors (Passini MA et al., 2003).
Translating these results to a large animal model has been successful for some 
extraneurological manifestations o f LSDs. Intravenous administration o f retrovirus 
vectors containing canine p- glucuronidase to neonatal MPS type VII dogs reduced the 
bone and joint abnormalities and heart valve defects that commonly occur in this animal 
model (Ponder KP et al., 2002) but enzyme activity in the brain was low, suggesting 
that neonatal systemic application may not prevent neurological pathology.
A 3 Development of the fetal Immune system
A 3.1 The human fetal immune system develops throughout 
gestation
The principle that fetal gene therapy may avoid the development o f immune reactions to 
the vector or transgene product depends critically on the time o f in utero gene delivery
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at which fetal tolerance might be induced. The human immune system develops 
progressively through the first trimester and is not fully functional until 1-2 years after 
birth (Riley RL, 1998). Definitive haematopoiesis is now believed to be established 
from an intraembryonic source of haematopoietic progenitors associated with the 
ventral endothelium of the aorta in the 4 - 5 week old human embryo and not from the 
yolk sac as previously thought (Tavian M et al., 1996,Tavian M et al., 1999). 
Haematopoietic stem cells then migrate to the liver from 5 weeks o f gestation and pre-B 
and B-cells are identifiable in fetal liver from 12 weeks o f gestation (Kamps WA and 
Cooper MD, 1984). B cells subsequently migrate to the bone marrow from 16 weeks o f 
gestation. T cell precursors increase in number in the fetal liver from 7 weeks of 
gestation and migrate to the fetal thymus between 8 and 9 weeks of gestation where 
they mature (Haynes BF et al., 1988). T lymphocytes are found in the circulation and 
the fetal liver from 13 weeks o f gestation (Pahal GS et al., 2000) but are not capable o f 
producing a definitive cytotoxic response until the end o f the first trimester (Mackenzie 
IZ and Maclean DA, 1980). Natural killer cells are present in the human fetal liver and 
spleen from 9 and 15 weeks o f gestation respectively. Even at this early gestation these 
cells can mount a cytotoxic reaction to selected target cells such as tumours and virus- 
infected cells without the presence o f MHC class I or II antigens to recognize their 
targets, although their lytic activity increases with gestational age (Phillips et al., 1992).
A 3.2 The development of the fetal sheep immune system parallels 
that in humans
The immune system o f the sheep develops similarly to humans making the sheep model 
particularly useful for investigating immune reactions to vector and transgene product. 
Haematopoiesis is thought to begin in the yolk sac and fetal liver from 17 days o f 
gestation (term = 145 days) although an intraembryonic source o f haematopoietic 
progenitors associated with the aorta has not yet been investigated in the fetal sheep.
The liver is the major haematopoietic organ from 20 days of gestation. There is 
evidence o f a pre-thymic population o f immature lymphoid cells that is no longer 
recognizable by 40 days of gestation (Miyasaka M and Morris B, 1988). It is probable 
these lymphoid cell precursors populate the primitive thymus and initiate lymphopoiesis 
that is observed from 35 days of gestation (Mackay CR et al., 1986). Lymphocyte 
migration within the thymus occurs at 45 days o f gestation and 5 days later the first T- 
cells are observed in the fetal circulation. By 60 days o f gestation the thymus has a 
distinctive cortex and medulla and by 100 days it has a mature complement of T-cells
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(Morris B and Miyasaka M, 1985). Lymphocytes are seen in the spleen from 55 days, 
the lymph nodes from 60 days, the bone marrow from 75 days and the Peyer’s patches 
from 80 days o f gestation (Alsalami MT and Filippich LJ, 1999). Immunoglobulin G 
and M first appear in fetal plasma at 56 and 77 days of gestation respectively and levels 
increase with gestational age (Sawyer M et al., 1978). Mature neutrophils however, are 
observed only from 123 days o f gestation and enzymes involved in degradation are not 
present until term.
A 3.3 The development of the fetal immune response in sheep has 
been extensively investigated.
Much of the early work on the ontogeny of the fetal immune response was performed in 
the fetal sheep because o f the easy surgical manipulation o f the fetus, and the 
synepitheliochorial placenta in the sheep which does not permit passage o f 
gammaglobulin from mother to fetus (Morris B, 1986). This ensures that all antibodies 
in the fetal serum are derived from the fetus and not from the mother and provides an 
ideal opportunity to test how a deliberate experimental exposure o f the fetus to antigen 
will affect the development o f immune competence.
The idea that the immune system ‘learns’ what is ‘se lf was first suggested following 
studies o f dizygotic twins in cattle that were found to be bom with and retain red blood 
cells of dizygotic origin (Owen RD, 1945). These naturally occurring chimeras arise 
because blood vessel anastomoses in the placenta allow reciprocal transfer of red blood 
cells between the twins. The concept that tolerance is induced during fetal life was thus 
proposed. A comprehensive set o f experiments tested this hypothesis o f ‘actively 
acquired tolerance’ in the fetal mouse (Billingham RE et al., 1953,Billingham RE et al., 
1956). Cells from the spleen, testis or kidney of one strain o f mouse were injected into 
the fetus o f another strain at 16-17 days o f gestation. The treated mice as adults did not 
reject skin grafts taken from the donor strain but could reject grafts from a third mouse 
strain. Injection o f neonatal mice elicited neither tolerance or immunity and a null 
period o f immunological reactivity was proposed. Later experiments showed that either 
tolerance or immunity could be induced in the neonatal mouse depending on the dose of 
innoculum (Howard JG and Michie D, 1962).
Attempts to induce tolerance in the fetal sheep using the conditions adequate for 
tolerance induction in the fetal mouse have failed to achieve comparable results. This is 
most likely because o f differences in the maturation o f the fetal immune response 
between the two species. Transplantation experiments in the fetal sheep show that skin
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allografts are uniformly rejected as early as 77 and 80 days o f gestation (Schinkel PG 
and Ferguson KA, 1953,Silverstein AM et al., 1964) and renal allografts are similarly 
rejected when placed at 70 days of gestation (Neiderhuber JE et al., 1971). Skin grafts at 
65 days of gestation however, were accepted for at least 21 days with no evidence of 
cellular infiltration, and permanent survival o f skin grafts beyond term has been 
achieved in fetuses transplanted with adult skin allografts at 55 days o f gestation 
(McCullagh P, 1988).
In addition to the time o f grafting, the nature o f the antigen is also important in 
determining whether tolerance is induced. For example fetal lambs at 55 days of 
gestation uniformly reject skin allografts from fetal sheep aged up to 85 days but retain 
skin allografts from fetal sheep at 95 days of gestation and adult sheep (McCullagh P,
1989). Transplantation o f other tissues such as blood products or splenic allografts into 
fetal sheep even at 50 and 60 days o f gestation has proved unsuccessful in inducing 
tolerance when the fetuses were challenged as adults with donor blood cells (Moore 
NW and Rowson LEA, 1961,Mitchell RM, 1959).
The fetal sheep immune response to intrauterine infection also shows a different 
modality depending on the antigen. Exposure to Border disease virus as a fetus results 
in a state of immunological tolerance as an adult and persistent shedding o f virus 
particles (Nettleton PF and Entrican G, 1995). In contrast, exposure o f the fetus to 
Akabane virus infection in early gestation produces a viraemia that persists until 75 
days o f gestation when neutralizing antibodies appear and eliminate the virus (McClure 
S et al., 1988).
Silverstein and his colleagues performed a series of investigations to determine the 
gestational age at which the fetal lamb is able to respond to a specific antigenic 
challenge (Silverstein AM et al., 1963a,Silverstein AM et al., 1963b). A hierarchy of 
response among the antigens was observed with the earliest antibody produced to 
bacteriophage <pX from 60 days, to ferritin from 96 days and to albumin from 120 days 
o f gestation. Responses to diphtheria toxoid, Salmonella typhosa organisms and BCG 
could not be elicited in the sheep until after birth. They could not correlate the 
appearance o f a particular immune capability with a stage o f lymphopoiesis. The 
development of the humoral immune response over time has also been studied by Fahey 
and colleagues using serial fetal blood sampling via vascular catheters implanted into 
fetuses challenged with various antigens (Fahey KJ and Morris B, 1978,Fahey KJ and 
Morris B, 1974). Most fetuses acquired a capacity to respond to several antigens 
between 60 and 75 days of gestation. For all antigens tested, there was a higher
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antibody titre, a longer duration o f response and a wider range o f antibody production in 
older fetuses, showing that the humoral immune response matures through gestation. 
The immune response to antigens again appeared in a sequential fashion as described by 
Silverstein and colleagues. The hierarchy however, was not particularly precise and 
there was also a wide variation amongst individual fetuses.
Many have proposed that a 'window o f opportunity' exists in the first third to half o f 
pregnancy during which time introduction o f foreign genetic material may not elicit an 
immune response but may allow development of tolerance. All these data however, 
would suggest that in the sheep fetus, the nature o f the antigen itself is o f prime 
importance in determining if  an immune response is mounted and whether tolerance is 
induced.
A 4 Gene delivery vectors 
A 4.1 Adenovirus vectors
Adenovirus vectors are attractive candidates for gene therapy since they have 
continually achieved highly efficient gene transfer in vivo. Adenovirus coding 
sequences necessary for viral reproduction are deleted, rendering them replication- 
incompetent. They are stable, have a relatively high capacity for transgene insertion and 
can be obtained at high titre, making systemic administration in humans and large 
animal models feasible. The adenovirus genome replicates in an extra-chromosome 
state, which circumvents the risk o f insertional mutagenesis but results in only transient 
transgene expression. Another advantage is their tropism for most cells o f the human 
body, including the respiratory epithelium and their efficient transduction of both 
quiescent and actively dividing cells. Adenoviruses are thus a popular choice as a gene 
delivery vehicle and are currently being used in approximately one-quarter o f all gene 
therapy clinical trials, second only to retroviruses (Journal o f Genetic Medicine website 
www.wilev.co.uk/genmed/clinican. For these studies we required a ‘pathfinder’ vector, 
suitable for exploring different technical approaches to fetal vector delivery, and 
adenoviruses were therefore chosen as the optimum vector.
A 4.1.1 The adenovirus virion
The adenovirus virion is a nonenveloped icosahedral particle about 70-90 nm in size 
with an outer protein shell surrounding an inner nucleoprotein core (Figure A 3).
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Figure A 3: An adenovirus particle.
The outer protein shell contains trimers o f  the hexon protein. A penton base forms the capsid vertices and 
anchors the fiber protein, the part responsible for primary attachment o f  virions to the cell surface. The 
core contains proteins and the linear double-stranded DNA that is approximately 36 kb long. Adapted 
from (McConnell MJ and Imperiale MJ, 2004).
A map of the double stranded DNA of the adenovirus genome and transcription units is 
shown in Figure A 4. Initial attachment of virion particles to the cell surface occurs by 
binding of the fiber knob to the coxsackievirus B and adenovirus receptor (CAR). CAR 
is a transmembrane protein of the immunoglobulin family present in many tissues 
including the heart, lung, liver and brain and it normally functions as a cell-to-cell 
adhesion molecule on the basolateral surface o f epithelial cells (Honda T et al., 2000). 
After initial attachment to the cell surface, an exposed RGD motif on the penton base 
interacts with members of the av  integrin family to trigger virus internalization by 
clathrin-dependent receptor-mediated endocytosis (Wickham TJ et al., 1993). Viral 
particles are captured within the endosome from which they escape and are trafficked in 
the cytoplasm along microtubules towards the nucleus. They dock with the nuclear 
pore complex, the capsid disassembles allowing importation of the viral genome and 
commencement o f DNA replication (McConnell MJ and Imperiale MJ, 2004).
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Figure A 4: M ap of the double stranded DNA of the adenovirus genome and 
transcription units.
Each end o f  the genome has an inverted terminal repeat (ITR) covalently linked to the terminal protein. 
The packaging sequence (T ) is at the left end o f  the genome. Genes encode on both strands o f  DNA in 
overlapping units and are transcribed in the direction o f  the arrows. The E l A unit is the first to be 
expressed. Its proteins transactivate the other adenovirus early transcription units and induce the cell to 
enter S phase in order to create an environment optimal for virus replication. Products o f  the E1B unit 
inhibit programmed cell death thus keeping the cell alive so as to maximize viral yields. The E2 region 
encodes the proteins necessary for replication o f  the viral genome: DNA polymerase, a preterminal 
protein to maintain integrity o f  the DNA ends, and a DNA-binding protein. Products o f  the E3 region 
undermine the host immune response and allow persistence o f  infected cells. The E4 region encodes 
proteins involved in cell cycle control and transformation. The late genes expressed from L1-L5 are 
transcribed from the major late promoter (MLP) and the transcripts encode structural proteins o f  the virus 
and other proteins involved in virion assembly. Adapted from (McConnell MJ and Imperiale MJ, 2004).
For virion assembly to occur, hexon trimerization takes place first in the cytoplasm. The 
trimers are then translocated to the nucleus where they associate with penton and other 
capsid components to form the protein shell around the genome core proteins. The 
structural proteins mature to form fully infectious virions that cause cell lysis and are 
released approximately 30 hours after infection.
For the studies described here we used first generation replication incompetent 
adenovirus vectors that are created by replacing the El region with a transgene of 
interest. To produce the viral vector, the El gene that is critical for viral replication is 
provided in trans by the 293 cell line, a human embryonic kidney-derived line that has 
been transformed by the adenovirus El region (Graham FL et al., 1977). Recombination 
between the El region sequences and recombinant virus can give rise to replication 
competent viral progeny that have functional El genes, and therefore all vector stocks 
are assayed to exclude the presence o f replication-competent viruses.
Problems with adenovirus vectors include their transient expression, significant toxicity 
and immunogenicity in vivo. Even fetal administration has been associated with an 
immune response (McCray PB et al., 1995) particularly after repeat exposure to the 
vector (Iwamoto HS et al., 1999). Attempts have been made to reduce the 
immunogenicity and toxicity o f adenovirus vectors by deleting parts of the adenovirus
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genome which has led to the generation o f the so called ‘gutless vectors’ in which 
essentially all adenovirus coding sequences have been eliminated (Chen HH et al., 
1997). However the use o f an immunogenic vector in these exploratory studies is 
advantageous because it is important that any immune response to the therapy is 
detected and evaluated.
A 4.2 Retrovirus
Vectors that are able to integrate into the host genome such as retroviruses and 
lentiviruses offer the possibility o f permanent gene delivery. Retrovirus vectors have 
single stranded RNA genomes and have been developed based on the Moloney murine 
leukaemia virus (MLV) whereby all structural genes are removed to render them fully 
replication-defective (Figure A 5).
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Figure A 5: Propagation of replication defective retrovirus vectors from wild type 
retrovirus.
Although only fairly low virus titres can be produced, virus gene transfer may be 
improved by complexing vectors with cationic agents (Themis M et al., 1998), or by the 
administration o f retrovirus producer cells in vivo to allow localised gene delivery close 
to the site o f cell transfer (Douar A-M et al., 1997,Russel DW et al., 1995).
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Pseudotyping o f the vector, by replacing the natural envelope o f the retrovirus with a 
heterologous envelope such as the G protein of Vesicular Stomatitis Virus (VSV-G), 
results in improved mechanical stability allowing concentration o f the vector by 
ultracentrifugation to increase viral titre (Bums JC et al., 1993).Retroviruses require 
dividing cells for gene transfer (Miller DG et al., 1990). They may be better suited 
therefore, for use in fetal rather than adult tissues where cells are rapidly dividing and 
are not fully differentiated. This is reflected by the relatively greater efficiency of 
retrovirus-mediated gene transfer to fetal hematopoietic progenitors when compared 
with adult cells from sheep and humans (Ekhterae D et al., 1990). They are also much 
less immunogenic than adenoviruses which is important for long term gene transfer and 
expression (McCormack et al., 1997).
The main problem with retrovirus vectors is their instability in vivo. Human serum can 
almost completely inactivate some retrovirus particles (Welsh RJ et al., 1975) which 
limits their use for intravenous administration although increased resistance to serum 
inactivation can be achieved by generating retroviruses from particular human 
packaging cells (Cosset FL et al., 1995) or by pseudotyping (Engelstadter M et al.,
2001). A particular problem with in utero application is that amniotic fluid has also 
been shown in vitro to have a mild inhibitory effect on retrovirus infection (Douar A-M 
et al., 1996). This may hinder transduction because fetal cell division is non­
synchronized and only those cells that are undergoing cell division at the time of 
infection will become integrated. Other problems include reports o f premature 
promoter shutdown (Palmer TD et al., 1991 ,Challita PM and Kohn DB, 1994) leading 
to transcriptional shutoff.
A 4.3 Lentivirus
Alternative vectors such as lentiviruses have been developed because o f the limitation 
o f infection to dividing cells by retroviruses. Significant progress has been made in 
recent years in the development o f lentivirus vectors, a retrovirus sub-group based on 
the Human Immunodeficiency Virus (HIV) (Trono D, 2000). To reduce the risk of 
pathogenesis, third generation HIV vectors are now available that use only a fractional 
set o f HIV genes and a conditional packaging system to protect against generating 
productive recombinants (Dull T et al., 1998). Self-inactivating vectors in which viral 
enhancer and promoter sequences have been deleted are also now available (Miyoshi H 
et al., 1998). HIV vectors are capable o f transferring genes into nondividing cells such 
as neurons (Naldini L et al., 1996) and quiescent haematopoietic progenitor cells, (Case
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SS et al., 1999) which will be particularly useful for these tissue targets.
Lentiviruses can be made more stable by pseudotyping that allows virus titres to be 
improved by ultracentrifugation. This offers the opportunity o f infecting a greater 
number o f cells in vivo and different envelopes allow targeted gene transfer to specific 
tissues, for example to the nervous system (Mazarakis ND et al., 2001) and airways 
(Kobinger GP et al., 2001). Both the EIAV vector, a vector derived from non-primate 
animal lentiviruses, (Mitrophanous K et al., 1999) and Feline Immunodeficiency Virus 
(FIV) (Wang G et al., 1999) have been developed in an attempt to create vectors for use 
in human treatment that are not associated with any human pathology. Recent work in 
our lab has shown that high level sustained transgene expression can be achieved in a 
variety o f tissues using a VSV-G pseudotyped EAIV vector in fetal mice after 
intravascular administration (Waddington SN et al., 2003c). A potential problem for 
lentivirus vectors is that they integrate into the genome randomly and may therefore be 
able to cause insertional mutagenesis.
A 4.4 Sendai virus
The negative strand RNA cytoplasmically replicating Sendai virus, a member o f the 
paramyxovirus family, has recently been developed as a gene transfer vector. Early 
vectors still capable o f self-propagation were found to provide very high levels of 
marker gene expression in a wide range of tissues including bronchial epithelium 
(Yonemitsu Y et al., 2000), skeletal muscle (Shiotani A et al., 2001) and vascular 
endothelium (Masaki I et al., 2001). Second generation vectors, although still capable of 
intra-cytoplasmic replication of the RNA genome, are incapable o f intercellular 
propagation. In these vectors, genes encoding surface glycoproteins including the 
haemaglutinin-neuraminidase (HN) protein or the fusion (F) protein, which are 
responsible for cell binding and infection, have been deleted from the viral genome 
(Inoue M et al., 2003). Injection o f F-deficient Sendai virus vector into the fetal mouse 
via various routes including intra-vascular, intra-amniotic, intra-muscular, intra- 
peritoneal and intra-spinal resulted in expression o f marker gene in gut wall, lung, 
muscle, peritoneal mesothelia and dorsal route ganglia respectively (Waddington SN et 
al., 2004a). Further optimisation will be needed to develop these first generation 
constructs into clinically applicable vectors.
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A 4.5 Reporter genes can be used as indicators of successful 
transduction
There is as yet no sheep model o f cystic fibrosis or haemophilia B in which correction 
o f the disease process using gene therapy can be tested. Instead reporter genes such as 
P-galactosidase and human Factor IX (hFIX) can be used as indicators o f successful 
transduction and to monitor for their expression, p-galactosidase allows tracking of 
vector gene transfer and expression in tissues at set time points, and can be detected in 
sacrificed tissues directly by a blue staining assay (X gal) or indirectly using 
immunohistochemistry. The level o f hFIX, detectable in the plasma by ELISA analysis 
can be used to follow gene expression after birth without the need for sacrifice. Later 
readministration o f hFIX or the vector to bom animals injected in utero can be used to 
examine whether immune tolerance has been achieved. PCR and RT-PCR can be used 
for both vectors to follow vector spread and expression on the DNA and RNA levels 
respectively.
A 5 Fetal gene therapy studies
In utero gene therapy has so far been investigated in a broad range o f small animals 
using a variety o f techniques. Studies in large animals have mainly used sheep, since 
primates are more costly and difficult to maintain.
A 5.1 Intravascular injection
Delivery o f vectors to the systemic fetal circulation appears to be a highly effective 
route for targeting gene therapy to a range o f fetal tissues, and particularly to the liver 
(Senoo M et al., 2000). This can be accomplished either by injection via the umbilical 
vein (Themis M et al., 1999,Yang EY et al., 1999,Senoo M et al., 2000), by intracardiac 
injection (Wang G et al., 1998), or by injection into the yolk sac vessels (Schachtner SK 
et al., 1996). In all small animals and in two sheep studies these procedures have been 
performed at laparotomy. The ductus arteriosus was transfected using a liposome/DNA 
plasmid after surgical exteriorization o f the ductus in fetal sheep at 90 days of gestation 
(Mason CA et al., 1999). Adenovirus vector injection into the umbilical vein at 60 days 
gestation in sheep has been achieved after extemalization o f a loop o f umbilical cord at 
laparotomy and hysterotomy (Yang EY et al., 1999).
Two studies have performed intravascular delivery via ultrasound guidance. In the late 
gestation fetal rabbit, ultrasound-guided intracardiac delivery o f adenovirus vectors was 
achieved (Wang G et al., 1998). Transgene expression was observed in up to 40% of
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fetal hepatocytes, with less in the fetal renal cortex and glomeruli. As expected 
transgene expression was transient, declining to <1% by 21 days after injection, 
although this was not associated with a fetal immune response to the vector or 
transgene. The procedure had a 25-40% mortality rate.
Our group performed ultrasound-guided percutaneous injection into the umbilical vein 
to deliver adenovirus vectors carrying the p-galactosidase marker gene or the human 
factor IX gene to fetal sheep from 102 days gestation (Themis M et al., 1999).
Similarly, 30% o f fetal hepatocytes were p-galactosidase positive and the fetal adrenal 
cortex also showed less but still significant transgene expression. Although vector DNA 
was found by PCR analysis in the gonads, extensive further investigation by RT-PCR 
could not detect any gene expression. The duration o f transgene expression was studied 
using the levels o f human factor IX in fetal and neonatal plasma, that reached 
therapeutic levels within a week o f delivery in two animals and subsequently declined. 
Maximum adenovirus expression is expected 48-72 hours after introduction of the 
vector. Several other factors that determine the kinetics o f transgene expression include 
vector elimination, promoter shutdown, the half-life o f the protein and immune 
reactions. Antibodies against the vector and transgene were observed in some animals 
with low plasma human factor IX levels.
A 5.2 Other routes for targeting the fetal circulation and liver
Gene delivery to the liver has also been observed after vector application via other 
routes. Intramuscular injection is mainly used to target the muscle for treatment of 
muscular dystrophies but this route may be used for ectopic production o f proteins such 
as hFIX in the treatment o f haemophilias. Intramuscular injection o f adenovirus vectors 
into fetal mice resulted in gene transfer to the muscle, liver and lung albeit transiently 
(Yang et al., 1999b). Hepatocytes were also targeted by intrahepatic injection o f fetal 
mice (Lipshutz GS et al., 1999a,Lipshutz GS et al., 1999b,Lipshutz GS et al., 2000) and 
rats (Hatzoglou M et al., 1995). Intraperitoneal injection has been used for successful 
gene transfer to multiple tissues including the liver in fetal mice (Lipshutz GS et al., 
1999b) and sheep (Porada CD et al., 1998,Tran ND et al., 2000). Retrovirus vectors 
were injected into the peritoneal cavity o f fetal sheep at 57-65 days o f gestation and 
long-term transduction o f hematopoietic stem cells (HSCs) in the bone marrow and 
blood could be demonstrated 5 years later. Since this indicated haematogenic spread, 
gene delivery to the germline was also investigated, but was not detected by extensive 
PCR analysis o f the sperm derived from rams injected in utero.
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A 5.3 Intra-amniotic application
Gene delivery to the amniotic cavity is#achieved by laparotomy in small animals such as 
rodents and guinea pigs (Papaioannou VE, 1990) and by ultrasound guided intra- 
amniotic injection in larger animals such as the sheep and primate. Sheep studies have 
so far used catheters implanted at laparotomy to deliver the vectors to the amniotic 
cavity (Iwamoto HS et al., 1999,Holzinger A et al., 1995). One group has performed 
ultrasound-guided intra-amniotic injection o f mid-trimester rhesus macaque fetuses 
(Larson JE et al., 2000b). Transgene expression was seen after vector delivery to the 
amniotic cavity in the amniotic membranes, the fetal skin, the gut and the mucosae in all 
investigated species (Douar A-M et al., 1997,Larson JE et al., 1997,Holzinger A et al., 
1995,Iwamoto HS et al., 1999,Sekhon HS and Larson JE, 1995). Indeed, therapeutic 
plasma concentrations o f human coagulation factor IX were achieved in fetal mice after 
intra-amniotic injection o f adenovirus vectors carrying the human factor IX gene 
(Schneider H et al., 1999) and the transgenic protein remained detectable after birth.
This suggests that transduction o f keratinocytes in utero may be able to deliver proteins 
to the circulation as well as to treat hereditary skin disease. Unfortunately the efficiency 
o f gene transfer particularly to the pulmonary epithelium is low (Boyle MP et al., 2001) 
which could be due to dilution o f the vector by the relatively larger volume o f the 
amniotic fluid. Fetal airway smooth muscle spontaneously contracts rhythmically from 
early gestation in humans and other mammals (McCray PB, 1993,Schittny JC et al., 
2000). Fetal breathing movements are observed in the sheep (Cooke IRC and Berger PJ, 
1990) from 50 days o f gestation and in the human from 10 weeks o f gestation 
(Baconnais S et al., 1999). These increase in incidence as gestation proceeds and lead 
to an intake o f amniotic fluid to the lungs against the continuous outflow o f tracheal 
fluid (Badalian SS et al., 1993). It may be possible to enhance these breathing 
movements using agents such as theophylline (Moss IR and Scarpelli EM, 1981) to 
carry the vector further into the fetal airways.
A 5.4 Vector delivery to the fetal airways
Direct injection o f the lung parenchyma has been attempted to access the fetal airways 
but with poor results. Our group delivered an adenovirus vector containing the p- 
galactosidase gene by ultrasound guidance at laparotomy through the intact uterine wall 
into the lung parenchyma o f a fetus at 98 days o f gestation. Gene transfer was restricted 
to the site o f injection and predominantly in alveolar macrophages and no spread within 
the airways could be detected (Prof T Kiserud, personal communication). In mid-
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gestation fetal primates, ultrasound guided delivery o f lentivirus vectors to the lung 
resulted in low level transgene expression in the fetal airways (Tarantal AF et al., 
2001a).
Direct instillation o f vector into the trachea has been more successful but this has so far 
only been attempted in fetal sheep using highly invasive techniques at laparotomy that 
carry a significant morbidity and mortality. Three groups instilled retrovirus (Pitt BR et 
al., 1995) or adenovirus (McCray PB et al., 1995,Vincent MC et al., 1995) vectors via 
catheters placed in the trachea under direct vision and demonstrated low level gene 
expression in the proximal airways. Another group used fetoscopic guidance to place 
catheters in the trachea for adenovirus vector delivery (Sylvester KG et al., 1997,Yang 
EY et al., 1999). This led predominantly to alveolar infection but the efficiency o f gene 
transfer o f the entire airway was improved by the use of a balloon catheter to occlude 
the trachea. As expected transgene expression was transient in many animals and may 
have been limited by the induced inflammatory response that was occasionally seen. 
Delivery to the fetal airways using ultrasound-guided embryofetoscopy should be 
possible but further work is needed on improving gene transfer to these tissues.
A 5.5 Agents to enhance epithelial cell transduction
The epithelium of the upper airways is notably resistant to adenovirus transfection 
(Grubb BR et al., 1994). Complexing adenovirus vectors with various polycations such 
as DEAE dextran, significantly increases gene transfer to the mouse lung (Kaplan JM et 
al., 1998). The polycations are believed to improve binding o f complexed adenovirus to 
the target cell surface via neutralisation of the adverse charge interaction between 
negatively charged adenovirus particles and the negative charge o f the cell glycocalyx 
and abundant sialic acid residues (Arcasoy SM et al., 1997b). Exposure o f epithelial cell 
monolayers to polycations may also transiently increase paracellular permeability 
(McEwan GT et al., 1993) allowing the virus to reach the basolateral surface where 
CAR and integrins are expressed.
Sodium caprate, the sodium salt o f a medium chain fatty acid improves adenovirus gene 
transfer to primary human airway epithelial cells in vitro (Coyne CB et al., 2000) and in 
vivo application to the mouse airways enhances adenovirus-mediated gene transfer 
(Gregory LG et al., 2002). The effect is believed to be mediated via the tight junction 
that is the strongest binding among cell junctions and creates a regulated barrier in the 
apical junctional complex. The tight junction consists o f a continuous ring o f associated 
proteins that include the occludins and claudins (Denker BM and Nigam SK, 1998). A
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reversible redistribution o f the cytoskeleton and structural dilations in the tight junction 
occur when sodium caprate is applied to epithelial cells (Figure A 6). Sodium caprate 
enhances transmucosal absorption in the gastrointestinal epithelia in vitro (Lindmark T 
et al., 1998) and is used as an absorption enhancing agent to promote intestinal 
transmucosal hydrophilic drug absorption (Anderberg EK et al., 1993).
Fluorocarbon liquids such as perflubron improve distribution o f adenovirus vectors to 
adult airways epithelia and enhance gene expression in normal and diseased lungs 
(Weiss DJ et al., 2001). Perflubron is used clinically in liquid ventilation o f neonates 
(Shaffer TH et al., 1992) and for adult resuscitation following shock (Younger JG et al.,
1997). It is believed to enhance gene transfer by reducing the surface tension at the air- 
liquid interface in the airways and recent evidence has suggested that it may also 
increase the permeability o f epithelial tight junctions (Weiss DJ et al., 2003).
Sodium caprate
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Figure A 6: The proposed mechanism of action of sodium caprate on epithelial 
tight junctions.
Sodium caprate increases the intracellular calcium levels through interaction with phospholipase C in the 
membrane. Calcium released in a chain o f  reactions activates calmodulin-dependent contraction o f  the 
actin microfilament which opens the tight junction. PIP2: phosphatidylinositol-4,5-diphosphate; PLC: 
phospholipase C; DAG: diacylglycerol; IP3: insitol-1,4,5-triphosphate; CaM: calmodulin; MLCK: myosin 
light chain kinase; My: myosin; Ac: actin. Adapted from (Hayashi M et al., 1999).
A 5.6 Gastrointestinal delivery
Intrapharyngeal delivery has been attempted in fetal rabbits at laparotomy to target the 
fetal gastrointestinal system as a model for the treatment o f meconium ileus due to 
cystic fibrosis (Wu Y et al., 1999). Gene transfer to the small bowel enterocytes was
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achieved but there was significant maternal and fetal loss related to anaesthesia and the 
invasive surgery used. Ultrasound-guided injection of barium into the fetal stomach of 
rabbits has been performed successfully (Brandt et al., 1997c) and this technique could 
be extended to deliver gene therapy to the fetal gut. We have observed gene delivery to 
the gut of fetal mice after intra-amniotic vector application most likely as a result of 
fetal swallowing (Douar A-M et al., 1997).
A 5.7 Delivery to the nervous system
Most o f the work on gene transfer to the fetal brain has involved engraftment of 
transduced fetal neural progenitors into adult small animals, for potential treatment o f 
neurodegenerative disorders such as Parkinson’s disease. Adenovirus vectors efficiently 
infect and transfer genes to fetal rat neurons (van Esseveldt KE et al., 1997) and long 
term expression up to 7 months after infection was observed (van Esseveldt KE et al.,
1998). Gene transfer to fetal human neurons is also achievable by recombinant 
retroviruses (Lin Q et al., 1997) and they have been applied to the fetal rat lateral 
ventricle to study cell lineage in the developing rat cortex (Walsh C and Cepko CL, 
1988). Such in vivo studies are techically demanding in small animals and no similar 
studies have been performed in any large animal fetal models.
A 6 Ultrasound-guided delivery techniques are commonly used 
in fetal medicine
Application o f prenatal gene therapy in the fetus must be safe, reliable and cost- 
effective. Ultrasound-guided percutaneous injection may help to fulfill these 
prerequisites because procedures are minimally-invasive, o f short duration and have 
already been developed for diagnostic and treatment purposes in clinical practice.
There are a range o f ultrasound-guided techniques available to target the human fetus 
from early in gestation, many o f which might be adapted to deliver gene therapy 
(Figure A 7). For some organ systems, such as the brain and gut, there was no suitable 
ultrasound-guided injection technique available.
Coelocentesis allows access to the extraembryonic coelom in the early first trimester 
with a success rate o f >95% at 6-11 weeks o f gestation (Wilson JM and Wivel NA,
1999). It may be o f little use, however for in utero gene therapy because of the limited 
transfer from the extraembryonic coelom via the amniotic membrane to the amniotic 
cavity (Jauniaux E and Gulbis B, 2000). Also, the risk o f miscarriage in ongoing 
pregnancies is approximately 25% (Ross J et al., 1997).
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Figure A 7: Ultrasound-guided injection techniques.
Routes in red were developed and applied in this thesis to the fetal sheep animal model. Routes in italics 
have not yet been applied to the fetal sheep by ultrasound guided injection.
Amniocentesis may be performed from 8 weeks, although it is more commonly used 
from 15 weeks o f gestation onwards because of the risk o f fetal limb defects. However 
as we have seen, intra-amniotic application may be of limited use in fetal gene therapy 
and accessing the systemic circulation has greater potential.
Fetal blood can be sampled in the second trimester under ultrasound-guidance either 
from the placental cord insertion or from the intrahepatic vein (Nicolaides KH et al., 
1986,Nicolaidis P et al., 1991). The procedure has a good success rate, is low risk and is 
used commonly for rapid karyotyping or fetal blood transfusion (Nicolini U et al.,
1990).
From 12 weeks of gestation ultrasound-guided intracardiac puncture for fetal blood 
sampling has been performed on patients undergoing surgical termination o f pregnancy 
(Jauniaux E et al., 1999a). Similarly, radiolabelled fetal liver cells were successfully 
injected into the heart o f fetuses aged 13 weeks of gestation under ultrasound-guidance
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(Westgren M et al., 1997) prior to prostaglandin termination o f pregnancy. No fetal 
heart rate abnormalities were detected and all fetuses were alive at least 6 hours after the 
procedure. In clinical practice however, intracardiac puncture is usually only reserved 
for delivery of potassium chloride for selective fetocide in multiple pregnancy (Golbus 
MS et al., 1988a).
Intraperitoneal injection has been used for in utero stem cell transplantation from 14 
weeks o f gestation (Touraine, 1999) and is an alternative route for blood transfusion 
prior to 18 weeks of gestation (Rodeck CH and Deans A, 1999). Ultrasound guided 
transabdominal liver biopsy has been performed in the second trimester for prenatal 
diagnosis o f some congenital metabolic syndromes from enzyme activity (Vaughan JI 
and Rodeck CH, 2001). The procedure has a low complication rate but has been mostly 
superseded by DNA analysis. Corticosteroid therapy for maturation o f preterm infant 
lungs and vitamin K have been delivered to the fetus in utero by ultrasound guided 
intramuscular injection (Larsen JF et al., 1978,Ljubic A et al., 1999).
Access to the fetal trachea is possible using fetoscopy. Detachable occlusive balloons 
have been placed via the fetal larynx under fetoscopic guidance and inflated within the 
tracheal lumen for prevention o f pulmonary hypoplasia in fetuses with congenital 
diaphragmatic hernia (Deprest JA et al., 1997b). Injection o f the fetal lung parenchyma 
has been used to decompress large unilocular macrocystic congenital cystic 
adenomatoid malformations o f the lung (Nugent CE et al., 1989).
A 7 The fetal sheep animal model is particularly suitable for 
investigating fetal gene therapy
The sheep fetus is well established as an animal model relevant to human fetal 
physiology, has a good tolerance to in utero manipulations and a consistent gestation 
period o f 145 days, which is approximately half that o f the human. As in humans, the 
gestational age o f the fetus can be accurately determined by ultrasound using fetal 
measurements similar to those used in clinical practice (Barbera A et al., 1995) and 
ultrasound is routinely used in farming practice to check for multiple pregnancy early in 
gestation (Aiumlamai S et al., 1992). Ultrasound-guided injection techniques in sheep 
such as fetal blood sampling (Newnham JP et al., 1994), intra-amniotic delivery of 
endotoxin (Moss TJM et al., 2002), fetal intramuscular steroid injection (Jobe AH et al., 
1996) and fetal intraperitoneal injection o f a DNA synthesis label (Greenwood PL et al.,
1999) have also been performed. More recently, ultrasound has been used to examine 
the fetal sheep trachea (Kalache KD et al., 2001). Unfortunately there are no sheep and
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few other large animal models o f human genetic disease available for testing o f gene 
therapy. It is for this reason that small animals such as mice are commonly used, 
although their size precludes development o f minimally invasive techniques o f 
application.
There are some differences between ovine and human biology particularly in the growth 
of the fetus that must be considered (Newnham JP and Kelly RW, 1993). The fetal 
growth rate in late gestation sheep is over double that in humans (36 vs 15 g/kg fetal 
wet weight per day) although the percentage body fat at term is a quarter of that in 
humans (2% vs 16%) (Fowden AL, 1995). These differences are responsible for the 
close relationship between maternal nutrition and lamb survival and the thermal 
disadvantage o f the neonatal lamb from its high surface area to weight ratio.
There are also differences in the structural development of the human and sheep fetus.
In particular the placenta, the stomach and lungs are considered in more detail below 
since they are relevant to the research described in this thesis.
A 7.1 The sheep placenta and membranes
The discoid human placenta provides only a single disk-like zone o f intimate 
matemofetal contact that can generally be avoided during ultrasound-guided fetal 
injection. The sheep placenta however, consists o f spot like regions o f maternofetal 
interdigitations (placentomes) containing a tuft o f fetal villi called a cotyledon attached 
to 60-150 endometrial thickenings called caruncles. The placentomes are spread 
throughout the uterine cavity and may be difficult to avoid during ultrasound-guided 
uterine interventions. Evidence from ultrasound-guided amniocentesis in the fetal goat 
that has a similar placental structure indicates that placentome puncture is an abortion 
risk (Lovell KL et al., 1995).
The matemofetal barrier in sheep is the most complete placental barrier possible, 
separating the maternal and fetal blood by six tissue layers, three derived from the 
mother (maternal capillary endothelium, maternal endometrial connective tissue, 
maternal endometrial epithelium) and three derived from the fetus (trophoblast, 
chorionic connective tissue, fetal endothelium) (Benirschke K and Kaufmann P, 1990) 
(Figure A 8 A). Syncytia are formed by fusion o f fetal chorionic binucleate cells and 
maternal endometrial epithelial cells producing an epitheliochorial placenta (Wooding 
FB, 1992).
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Figure A 8: Potential barriers between fetal and m aternal circulations.
(A) The six layers o f  the epitheliochorial placenta in the sheep are illustrated. (B) Comparative 
placentation showing the cellular barriers between maternal and fetal blood for several species.
In humans however, there is extensive invasion of the endometrium by the trophoblast 
that removes the three maternal tissue barriers and results in a hemomonochorial 
placenta at term (Figure A 8 B). Probably as a result o f these structural differences, 
gammaglobulin does not pass from the mother to the fetus in the sheep, but is able to 
cross the placenta in humans.
The placental weight in sheep increases to a maximum at about 90 days of gestation and 
then declines (Barcroft J and Barron DH, 1946) while in humans placental weight 
increases to a maximum at 34-36 weeks and then remains static. Placental transport 
capacity keeps pace with fetal growth however, with similar increases in uterine blood
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flow in late gestation sheep and humans (Reynolds LP and Redmer DA, 20021).
The exocoelomic cavity or extraembryonic coelom surrounds the embryo and fetus 
during most o f the first trimester. Although not directly in contact with the embryo, the 
coelomic fluid is only separated from it by the thin amniotic membrane and thus might 
provide an alternative route to access the embryo and early fetus. The sheep has a 
substantial allantoic compartment that increases in size through gestation reaching a 
volume of 750ml at term. The allantoic fluid is largely derived from the fetal urine via 
the urachus which drains up to 50% of the urine in the fetal bladder, whilst the 
remaining urine drains via the urethra to the amniotic compartment (Wlodek ME et al., 
1988).
In the human fetus the allantois is relatively rudimentary, arising from the roof o f the 
yolk sac as a posteriorly directed diverticulum after the formation o f the tail fold. It 
eventually opens into the cloaca, the proximal end forming the apical part o f the bladder 
and the distal end becoming a fibrous cord connected to the umbilicus (Sadler TW,
1990). The amniotic cavity develops and grows inside the extraembryonic coelom 
before fusing with the placental chorionic plate at the end o f the first trimester (Jauniaux 
E and Gulbis B, 2000).
The secondary yolk sac lies within the extraembryonic coelom from the 6th week o f 
gestation and is connected to the ventral part o f the embryo, its gut and main circulation 
via the vitelline duct. There is evidence that the yolk sac membrane may transfer 
molecules from the extraembryonic coelom to the embryonic compartments and into the 
gut and circulation (Gulbis B et al., 1998). In addition, haemopoietic stem cells of 
myeloid potential are generated within the yolk sac although the multipotent, lympho- 
myeloid stem cells are now thought to emerge within the ventral wall o f the aorta, 
within the embryo itself (Peault B and Tavian M, 2003). As in the human, the yolk sac 
in the sheep is rudimentary.
A 7.2 The sheep lung
Lung development is divided into stages based on the events occurring primarily in the 
gas-exchange area. The sheep and human lung undergo similar stages o f development 
but the timing o f these stages in gestation is different. Human lung development can be 
divided into three chronological periods, the embryonic, fetal and postnatal periods. In 
the early embryonic period the lung bud appears towards the end o f the fourth week as a 
ventral bud of the prospective oesophagus that grows into the surrounding mesenchyme
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by successive dichotomous divisions. By the end o f seven weeks the lung resembles a 
small tubulo-acinar gland termed the pseudoglandular phase o f development.
The embryo enters the fetal period during which there are three morphologically defined 
phases to reach a functionally mature organ at birth. Development occurs from proximal 
to distal tissues, and there is considerable overlap between the phases and from segment 
to segment within the lung. In the pseudoglandular stage up to 17 weeks o f gestation, all 
the prospective conductive airways form and the most distal tubules representing the 
future acini appear (Figure A 9 A). In the canalicular phase there is widening o f the 
tubules and further branching within the acini to produce canaliculi. Thinning o f the 
epithelium occurs and the respiratory surface becomes vascularized (Figure A 9 B).
The cuboidal epithelium differentiates into type I and type II pneumocytes towards the 
end o f this phase. The saccular phase from 24 weeks up to birth, is marked by 
completion o f respiratory surface vascularization. There is a marked decrease in 
interstitial tissue and elastin is deposited underneath the epithelium (Figure A 9 C).
This initiates the formation o f alveoli in the alveolar phase (Figure A 9 D) that extends 
from 36 weeks through to the postnatal period.
In humans, with an extended period o f gestation, the pseudoglandular stage is virtually 
complete by 50% of gestation and the alveolar stage is clearly established by 90% 
gestation although many areas of the lung are still in the saccular stage beyond term 
(Figure A 10).
In the fetal sheep the pseudoglandular stage extends further to 85 -  90 days (60%) 
gestation, the canalicular and saccular stages are foreshortened but the alveolar stage is 
clearly established by 125 days o f gestation (86%, Figure A 10) (Pringle KC, 1986). 
Mature type II surfactant producing pneumocytes are abundant by 120 days of 
gestation, although lambs delivered before 140 days o f gestation seldom survive unless 
they receive exogenous surfactant
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Figure A 9: The histological and functional development of the lung.
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Figure A 10: A comparison of fetal lung development in the human and sheep 
according to the percent of gestation.
A 7.3 The sheep stomach
In the human fetus, the stomach appears as a fusiform dilatation o f the foregut in the 4th 
week of development. It rotates around its longitudinal and anteroposterior axis as a 
consequence of differential growth coming to assume its final position by 12 weeks of 
gestation.
In ruminants the stomach is highly specialized. It is composed o f four chambers, the 
rumen, reticulum, omasum and abomasum through which food passes successively 
during rumination (Figure A l l )  (Thyagarajan B et al., 2001). The first three, known 
collectively as the forestomach, are developed to cope with the complex carbohydrates 
that form a large part of ruminant diet, and only the last chamber is comparable in 
structure and function to the simple stomach of the human.
The rumen, reticululum and omasum are thin walled, and lined by a stratified cutaneous 
epithelium, which in the reticulum and omasum, contains numerous papillae. In 
contrast, the abomasum is lined by pink slime-covered glandular mucosa that has large 
folds to increase the secretory area (Dyce KM et al., 2002).
54
A. INTRODUCTION
(a) Swallow
oesophagus
rumen
reticulum
omasum
abomasum
pylorus
Gas
(b) Mix(d) Passage
floating
plant
material
fluid
(c) Remasticate
Figure A l l :  Rumination in the ovine stomach.
(a) The large rumen, which is about 75% o f  the stomach volume, receives the food after it is swallowed  
and serves as a large holding and fermentation vat. The smaller reticulum represents about 8% o f  the 
stomach volume, (b) During rumination, rhythmic contractions pass through the rumen and reticulum to 
circulate the food round the two compartments. Small food particles sink and pass into the reticulum 
while large undigested plant fibers float on the surface o f  the ruminal fluid and (c) are regurgitated for 
remastication in the mouth. The omasum, which occupies 4% o f  the stomach volume, absorbs fatty acids 
and water, and (d) is responsible for transferring food from the reticulum to the abomasum. The 
abomasum, representing about 13% o f  the stomach volum e, is the true stomach in which enzymatic and 
acidic hydrolysis take place.
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The primitive stomach is identifiable as an expansion o f the foregut spindle in the early 
sheep embryo from 18 days o f gestation. The spindle rotates 90° to the left by 23 days 
and the four chambers are discernible by 26 days of gestation (Latshaw WK, 1987). By 
34 days of gestation the rumen has developed two cranially directed growths, the dorsal 
and ventral sacs, and the reticulum is clearly separated from it. As the rumen grows it 
comes to lie on the left side o f the abdominal cavity and the dorsal and ventral sacs 
become directed caudally. Rapid expansion of the rumen pushes the omasum and 
abomasum to the right of the abdominal cavity and by the end o f the embryonic period 
the position and relative sizes o f the compartments o f the ruminant stomach are the 
same as in the adult. The growth o f the rumen slows while the abomasum expands, so 
that at birth the abomasum accounts for more than half the stomach volume. This is 
because in the suckling neonate, fermentation is unnecessary, and the milk bypasses the 
rumen through a reticular groove entering the abomasum for digestion. Ruminal growth 
catches up after birth on weaning and the relative sizes o f compartments reach that of 
the adult by 1 year o f age.
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B. Aims
Fetal gene therapy has been extensively investigated in small animal models. There is a 
need however, to translate this research into a large animal model using clinically 
applicable delivery methods before application in the human fetus.
The aims o f this study are:
B .l To establish a large animal model to test minimally invasive delivery methods in 
preparation for future application o f in utero gene therapy in humans.
B.2 To target gene therapy to the fetus for treatment of haemophilia, cystic fibrosis in 
the airways and small bowel, and mucopolysaccharidosis type VII using ultrasound 
guided delivery methods.
B.3 To investigate reporter gene spread, expression, the fetal and maternal immune 
response, and the morbidity and mortality using adenovirus as a pathfinder vector.
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C. Methods
C 1. General chemicals and reagents
The manufacturers of chemicals and reagents, and the details o f buffers and solutions 
are listed in Appendix 1 and 2.
C 1. Care of sheep and ultrasound guided procedures
Sheep of Romney breed were used. Each ewe was ear tagged twice with an 
identification number and the sheep flock was vaccinated against Toxoplasma, 
Chlamydia and Clostridium annually. All procedures on animals were conducted in 
accordance with UK Home Office regulations and the Guidance for the Operation o f 
Animals (Scientific Procedures) Act (l 986).
C 1.1 Timed mating of ewes
Tupping o f sheep was begun in early autumn during the sheep breeding season and 
approximately 50 sheep were tupped each year. To enable timed mating o f sheep, 
Chronogest® sponges (Flugestone acetate) containing 30mg progesterone were placed 
in the vagina o f ewes for 2 weeks to induce ovulation. Two days after removal o f the 
progesterone sponges, ewes were put in a pen with the ram overnight. The ram was 
marked on its belly with Ram Raddle®, a coloured powder mixed with liquid paraffin 
which is transferred and marks the back of the ewe once she has been served. Marked 
ewes were presumed to have been tupped. Ewes that were unmarked or not marked 
clearly were put back for a ‘return service’ with the ram 2 weeks later. In some cases 
ewes were tupped but were not pregnant when scanned. These ‘empty’ ewes were not 
used in experiments. When the sheep breeding season was advanced (March onwards) 
superovulation was occasionally required. Chronogest® sponges were placed vaginally 
for 12 days followed by an intramuscular injection o f 1000 IU Folligon® (Pregnant 
Mares Serum Gonadotrophin). The ewe was placed in with the ram 2 days later.
C 1.2 Confirmation of pregnancy using ultrasound
Following tupping, sheep on the farm were scanned every month by a commercial 
sheep sonographer using a wide sector ultrasonic scanner (Oviscan 3, BCF Technology 
Limited, Livingston, Scotland). This operates on an 85° or 170° sector at varying depths 
of field that allows the sonographer to image the entire uterus and its contents by
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placing the transducer on the naturally bare areas in front o f the udder. The pregnancy 
and fetal number were confirmed and entered onto a spreadsheet (Excel 7.0, Figure C 
1) to manage the details of tupping.
Ewe
No.
Sponging
Date
Tupping
Date
USS Week beginning Monday 
14-Jan-02 21-Jan-02 28-Jan-02 04-Feb-02 11-Feb-02 18-Feb-02
2451
2479
27-Sep-01 
27-Sep-01
11-Oct-01 
11 -Oct-01
s
s
95
95
102
102
109
IT7
IT8
24? 1 05-Oct-01 19-Oct-01 $ 87 94 101 108 115 ' ITI0
2450 05-Oct-01 19-Oct-Ol s 87 94 101 108 IT9
2181 15-Nov-01 29-Nov-01 s 46 53 60 UV5
2486 15-Nov-Ol 29-Nov-01 s 46 53 IC1
2469 22-Nov-01 06-Dec-01 s 39 46 53 60 UV6
2540 22-Nov-01 06-Dec-01 s 39 46 : 53 IC2
2546 29-Nov-01 13-Dec-01 T 32 39 46 53 60 UV 7 + UV8
2523 29-Nov-01 13-Dec-01 R returned 31/12/02
2544 06-Dec-01 20-Dec-01 T 25 32 39 46 53 IIE6+ I1E7
2533 06-Dec-01 20-Dec-01 E empty
Figure C 1: Example of a sheep tupping list.
Ewes were put in overnight with the ram for tupping 2 weeks after placement o f  intravaginal progesterone 
sponges. Ewes not tupped were put back in with the ram 2 weeks later (returned). Sheep were delivered 
to the sheep holding facility one week before surgery and designated an experimental code (eg IT8) at 
surgery. USS: ultrasound scan; S: singleton; T:twin; E: empty; R: returned
C 1.3 Sheep diet
Ewes were housed on the farm out on grass or in sheds during the winter. Pregnant ewes 
were moved to the sheep holding facility in a lorry one week before use to allow 
acclimatization and condition scored on arrival. They were housed together in pairs in 
pens on straw at ambient temperature. They had free access to running water and hay 
and were given a daily portion of Super Ewe & Lamb UFAS compound feed according 
to their gestational age (Table C l) .
Table C 1: Daily feeding of sheep according to gestational age.
Gestational
age
Ewe carrying twins Ewe carrying singleton
Low condition 
score (2 -  3)
High condition 
score ( 4 - 5 )
Low condition 
score (2 -  3)
High condition 
score ( 4 - 5 )
Up to 91 days 200g 100g 100g 50g
9 2 -  105 days 400g 200g 200g 100g
106 -  119 days 600g 400g 400g 200g
1 2 0 - 133 days 800g 600g 500g 350g
134-b irth lOOOg 800g 700g 500g
The feed is a concentrated source o f oil, protein and vitamins and the amount given to 
sheep was increased as gestation progressed. This ensures adequate nutrition for the ewe
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and reduces the risk o f toxaemia caused by the large late gestation fetus compressing the 
rumen and reducing the ability o f the ewe to digest enough hay for nutrition.
C 1.4 Confirmation of gestational age using ultrasound
All pregnant sheep were scanned the day after arrival at the sheep holding facility to 
confirm pregnancy, fetal number and gestation age. Ewes were caught, turned up and 
held in a sitting position for scanning using a Vingmed Sonotron CFM 800 ultrasound 
scanner (Horten, Norway) as shown in Figure C 2. The sonographer applied ultrasound 
coupling medium to the lower abdomen and scanned the uterus using a 5.0 MHz probe 
(TNI 00119A) held just above the udders. Gestational age was checked from 
measurements o f fetal abdominal circumference, occipito-snout length and biparitetal 
diameter according to standard tables (Barbera A et al., 1995,Kelly RW and Newnham 
JP, 1989).
Figure C 2: C onfirm ation of gestational age in the sheep fetus by ultrasound.
(A ) A Vingmed Sonotron 800 CFM ultrasound scanner being used to check the gestational age in a 
pregnant ew e that has been turned up (B).
C 1.5 Sheep anaesthesia
Before surgery ewes were starved for twelve hours with free access to water and bedded 
on wood chips. This is to prevent bloating which can occur when sheep under 
anaesthesia are unable to belch (eructate) normally and release methane gas which is a 
by-product o f fermentation o f their food (Wolfensohn S and Lloyd M, 1998).
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On the morning o f surgery sheep were moved to theatre restrained in a cart. The wool 
was clipped from their necks, the jugular vein was cannulated using a 19 Gauge 
butterfly winged perfusion set (Terumo Europe NV, Leuven, Belgium) and 15 ml of 
sodium thiopentone (10% w/v), was given intravenously over 1 minute for induction. 
Once asleep the ewes were rolled onto the operating table and intubated supine with a
9.0 mm cuffed endotracheal tube (Portex, UK) using a laryngoscope (Penlon, UK) to 
visualize the vocal cords. A cuff was inflated on the endotracheal tube to prevent 
inhalation o f regurgitated ruminal contents and the head was lowered to allow drainage 
of saliva and ruminal fluid (Taylor PM, 1991). Because access to the whole abdomen 
was needed for procedures the animals were kept in dorsal recumbency. Over long 
periods the rumen can compress the lungs causing dyspnoea and the vena cava reducing 
venous return to the heart. This was not felt to be a problem in our procedures because 
they were of sufficiently short duration. Anaesthesia was maintained on 1.5-2 
litres/minute halothane and 4 litres/minute oxygen using a Magill circuit (Medishield 
ventilator, Manley Serovent, Figure C 3).
Figure C 3: G eneral anaesthesia in the sheep.
The pregnant ew es were intubated and maintained on halothane and oxygen. The pulse oximeter is 
arrowed.
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A pulse oximeter (5250 RGM, Ohmeda) placed on the ewe’s ear was used to monitor 
oxygen saturation and pulse rate (Figure C 3) and this data was documented every 15 
minutes together with respiration rate, halothane concentration and level of anaesthesia. 
Maternal blood was taken for pre-operative analysis o f antibodies to the vector and 
transgene and for human factor IX levels. Blood was collected into BD Vacutainer 
tubes (BD Vacutainer systems, Plymouth, UK) containing 0.105 M sodium citrate for 
plasma (9NC, blue topped bottle) and into plain tubes for serum (SST, brown topped 
bottle).
Following surgery sheep were recovered while placed on their sternum in a cart and 
extubated once strong swallowing reflexes returned. They were then returned to their 
pen.
C 1.6 Ultrasound guided procedures on sheep
Once anaesthetized, the wool was clipped from the ewe’s abdomen and a detailed 
ultrasound examination of the uterus and its contents was performed using a 3.3 MHz 
probe (TK100105A) on the Vingmed ultrasound scanner (Figure C 4).
Figure C 4: Ultrasound examination of the fetus p rio r to fetal injection.
Ultrasound coupling medium was used during scans and small aliquots were sterilized 
by irradiation for use during operative procedures. The following fetal measurements
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were taken of each fetus where fetal size allowed: crown rump length, femur length, 
abdominal circumference, biparietal diameter and occipito-snout length (Figure C 5)
Figure C 5: Ultrasound measurements of fetal sheep.
(A) FL (10.1mm) and (B) OSL (40.2mm) at 60 days o f  gestation (U V5). (C) AC (162mm) at 83 days o f  
gestation (UV14). (D) BPD (22mm) at 60 days o f  gestation (B2). (E) CRL (27.4mm) at 36 days o f  
gestation (A7).
The abdomen was then scrubbed with povidone iodine antiseptic solution prior to 
injection. Analgesia was not considered necessary since all procedures involved a single
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injection o f the needle and these procedures are routinely carried out in humans without 
the need for analgesia.
Under ultrasound guidance the needle was inserted through the maternal skin, the uterus 
and into the amniotic cavity avoiding passage through the placentomes if  possible. For 
each injection route a freehand technique was used. The needle was positioned and the 
viral vector or colloidal carbon was injected followed by 40pl 0.9% saline to flush the 
vector from the dead space of the spinal needle, the volume o f which was confirmed by 
the manufacturer. This was important because in many o f these experiments, very small 
volumes o f virus were applied. The time to successful injection was measured from the 
first insertion o f the needle through the fetal skin to removal o f the needle from the fetus 
after successful delivery o f the viral vector and/or other agents into the appropriate part 
o f the fetus. A failed attempt at injection was defined as insertion o f the needle through 
the fetal skin and then failure to access the appropriate part of the fetus that was being 
targeted. All ultrasound examinations and procedures were videotaped so that 
intraoperative events could be reviewed after surgery. As fluid was being delivered to 
fluid filled areas o f the fetus such as the trachea, stomach, peritoneal and amniotic 
cavity, umbilical vein and lateral cerebral ventricles, turbulence was observed, which 
we termed “microbubbles”.
Dr Donald Peebles, Senior Lecturer in Fetal Medicine at University College London 
performed the intravascular injection procedures in early to mid gestation fetal sheep, 
developed the transthoracic tracheal injection and intraventricular injection techniques. 
During the course o f the work for this thesis he trained Dr Anna David to perform mid­
gestation intravascular injection procedures and early gestation intramuscular, 
intraperitoneal and intrahepatic injections. Dr Anna David performed the intra-amniotic 
and intragastric injection procedures and was also responsible for pre and post-operative 
ultrasound surveillance o f the fetal sheep.
C 1.6.1 Intravascular injections
A 22 Gauge Quincke type point spinal needle (Becton Dickinson, UK) was used for all 
procedures up to 84 days o f gestation. A size 20 Gauge Quincke type point spinal 
needle (Becton Dickinson, UK) was used for experiments at later gestational ages. The 
inner-to-inner diameter o f the umbilical vein was measured at the intrahepatic portion 
and at the placental cord insertion before injection. For umbilical vein injections, the 
needle was placed directly into the umbilical vein and a small volume o f blood 
withdrawn to confirm correct needle placement. If  a large enough blood sample was
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obtained, fetal serum and plasma was kept for pre-operative analysis o f antibodies to the 
vector and transgene and for human factor IX levels. On injection o f the vector, 
microbubbles were viewed passing along the vessel. The inner-to-inner diameter o f the 
umbilical vein was measured after injection at the injection site.
Intracardiac injections involved placement o f the needle through the anterior chest wall 
directly into the left ventricle and blood was again withdrawn to confirm correct needle 
placement. On injection o f the vector, microbubbles were viewed in the heart chambers.
C 1.6.2 Intra-amniotic injections
A 22 Gauge Quincke type point spinal needle (Becton Dickinson, UK) was used for all 
procedures. For intra-amniotic injections, 1ml amniotic fluid was first withdrawn and 
frozen at -80°C for later analysis. Correct placement o f the needle was confirmed by 
observing microbubbles moving around the fetus in the amniotic sac after injection of 
100(4.1 0.9% saline fluid. The viral vector was then injected.
C 1.6.3 Tracheal injections
Larger Echotip spinal needles (Cook, UK) were used during these procedures varying 
from 17-22 Gauge. The trachea was injected either in the fetal neck or via the fetal 
thorax. At each procedure the needle was inserted into the trachea under ultrasound 
guidance and tracheal fluid was withdrawn using a syringe to check correct needle 
placement. The viral vector and other solutions were instilled down the needle or down 
catheters inserted through the needle in some experiments. Microbubbles could be seen 
flowing down the trachea and distal airways on ultrasound. The inner-to-inner diameter 
o f the trachea was measured before and after injection in the distal third o f the fetal neck 
and just superior to the level o f the pulmonary artery in the fetal chest.
C 1.6.4 Placement of detachable balloons in the trachea
Detachable goldvalve embolisation balloons (CathNet-Science, Paris, France) were 
placed in the trachea under ultrasound guidance. These balloons are used in clinical 
practice during endovascular interventions to therapeutically occlude aneurysms, 
arterio-venous fistulae and great vessels. They have also been used in the treatment of 
congenital diaphragmatic hemiae in the fetal sheep model and in humans (personal 
communication, Prof Jan Deprest, Center for Surgical Technologies, Faculteit 
Geneeskunde, Leuven, Belgium).
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The catheter on which the detachable balloon is mounted was first primed with 0.9% 
normal saline solution. The “Y” connector attached to the proximal end of the catheter 
was similarly primed. The wire mandrel was passed through the catheter until only 
1 mm extended beyond the distal end o f the catheter. The integrity o f the balloon was 
tested prior to the experiment. A blunt needle (22 Gauge) was primed with 0.9% normal 
saline solution and the balloon was placed on the end so that the tip was inserted to the 
top of the valve. The balloon was inflated with a volume o f 0.9% normal saline fluid 
according to manufacturer’s instructions (Figure C 6 A), and detached from the needle. 
The solution used to inflate the balloon must be the same osmolality as the lung fluid to 
prevent rapid deflation or inflation of the balloon by movement of water across the 
latex.
Figure C 6: Preparation of the balloon and catheter system before injection into 
the fetal trachea.
Testing the integrity o f  the balloon by inflation with 0.9% normal saline fluid down a 22 Gauge blunt 
needle (A). The deflated balloon is mounted on the end o f  the support catheter and passed down the 
injection needle to check for smooth passage (B).
The inflated balloon was placed on the wire mandrel and inserted onto the distal end of 
the support catheter. The wire mandrel was withdrawn 1cm to avoid damaging the 
balloon and the distal end of the support catheter was inserted to the top o f the balloon 
valve. The wire mandrel was withdrawn a further 4cm to allow the balloon to deflate 
completely. The wire mandrel was then reinserted up to the balloon but not beyond, to 
provide support during balloon placement.
The needle used for the injection procedure was prelubricated with 0.9% normal saline 
solution and the fit o f the balloon and catheter system tested down the needle (Figure C 
6 B). It was then placed in the trachea under ultrasound guidance, the cannula 
withdrawn and tracheal fluid aspirated to confirm correct needle placement. The
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detachable balloon mounted on the catheter was passed down the needle until it was in 
the trachea just proximal to the carina. The wire mandrel was withdrawn and at the 
same time 0.9% normal saline was injected via the “Y” connector to compensate for the 
dead space. The balloon was inflated by injection o f 0.9% normal saline down the 
catheter to its maximal dimensions that were visualised on ultrasound. The needle was 
then withdrawn from the fetal skin so as to avoid damaging the catheter and the catheter 
was detached from the balloon by a firm pull leaving the inflated balloon in place. The 
dimensions o f the inflated balloon and the inner-to-inner diameter o f the trachea above 
and below the balloon were measured. The chest dimensions including the 
anteroposterior, transverse and longitudinal diameters were measured by ultrasound at 
surgery. The ewe was recovered and the fetuses were scanned the day after surgery and 
weekly thereafter for viability, fetal well being and assessment o f the diameter o f the 
balloon and trachea. The chest dimensions were measured again immediately prior to 
post mortem examination when the ewe was given a terminal general anaesthetic.
C 1.6.5 Intragastric injections
A 22 Gauge Quincke type point spinal needle (Becton Dickinson, UK) was used in all 
procedures. The needle was placed directly into the fetal stomach viewed in a transverse 
plane either through the anterior abdominal wall or occasionally via the abdominal ribs. 
The position o f the needle was viewed in two planes to confirm correct placement and 
lOOpl gastric fluid was withdrawn. On injection o f the vector, microbubbles could be 
seen flowing inside the fetal stomach. The inner-to-inner diameter o f the stomach and 
its cavities was measured before and after injection in the anteroposterior, transverse 
and longitudinal planes.
C 1.6.6 Intraperitoneal or intrahepatic injections
A 22 Gauge Quincke type point spinal needle (Becton Dickinson, UK) was used for all 
procedures. The needle entered the anterior abdominal wall superior to the intrahepatic 
portion o f the umbilical vein for intrahepatic injections or below the level o f the cord 
insertion just superior to the fetal bladder for intraperitoneal injections. The position of 
the needle was viewed in 2 planes to confirm correct placement before delivery o f the 
viral vector. Microbubbles could be seen flowing in the peritoneal cavity confirming 
intraperitoneal injection. On intrahepatic vector administration, an echodense area 
developed within the hepatic parenchyma at the injection site.
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C 1.6.7 Intramuscular injections
For intramuscular delivery a 22 Gauge Quincke type point spinal needle (Becton 
Dickinson, UK) was inserted along the length o f the femur and/or the buttock. On 
intramuscular vector administration, an echodense area could be seen along the length 
of the muscle.
C 1.6.8 Intraventricular injections
A 22 Gauge Quincke type point spinal needle (Becton Dickinson, UK) was inserted 
through the coronal suture or skull in a posterior direction into the posterior horn o f the 
lateral ventricle. The position o f the needle was viewed in 2 planes to confirm correct 
placement before delivery o f the viral vector. Microbubbles could be seen within the 
lateral ventricles on vector instillation.
C 1.7 Post-operative care
The day after a procedure, the wellbeing of the ewe was assessed and fetal survival was 
determined on ultrasound scan. Ewes and fetuses were subject to post mortem analysis 
at various time points following procedures and some animals were allowed to come to 
birth. This was to allow examination o f fetal transgene expression in blood at time 
intervals following injection and to assess the humoral immune response to the vector 
and transgene. Ultrasound examination of fetal wellbeing and growth was performed 
weekly on those animals surviving longer than 2 days after operation.
C 1.8 Post mortem examination
Ewes were euthanized using an overdose (40ml) o f intravenous 20% pentobarbitone. 
Maternal and fetal serum and plasma was collected for analysis o f antibodies and 
human factor IX levels. The ewes were subjected to a limited post-mortem examination 
and samples o f liver, spleen, lung, heart, thymus, adrenal, kidney, brain and ovary were 
taken into 10% formaldehyde for histology and snap frozen in liquid nitrogen for PCR 
analysis. A lull post-mortem examination was performed on the fetal sheep with 
widespread sampling of tissues from all organ systems according to the post mortem 
sheet (Appendix 3). Multiple tissue blocks were taken from the sites o f injection. The 
peritoneum was stripped from the small and large bowel prior to fixing or freezing.
The lung and trachea were removed en bloc in tracheal injection experiments before 
sectioning.
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For tracheal occlusion experiments using an inflated balloon, the trachea was cannulated 
with a 4mm paediatric endotracheal tube (Portex) and the lungs were inflated with 6% 
formalin and fixed at 25cm H20  using a manometer for 72 hours, before sectioning. 
Tissues from ewes or fetal sheep that died following procedures were subject to 
microbiological examination at the Royal Veterinary College, Hawkshead, Potters Bar, 
Herts to help determine the cause o f death. All post mortem procedures were performed 
by Dr Anna David.
C 1.9 Care and investigation of lambs born following in utero 
procedures
Ewes that were allowed to come to birth were vaccinated with Heptavac-P plus® one 
month before their delivery date to prevent Clostidium and Pasteurella infection in the 
lambs. A further 2 doses were given to the lambs at 10 weeks and 16 weeks o f age. 
Blood was taken from Iambs as soon as possible after delivery for analysis o f antibodies 
and human factor IX levels and then six weekly thereafter. Analysis o f blood count, 
biochemistry, liver function and bile acids was also performed at birth and 3 monthly 
thereafter at the Royal Veterinary College pathology department. After discussion with 
Dr Kathleen Tennant, Veterinary Pathologist at Royal Veterinary College, Hawkshead, 
Potters Bar, an optimum data set for blood analysis was drawn up (Table C 2).
Table C 2: Blood analysis of Iambs born after ultrasound-guided in utero injection.
Cone.: concentration
Haematological analysis Serum biochemistry Liver function tests
White blood cell count Total protein conc. Glutamate dehydrogenase
Neutrophil count and % Albumin conc. Aspartate transaminase
Lymphocyte count and % Globulin conc. Gamma-glutamyltransferase
Monocyte count and % Sodium conc. Creatine kinase
Eosinophil count and % Potassium conc. Total bilirubin conc.
Basophil count and % Chloride conc. Bile acids
Red blood cell count Bicarbonate conc.
Haemoglobin conc. Anion gap
Haematocrit Calcium conc.
Mean red cell volume and 
haemoglobin conc.
Inorganic phosphorus 
conc.
Platelet count Urea conc.
Creatinine conc.
For blood count determination, 4.5ml blood was collected into a BD Vacutainer (BD 
Vacutainer systems, Plymouth, UK) containing 0.054ml potassium EDTA (K3E, purple
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topped bottle). Results of blood tests from animals older than 1 year were compared 
with normal ranges from adult sheep. There are no normal ranges available for lambs 
however, and therefore results of blood tests from lambs were compared with those 
from non-experimental lambs of the same age and breed that were also on the farm. All 
analyses were performed by the Department of Pathology, Royal Veterinary College, 
Hawkshead, Potters Bar.
Lambs were kept with their mothers until weaning at approximately 16-20 weeks of 
age. Ewes were then subject to post mortem examination, serum and plasma collection 
and tissue sampling for histology and PCR analysis. Tail docking was performed 
routinely on lambs using rubber rings before they were one week old.
C 1.10 Liver biopsy of lambs born following in utero procedures
Liver biopsy was performed with lambs standing up without sedation by a qualified 
veterinary surgeon (Dr John Fishwick, Royal Veterinary College, Hawkshead, Potters 
Bar). The right flank was clipped and the site o f the biopsy identified as the 11th 
intercostal space at a level just anterior to the tuber coxae, the most cranial part o f the 
pelvis (Figure C 7). The area was scanned with ultrasound to confirm the liver was 
adjacent to the body wall at this point and to identify any liver pathology. The diameter 
o f the bile duct was measured.
Figure C 7: Liver biopsy in an adult sheep.
The unsedated standing sheep has local anaesthetic placed into the skin just over the 11th rib (arrowed). 
The landmarks o f  the 11th, 12th and 13th ribs have been marked on the shaved skin. The biopsy is 
performed in the 11th intercostal space.
The skin was cleaned with povidone iodine antiseptic solution and infiltrated with 2.5ml 
o f 5% procaine hydrochloride for local anaesthesia. A 9cm long 14 Gauge veterinary
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Quick-Core Biopsy Needle (Cook, Australia) was inserted approximately 4cm into the 
liver to obtain a liver core. Four liver cores were taken, placed in 70% formalin for 24 
hours and then processed as for other pathology specimens. To close the wound, two 
nylon skin sutures were placed in the skin. An intramuscular injection of 750mg 
amoxycillin trihydrate was given for infection prophylaxis.
C 2. Production of viral vectors 
C 2.1 Cell culture
The following cell lines were used for investigations in this thesis: 293 cells, NIH 3T3 
cells, HeLa cells, HT1080 cells and HBE cells. Cell lines were taken either from 
existing cell culture plates or from liquid nitrogen frozen stocks. These were defrosted 
quickly to 37°C in a waterbath, and washed to remove residual dimethylsulfoxide in the 
storage media by diluting lOx in D-Mem containing 10% FCS and 5% pen/strep, and 
pelleting by centrifugation for 5 minutes at 100 x g (Centurion 4000 Series). Cells were 
then resuspended in fresh media and cultured at 37°C, 5% CO2 in Nunclon™ 75 cm2 
triple flasks for adenovirus production or 6 well culture cluster plates for transfection 
experiments.
When cells grown in triple flasks were 50% confluent, the growth media was removed 
and the cells washed with 25ml PBS. To remove the cells, 25ml 1 x trypsin-EDTA was 
added and the flasks tapped gently for 30 -  45 seconds before 25ml growth medium was 
added to neutralize the trypsin. Cells were pelleted by centrifugation for 5 minutes at 
100 x g and the supernatant discarded before resuspension in 10ml new growth medium 
by vigorous pipetting. This was then diluted 200x in new growth medium, distributed 
between 4 new Nunclon™ 75 cm2 triple flasks equally and cultured at 37°C, 5% CO2. 
Cells could be split every 2 - 3  days.
C 2.2 Adenovirus vector production
Replication deficient first generation adenovirus constructs deleted for the El and E3 
regions and containing the lacZ reporter gene (Stratford-Perricaudet LD et al., 1992) 
and the human Factor IX gene (unpublished construct) were originally supplied by 
Transgene, Strasbourg, France. Replication first generation adenovirus constructs 
deleted for the El and E3 regions and containing the hCFTR gene (AV1CF2) were 
originally supplied by B. Trapnell, Cincinatti, Ohio, USA. Dr Anna David was 
responsible for production, purification and titration o f adenovirus vectors for the first
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year o f the research under the supervision o f Dr Michael Themis, Lecturer, Gene 
Therapy Research Group, Imperial College, London. Production o f adenovirus vectors 
for further work was performed by other members o f the Gene Therapy Research 
Group.
C 2.2.1 Adenovirus vector preparation
The human embryonic kidney 293 cell line was used to produce adenovirus vectors. 
These provide the El A gene that has been deleted from the adenovirus vector construct 
in trans. 293 cells were grown to 70% confluence in twelve 75cm3 triple flasks in 
125ml D-Mem, 10% FCS and 5% pen/strep at 37°C and 5% CO2. Cells were infected 
with new media containing D-Mem, 5% FCS, 5% pen/strep and 5 x 108 plaque forming 
units adenovirus and incubated at 37°C and 5% C 0 2 for two to three days until cells 
began to lift off the plate. Cells were completely dislodged from the plate by gentle 
tapping o f the flask and the bathing medium was then centrifuged at 4,000 x g for 10 
minutes. The supernatant was discarded and the cells were resuspended in 10ml o f new 
10% medium and freeze/thawed three times to lyse the cells and release the virus. This 
was then centrifuged at 2000 xg for 10 minutes to remove cell debris.
The supernatant was subjected to two rounds o f ultra-centrifugation in a caesium 
gradient to purify the adenovirus particles. The three caesium chloride solutions were 
prepared and filtered using a 0.20pm syringe filter (Sartorius AG, Goettingen,
Germany) into a sterile bottle. The first caesium gradient was prepared by placing 12ml 
o f 1.4g/ml CsCl (heavy solution) underneath 12ml o f 1.25g/ml CsCl (light solution) in 
two 35ml Polyallomer centrifuge tubes (Beckman, Palo Alto, CA, USA). The 
supernatant was split into two, added to the top with a covering o f mineral oil and the 
tubes balanced. Ultra-centrifugation was at 28,000 rpm for 2 hours at 4°C (Sorvall 
Ultra-Pro 80 centrifuge). The bottom band containing the adenovirus particles was 
retrieved with a sterile 21G needle (BD Microlance, Becton Dickinson, UK), care being 
taken not to remove genomic DNA in the top band. The virus was split into two samples 
and each sample was added on top o f 5ml o f 1.34 g/ml CsCl (medium solution) in a 
15ml Polyallomer centrifuge tube (Beckman, Palo Alto, CA, USA) to form a new 
gradient. Mineral oil was added on top, the tubes balanced and ultracentrifuged at
35,000 rpm for 20 hours at 4°C (Sorvall Ultra-Pro 80 centrifuge). The bottom band 
containing adenovirus was removed with a sterile 21G needle (BD Microlance, Becton 
Dickinson, UK) and then purified to remove all traces o f cytotoxic CsCl. The virus 
solution was injected into a 3-50pl dialysis cassette (Pierce, Rockford, USA) containing
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an equal volume of 2 x sucrose. This was then dialysed overnight in three washes of lx  
5M sucrose solution and the cleaned adenovirus solution was kept at 4°C prior to 
titration.
C 2.2.2 Titration of adenovirus vectors
The titre of adenovirus vectors was determined using a physical method of 
measurement at a range o f optical densities (OD). This method is based on the 
correlation between protein concentration of adenovirus preparations and absorbance at 
260nm: one absorbance unit is equivalent to 1.1 x 1012 adenovirus particles (Maizel JV 
et al., 1968).
Vector titration using biological methods such as plaque assay is imprecise because they 
depend on factors such as the cell type used and the diffusion rate o f the viral vector. 
Results can vary by as much as 30% within a day. Physical methods however are much 
less variable with interday precision values o f less than 5% (Hutchins B et al., 2000) 
and have been recommended by the Food and Drug Administration in their Guidance 
for Industry (Food and Drug Administration, 1998). OD measurement o f viral titre also 
has drawbacks. For example the purity and formulation o f the vector preparation 
influence the absorbance of the sample, and physical measurement o f viral titre does not 
give an indication of the infectious titre which makes analysis o f toxicity effects 
difficult.
For OD measurement of viral titre the dialysed virus was diluted with lOmM Tris-HCl, 
pH 8.0 and the absorbance at 220, 260, 280, 320 and 340 nm determined using a 
spectrophotometer (Lucy 1, Anthos).
Quality o f vector: The virus is dead if OD320nm/OD260nm > OD220nm
The virus is aggregated if  OD340nm/OD260nm>OD220nm 
Titre o f vector: Titre (particles/ml) = OD260nm x 1.1 x 1012 particles/ml.
C 2.2.3 Testing for replication competent adenovirus
Virus batches were tested for the absence o f replication competent adenovirus (RCA).
A rapid method used primers to amplify the E l A region o f adenovirus (Genbank 
AY 147066) which is deleted in the replication incompetent adenovirus vector. A PCR 
product from amplification o f the E l A region will arise from replication competent 
virus particles or by contamination o f the virus with genomic DNA from the human 
embryonic 293 kidney producer cell line. Samples o f virus batches were subjected to 40 
cycles o f 1st round amplification followed by 30 cycles o f nested amplification (Table
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C 3). The detection limit of the PCR reaction was one replication competent adenovirus 
in 1 x 109 replication competent particles.
Table C 3: PCR conditions for amplification of the E l A adenovirus gene.
1st round product size 795bp
1st round forward primer GGACCAGCTGATCGAAGAGG
1st round reverse primer CCACCGGGTGTATCTCAGG
Annealing temperature 60°C
MgCh concentration in reaction 1.3 mM
Nested product size 580bp
Nested forward primer GTAATGTTGGCGGTGCAGGA
Nested reverse primer CTCTAGACACAGGTGATGTCG
Annealing temperature 58 °C
MgCh concentration in reaction 1.5 mM
AdRSVpgal contains a Rous Sarcoma Virus (RSV) promoter driving the expression of 
the p-galactosidase reporter gene. The human factor IX gene on AdTG9397 is driven by 
the Cytomegalovirus (CMV) promoter and contains the adenovirus tripartite leader 
sequence and the simian virus 40 polyadenylation site. The human CFTR gene on 
AV1CF2 is driven by the Rous Sarcoma Virus (RSV) promoter.
Viruses were prepared freshly in PBS prior to injection into fetal sheep. In this study we 
used fetal sheep from a wide range of gestational ages that were growing rapidly. The 
dose of vector applied to each fetus was therefore standardized to a dose (particles) per 
kg fetal weight using estimated fetal weight according to the gestational age at injection. 
There was no published data on fetal weight according to fetal measurements or fetal 
weight in sheep o f Romney Marsh breed. We initially used data on fetal weight at 
gestational age from studies in Merino sheep (Cloete JHL, 1939) and unspecified breeds 
(Joubert DM, 1956)(Figure C 8). As our study progressed, we were able to use data 
from fetal weight at post mortem examination to estimate the fetal weight in our sheep. 
The dose per kg was then confirmed using the fetal weight at post mortem 2 days after 
injection. This was because about 20% of our fetuses were from twin gestations and 
were slightly smaller than singletons of the same gestational age. For fetuses that were
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euthanased longer than 2 days after injection, we reported the fetal weight for the 
gestational age at injection.
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Figure C 8: Weight of singleton male sheep fetuses according to gestational age.
Taken from (Joubert DM, 1956).
C 2.3 Alternative vectors 
C 2.3.1 Retrovirus vectors
Retrovirus vectors (Moloney leukemia virus, MLV) containing the lacZ reporter gene 
under the control o f the LTR were provided by Francois Cosset, University o f Lyon, 
France.
C 2.3.2 Lentivirus vectors
EIAV vectors pseudotyped with the VSV-G or the Mokola envelope and containing the 
lacZ reporter gene or hFIX gene were provided by Oxford BioMedica, Oxford, UK. 
F1IV vectors pseudotyped with the VSV-G or Mokola envelope and containing the lacZ 
reporter gene were provided by Professor Adrian Thrasher, Institute o f Child Health, 
London, UK.
75
C. METHODS
C 2.3.3 Sendai vectors
Second generation Sendai vectors deleted for the fusion (F) protein, a gene that encodes 
a surface glycoprotein, and containing the lacZ reporter gene were provided by Dr 
Michael Bitzer, Tuebingen, Germany.
C 2.4 Ex vivo transfections
Tissue from the small bowel, trachea and liver of fetal sheep at various gestational ages 
were transfected ex vivo to determine adenovirus mediated gene transfer. The effects of 
the transduction enhancing agents sodium caprate and DEAE dextran were also 
evaluated in the fetal small bowel and trachea ex vivo. Experiments were performed by 
Dr Anna David, Dr Lisa Gregory and Dr Michael Themis, Gene Therapy Research 
Group, Imperial College, London.
C 2.4.1 Ex vivo transfection of the fetal liver
Thin sections of fetal liver taken at post mortem analysis were cultured in a 100mm x 
20mm cell culture dish with D-Mem containing 10% FCS and 5% pen/strep in an 
incubator at 37°C and 5% CO2. Adenovirus vectors (5x108 particles) containing the (3- 
galactosidase reporter gene with or without complexing with DEAE dextran (5pg/ml) 
were applied to the medium for 24 hours. The medium was replaced with fresh medium 
for a further 24 hours and then the tissues were stained with X-gal solution for 
assessment o f p-galactosidase transgene expression.
C 2.4.2 Ex vivo transfection of the fetal trachea
A 4cm long piece o f trachea from a mid-gestation fetal sheep was opened and divided 
into 4 sections. These were cultured in a liquid-air interface on a filter paper platform 
soaked in D-Mem culture medium containing 10% FCS, 10% NCTC-135 medium, 
2mM L-glutamine, lOOU/ml pen/strep, lpg/ml insulin and 30ng/ml dexamethasone in a 
100mm x 20mm cell culture dish. PBS or sodium caprate was applied to the epithelial 
surface. The cell culture dishes were sealed within a pressure jar (Oxoid) filled with 
95% CC>2/5%02 to 1.5 bar (BOC) and the jar and contents were incubated at 37°C for 
10 min. Following pre-treatment with sodium caprate or PBS, adenovirus vectors 
containing the p-galactosidase reporter gene (5x108 particles) were applied to each 
section of trachea for 30 min, with or without DEAE dextran complexation (5pg/ml). 
Tracheae were washed with PBS and incubated for 28 h in the same gas mixture which
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was replaced after 4 h and 15 h. Tissues were homogenised in lysis buffer and levels of 
transduction were determined by ELISA. Results of gene transfer were grouped 
according to treatment and analysed statistically.
C 2.4.3 Ex vivo tranfection of the fetal gut
This was performed in a similar way as ex vivo transfection o f the fetal liver. The small 
bowel was opened and cultured in a 100mm x 20mm cell culture dish with D-Mem 
containing 10% FCS and 5% pen/strep in an incubator at 37°C and 5% CO2. Adenovirus 
vectors containing the p-galactosidase reporter gene (5x108 particles) were applied to 
the medium together with sodium caprate and/or DEAE dextran in the same 
combinations and incubated for 24 hours. The medium was replaced with fresh medium 
for a further 24 hours and a section o f the small bowel was stained with X gal solution 
to determine qualitatively the areas o f the small bowel that had been transfected. The 
remainder of each section was taken for assessment o f gene transfer by p-galactosidase 
ELISA analysis and results were grouped according to treatment and analysed 
statistically.
C 3. Histological analysis 
C 3.1 Tissue samples
Tissue samples were fixed in 10% formaldehyde overnight, transferred to 70% ethanol 
and processed into paraffin in cassettes. Paraffin sections were cut at 2-5 pm thickness, 
floated out on warm water and mounted and air-dried onto glass slides. These were 
immersed in hematoxylin solution made up in PBS pH 7.2 for 5 minutes, washed 3 
times in PBS before being immersed in 1% eosin counterstain solution made up in PBS 
pH 7.2 for 5 seconds and washed 3 times in PBS. Sections were processed through 
alcohol into xylene and then mounted in DPX mountant medium and a coverslip placed 
over the section and allowed to dry. Slides were analysed under normal light 
microscopy with the assistance o f Professor Terry Cook, Department o f Pathology, 
Hammersmith Hospital, Imperial College, London.
C 3.2 Fixation of brains
At post mortem examination 2 days following ultrasound guided intraventricular 
injection, the fetal abdomen and chest were opened and a sample o f fetal liver and 
gonad was snap frozen in liquid nitrogen for PCR analysis. The thoracic aorta was
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cannulated with an 18 Gauge intravenous cannula (Becton Dickinson, Franklin Lakes, 
NJ, USA) which was held in place by a 3.0 silk tie and the left atrium opened to allow 
perfusion to occur. The fetal brain was initially perfused with 100ml PBS (pH 7.4) 
followed by 100ml 4% paraformaldehyde buffered with H3PO4 at pH 7.4 for 20 
minutes. The skull bone was removed and the brain, brain stem and upper thoracic 
spinal cord removed in one piece and placed in 1% paraformaldehyde at 4°C with 
rotation for 2 hours. The brain was then placed overnight in 30% sucrose in lOmM PBS 
for cryoprotection, and then snap frozen. The tissue was mounted on a Leica CM 1900 
cryostat (Leica microsystems, Nuslock GMBH, Germany) at -20°C. Approximately 250 
sections were cut alternating at 20pm or 50pm thickness and placed onto gelatinized 
slides (BDH twin frost Super Premium microscope slides 1.0-1.2mm thick, dipped in lg  
gelatin dissolved in 200ml water and left to set overnight) and kept at -80°C.
Frozen sections were hydrated with distilled water and spread on the slide, which was 
then air dried at room temperature for 10 minutes. Sections were fixed in 4% 
formaldehyde in PBS for 5 minutes, rinsed with PBS and then stained accordingly. For 
X-gal staining the slides were placed in X-gal solution overnight in the dark, rinsed with 
PBS and counterstained with neutral red. Haematoxylin & eosin staining for histology 
and p-galactosidase immunohistochemistry was performed as previously described. All 
procedures were performed by Dr Anna David.
C 4. Evaluating the effect of viral vectors on the composition 
fetal fluids
All analyses were performed by Dr Anna David.
C 4.1 Amniotic fluid
The osmolality and electolyte content o f the amniotic and allantoic fluids differ greatly. 
The results from fluid samples taken prior to vector injection were compared to those 
from samples o f allantoic fluid taken at post mortem. This was used to confirm that the 
vector had been correctly delivered into the amniotic cavity.
Amniotic fluid was analysed at postmortem analysis to determine if the adenovirus 
vector had affected the biochemical composition and osmolality. Because amniotic fluid 
was snap frozen immediately after removal at post mortem, it was not possible to 
analyse for an inflammatory response to the vector.
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C 4.1.1 Determination of electrolyte content and osmolality of amniotic 
fluid
An osmometer was used to determine the osmolality or concentration of solution by 
means o f freezing-point measurement (The Advanced™ Micro-Osmometer Model 
3MO, Advanced Instruments, Mass, USA). After calibration with known osmolality 
standards, 20pl o f amniotic fluid was presented to a thermistor probe and was rapidly 
cooled to below its freezing point. A mechanical pulse induced the sample to freeze and 
the heat o f fusion then released caused the sample temperature to rise to the equilibrium 
temperature where ice and water are maintained, which is the freezing point o f the 
solution. The osmometer routinely determined differences of 2 mOsm/kg H2O and each 
sample was tested twice.
C 4.2 Tracheal fluid
C 4.2.1 Inflammatory response to vector injection
Tracheal fluid (500pl,TF) was removed from the fetal trachea into a syringe at post 
mortem using a needle inserted through the tracheal wall once the lungs and trachea 
were exposed by dissection. Broncho-alveolar lavage (BAL) was performed after 
removal of the lungs and trachea from the fetus by flushing 2ml PBS down the trachea 
and recollecting the fluid. Cells and debris in the TF and BAL fluid was pelleted by 
centrifugation at 2000 rpm for 10 minutes and the pellet was resuspended in 500 pi 
0.1% BSA in PBS. Cytospin preparations were prepared by centrifugation o f lOOpl cell 
suspension onto glass slides at 350 rpm for 5 minutes (Cytospin 3, Shandon). The slide 
was air-dried and fixed in methanol for 5 minutes. Following Wright-Giemsa staining, 
cells were identified, differentially counted and the number expressed per high power 
field and compared to results from tracheal fluid taken just before vector injection.
C 4.2.2 Electrolyte changes in response to vector injection
The osmolality and electolyte content o f tracheal fluid taken prior to vector injection 
and at post mortem examination were compared as previously described to assess the 
fetal response to the vector.
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C 4.3 Gastric fluid
C 4.3.1 Inflammatory response to vector injection
Gastric fluid taken before and after vector injection was analysed for an inflammatory 
response to the vector in a similar way to tracheal fluid.
C 4.3.2 Electrolyte changes in response to vector injection
The osmolality and electolyte content of gastric fluid taken prior to vector injection and 
at post mortem examination as described previously were compared to assess the fetal 
response to the vector.
C 5. Evaluating the effect of fetal fluids on adenovirus 
transfection in vitro
All experiments were performed by Dr Anna David.
C 5.1 Effect of fetal tracheal fluid on adenovirus transfection in vitro
Human bronchial epithelial cells (HBEs) were grown from existing cell cultures in the 
laboratory. Dead cells and old culture medium was removed from HBE cells at 70% 
confluence grown in 75 cm2 cell culture flasks. The flasks were washed with 10ml PBS, 
incubated with 3ml 1 x trypsin-EDTA at 37°C for 2 minutes and the flasks gently 
tapped to remove the cells. The cells were washed in 7ml culture medium, D-Mem 
containing 10% FCS and 5% pen/strep and pelleted by centrifugation for 5 minutes at 
100 x g (Centurion 4000 Series). The supernatant was discarded before resuspension in 
10ml new growth medium by gentle pipetting. To determine the number o f cells per ml 
culture medium, the cells were counted using a haemocytometer (Superior, Marienfeld, 
Germany). Four 24-well culture plates were plated with 7 x 104 cells in 1 ml new 
culture medium per well and cultured at 37°C, 5% C 0 2 for 24-48 hours until cells were 
30% confluent. The culture medium was removed from the 24-well plates and replaced 
with 500pl fresh medium.
Adenovirus vector (1011 particles in lOpl, AdlacZ) was incubated with fetal tracheal 
fluid (lOOpl) at various gestational ages for 30 minutes at room temperature. Serial 
dilutions o f the vector in tracheal fluid were then made with PBS to achieve the 
following concentrations: 108, 107, 106, 105, 104 and 103 adenovirus particles in lOpl 
fluid to give a multiplicity o f infection (MOI) o f 10,000, 1,000, 100, 10, 1 and 0.1 
respectively. The serial dilutions o f adenovirus vector were added to the 24-well plates
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in quadruplicate to give one plate for tracheal fluid at each gestational age and a further 
plate for virus that had not been preincubated with tracheal fluid. Plates were incubated 
at 37°C, 5% CO2 for 24 hours and the medium was then refreshed for a further 24 hours. 
After removal o f the medium, the cells were fixed by adding 1 ml o f fix solution to each 
well for 20 minutes and washing three times with PBS. The cells were incubated with X 
gal solution (1ml per well) overnight in the dark and the number o f blue cells per well 
were counted. The experiment was repeated in triplicate using adenovirus 
concentrations at which it was possible to count the number o f blue cells per well.
C 5.2 Effect of fetal gastric fluid on adenovirus transfection in vitro
Using the same method as for fetal tracheal fluid experiments, adenovirus vector was 
incubated with gastric fluid from fetal sheep at three different gestational ages and then 
applied to human bronchial epithelial cells cultured in 24-well culture plates. The 
number of blue cells per well were counted and the experiment repeated in triplicate 
using appropriate adenovirus concentrations.
C 6. Detection and quantitification of p-galactosidase transgene 
expression 
C 6.1 X-gal histochemistry
Tissue samples were placed in 100% ethanol at post-mortem and fixed overnight before 
washing with PBS. Samples were then incubated in X-gal staining solution containing 
40 mM potassium ferrocyanide, 40mM potassium ferricyanide, ImM MgCh in PBS and 
X-gal dissolved in DMSO at 40mg/ml overnight in a rotary shaker protected from the 
light. For the intra-tracheal injection experiments, X-gal staining solution was injected 
down the main bronchioles to ensure distal airways were reached. Samples were washed 
five times in PBS, and stored in 10% formaldehyde. X-gal blue staining was visualised 
by light microscopy. After washing with PBS, tissue samples were fixed in 100% 
methanol prior to clearing with benzyl benzoate: benzylalcohol (2:1). Cleared samples 
were then visualised by light microscopy. Stained tissue was fixed in paraffin blocks 
and 3 pm sections cut. Sections were counterstained with eosin and nuclear localisation 
of the lac Z stain was observed within the airway epithelia. Analysis was done by Dr 
Anna David, Dr Lisa Gregory and Mr Dany Perocheau, Gene Therapy Research Group, 
Imperial College, London.
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C 6.2 X gal ELISA
A commercially available kit (Boehringer Mannheim, Mannheim, Germany) was used 
to quantify the levels o f X gal expression according to manufacturer’s instructions. 
Tissues were cut into 5mm cubes, washed with PBS, freeze thawed in 1ml lysis buffer 
and then homogenized using a Polytron PT 1200 CL homogenizer (Kinematica PG). 
Homogenized tissues containing soluble components o f the cells including the p- 
galactosidase enzyme were centrifuged at 13000xg for 10 minutes to remove cellular 
debris and tested immediately or frozen at -60°C.
The protein concentration in the tissue samples was determined by a colorimetric 
method using the bicinchoninic acid (BCA) protein assay kit. This uses the reduction o f 
Cu2+ to Cu+ by protein in an alkaline medium and the chelation o f two molecules o f 
BCA with Cu+ to form a purple-coloured reaction product (Smith PK et al., 1985). 
Protein standards were prepared using BSA (fraction V) diluted in distilled water to 2,
1, 0.5, 0.25, 0.125 and 0.063 mg/ml protein. The standard or sample (lOpl per well) was 
incubated with BCA reagent (200pl per well) in a 96 well plate at 37°C for 20 minutes. 
The plate was cooled and the absorbance was read on a spectrophotometer (Lucy 1, 
Anthos) at 562nm. Every serial dilution or tissue sample was tested on two wells and 
the final result taken as the average. The absorbance values for the calibration dilutions 
were plotted against the standard concentrations o f BSA to produce a linear calibration 
curve and the protein concentration o f the tissue samples was determined. Tissue 
samples were diluted so that the absorbance of the sample fell within the linear range o f 
the p-galactosidase assay, usually at a protein level of less than lOOOpg/ml.
The p-galactosidase assay consisted of a microtiter plate containing 1 2 x 8  wells 
precoated with a monoclonal mouse antibody to p-galactosidase. The p-galactosidase 
enzyme standard dilutions were prepared to obtain a calibration curve. The sensitivity o f 
the assay is to a level o f 30pg/ml. To each well was added 200pl o f the calibration 
dilutions or tissue extracts containing 200pg protein and the plate was incubated for 1 
hour at 37°C. The plate was washed three times with washing solution and then 
incubated with digoxigenin-labelled antibody to p-galactosidase (200pl per well) for 1 
hour at 37°C. Wells were washed three times with washing solution and then incubated 
with a digoxigenin antibody conjugated with peroxidase (200pl per well) for 1 hour at 
37°C. Wells were washed three times with washing solution and the bound peroxidase 
revealed by incubation with the peroxidase substrate ABTS for 15-40 minutes at room 
temperature yielding a green coloured reaction product. The absorbance of samples was
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measured at 405nm using a spectrophotometer (Lucy 1, Anthos). Every serial dilution 
or sample was tested on two wells and the final result taken as the average. The 
absorbance values for the calibration dilutions were plotted against the standard 
concentrations of p-galactosidase to produce a nearly linear calibration curve and the p- 
galactosidase concentration of tissue samples was determined. Analysis was done by Dr 
Anna David, Dr Lisa Gregory and Mr Dany Perocheau, Gene Therapy Research Group, 
Imperial College, London.
C 6.3 p-galactosidase immunohistochemistry
p-galactosidase was detected immunohistochemically in tissues using a mouse 
monoclonal and a rabbit polyclonal antibody, respectively, followed by a standard 
avidin-biotin peroxidase method (Polak JM and Van Noorden S, 1997). Paraffin 
sections on slides were dewaxed in 3 changes of xylene, and brought to water through 3 
changes of 100% ethanol and one change of 70% ethanol. Endogenous peroxidase from 
red blood cells was blocked by immersion o f slides in 0.3% hydrogen peroxide in water 
for 30 minutes. Slides were washed in water and then subjected to trypsin digestion to 
unmask antigen sites that may have become cross-linked during fixation. A fresh 
solution o f 0.1% trypsin was added to 0.1% calcium chloride in 0.0005M Tris buffered 
saline at 37°C and brought to pH 7.8 with 0.1M sodium hydroxide. Slides were 
immersed for 10 minutes, rinsed in water, placed in PBS and then onto the Sequenza 
(Shandon, UK), a modified rack system in which each well has a low volume (lOOpl) 
for easy processing o f large numbers of slides. Non-specific antibody binding to 
proteins in the tissue preparations was prevented by applying 5% non-immune goat 
serum to each slide for 10 minutes, the serum being from the species which provided 
the second layer antibody. The slide was drained off, avidin applied for 15 minutes, 
rinsed with PBS and biotin applied for 15 minutes followed by a final rinse with PBS. 
For p-galactosidase immunohistochemistry, slides were then incubated overnight at 4°C 
with anti-Pgalactosidase primary antibody raised in mouse diluted to 1/1000 in 1% PBS. 
They were then rinsed for 5 minutes with PBS before application o f biotinylated 
secondary goat anti-mouse antibody at 1/500 dilution in 1% PBS for 30 minutes at room 
temperature. Slides were rinsed for 5 minutes with PBS and peroxidase-labelled 
streptavidin at 1/500 dilution in 1% PBS added for 30 minutes at room temperature. A 
final 5 minute rinse o f 1% PBS was done before the peroxidase was developed by 
immersion o f the slides in 50mg/ml diaminobenzidine tetrahydrochloride in 1% PBS
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and 0.01% hydrogen peroxide for 10 minutes. Slides were counterstained with 
hematoxylin, dehydrated through graded alcohols, cleared in xylene and allowed to dry. 
Positive staining was seen as a dark brown reaction product when viewed with a light 
microscope. A positive control and negative control were used throughout. The positive 
was a section o f fetal liver with strong staining from a previous experiment; the 
negative was a test section which was not exposed to the primary antibody but 
immersed in 1% PBS. Immunohistochemistry analysis was performed at Department of 
Pathology, Hammersmith Hospital, Imperial College under the supervision o f Professor 
Terry Cook.
C 7. Detection and quantitification of human factor IX transgene 
expression 
C 7.1 Determination of human factor IX concentration in plasma 
C 7.1.1 Optimisation of human factor IX ELISA
The ELISA kit for hFIX measurement was designed for use on human plasma and had 
been evaluated for use with late gestation sheep plasma. To check that the assay was 
suitable for testing early gestation sheep plasma we spiked plasma from a non-injected 
fetal sheep with serial dilutions of hFIX. This was analysed, together with a sample o f 
normal human plasma to act as a control and with a serial dilution o f  hFIX in buffer.
The resulting calibration curve showed that the assay was able to detect hFIX in early 
gestation sheep plasma to the same level o f detection as in human plasma.
Expression o f hFIX in fetal plasma following injection in early gestation was much 
lower than expression after late gestation intravascular injection. The lowest accurate 
level of detection of the ELISA kit was not known although the standard calibration 
curve went only to a hFIX level o f 25ng/ml. To test the lowest detection level o f hFIX 
in our experiments we serially diluted early gestation fetal sheep plasma with hFIX to a 
level o f 0.21% of normal hFIX levels (10.5ng/ml). Similarly we analyzed the standard 
calibration series o f hFIX in dilution buffer to this level. Figure C 9 shows that that the 
concentration o f hFIX in the fetal sheep plasma could be accurately determined to this 
level.
Initial optimisation of the hFIX ELISA and analysis o f samples from the first year of 
work was done by Dr Anna David. Further analysis by Dr Megha Nivsarkar, Gene 
Therapy Research Group, Imperial College, London has taken the lower limit of
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detection of the hFIX ELISA to 0.11% (5ng/ml) and this is the lowest limit o f detection 
that was used for analysis of fetal sheep plasma samples in this thesis.
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Figure C 9: Determining the lower limit of detection of hFIX in early gestation 
fetal sheep plasm a by ELISA analysis.
Early gestation fetal sheep plasma was spiked with reducing concentrations o f  hFIX and the absorbance at 
OD 492 nm plotted on a double logarithmic graph.
C 7.1.2 Human factor IX ELISA
Whole blood (4.5ml) was collected into tubes containing 0.109 M trisodium citrate 
(0.5ml). Plasma was obtained after centrifugation at 2500 x g for 10 minutes and kept 
frozen at -30°C until analysis. A calibration series o f six serial dilutions was prepared 
by dissolving a human factor IX antigen standard, t, in dilution buffer from t/16 to 
t/512. The standard, t, corresponded to a concentration o f 105% o f adult human factor 
IX levels or 5 pg/ml, according to the kit manufacturer. Two blanks were also tested, a 
buffer blank containing only dilution buffer and a sheep blank containing a 1+50 
dilution o f fetal serum from a non-experimental animal o f the same gestational age in 
dilution buffer. Serum samples were diluted 1+50 with dilution buffer.
The assay consisted of a plate o f sixteen wells coated with specific rabbit anti-human 
factor IX primary antibody that captures the human factor IX to be measured. Each well 
was incubated for 2 hours at room temperature with 200 pi o f serial dilution, blank or
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sample. Wells were washed five times with washing solution and then incubated with 
200 pi o f rabbit anti-factor IX secondary antibody coupled with peroxidase for a further 
2 hours at room temperature. Wells were washed five times with washing solution again 
and the bound peroxidase enzyme in the wells was revealed as a yellow colour by 
incubation with 200 pi ortho-phenylenediamine in hydrogen peroxide for exactly 3 
minutes at room temperature. The reaction was stopped by adding 200 pi o f 3 M 
sulphuric acid and the absorbance at 492nm was measured ten minutes later on a 
spectrophotometer (Lucy 1, Anthos). Every serial dilution, blank or sample was tested 
on two wells and the final result taken as the average. The absorbance from samples and 
serial dilutions were adjusted for the sheep blank by subtraction and the calibration 
results plotted on log-log graph paper. The calibration curve was drawn and the human 
factor IX levels for samples were derived by reading directly from the curve.
C 7.2 Immunohistochemistry for human factor IX
The method was essentially the same as for p-galactosidase immunohistochemistry but 
used a primary rabbit anti-human factor IX antibody and a secondary swine anti-rabbit 
antibody. The standard avidin-biotin peroxidase method was then followed (Polak JM 
and Van Noorden S, 1997). Non-specific antibody binding to proteins in the tissue 
preparations was prevented by applying 5% non-immune swine serum to each slide for 
10 minutes, the serum being from the species which provided the second layer antibody. 
The positive was a section o f fetal liver with strong staining from a previous 
experiment; the negative was a test section that was not exposed to the primary antibody 
but immersed in rabbit serum at 1/4000 dilution. Immunohistochemistry analysis was 
performed at Department of Pathology, Hammersmith Hospital, Imperial College under 
the supervision o f Professor Terry Cook.
C 8. Assessment of cell division by BrdU 
immunohistochemistry
Tissues for BrdU staining were fixed in carnoys solution (60ml methanol, 30ml 
chloroform and 10ml glacial acetic acid). Immunohistochemistry for BrdU proliferation 
was performed using a similar technique to that for p-galactosidase staining. The slides 
were dewaxed and endogenous peroxide was blocked as above. After rinsing in PBS the 
slides were immersed in 1M HC1 preheated to 60°C for 5 minutes to dissociate the 
histones and partially denature the DNA. After a further rinse in PBS, non-specific
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antibody binding to proteins in the tissue preparations was prevented by applying 20% 
non-immune rabbit serum to each slide for 30 minutes at room temperature. The serum 
was tapped off and the slides then incubated with a 1/50 dilution o f mouse anti-BrdU 1° 
antibody with 5% normal sheep serum overnight at 4°C. Slides were rinsed twice with 
PBS and then incubated with a 1/200 dilution o f rabbit anti-mouse biotinylated 2° 
antibody and 5% normal sheep serum for 45 minutes at room temperature. This was 
followed by a standard avidin-biotin peroxidase method (Polak JM and Van Noorden S, 
1997) and slides were counterstained with hematoxylin, dehydrated through graded 
alcohols, cleared in xylene and allowed to dry. Each tissue had a test negative that was 
not exposed to the primary antibody but immersed in 20% non-immune rabbit serum. 
Immunohistochemistry analysis was performed by Dr Anna David at Department of 
Pathology, Hammersmith Hospital, Imperial College under the supervision o f Professor 
Terry Cook.
C 9. PCR analysis of vector spread in tissues
Preparation o f genomic DNA from tissue samples and PCR analysis for the first half o f 
the work in this thesis was performed by Dr Anna David. Subsequent analysis was done 
by Mr Maznu Miah and Mr Dany Perocheau, Gene Therapy Research Group, Imperial 
College, London. Preparation of genomic DNA from sheep semen samples, and 
optimisation of PCR amplification o f the hFIX transgene and endogenous sheep 
sequences was performed by Dr Anna David.
C 9.1 Preparation of genomic DNA from tissue samples
Tissues were chopped with a sterile blade on a sterile petri dish and ground well with a 
sterile pellet mixer in a 1.5ml Eppendorf tube to which was added 700pl proteinase K 
buffer and 17.5pl of proteinase K (10 mg/ml) solution. After incubation at 55°C 
overnight, RNA was digested by incubation with 5pl o f Rnase (500 pg/ml) at 37°C for 4 
hours. Insoluble material was removed by centrifugation at 4000 x g for 10 minutes at 
room temperature and the supernatant transferred into a new tube. To this was added 
750pl equilibrated phenol at pH 7.9 and the contents were mixed vigorously on a 
vortex. After centrifugation at 14,000 x g for 10 minutes at 4°C, the supernatant 
containing the phenol and genomic DNA was transferred into a new tube. To remove 
any remaining protein and traces o f phenol, 500pl chloroform was added and the 
contents mixed vigorously on a vortex. Another centrifugation at 14,000 x g for 10 
minutes at 4°C was performed and the supernatant transferred to a new tube. To aid
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DNA precipitation, 10% by volume sodium acetate (pH5.0, 3M) was added followed by 
2-3 x volume of cold isopropanol and the DNA was seen to precipitate on inversion.
The DNA was pelleted by centrifugation at 14,000 x g for 10 minutes at 4°C and the 
supernatant carefully removed and discarded. The pellet was washed with 500pl cold 
70% ethanol, centrifuged at 14,000 x g for 10 minutes at 4°C and the supernatant was 
discarded. The DNA was carefully air-dried and resuspended in 200pl TE buffer pH 8.0 
overnight. To determine the correct concentration for PCR analysis, serial dilutions of 
the DNA solution were electrophoresed along with a 1Kb DNA ladder on a 0.3% 
agarose gel (electrophoresis grade) containing ethidium bromide (lOmg/ml) at 50kv for 
1 hour. The gel was visualized under an ultra-violet transilluminator (Uvitec 
STX.20.M). The dilution that was just visible under transillumination was used for 
PCR analysis, equivalent to lOOng DNA.
C 9.2 Preparation of genomic DNA from sheep semen samples
Attempts to extract genomic DNA from lamb semen samples using the standard DNA 
extraction protocol were unsuccessful. Sperm nuclei are impervous to lysis with 
SDS/proteinase K because they are ramified with cross-linked thiol rich proteins 
(Calvin HL and Bedford JM, 1971). A protocol for DNA extraction from human sperm 
was provided by the Home Office Forensic Science Service (Gill P et al., 1985) and 
tested on sheep semen samples as described below.
Fresh sheep semen samples were incubated overnight in a 1.5ml Eppendorf tube at 37°C 
in 0.01 M Tris-HCl, 0.01 M EDTA, 0.1 M NaCl (pH8.0) containing 2% SDS, 20 pg/ml 
proteinase K and 0.039 M DTT. The DNA was purified by two phenol/chloroform 
extractions as described above and precipitated by addition o f 0.1 volume 2M sodium 
acetate and 2.5 volumes of absolute ethanol. The DNA was pelleted by centrifugation at 
15,000g for 5 minutes at 4°C, washed with 70% ethanol, repelleted and resuspended in 
200pl TE buffer pH 8.0 overnight. Samples were diluted and electrophoresed on a 0.3% 
agarose gel (electrophoresis grade) containing ethidium bromide (lOmg/ml) as 
described above and visualized under an ultra-violet transilluminator (Uvitec 
STX.20.M). To confirm the presence o f genomic sheep DNA, samples were amplified 
in a PCR using primers designed to endogenous sheep sequences (TATA box binding 
protein, TBP, see later).
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C 9.3 PCR analysis
Spread o f the adlacZ or adhFIX vector after the different routes o f fetal injection was 
tested by PCR analysis for the presence o f adenovirus p-galactosidase or hFIX cDNA 
respectively in a range of fetal and maternal tissues. The specificity and sensitivity of 
the tissue analysis are both important factors in the polymerase chain reaction and these 
aims were addressed by performing first round followed by nested PCR analysis. The 
first round primers amplify DNA from part of the target gene and the products 
accumulate exponentially. Generally 30 cycles are performed before one of the reaction 
components becomes limiting. To improve the sensitivity a further amplification step is 
required. Nested PCR analysis also allows improvement in the specificity o f the 
reaction by using primers that amplify a shorter part o f the DNA from the target gene, 
within the sequence targeted by the first round primers.
The primers and conditions optimal for PCR analysis o f adlacZ DNA were already 
determined in the laboratory. Primers designed to amplify part o f the hFIX gene and 
endogenous sheep sequences were tested and the conditions for amplification o f DNA 
optimized. In all cases a Biometra T3 Thermocycler was used and the PCR final 
reaction volume was 20pl. Each reaction contained lx  Mg free reaction buffer, 0.5 U 
Taq polymerase, 200 pM dNTPs, 2.5pM forward and reverse primers and MgCl2 at 
different concentration according to the primers used (Table C 4). The PCR cycle was 
94°C for 1 minute, annealing temperature o f Tm -  4oC for 1 minute (Table C 4), 72°C 
for 1 minute for 35 cycles followed by a final extension step o f 72°C for 10 minutes. 
PCR amplified products were subjected to electrophoresis alongside a lOObp DNA 
ladder on a 2% agarose gel containing ethidium bromide (lOmg/ml) at lOOkv for 1 hour. 
The gel was visualized with an ultra-violet transilluminator (Uvitec STX.20.M).
Samples that were negative for first round product were subjected to 20 cycles of nested 
PCR using 2 pi o f first round product applying the above conditions. Nested PCR 
amplified products were also subjected to gel electrophoresis and visualized as above. 
For each PCR amplification of transgene, DNA samples from non-injected fetuses of 
similar gestational ages and a water blank were used as negative controls, and the viral 
vector used as a positive control. PCR amplification o f endogenous sheep sequences 
used the viral vector and water blank as a negative control and DNA samples from non­
injected fetuses of similar gestational ages as a positive control. Each tissue was 
subjected to PCR analysis twice.
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C 9.3.1 PCR amplification of adenovirus P-galactosidase vector
First round primer sequences were designed to amplify DNA sequences from position 
4105-4879 o f the AdRSVpgal virus from a range o f sheep tissues. This region contains 
a part o f the p-galactosidase reporter gene and adenovirus E1B sequences 3’ to this 
region. Nested primer sequences were designed to amplify AdRSVPgal virus DNA 
between positions 4271-4779.
Table C 4: PCR conditions for amplification of the AdRSVpgal vector.
1st round product size 774bp
1st round forward primer GTTCAACATCAGCCGCTACAG
1st round reverse primer TATGTTTACCGCCACACTCGC
Annealing temperature 56°C
MgCl2 concentration in reaction 1.5mM
Nested product size 508bp
Nested forward primer GTCGCTACCATTACCAGTTGG
Nested reverse primer TTATCGATACCGTCGACCTCG
Annealing temperature 60 °C
MgCl2 concentration in reaction 
1----------------------------------------------------------
1.5mM
C 9.3.2 Optimization of PCR amplification of human factor IX 
transgene
The conditions and primers for amplification of hFIX DNA were not known in the 
laboratory and therefore first round and nested primers specific to the human factor IX 
gene were designed and the conditions needed for amplification and their specificity 
were investigated. First round primers and nested primers were designed to amplify 
DNA sequences from position 997-1502, and from position 1047-1444 respectively of 
the human factor IX gene.
The optimal magnesium chloride (MgCl2) concentration in the final reaction mix for 
amplification o f hFIX DNA was determined for the first round reaction by performing 
the same PCR reaction at a range o f MgCl2concentrations from 4.0mM to l.OmM. At 
each MgCl2 concentration there were four PCR reactions which amplified DNA 
extracted from (1) adhFIX vector, (2) the liver o f a fetal sheep that had received an 
intraperitoneal injeciton o f adhFIX, (3) the liver o f a non-injected sheep fetus as a sheep
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blank and (4) distilled water as a second blank. The optimal MgCb concentration was 
found to be 1.5mM (data not shown).
To confirm the same optimal MgCb concentration for nested PCR analysis the same 
four PCR reactions were repeated using the nested hFIX primers at the range of M gCf 
concentrations. Figure C 10 shows the product o f the nested PCR amplification of 
DNA from the liver of a fetus that received an intraperitoneal injection o f adhFIX at the 
range of MgCbconcentrations from 4.0mM to l.OmM. Again the optimal MgCh 
concentration was found to be 1.5mM. Annealing temperatures between 55°C and 70°C 
were also tested to determine the optimal temperature for the first round and nested 
PCR reaction (data not shown).
MgCl2
(mM) 4.0 3.5 3.0 2.5 2.0 1.5 1.0
397bp product
Figure C 10: Optimization of nested PCR analysis of hFIX for magnesium chloride 
(M gCh) concentration in the reaction mix.
DNA was amplified for 30 cycles using 1st round primers designed to amplify the hFIX gene. 5pl o f  the 
1st round product was then amplified for a further 20 cycles using nested hFIX primers at reducing M gCl2 
concentrations in the nested PCR reaction mix from 4.0mM  to 1 .OmM. The gel shows the product o f  
amplification o f  DNA from the liver o f  a fetal sheep that received an intraperitoneal injection o f  adhFIX, 
at reducing concentration o f  MgCF from 1 .OmM to 4.0mM.
To determine the specificity o f the hFIX primers for hFIX DNA they were also tested 
on fetal sheep DNA, and DNA extracted from two cell lines, mouse fibroblast NIH 3T3 
cells and human fibrosarcoma HT 1080 cells, that had been transfected with adlacZ or 
adhFIX vectors, as used to test the specificity o f the endogenous sheep sequence 
primers. The hFIX primers only amplified DNA from cell lines that had been 
transfected with the adhFIX vector (data not shown)
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C 9.3.3 PCR amplification of human factor IX transgene
The final reaction conditions are listed below (Table C5).
Table C 5: PCR conditions for amplification of the hum an FIX transgene.
1st round product size 505 bp
1st round forward primer TGGAAGCAGTATGTTGAT
1st round reverse primer GCATTCTGTGGAGGCTCTAT
Annealing temperature 60°C
MgCh concentration in reaction 1.5mM
Nested product size 397 bp
Nested forward primer TGGCGGC AGTT GC A AGG AT G AC
Nested reverse primer GGAGAAGATGCCAAACCAGGTGA
Annealing temperature 67°C
MgCh concentration in reaction 1.5mM
C 9.3.4 Optimization of PCR amplification of endogenous sheep 
sequences
As a positive control to show the presence o f sheep genomic DNA in DNA extractions 
from tissue samples we obtained primers to endogenous sheep sequences (kindly 
provided by Dr Jill Maddox, University o f Melbourne) and tested them for specificity. 
These primers were designed from cattle sequences and amplified sheep sequences o f 
transcription factor COUP-TF1 (COUPTF1, GenBank ref AJ249440), TATA box 
binding protein (TBP, GenBank ref L47974) and scavenger receptor class B type 1 
(SRB1, GenBank ref AFO19384). Primers were first tested on fetal sheep DNA, and 
DNA extracted from two human cell lines, mouse fibroblast NIH 3T3 cells and human 
fibrosarcoma HT 1080 cells, that had been transfected with adlacZ or adhFIX vectors. 
Figure C 11 shows three gels on which products o f PCR amplification using the three 
sheep primers were run. The COUP-TF1 primer amplified DNA from fetal sheep 
(Figure C 11 C, lane 7) and NIH3T3 cells transfected with adlacZ vector (Figure C 11 
C, lane 2) and both bands were weak. The SRB1 primer amplified DNA from almost 
all samples tested (Figure C 11 B) and therefore was non-specific for sheep DNA.
The TBP primer amplified DNA from fetal sheep only (Figure C 11 A) and did not 
amplify DNA from two cell lines transfected with the adlacZ or adhFIX vector.
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Gel lanes:
1: NIH3T3 cDNA
2: NIH3T3 adlacZ cDNA
3: NIH3T3 adhFIX cDNA
4: HT1080 cDNA
5: HT1080 adlacZ cDNA
6: HT1080 adhFIX cDNA
7: sheep cDNA
8: dFhO blank
127bp product, TBP
156bp product, SRB1
345bp product, COUP-TF1
Figure C 11: Testing the specificity of oligonucleotide prim ers to endogenous sheep 
sequences by PCR analysis.
DNA samples extracted from 2 human cell lines (NIH3T3 cells and HT1080 cells) transfected with 
adlacZ or adhFIX vector were amplified for 30 cycles using primers designed to amplify endogenous 
sheep sequences. The three gels show amplification with primers to (A) TATA box binding protein 
(TBP), (B) 3 ’UT o f  scavenger receptor class B type 1 (SR B1) and (C) 3 ’UT o f  transcription factor 
COUP-TF1 (COUPTF1).
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The TBP primer was therefore the most specific for fetal sheep and it was used in future 
investigations as a positive control for sheep DNA.
C 9.3.5 PCR analysis of endogenous sheep sequences
The final reaction conditions are listed below (Table C 6).
Table C 6: PCR conditions for amplification of the TBP gene.
1st round product size 127 bp
1st round forward primer TCTGTCT ATTCTGG AGG AGC AGC AAC
1st round reverse primer TGCCTGCTGGGACGTCGACT
Annealing temperature 65°C
MgCh concentration in 
reaction
1.5mM
C 10. Determination of fetal and maternal antibody responses 
to transgene and vector
Antibody analyses were performed by Dr Megha Nivsarkar, Gene Therapy Research 
Group, Imperial College, London. Sera were taken from each treated fetus at post­
mortem or after birth o f the treated lambs at six-weekly intervals. Maternal serum 
samples were taken prior to operation as a negative control and at post mortem analysis. 
Because o f the small size of early gestation fetuses no pre-treated fetal serum was 
obtainable and therefore serum from non-treated fetuses at similar gestational ages were 
used for comparison as a sheep blank.
Whole blood (l 0ml) was collected into a serum separation tube, allowed to clot before 
centrifugation at 2500 x g for 10 minutes and the serum was stored at -30°C.
C 10.1 Detection of antibodies to adenovirus by ELISA
A 96 well plate was incubated overnight at 4°C with stock adlacZ vector at lx l0 9 
particles/ml in 200 pi dilution buffer from the human factor IX ELISA kit followed by 
five washes with PBS. A calibration series was prepared by diluting a cross-reactive 
goat anti-adenovirus antibody in dilution buffer and deriving a standard curve (Figure 
C 12). The lower limits of detection of the assay are shown in Table C 7.
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Figure C 12: Example of a standard curve to calibrate the anti-adenovirus 
antibody ELISA.
The lower limit o f  reliable estimation o f  antibody concentration is the point at which the dotted line 
crosses the x axis (A).
Table C 7: The lower limits of detection of the antibody ELISA assays on fetal 
sheep serum.
ELISA antibody 
assay
Lower limit of detection of 
antibodies (ng/ml)
Lower limit o f reliable estimation 
o f antibody concentration (ng/ml)
Anti-adenovirus 40 300
Anti-hFIX 20 200
Anti-|3-galactosidase 70 580
Samples and sheep blanks (serum from non-treated fetuses o f similar gestational ages) 
were diluted 1+50 with dilution buffer and 200 pi incubated in each well at room 
temperature for 4-12 hours. After washing six times with washing solution, a 
horseradish peroxidase labelled rabbit anti-sheep IgG was applied in 200 pi dilution 
buffer and incubated for 4 hours. Wells were washed six times with washing solution 
and the bound peroxidase was allowed to react with 200 pi ortho-phenylenediamine in 
hydrogen peroxide for exactly 3 minutes at room temperature. This produces a 
characteristic yellow colour, the intensity o f which is proportional to the antibody level. 
The reaction was stopped with 200 pi o f 3 M sulphuric acid and the absorbance at
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450nm was measured ten minutes later on a spectrophotometer (Lucy 1, Anthos). Every 
serial dilution, blank or sample was tested on two wells and the final result taken as the 
average. A standard calibration curve was drawn (Figure C 12) and the concentration of 
antibody to adenovirus determined.
C 10.2 Detection of antibodies to human factor IX transgene by 
ELISA
The presence of human factor IX antibodies was detected similarly on 96-well plates 
coated with human factor IX at a standard dilution o f 1 ng/ml. A cross-reactive goat 
anti-human factor IX antibody was used as a positive control to derive the calibration 
series and the lower limits of detection of the assay are shown in Table C 7. The 
concentration o f antibody to human factor IX in serum samples was determined by 
reading the absorbance at 450nm from the standard calibration curve.
C 10.3 Detection of antibodies to p-galactosidase transgene by 
ELISA
The presence o f antibodies to the p-galactosidase transgene were detected similarly on 
96-well plates coated with p-gal protein at a standard dilution o f 0.25 pg/ml. A cross­
reactive sheep anti-p-gal antibody was used as a positive control to derive the 
calibration series. The lower limits o f detection o f the assay are shown in Table C 7.
The concentration of antibody to P-gal in serum samples was determined by reading the 
absorbance at 450nm from the standard calibration curve.
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D Prenatal gene therapy of haemophilia B
For treatment o f Haemophilia B the primary target organ would be the liver and this is 
therefore also a model for many diseases caused by mutations in proteins synthesized in 
the liver. The clotting factor protein that is deficient in haemophilia B however, is 
secreted into and required in the general circulation. Thus any other organ that is able to 
secrete the functional protein efficiently may serve as a producer of therapeutic protein. 
We therefore first investigated intravascular delivery and then moved on to alternative 
routes o f injection.
D 1. Targeting the liver and circulation for treatm ent o f  
haemophilia B 
D 1.1 Adenovirus efficiently transduces early gestation fetal sheep 
liver ex vivo
Previous experiments showed that the adlacZ vector was able to transduce late gestation 
fetal sheep liver with high efficiency after umbilical vein administration (Themis M et 
al., 1999). Before applying our vector to fetal sheep in vivo at earlier gestations, we 
tested whether adenovirus vectors were able to transfer genes to the early gestation fetal 
liver ex vivo. The livers of two non-injected animals (55 and 60 days o f gestation) were 
sectioned at post mortem examination and infected with 1 x 108 particles adlacZ vector 
with or without DEAE dextran complexation (Figure D 1).
blue cells 
on liver 
surface
Figure D 1: p-galactosidase transgene expression in the early gestation fetal sheep 
liver after ex vivo application.
AdlacZ vector complexed with DEAE dextran (5pg/m l) was applied to the liver o f  a fetal sheep aged 55 
days o f  gestation ex vivo. Blue dots are seen all over the surface o f  the liver to which the vector has been 
applied, indicating positive X-gal staining.
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X-gal staining 48 hours after application showed moderate p-galactosidase expression 
was improved as judged by subjective analysis, with DEAE dextran complexation.
D 1.2 Evaluation of the umbilical vein for ultrasound guided injection
Direct intravascular administration to the umbilical vein is the most effective route for 
gene application to the whole fetus with predominant delivery to the liver, which is also 
the natural site o f production o f hFIX (Themis M et al., 1999). Ultrasound-guided 
injection of the umbilical vein (UV) can be performed at three sites, the placental cord 
insertion, the fetal cord insertion as the UV enters the liver, termed intrahepatic UV or 
in the free umbilical cord. Clinically the UV is accessed either at the placental cord 
insertion or intrahepatically because the free cord is too mobile to inject. There were no 
studies on ultrasound examination o f the fetal sheep UV and so before commencing 
experiments to inject the UV we examined it using ultrasound from early to mid­
gestation. Fetal sheep undergoing other injection procedures were examined and ewes 
were also scanned prior to surgery to determine fetal number in order to confirm 
viability and gestational age. The ability to visualise the UV was assessed and its inner- 
to-inner diameter was measured. The intrahepatic UV was seen in all but one o f the 
fetuses examined (n = 67) and was measured in the transverse plane as it passed into the 
anterior third of the liver. We found a virtually linear increase in diameter with age 
between 51 and 105 days of gestation from 1.2mm up to 5.4mm (Figure D 2).
The placental cord insertion was visualised in only 27 out o f 67 fetuses examined and 
was less likely to be seen at the earlier gestational ages (Figure D 3). The difficulty 
visualising the placental cord insertion was due to the placentomes that line the whole 
uterine cavity. These tended to obscure the placental cord insertion, particularly in early 
gestation when the cord is narrow and the blood flow velocity was so low that it was not 
possible to use Doppler examination to visualise flow in the umbilical vessels.
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Figure D 2: The diameter of the intrahepatic UV in the sheep fetus.
The mean diameter is shown ± SD. Refer to Figure D 3 for number per age group.
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Figure D 3: U ltrasound visualisation of the UV at the placental cord insertion in 
the sheep fetus.
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D 1.3 Ultrasound guided injection of the umbilical vein of early 
gestation fetal sheep
We began our experiments in early gestation because we believed that the fetus would 
be large enough to tolerate vector delivery but may not yet have developed immune 
competence. We wanted to determine the earliest gestational age at which we could 
confidently and safely inject the fetal circulation using ultrasound-guidance.
We first studied ultrasound guided injection o f the umbilical vein between 53-54 days 
of gestation (0.37 term), which is equivalent to 14 weeks o f gestation in humans.
The tolerance dose of adenovirus in early gestation fetal sheep was unknown but our 
previous study in late gestation fetal sheep had shown that a dose o f 4.8 x 1011 pfu was 
tolerated at intrahepatic UV injection (Themis M et al., 1999). From measurement o f 
the weight o f late gestation fetuses we therefore calculated the dose per kg tolerated in 
late gestation to be 1-2 x 1011 pfu/kg which is approximately equivalent to 1-2 x 1012 
p/kg. The tolerance dose of early gestation sheep was unknown to us and we anticipated 
fetuses may be more sensitive to adenovirus toxicity in early gestation, so we started 
with a dose of 1 x 1011 p/kg.
D 1.3.1 Ultrasound guided injection of the umbilical vein at 53 days 
gestation results in procedure-related fetal death
We first attempted delivery of the vectors into the umbilical vein (UV, n = 4) at 54 days 
o f gestation by ultrasound guided percutaneous injection applying 1.0 xlO11 -  2.2 x 1013 
p/kg adlacZ or adhFIX vector (Table D 1).
Table D 1: Ultrasound-guided intravascular injection of adenovirus vectors or 
colloidal carbon to early gestation fetal sheep.
GA: gestational age; F: injection at the fetal cord insertion; IH: injection at the intrahepatic UV; P: 
injection at the placental cord insertion.
Sheep
code
Injection
position
GA
(d)
Vector Volume
(Hi)
Dose
(P/kg)
Time of death
(h)
Umbilical vein injection
UV2 IH 54 adlacZ 100 1.0 x 1011 24
UV1 F 54 adhFIX 500 6.6 x lO 12 24
UV4 IH 54 adhFIX 200 2.2 x 1013 20
UV3 P 54 carbon 200 - 24
Intracardiac injection
IC1 - 53 adlacZ 100 2.8 x 101U 20
IC2 - 53 carbon 100 - 24
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The intrahepatic UV measured between 1.4-1.9mm and the UV at the placental cord 
insertion measured between 1-1.3mm in diameter and was very difficult to detect. 
Insertion o f the 22 Gauge needle near or within the UV resulted in vessel narrowing 
probably caused by fluid extravasation compressing it.
Administration of vector to the UV at its insertion into the fetus (n = 1) or within the 
fetal liver parenchyma (n = 2) resulted in death within 24 hrs o f the procedure. Post 
mortem analysis showed extensive intraperitoneal haemorrhage in both fetuses injected 
at the intrahepatic UV probably due to bleeding from the site o f UV injection. There 
was autolysis with bacterial colonisation of the fetal lung and liver on histological 
analysis o f one fetus but not in the other; bacterial culture o f the vector preparation was 
negative.
In clinical practice, fetal blood sampling is more commonly performed in the UV at the 
placental cord insertion rather then the fetal cord insertion or intrahepatic UV 
(Nicolaides and Rodeck, 1987). However the placental cord insertion was difficult to 
visualise at this gestational age because placentomes obscured the view. To determine 
whether fetal death was as a result of virus toxicity or due to the injection procedure, we 
injected colloidal carbon marker dye into the placental cord insertion (n = 1). In this 
fetus o f a twin pregnancy fetal positioning prevented visualisation of the intrahepatic 
UV although the placental cord insertion was clearly visible. Fetal death was again 
observed within 24 hours of the procedure and post mortem findings were similar to 
those observed before, suggesting that the intravascular injection procedure rather than 
adenovirus toxicity was the cause o f death.
We considered using a finer needle such as a 25 Gauge that would cause less trauma, 
and that has been used successfully for fetal blood sampling from the placental cord 
insertion at an equivalent gestational age in humans (Orlandi F et al., 1990). On testing 
the 25 Gauge needle at post mortem examination, we found it to be too pliable for easy 
use and withdrawal o f blood or injection o f fluid was very slow. We concluded that 
injection o f the UV at this gestational age in the fetal sheep was not technically 
possible.
D 1.3.2 Ultrasound guided intracardiac injection at S3 days of 
gestation results in procedure related fetal death
Having failed to achieve umbilical vein injection at 53 days of gestation, we attempted 
intracardiac injection (IC, n = 2) as an alternative route into the circulation at the same 
early gestational age, applying 2.8 x 1010 p/kg adlacZ vector or colloidal carbon (Table
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D 1). Technically this procedure was relatively straightforward compared with 
umbilical vein injection at this gestational age. Fetal bradycardia however, was evident 
immediately after insertion of the needle into the left ventricle. The vector or colloidal 
carbon was injected and following removal of the needle a pericardial effusion was 
clearly seen suggestive of haemorrhage into the pericardial cavity (Figure D 4A and B) 
and fetal death occurred within 24 hours.
Figure D 4: U ltrasound guided intracardiac injection in an early gestation fetal 
sheep.
The ultrasonograms show a fetus (IC1) in longitudinal section at 53 days o f  gestation during intracardiac 
delivery o f  adlacZ vector. (A) shows a 22 Gauge spinal needle entering the left ventricle o f  the fetal heart. 
Following injection fetal bradycardia occurred and (B) a pericardial effusion was visible suggesting 
haemorrhage from the left ventricle into the pericardial sac.
Postmortem analysis of one fetus 24 hours after the operation showed a large pericardial 
blood clot suggesting haemorrhage and tamponade as the cause of death. No evidence 
of bacterial infection was found on culture of fetal tissues. The other fetus sacrificed 48 
hours after operation showed signs of autolysis, and a heavy growth of Bacillus 
licheniformis, a fleece commensal, was found on culture o f the fetal tissues and 
placenta. It is likely this bacterial infection was a postmortem event.
D 1.4 Ultrasound guided injection of the umbilical vein of fetal sheep 
at 60 days of gestation
Our results had so far suggested that the intravascular procedure was the cause of fetal 
death at 53 days o f gestation, probably due to the size disparity between the UV at this 
gestation and the 22 Gauge needle. We therefore investigated whether fetuses that were 
one week older (60 days of gestation) would tolerate the UV injection procedure better.
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This is equivalent to 16 weeks gestation (0.4 gestation) in humans, at an age when a 22 
Gauge needle has been successfully used clinically for fetal blood sampling (Orlandi F 
etal., 1990)
D 1.4.1 The umbilical vein can be injected at 60 days of gestation but 
not always reliably
At 60 days of gestation it was still not possible to see the placental cord insertion 
reliably and the umbilical vein at the fetal cord insertion was fragile. We injected the 
umbilical vein therefore within the hepatic parenchyma (n = 11) and delivered 1.0-1.4 x 
1011 p/kg adlacZ or adhFIX vectors (Table D 2). The mean intrahepatic UV diameter in 
these animals before injection was 2.3 mm. A view o f the fetal abdomen in transverse 
section at the level o f the fetal cord insertion was obtained during injection (Figure D 5 
A) and the needle passed through the fetal liver into the UV (Figure D 5 B). Fetal blood 
(20pl) was withdrawn at each attempt to confirm correct positioning o f the needle 
before the vector was injected.
Table D 2: Post mortem and histological findings following intrahepatic UV 
injection of fetal sheep at 60 days of gestation.
PM: post mortem; h: hours; d: days; m: months; Vol: volume o f  vector injected; Microbubbles: 
visualisation o f  microbubbles during vector injection; IP: intraperitoneal;
Sheep PM
sampling
vector Dose
(P/kg)
Vol
Oil)
Micro­
bubbles
PM findings Liver
histology
UV13 died 24 h adhFIX 1.2x 1011 100 no IP blood clot tissue autolysis
UV9 died 24 h adhFIX 1.17 x
1011
100 no IP blood clot tissue autolysis
UV5 2 d adlacZ 1 x 1011 100 no friable liver infarcts & 
haemorrhage
UV16 2 d adlacZ 1.4x 1011 200 no normal normal
UV6 2 d adhFIX 1.1 x 1011 100 yes normal infarcts & 
haemorrhage
UV10 2 d adhFIX 1.15 x 
1011
100 no IP blood clot infarcts
UV7 9 d adhFIX 1 x 1011 100 no pale mottled area 
distal liver
infarcts
UV8 9 d adhFIX 1 x lO 11 100 yes pale mottled area 
distal liver
infarcts
UV11 29 d adhFIX l x l O 11 100 no normal normal
UV12 78 m adhFIX 1 x 10u 100 yes normal normal
UV15 70 m adhFIX 1 x 1011 100 yes normal normal
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Figure D 5: Ultrasound-guided injection of the intrahepatic UV in an early 
gestation sheep fetus.
A sheep fetus (60 days o f  gestation) is shown in cross-section during UV delivery o f  adhFIX vector. (A) 
22 Gauge spinal needle approaches the fetus from the right side, passes through the hepatic parenchyma 
and (B) the tip can be seen within the UV as it traverses the fetal liver. (C) UV narrowing post op at the 
site o f  injection.
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The presence o f microbubbles in the UV during vector injection was recorded at the 
time of injection and rechecked on the videotape recording. We observed the liver for 
echogenicity surrounding the UV that would suggest injection of the hepatic 
parenchyma rather than intravascular delivery. Such extravascular injection occurred in 
one case (UV9), and attempts to reposition the needle were unsuccessful. This case was 
deemed to be a procedure failure (Figure D 6).
echogenicity 
at the UV 
injection site
fetal spine
fetal rumen
Figure D 6: Failed injection of the intrahepatic UV.
Ultrasonogram o f  a sheep fetus in cross-section at 60 days o f  gestation (U V 9) after attempted umbilical 
vein injection o f  adhFIX vector. There is echogenicity o f  the liver parenchyma surrounding the umbilical 
vein after inadvertant extravascular injection o f  the vector.
Blood was successfully withdrawn prior to vector injection in all fetuses, at the first 
attempt in 7 fetuses, at the second attempt in 4 fetuses and requiring a third attempt in 1 
fetus. The reason for repeated attempts at UV injection was narrowing o f the UV that 
occurred after the majority of injection attempts, successful or unsuccessful (Figure D 5 
C). This obscured the view of the UV and lengthened the procedure time. Excluding the 
procedure failure, the mean UV diameter reduced from 2.3mm to 1.8mm and this 
change was statistically significant (paired Students rtest < 0.002, Table D 3).
The mean time to successful injection was 12 min 58 sec (SD 11 min 23 sec, range 3 
min 43 sec -  41 min 33 sec). Microbubbles were only seen in 4 of the 11 cases (Table 
D 2), on two occasions passing along the UV, through the chambers of the heart and 
down the aorta. Although there was no echogenicity o f the hepatic parenchyma seen in 
the remaining cases, microbubbles were not observed, even with the UV in clear view.
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On this basis therefore, we can only be confident that the vector had been successfully 
delivered into the circulation in 4 of 11 cases (36%).
Table D 3: The change in the intrahepatic UV diameter with ultrasound-guided 
UV injection in fetal sheep aged 60 days of gestation.
There was no data available from UV12 and data from UV9 was excluded because the vector injection 
was extravascular.
Sheep UV diameter (mm) change in UV diameter
before after
UV5 2.5 2.0 -20%
UV6 2.4 2.4 0
UV7 2.3 2.1 -9%
UV8 2.3 1.6 -30%
UV10 2.6 1.6 -38%
UV11 2.3 1.9 -17%
UV13 2.1 1.9 -10%
UV15 2.1 1.4 -33%
UV16 1.9 1.7 -11%
D 1.4.2 Umbilical vein injection at 60 days of gestation has low 
morbidity and mortality
Fetal survival using this technique was 82% (Table D 2). Two fetuses died within 24 
hours o f injection o f adhFIX injection. In both animals, the umbilical vein became 
severely narrowed after an unsuccessful first attempt at injection and fetal bradycardia 
was observed. After allowing recovery of the fetal heart rate, a second injection attempt 
was made. In one fetus the vector appeared to be delivered into the umbilical vein 
(UV13) although no microbubbles were seen in the UV. In the other (UV9) an 
echogenic area appeared within the liver parenchyma suggesting extravascular 
intrahepatic injection. Post mortem analysis of both fetuses the following day showed 
extensive intraperitoneal haemorrhage suggesting this as the cause of death. Culture of 
fetal tissues demonstrated the presence of Aeromonas hydrophila, a common fleece 
commensal in one animal and Escherichia coli, a common gut commensal in the other, 
and these were most probably post mortem infections. Culture o f the adenovirus vector 
showed no evidence of bacterial infection.
Analysis o f four fetuses at post mortem 2 days after operation showed no obvious site of 
injection although there was a small blood clot on the lower left surface o f the liver in 
one animal (UV10). There was an obvious needle track in the liver of two animals
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(UV5 & UV6) with haemorrhage and necrosis surrounding the UV confirming that 
bleeding had occurred from the UV injection site (Figure D7 A).
Figure D 7: Histological analysis of the fetal liver after intrahepatic UV injection of 
adhFIX vector
Light microscopy (H & E stain) 2 days after injection o f  1.1 x 1011 p/kg adhFIX vector at 60 days o f  
gestation shows (A) infarction, haemorrhage and necrosis o f  the central liver and (B) infarction and 
necrosis in the peripheral left lobe o f  the liver o f  one fetus (UV6) 2 days after UV injection. Original 
magnifications are as indicated.
In three cases histological analysis showed small areas o f infarction, particularly 
subcapsular in the left or right lobes of the liver in all fetuses (Figure D 7 B).
Analysis of two fetuses sampled 9 days after injection of adhFIX showed only pale 
areas on the periphery o f the liver at post mortem (Figure D 8 A & B) which were 
confirmed to be subcapsular infarcts on histological analysis (Figure D 8 C & D). We 
postulated that the infarcts could be due to narrowing of the UV following the vector 
injection that temporarily reduced the blood supply to the peripheral liver. We did not 
believe that adenovirus toxicity would have caused the necrosis since injection o f the 
vector into the UV is unlikely to have preferentially entered the peripheral liver.
There were no abnormal findings on analysis of one fetus 29 days after injection of 
adhFIX vector. Two sheep were allowed to survive postnatally and studied for 18 
months. Serum levels of liver enzymes and bile acids were initially raised but then 
returned to within normal limits and the data is presented in Section D 5. Post mortem 
and histological examination of the animals at 18 months of age showed mild chronic 
portal inflammation that was commonly seen in ewes, but no other abnormality.
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Figure D 8: Post mortem and histological analysis of the fetal liver 9 days after 
intrahepatic UV injection of adhFIX vector.
After intrahepatic injection o f  1 x 10n p/kg adhFIX vector there are pale areas on the periphery o f  the 
fetal liver at post mortem analysis (A and B) that were confirmed to be subcapsular infarcts on light 
microscopy (H & E stain, C and D). Original magnifications are as indicated.
D 1.4.3 T ran sgen e exp ression  is ob served  fo llow in g  u m b ilica l vein  
in jection  at 60 days o f  gestation
X-gal staining and immunohistochemistry for expression of p-galactosidase was 
negative in both fetuses sampled 2 days after UV injection, at a time when we would 
expect to see maximum transgene expression (Table D 4).
For hFIX expression, fetal blood was sampled at post mortem examination rather than 
by ultrasound guided injection. At that stage of the project we were not confident of our 
ability to retrieve blood from the UV safely or reliably in mid-gestation and we were 
only able to anaesthetise each animal once. We have now amended the Home Office 
project licence to permit two anaesthetic procedures on one animal, allowing blood to 
be sampled from the fetus once under anaesthesia at a later gestational age. 
Measurement o f hFIX levels 2, 9 and 29 days after injection and at birth were 582 and 
Ong/ml (UV6 and UV10), 199.5 and 145ng/ml (UV 7 and UV8), Ong/ml (UV 11) and 
Ong/ml (UV12 and UV15) respectively (Table D 4 and Figure D 9).
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Table D 4: Transgene expression after ultrasound-guided intraheptatic UV 
injection in early gestation.
Adenovirus vectors (1 -  1.4 x 1011 p/kg) were delivered to fetal sheep at 60 days o f  gestation, h: hours; d: 
days; Microbubbles: microbubbles visualised during vector injection; nt: not tested
Sheep Sampling Vector Micro­
bubbles
X gal or FIX 
expression (ng/ml)
P~gal immuno or FIX 
immuno
UV13 died 24 h adhFIX no nt nt
UV9 died 24 h adhFIX no nt nt
UV5 2 d adlacZ no negative negative
UV16 2 d adlacZ no negative negative
UV6 2 d adhFIX yes 582 positive cells in central 
liver round haemorrhage
UV10 2 d adhFIX no 0 nt
UV7 9 d adhFIX no 199.5 negative
UV8 9 d adhFIX yes 145 positive cells in central & 
left liver, no haemorrhage
UV11 29 d adhFIX no 0 nt
UV12 birth adhFIX yes 0 nt
UV15 birth adhFIX yes 0 nt
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Figure D 9: Expression of hFIX transgene after ultrasound-guided UV injection of 
adhFIX vector.
After injection o f  adhFIX vector (1 -  1.4 x 10u p/kg) into fetal sheep at 60 days o f  gestation, fetal blood 
was sampled at post mortem analysis. The concentration o f  hFIX in fetal or lamb plasma was determined 
by ELISA. The dotted line represents the lowest level o f  detection (5ng/ml) in the assay.
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Immunohistochemistry for hFIX expression was positive in two fetuses, sampled at 2 
and 9 days respectively after intrahepatic UV injection (UV6 and UV8, Figure D 10). 
These fetuses were those in which microbubbles were observed passing along the 
intrahepatic UV and in which fetal plasma hFIX levels o f 582 and 145ng/ml 
respectively, had been found. Therapeutic levels of hFIX (199.5ng/ml) were also 
observed in the plasma of the injected cotwin of one o f these animals (UV7). 
Microbubbles were not observed within the UV at the time of injection and 
immunohistochemistry for hFIX expression was negative. This may be due to sampling 
of the liver in this particular fetus since each liver was divided into three and then 
subdivided into two further samples for PCR or histological/immunohistochemical 
analysis.
►haemorrhage
Figure D 10: Immunohistochemistry for hFIX expression after ultrasound-guided 
intrahepatic UV injection of adhFIX  vectors.
Fetuses were sampled 2 days and 9 days after intrahepatic UV injection o f  adhFIX vector (1 - 1 .1  x 1011 
p/kg) at 60 days o f  gestation. Two days after injection (UV6) there is positive staining o f  hepatocytes 
adjacent to an area o f  haemorrhage in the central portion o f  the liver (A and B) and staining o f  scattered 
hepatocytes around the area o f  haemorrhage (C). N ine days after injection (U V 8) there are scattered 
positively stained hepatocytes in the left lobe o f  the liver (D).
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D 1.4.4 Haematogenic vector spread is observed after umbilical vein 
injection at 60 days of gestation
We investigated the biodistribution of vector in two animals sampled two days after 
intrahepatic UV injection of adlacZ and adhFIX vector respectively. PCR of tissues two 
days after adlacZ injection (UV16) showed no evidence o f vector on the 1st round or 
more sensitive nested PCR analysis in fetal or maternal tissues. PCR of tissues two days 
after adhFIX (UV6), showed the presence o f transgenic hFIX cDNA in the fetal adrenal 
gland and spleen on 1st round analysis. Low level spread was detectable in a wide range 
o f tissues including the placenta, fetal liver, umbilical cord and heart by nested PCR 
analysis (Table D 5).
Table D 5: Vector spread after intrahepatic UV injection.
AdhFIX vector (1.1 x 1011 p/kg) was delivered into the UV o f  a fetal sheep at 60 days o f  gestation (U V6) 
and was detected in fetal and maternal tissues by PCR analysis 48 hours after injection. 1st: 1st round PCR 
analysis; 2nd: nested PCR analysis; nt: not tested, m denotes maternal tissues.
Tissue 1st 2nd
Right lobe - +
Liver m m
Left lobe - +
n tm n tm
Gonad - -
m m
Lung - +
m m
Placenta — +
Umbilical cord - +
Thymus — -
Heart - +
Spleen + +
Small bowel — +
Adrenal + +
Kidney — +
Skin — +
CNS cortex +
We concluded that ultrasound-guided injection o f the umbilical vein at 60 days of 
gestation gave therapeutic levels o f hFIX expression and haematogenic vector spread. 
The injection technique was difficult to reproduce reliably however,and was associated 
with significant morbidity.
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D 1.5 Ultrasound-guided umbilical vein injection is technically easier 
and is reliable at or after 67 days of gestation in the sheep fetus
Because of the technical difficulties in performing umbilical vein injections at 60 days 
o f gestation, we investigated this application route at later gestations to determine the 
earliest gestational age at which umbilical vein injection could be performed reliably. 
We performed experiments from 67 up to 95 days o f gestation (n = 13). We used the 
adlacZ vector (n = 11) and adhFIX vector (n = 1, UV14) and sampled fetal tissues 2 
days after injection (Table D 6). We injected the adlacZ vector rather than the adhFIX 
vector for most of these experiments because we wanted to locate transgene expression 
within the tissues, especially the liver. To define at which gestational age UV injection 
could be performed reliably, we studied fetuses at increasing age from 60 days of 
gestation.
We also performed an intrahepatic UV injection of retrovirus (MLV) containing the 
lacZ gene complexed with DOGS (n = 1, UV24). This fetus was sampled 7 days later 
and the data on the technique and post mortem findings are presented here. Results of 
transgene expression for this fetus are presented in Section H.
We did not perform experiments later than 95 days o f gestation since a previous study 
had already established that ultrasound-guided injection o f the intrahepatic UV was 
possible from 102 days of gestation (Themis M et al., 1999). These experiments had 
shown therapeutic levels o f hFIX expression (221ng/ml) in the fetal blood 24 hours 
after injection and widespread p-galactosidase expression was observed immuno- 
histochemically 3 days after injection.
To confirm intravascular delivery in the earlier gestation injections, colloidal carbon 
was delivered with the vector in two cases. In four cases the adlacZ vector was 
complexed with DEAE dextran (5pg/ml) that we had shown to improve adenovirus 
transfection of fetal liver ex vivo. We were unsure however, o f the effect of 
intravascular DEAE dextran on fetal wellbeing and so it was not used in every 
experiment.
D 1.5.1 Visualisation of the UV at the placental insertion is not 
adequate enough for ultrasound-guided injection at or after 67 days of 
gestation in the sheep fetus
In all cases during initial ultrasound examination of the fetus we examined the UV at 
the placental or fetal cord insertion or during its intrahepatic course. A decision was
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made on the most suitable position to inject the UV on the basis o f visualisation.
Initially we planned to inject the UV at the placental cord insertion since this is the 
route o f choice in clinical practice (Vaughan JI and Rodeck CH, 2001). Cordocentesis at 
the fetal intrahepatic UV is usually used when difficulties arise either with access or due 
to sampling failure at the placental UV insertion. There were however, some problems 
with the placental insertion injection route in the sheep fetus. The placental UV 
insertion was only visualised adequately in 9 out o f 13 cases. To distinguish between 
the two UVs and two UAs in the sheep fetus, the vessels were insonated with Doppler 
(Figure D 11). It is important to identify the UV since fluids injected into the UA would 
be directed first towards the placenta and not towards the fetus. In contrast the normal 
human fetus has only one UV that is easy to identify.
Blood flow in the UV vessels was always detected by Doppler examination from 71 
days of gestation onwards. At earlier gestational ages however, UV blood flow was 
detected in only one of the three fetuses in which the placental insertion was adequately 
visualised. This was most likely due to the low flow rate in the vessels at earlier 
gestations and a more advanced ultrasound machine may have been able to detect such 
flow.
At all gestational ages examined the placental insertion o f the UV ran along the inner 
surface of the uterus making it difficult to determine the optimum injection site. The 
umbilical cord was short so that frequently the fetal abdomen was positioned close to its 
placental insertion and the UV appeared to run within the membranes along the uterine 
wall and over the placentomes. The diameter o f the vessel became narrower the more 
distal it was from the umbilical cord. Postmortem examination o f a placenta at 74 days 
of gestation (Figure D 12) revealed that the umbilical cord approached the uterine wall, 
entered the chorion where the two UAs and UVs divided, one o f each distributed to 
each uterine horn. Within the chorionic mesoderm the UA gave off branches to the 
placentomes, the more proximal branches being the largest and the diameter of the UA 
reduced the further the distance from the umbilical cord.
The fetal cord insertion was examined as another possible site of UV injection. In 
clinical practice this route is rarely used because o f the passive movements o f the fetus 
on the needle and this was also a problem in the sheep fetus. The UV was clearly visible 
in free loops o f cord although detection o f blood flow using Doppler was not usually 
possible. Early gestation injection o f the UV in a free loop o f cord can lead to traumatic 
haemorrhage because of the paucity of Wharton’s jelly, an embryonic connective tissue 
that surrounds and supports the umbilical vessels. In the human fetus, the Wharton’s
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jelly area in the umbilical cord increases with gestational age (Ghezzi F et al., 2001). 
Histologically we noted an increase in the amount of Wharton’s jelly in the fetal sheep 
umbilical cord as gestation advanced.
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Figure D l l :  Doppler measurement of blood flow in the umbilical vein and artery 
of fetal sheep.
Ultrasonograms show (A) the umbilical artery and (B) umbilical vein at the placental cord insertion o f  a 
fetal sheep aged 71 days o f  gestation (UV19). The top part o f  each sonogram shows the vessel being 
imaged with color-flow. A sample volume is placed on the vessel o f  interest and a Doppler sonogram is 
produced in the bottom part o f  each sonogram showing the Doppler frequencies measured. The Doppler 
frequency is a measure o f  velocity in the direction o f  the ultrasound beam from which the color-flow and 
Doppler spectrum displays are produced. In sonogram (A) the waveform is pulsatile indicating this is the 
umbilical artery, whereas in sonogram (B) the waveform is non-pulsatile indicating this is the umbilical 
vein. Both waveforms are inverted indicating blood flow away from the probe.
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Figure D 12: The umbilical cord and placenta in a sheep fetus aged 74 days of 
gestation.
The intrahepatic UV was the most easily visualised in all fetuses. An advantage o f this 
route is that there is no need to insonate the vessel with Doppler to determine its origin. 
This was therefore the injection route of choice in the sheep fetus.
D 1.5.2 Ultrasound-guided injection of the intrahepatic UV is achieved 
at or after 67 days of gestation in the sheep fetus with low morbidity 
and mortality
Injection procedures were straightforward in 10 out of 13 fetuses (Table D 6). The 
intrahepatic UV was injected in 9 cases and the placental UV insertion was injected in 1 
case (Figure D 13). Injection of the UV was achieved at the first attempt in 10 cases 
and at the second attempt in 1 case; microbubbles were visible in all these cases. The 
mean time to successful injection in these cases was 10 min 8 secs (± 7 min 5 secs, 
range 1 min 44 secs -  20 min 7 secs).
In two cases there were multiple attempts to inject the UV at various positions but no 
microbubbles were visualised during vector injection. In the first fetus (UV19), the 
placental UV insertion was clearly visible and blood flow was detected within the UA 
and UV on Doppler examination. A 22 Gauge spinal needle was inserted into the UV in 
two separate attempts but no blood was withdrawn. The intrahepatic UV was obscured
umbilical
cord
umbilical 
artery 
running in 
chorion
umbilical artery
branches o f umbilical 
artery supplying 
placentomes
placentome
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by the fetal spine and an attempt at UV injection failed. A final attempt to access the 
UV in a free loop o f cord successfully withdrew fetal blood but no microbubbles were 
seen during injection of the viral vector. Ultrasound assessment of the fetus 16 hours 
after injection showed no heartbeat. At post mortem examination there was 
haemorrhage at the placental cord insertion, in the free loop o f cord and a small blood 
clot posterior to the liver at the UV insertion. Microbiological culture o f fetal tissues 
was sterile and the cause of death was haemorrhage.
Table D 6: Post mortem and histological findings following UV injection of fetal 
sheep from 67 days of gestation.
* denotes twin fetus; GA: gestational age; d: days; h: hours; IH: injection o f  the intrahepatic UV; cord: 
injection o f  the UV in the umbilical cord; P: injection o f  the placental cord insertion; C: colloidal carbon; 
D: DEAE dextran (5pg/ml); Vol: volume o f  vector injected; Microbubbles: visualisation o f  microbubbles 
during vector injection; IP: intraperitoneal;
Sheep sampling route GA
(d)
Dose
(P/kg)
C D Vol
(pl)
Micro­
bubbles
PM
findings
Histological
findings
UV20 2 d IH 67 4.4 x 1011 + - 300 yes normal normal
UV17 2 d IH 68 8.2 x lO 10 - - 150 yes IP blood clot normal
UV18 2 d P 68 9.7 x lO 10 - - 150 yes normal normal
UV19 died 16 h cord; IH 
+ P x 2 
failed
71 1.5 x lO 11 + 300 no cord + 
placental 
haemorrhage
cord
haemorrhage
UV21* 2 d IH 71 1.7 x 1011 - + 350 yes normal normal
UV22* 2 d IH 71 1.7x 1011 - + 350 yes injection site normal
UV23 2 d IH; 
P x 2 
failed
74 4.3 x lO 10 + 500 no injection site 
blood clot
normal
UV24 7d IH 76 3.2 x 109 - - 4000 yes IP adhesion normal
UV14 2 d IH 83 2.5 x 1010 - - 100 yes normal normal
UV28 2 d IH 87 1.1 x 1011 - + 500 yes normal normal
UV25* died 24 h IH 95 5 x 1012 — —1000 yes injection site autolysed
liver
UV26* 2 d IH 95 2.7 x 1012 — —1000 yes injection site 
blood clot
normal
UV27 2 d IH 95 8.5 x lO 10 — — 500 yes injection site 
blood clot
liver
haemorrhage
In the second fetus (UV23) the intrahepatic UV was accessed and fetal blood was 
withdrawn. We were unsure however, that the needle tip was correctly placed within the 
UV and injection of PBS (lOOpl) went into the hepatic parenchyma. The extravascular
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PBS and resulting narrowing of the intrahepatic UV obscured the view. At the placental 
insertion blood flow was detectable within the UV by Doppler examination. As the 
needle tip was advanced into the vessel, it slipped away and despite attempts at three 
different positions along the vessel, no blood was withdrawn. At a final injection 
attempt into the intrahepatic UV blood was withdrawn but no microbubbles were seen 
during injection of the viral vector.
needle tip 
within UV
Figure D 13: Injection of the UV at the placental cord insertion in a sheep fetus.
In a fetus aged 68 days o f  gestation (U V18) the sonograms show (A ) the tip o f  a 22 Gauge spinal needle 
within the UV and (B) Doppler examination o f  the injected vessel showing non-pulsatile blood flow, 
confirming this is the UV prior to injection o f  the adenovirus vector.
There were 2 fetal deaths (mortality rate 15%), one as previously described. The other 
was of a twin fetus (UV25) in which no heartbeat was detected 24 hours after 
straightforward intrahepatic UV injection and no analysis for transgene expression was 
performed. Its cotwin was alive (UV26) and therefore post mortem examination was
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deferred until 48 hours after injection to allow for maximal transgene expression. There 
was no haemorrhage or injection site visible at post mortem examination and 
microbiological culture of fetal tissues was negative. Because of the delay in post 
mortem examination the liver was autolysed and this prevented useful histological 
analysis. The cause of death was thought to be the inadvertently high dose of vector (5 x 
1012 p/kg) that this fetus received because o f its unexpected small size.
Post mortem examination of the remaining fetuses showed minor abnormal findings 
(Table D 6). The injection site was visible on the fetal liver surface in 5 fetuses (Figure 
D 14 A) and a small intraperitoneal blood clot was seen at the site o f liver injection in 3 
fetuses (Figure D 14 B). Histological examination of the central liver lobe of one fetus 
(UV27) 2 days after injection showed haemorrhage (Figure D 14 C).
injection site on anterior 
surface of fetal liver
blood clot on anterior surface 
o f fetal liver at injection site
Figure D 14: Post mortem and histological findings after intrahepatic UV 
injection.
Two days after receiving intrahepatic UV injection o f  adhFIX vector (8.5 x 1010 -  2.7 x 1012 p/kg), on the 
anterior surface o f  the fetal liver (A) the injection site is visible after injection at 71 days o f  gestation 
(UV22) and (B) a small intraperitoneal blood clot is adherent to the injection site after injection at 95 days 
o f  gestation (UV26). (C) Histological examination (H & E stain) shows haemorrhage in the central liver 
lobe 2 days after intrahepatic UV injection at 95 days o f  gestation (UV27).
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Histology of the remaining fetal tissues 2 days after injection o f adenovirus was normal. 
A small peritoneal adhesion was present in the fetus examined 7 days after intrahepatic 
UV injection of retrovirus vector (UV24).
Post mortem analysis of the fetus that received intrahepatic UV injection o f colloidal 
carbon (UV20) revealed carbon deposits in the liver (Figure D 15 A), peritoneal cavity, 
thoracic duct and inferior vena cava. Histological section showed carbon was present in 
the Kupffer cells of the liver (Figure D 15 B) and in a lymph node adjacent to the 
thymus on histological examination (Figure D 15 C). This demonstrates that there was 
broad haematogenic spread of colloidal carbon following UV injection.
m m
Figure D 15: Systemic spread of colloidal carbon after umbilical vein injection.
Post mortem and histological analysis o f  fetal tissues 2 days after UV injection o f  adhFIX vector (4.4 x 
1011 p/kg) and colloidal carbon in a sheep fetus aged 67 days o f  gestation. Colloidal carbon can be seen 
(A) throughout the fetal liver parenchyma on post mortem analysis, and on histological analysis (H & E 
stain) black deposits o f  colloidal carbon (arrowed) are seen (B) within the Kupffer cells o f  the fetal liver 
and (C) within a thymic lymph node. Original magnifications are as indicated.
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D 1.5.3 Ultrasound guided umbilical vein injection at or after 67 days 
of gestation does not result in significant narrowing
The UV diameter at the site of injection was measured before and after injection (Table 
D 7). The change in the UV diameter ranged from a slight increase (n = 3), no change (n 
= 5) to a reduction (n = 4) and was not statistically significant (one tailed, paired 
students t test, p = 0.09). The different effects of injection on the UV diameter at 60 
days and from 67 days of gestation is probably due to the larger fetal size and the UV 
being less fragile that would reduce the impact o f bleeding and fluid extravasation.
Table D 7: Change in the UV diameter after ultrasound-guided injection in fetal 
sheep from 67 days of gestation.
* denotes twin fetus; GA: gestational age; d: days; IH: injection o f  the intrahepatic UV; cord: injection o f  
the UV in the umbilical cord; P: injection o f  the placental cord insertion.
Sheep GA
(d)
Injection
route
UV diameter (mm) change in UV diameter
before after
UV20 67 IH 2.3 2.4 + 4%
UV17 68 IH 2.6 2.2 -15%
UV18 68 P 2.9 2.5 -14%
UV19 71 cord 2.8 2.7 -4%
UV21* 71 IH 2.0 2.0 0
UV22* 71 IH 2.7 2.7 0
UV23 74 IH 2.7 2.7 0
UV24 76 IH 3.1 3.2 +3%
UV28 87 IH 4.2 4.3 +2%
UV25* 95 IH 4.7 4.7 0
UV26* 95 IH 4.1 4.1 0
UV27 95 IH 5.1 4.1 -20%
D 1.5.4 Transgene expression after umbilical vein injection of 
adenovirus vectors at or after 67 days of gestation
Fetal and maternal tissues were tested for expression o f the lacZ transgene 48 hours 
after UV injection of adlacZ vector. Very little positive staining was detectable (Table 
D 8), particularly at earlier gestations. Two preparations o f adlacZ vector were used in 
these experiments. The first preparation (UV17-UV22) was simultaneously used in fetal 
sheep gastric injection experiments in which strong lacZ transgene expression was 
detectable. In two cases (UV 17 and UV 18), a diluted aliquot o f the vector was made to 
reach the correct concentration for injection. Following UV injection, titration of this 
diluted aliquot by OD260nm, was found to be negative, although the OD260nm of the
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undiluted vector preparation following manufacture had measured 1 x 1013 p/ml. These 
fetuses received a slightly lower vector dose (8.2 -9 .7  x 1010p/kg) than we had planned 
(1 x 1011 p/kg) because their weight was greater than we had estimated by ultrasound 
biometric examination, although the difference is small. Two further fetuses received 
this vector (UV21 and UV22) but a fresh dilution o f the original vector preparation was 
used. In all four fetuses, no transgene expression was detectable and we were concerned 
that the vector preparation might be degrading with age.
A second fresh adlacZ vector preparation o f lower titre (2 x 1011 p/ml) was used for 
experiment UV23 (4.3 x 1010 p/kg complexed with DEAE dextran 5|ig/ml)) because of 
concerns with the first preparation but no transgene expression was detectable. It 
became apparent from simultaneous adult mouse experiments that this fresh preparation 
was not functional in vivo despite showing activity in vitro. Subsequent testing o f the 
first adlacZ vector preparation showed it still to have good activity in vitro and in in 
vivo adult mouse experiments, and it was used therefore for experiments UV25 - UV28.
Table D 8: Transgene expression 2 days after ultrasound-guided UV injection of 
adenovirus vectors.
* denotes twin fetus; GA: gestational age; d: days; good: vector shown to be active in vivo in adult mice 
or fetal sheep gut; poor, vector inactive in vivo or in experimental aliquot; C: colloidal carbon; D: DEAE  
dextran (5pg/ml); + to (+) indicates degree o f  transduction observed after X  gal staining or (3- 
galactosidase immunohistochemistry. (+) indicates single positive cells or sparse staining; -  indicates no 
staining; nt: not tested
Sheep sampling GA
(d)
Dose
(p/kg)
Vector
quality
C D X gal or hFIX expression (3-gal
immuno
UV20 2 d 67 4.4 x 1011 good + - (+) UV in cord -
UV17 2 d 68 8.2 x 1010 poor - - - -
UV18 2 d 68 9.7 x 1010 poor - - - -
UV21* 2 d 71 1.7 x 1011 good - + - -
UV22* 2 d 71 1.7 x 1011 good - + - -
UV23 2 d 74 4.3 x 1010 poor - + - -
UV14 2 d 83 2.5 x 1010 good - - 0% hFIX nt
UV28 2 d 87 1.1 x 1011 good - + - -
UV26* 2 d 95 2.7 x 1012 good — —+ small bowel, duodenum & 
caecum
(+) right 
liver
UV27 2 d 95 8.5 x 1010 good — — + bladder, surface o f gonad, 
thymus, adrenal, brain
—
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Injection of the intrahepatic UV at 67 days of gestation with adlacZ (UV20, 4.4 x 1011 
p/kg) following sodium caprate pretreatment, resulted in positive p-galactosidase 
expression limited to the UV in the cord (Figure D 16 A) despite post mortem and 
histological evidence of widespread distribution o f colloidal carbon via this injection 
route. Immunohistochemical analysis for p-galactosidase expression in the UV was 
negative; this could have been due to the effect o f different sampling sites for X gal 
staining and P-galactosidase immunohistochemistry tissue analysis. The vector quality 
was good since it was the same batch as that used in gastric injection experiments. 
Biologically active vector was also used in experiments UV21, UV22 and UV28 (1.1 -  
1.7 x 1011 p/kg), in which the vector was complexed with DEAE dextran (5pg/ml) but 
there was no transgene expression detectable.
Figure D 16: p-galactosidase transgene expression 2 days after umbilical vein 
injection of adlacZ vector.
After injection o f  adlacZ vector (4.4 x 10" and 2.7 x 1012 p/kg) there is (A) positive X gal staining 
(arrowed) o f  the umbilical vein within the umbilical cord o f  a fetus aged 67 days o f  gestation (UV20). (B) 
Scanty positive expression (arrowed) is seen in the hepatocytes on P-galactosidase immunohistochemical 
analysis o f  the right lobe o f  the liver o f  a fetus aged 95 days o f  gestation (U V26).
The two fetuses injected at the latest gestational age (95 days) showed low level p- 
galactosidase expression. In one fetus (UV26, 2.7 x 1012 p/kg) immunohistochemical 
analysis of the right lobe of the liver showed occasional positive P-galactosidase 
expression in cells (Figure D 16 B). There were occasional positively stained villi in the 
fetal small bowel following X-gal staining which was not confirmed on P-galactosidase 
immunohistochemistry (data not shown). Positively X-gal stained cells were also 
detected within the bladder, thymus, brain, adrenal and on the surface of the fetal gonad
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(UV27, 8.5 x 1010 p/kg, Figure D 17) although immunohistochemical analysis of these 
tissues was negative.
In conclusion we observed variable and only low level transgene expression after 
umbilical vein injection of adlacZ vectors. The experiments were complicated by the 
difficulties we experienced with the vector efficacy. It is o f note that X gal staining was 
seen in the two fetuses that received the highest adlacZ vector doses, one o f which also 
received sodium caprate pretreatment.
Figure D 17: X gal staining of fetal tissues after injection of adlacZ vector into the 
umbilical vein.
After UV injection o f  adlacZ vector (8.5 x 1010 p/kg) o f  a fetal sheep aged 95 days o f  gestation (UV27) 
there is scanty positive staining in the fetal adrenal (A), bladder lumen (B), thymus (C) and the serosal 
surface o f  the gonad (D). Original magnifications are as shown.
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D 2 Other routes of vector administration in early gestation: 
intrahepatic injection
Our limited success in delivering adenovirus vectors directly to the fetal circulation of 
early gestation sheep fetuses prompted us to explore alternative routes o f vector 
administration. Hepatocytes have been successfully targeted in fetal mice by direct 
intrahepatic injection (Lipshutz GS et al., 1999b,Lipshutz GS et al., 1999a) and some 
spread to other organs and tissues was observed.
D 2.1 Ultrasound guided intrahepatic injection in the early gestation 
sheep fetus is a straightforward procedure with low morbidity and 
mortality
We began to investigate this route o f application by injecting colloidal carbon marker 
dye (200pl) into the fetal liver at 54 days of gestation (n = 1, Table D 9) to test the 
procedure related morbidity and mortality and to look for evidence o f systemic spread 
from this injection route. A small peritoneal haemorrhage was seen at post mortem 
analysis and light microscopy showed local carbon deposits but no liver damage was 
observed. There was no spread of carbon to other organs suggesting that direct delivery 
into the liver at this gestational age did not achieve systemic spread.
A low and a high dose (HEl, 2.9 -  8.6 x 1010 p/kg and HEh, 1.8- 3.2 x 1013 p/kg, Table 
D 9) of adenovirus vector were then used in this set o f experiments on fetuses (n = 11) 
at 52-57 days o f gestation to test whether gene transfer could be achieved. The mean 
time for injection was 7 min 34 sec (± SD 2 min 24 sec, range 4 min to 12 min) and all 
injections were successful at the first attempt. We observed echogenicity o f the hepatic 
parenchyma confirming correct injection placement (Figure D 18).
Fetal survival was 81%. Two fetal deaths were in twin fetuses injected with low dose 
adhFIX vector that aborted 48 hours after injection. This was most likely due to a 
procedure related extensive bacterial infection that was detected by histological analysis 
of fetal and placental tissues and confirmed as Escherichia coli by culture.
Post mortem examination of fetuses 2 days after HEl adenovirus vector injection was 
normal (Table D 9). Injection o f HEl adlacZ (n = 2) resulted in central necrosis at the 
site o f vector administration observed by light microscopy o f the fetal liver in one fetus 
(Figure D 19 A).
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22 Gauge spinal 
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liver under the 
diaphragm
tomach
Figure D 18: Ultrasound guided intrahepatic injection.
The ultrasonogram shows intrahepatic injection o f  adhFIX to a sheep fetus at 53 days o f  gestation. The 
fetus is in longitudinal section and the needle passes up into the liver parenchyma on the right side o f  the 
fetal abdomen under the diaphragm.
Table D 9: Post mortem and histological findings after ultrasound-guided 
intrahepatic injection of adenovirus vectors or colloidal carbon to early gestation 
sheep.
d: days; h: hours; m: months; Vol: volume o f  vector, *: twin fetuses; PM: postmortem; IP: intraperitoneal.
Sheep sampling GA
(d)
Vector Vol
(pi)
Dose
(P/kg)
PM
findings
Histological
findings
HE 12 2d 54 carbon 200 - IP clot normal
Low dose vector (HEl)
HEl 1 2d 52 adlacZ 100 3.5 x 101U normal liver necrosis
HE8 2d 53 adlacZ 100 7.0 x 101U normal normal
HE6* died 24 h 54 adhFIX 50 5.7 x 101U aborted bacteria
HE7* died 24 h 54 adhFIX 100 2.9 x 101U aborted bacteria
HE9* 2d 53 adhFIX 100 8.6 x 10IU normal normal
HE10* 2d 53 adhFIX 100 8.0 x 101U normal normal
High dose vector (HEh)
HE2 2d 54 adlacZ 200 1.8 x lO 13 liver
bruising
liver haemorrhage 
+ necrosis
HE3 2d 52 adhFIX 200 3.2 x 1013 liver
bruising
normal
HE4 9d 57 adhFIX 200 2.0 x 1013 normal normal
HE5 40 m 57 adhFIX 200 2.0 x lO 13 normal mild portal chronic 
inflammation
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We had observed that an adenovirus dose o f 1013 p/kg was tolerated when injected into 
the fetal muscle and therefore next applied this high dose to the fetal liver (n = 4). To 
achieve delivery of a higher dose of adenovirus vector, we increased the volume 
injected from 100 to 200 pi but we did not observe any associated complications. At 
post mortem analysis there was bruising of the anterior abdominal wall and liver in two 
animals sampled 2 days after injection but no evidence o f the injection site was 
detectable in the animal sampled 9 days after injection. Histological analysis o f the 
central liver showed necrosis around an area of haemorrhage at the site o f vector 
administration in one animal (Figure 19 B, HE2). Neither macroscopy nor histology of 
the two fetuses injected with high dose adhFIX vector showed evidence of hepatic 
trauma, necrosis or inflammation when analysed 2 days and 9 days after injection 
although this was possibly due to not sampling exactly at the site o f injection.
injection sftg'7 ^  ..
Figure D 19: Histological analysis of the liver after intrahepatic adlacZ vector 
injection.
Two days after ultrasound-guided intrahepatic delivery o f  adlacZ vector to two fetal sheep at 52 days o f  
gestation, light microscopy (H & E stain) shows necrosis around an area o f  haemorrhage at the site o f  
vector administration. The dose o f  vector delivered was (A ) low (3.5 x 1010p/kg, H El 1) and (B) high (1.8  
x 1013 p/kg, HE2). Original magnifications are as indicated.
Post mortem and histological examination o f the animal that came to birth following 
early gestation intrahepatic injection of adhFIX (HE5) was performed at 40 months of 
age. This showed mild chronic portal inflammation that was a common finding in the 
liver of many o f the ewes.
To conclude, intrahepatic injection was technically much easier than intravascular 
injection because o f the larger target, and it had a low mortality rate. Adenovirus is 
known to be hepatotoxic and therefore the morbidity we observed could have been 
related to delivery o f the adenovirus vector itself rather than the injection technique.
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D 2.2 Intrahepatic delivery of adenovirus vectors in early gestation 
fetal sheep does not result in good transgene expression
Transgene expression was only detectable in one fetus receiving the low dose of 
adenovirus vector (Table D 10) where immunohistochemical analysis for p- 
galactosidase 2 days after adlacZ vector injection showed positively stained hepatocytes 
around an area of necrosis (Figure D 21 A). X gal staining was negative and there was 
no detectable transgene expression in the remaining fetal tissues.
Table D 10: Transgene expression after ultrasound-guided intrahepatic injection 
of adenovirus vectors in early gestation fetal sheep.
* denotes twin fetus; GA: gestational age; d: days; ++ to (+) indicates degree o f  transduction observed 
after X gal staining or (3-galactosidase immunohistochemistry. (+) indicates single positive cells or sparse 
staining; -  indicates no staining; nt: not tested
Sheep Vector Sampling
(d)
Dose
(p/kg)
X gal staining or 
hFIX plasma level
p-gal or hFIX 
immuno­
histochemistry
Low dose vector (HEl)
HEl 1 adlacZ 2 3.5 x 101U - ++ central liver
HE8 adlacZ 2 7.0 x 1010 - —
HE9* adhFIX 2 8.6 x 101U 0% nt
HE 10* adhFIX 2 8.0 x 101U 0% nt
High dose vector (HEh)
HE2 adlacZ 2 1.8 x lO 13 - (+)
HE3 adhFIX 2 3.2 x lO 13 30 ng/ml (0.6%) —
HE4 adhFIX 9 2.0 x 1013 0% nt
HE5 adhFIX birth 2.0 x lO 13 7 ng/ml (0.14 %) nt
D 2.3 Increasing the dose of adenovirus vector does not improve 
transgene expression following intrahepatic injection.
We increased the dose o f adenovirus vector delivered in an attempt to increase 
transgene expression (Table D 10). The animal sampled 2 days after injection o f high 
dose adhFIX showed only low levels o f hFIX at 30ng/ml (0.6%) and no hFIX was 
detectable in the animal sampled 9 days after injection (Figure D 20). The lamb bom 
after in utero therapy expressed very low levels of hFIX at the limit o f reliable detection 
of the assay (7ng/ml, (0.14%) at birth, 6.5ng/ml (0.13%) at 8 weeks and 12ng/ml 
(0.24%) at 16 weeks postnatal. No hFIX was found by 6 months o f age (Figure D 20).
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Figure D 20: Expression of hFIX transgene after ultrasound guided delivery of 
adhFIX vector to early gestation fetal sheep.
Sheep fetuses aged 33-60 days o f  gestation were delivered adhFIX vector via intrahepatic (1.8 -  3.2 x 
1013 p/kg), intraperitoneal (8.2 x 1011 -  5.3 x 1012 p/kg), intramuscular (6.8 x 1011 -  3 x 1013 p/kg) or 
intra-amniotic (1 -  4.5 x 1013 p/kg) injection. Concentrations o f  human factor IX in fetal or lamb plasma 
were determined by ELISA analysis. Fetal samples were collected at postmortem. The dotted line 
represents the limit o f  reliable detection by the assay (5 ng/ml).
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A single p-galactosidase expressing hepatocyte was detected surrounding an area of 
necrosis on immunohistochemical analysis 2 days after high dose adlacZ injection 
(Figure D 21 B) although X gal staining was negative.
In conclusion we found very low levels o f gene transfer after intrahepatic injection of 
low or high dose adenovirus vectors suggesting this route o f injection cannot be used as 
an alternative to intravascular delivery to achieve systemic gene transfer in early 
gestation fetal sheep.
Figure D 21: p-galactosidase transgene expression after ultrasound-guided 
intrahepatic injection.
Two days after ultrasound guided intrahepatic delivery o f  adlacZ vector to two fetal sheep at 52 days o f  
gestation, p-galactosidase immunohistochemical analysis shows (A) a few  P-galactosidase expressing 
hepatocytes following low dose adlacZ injection (3.5 x 1010p/kg, HEl 1) and (B) a single p-galactosidase 
expressing hepatocyte after high dose adlacZ injection (1.8 x 1013 p/kg, HE2) surrounding an area o f  
central necrosis. Original magnifications are as indicated.
D 2.4 Intrahepatic injection of adenovirus vectors did not achieve 
significant vector spread to other fetal tissues
To test if the injury to the liver parenchyma would have inhibited or promoted the 
escape of vector into the general circulation via the hepatic sinus we studied its 
biodistribution in two animals by sensitive PCR analysis o f various fetal tissues. We 
investigated the presence o f adlacZ vector in the fetus that had received high dose 
vector (HE2) and in which a single positive P-galactosidase expressing hepatocyte was 
observed. AdlacZ vector was not detected in any fetal or maternal tissues investigated 2 
days after injection (Table D l l ,  gel electrophoresis not shown).
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Table D l l :  Vector spread after delivery of adenovirus vectors to fetal sheep in 
early gestation.
Transgenic hFIX (Table A) or adenovirus lacZ vector (adlacZ, Table B) was detected in fetal and 
maternal tissues (n = 7) by PCR analysis after intrahepatic (HE), intraperitoneal (IP) or intramuscular 
(IM) injection o f  7 fetal sheep sacrificed 48 hours after injection. Tissues that tested positive on 1st round 
PCR analysis (1st) were not generally subjected to nested PCR analysis (2nd). n: not available; m denotes 
maternal tissues; * indicates tissue from experiment IM1.
A: hFIX HE (HE3) IP (IP9) IM (IM 1* or IM2)
Tissue 1st 2nd 1st 2nd 1st 2nd
Liver + + + +
+ m m +m +m
Gonad — - + - -
m m - +m m* m *
Lung - - + +
m m +m m m
Placenta - - - + — +
Umbilical cord - - + n
Thymus - - + +
Heart + + + +
Spleen - - + +
Small bowel - - + n
Adrenal - - + +*
Kidney - - + — —
Skin n + +
Muscle n n +
CNS cortex - - - - -* *
B: adlacZ HE (HE2) IP (IP3) IM  (IM 5)
Tissue 1st 2nd 1st 2nd 1st 2nd
Liver - - + +
m m m +m — m
Gonad - - - + — +
m m — + m m _m
Lung - - + + — +
m m m m m m
Placenta - - - + - +
Umbilical cord - — + + n
Thymus - - n — +
Heart - - - + — +
Spleen - - n + +
Small bowel - - + + n
Adrenal - - - - — +
Kidney - - — + — +
Skin n — + + +
Muscle n n + +
CNS cortex - - - + - -
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It is possible that the liver tissue used in the PCR analysis was not taken from the 
injection site since each tissue was split into three sections at post mortem for X gal 
staining, immunohistochemistry and PCR analysis. We therefore investigated spread of 
the adhFIX vector in the animal that showed low level expression o f hFIX 2 days after 
injection o f high dose adhFIX (HE3). The hFIX transgene was detected in the fetal liver 
and heart, and in the maternal liver by 1st round PCR analysis. Nested PCR analysis 
revealed no further spread to any other fetal or maternal organs (Table D 11, gel 
electrophoresis not shown). The finding of vector in the maternal liver was surprising in 
view of the lack of vector spread to the majority o f fetal tissues. It indicates that 
haematogenic spread occurred, perhaps at the time o f injection via the placentome or 
uterus, although lacZ expression was not detected in any maternal tissues including the 
liver, heart, lung or gonad. We concluded that the high adenovirus dose of 1013 p/kg 
injected into the hepatic parenchyma might have caused the hepatic necrosis observed in 
one fetus and did not result in significant vector spread to other fetal tissues.
D 3 Other routes of vector administration in early gestation: 
intraperitoneal injection
Intraperitoneal injection has been used successfully as an indirect route to the 
circulation and the liver for the delivery o f fetal haematopoietic cells (Touraine, 1999) 
and for transduction of hematopoietic precursor cells (Porada CD et al., 1998). Gene 
therapy studies have shown that this route gives access to the liver in fetal mice 
(Hatzoglou M et al., 1995,Lipshutz GS et al., 1999b) and fetal sheep (Tran ND et al., 
2000), probably via the lymphatic system. We therefore tested this route in the fetal 
sheep as an alternative to intravascular delivery in early gestation.
D 3.1 Ultrasound guided intraperitoneal injection is a straightforward 
procedure in the early gestation sheep fetus
We first applied colloidal carbon marker dye (200pl) to the peritoneal cavity o f a fetal 
sheep at 52 days o f gestation to test the technical aspects o f the procedure (Table D12). 
Light microscopy 2 days after injection showed a small blood clot in the peritoneal 
cavity and widespread carbon deposits in the glomeruli o f the kidney, the liver sinusoids 
and spleen (Figure D 22).
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Figure D 22: W idespread deposition of carbon after ultrasound-guided 
intraperitoneal injection of colloidal carbon in early gestation.
Light microscopy (H & E stain) o f  a fetal sheep 2 days after intraperitoneal injection at 52 days o f  
gestation shows carbon deposits in (A) the glomeruli o f  the fetal kidney, (B) the liver sinusoids and (C) 
the spleen. Original magnification was x 40 in all cases.
We then applied both lacZ and hFIX encoding adenoviruses at doses between 4.8 x 1011 
and 1.1 x 1013 p/kg into the peritoneal cavity o f sheep fetuses (n = 15) at 40-56 days o f 
gestation (Table D 12, Figure D23).
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Figure D 23: Ultrasonogram showing intraperitoneal delivery of adhFIX to an 
early gestation sheep fetus.
The fetus (53 days o f  gestation) is in longitudinal section, with the 22 Gauge needle entering the 
peritoneal cavity just superior to the fetal bladder.
Three fetuses in this series of experiments were found to be unexpectedly 2 weeks 
younger in their gestational age at operation due to an error in tupping dates (40 days 
instead of 54 days o f gestation). Fetal injection was still performed, although in one 
fetus, review of the videotape recording after the intervention showed the needle
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passing beyond the fetal peritoneal cavity and the vector was actually delivered into the 
amniotic cavity. Results from this fetus (IP1) and its twin that received a poor stock of 
adhFIX vector (IP2) are not reported further. After these initial difficulties, the 
technique was as simple to perform as intrahepatic injection and the procedure was 
successful at the first attempt. The needle position could be confirmed by the 
observation of microbubbles in the injected fluid moving within the peritoneal cavity. In 
one case the procedure took over 20 minutes due to difficult fetal lie and inexperience 
of the operator. Excluding this case, the mean time to successful injection was 3 min (±
1 min 39 sec, range 45 sec to 5 min 9 sec).
D 3.2 Ultrasound guided intraperitoneal injection has a low 
morbidity and mortality in the early gestation sheep fetus
Fetal survival was 80% (Table D 12). In two of the three fetuses that died 24 hours after 
injection (IP11 + IP14), post mortem analysis showed severe bleeding into the 
abdominal cavity and histological evidence o f placental inflammation and bacterial 
colonization. Neither culture of the vector nor o f the fetal tissues showed any infectious 
agent. We concluded that these fetal losses were a result o f the procedure itself rather 
than vector related. The other fetal death (IP 16) was most likely due to bacterial 
infection introduced at the time o f injection, since there was no evidence of 
haemorrhage on post mortem or histological analysis and the culture of fetal tissues 
confirmed Bacillus licheniformis, a common fleece commensal.
O f those fetuses surviving the procedure, four (27%) showed evidence o f peritoneal 
inflammation at post mortem or histological analysis. At two days after injection, one 
fetus (IP9) had focal fibrosis over the small bowel with moderate chronic inflammation 
that may have been associated with an intraperitoneal bleed. In one fetus analysed 29 
days after injection (IP7) there were dense peritoneal adhesions at post mortem 
examination and fibrosis over the surface o f the bowel, testes and heart on light 
microscopy. In its cotwin (IP6), the small bowel serosa was oedematous.
One o f two sheep bom after intraperitoneal injection o f adhFIX had a marked 
kyphoscoliosis. Clinical examination and X-ray o f the skeleton did not reveal any other 
abnormalities. By 6 months o f age however, it was noted that the lamb had bilateral 
undescended testes. Kyphoscoliosis and undescended testis are both relatively common 
unrelated abnormalities in lambs. The rate o f cryptorchidism is around 1% with a 
possible autosomal recessive basis (Jubb KVF et al., 1993) and kyphoscoliosis occurs in
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approximately 0.5% of lambs (Dennis SM, 1993). It is possible that inflammation in the 
peritoneal cavity following intraperitoneal injection o f adhFIX vector may have 
prevented the normal movement of the testis into the scrotal sac in late gestation, 
resulting in undescended testis. All other lambs have been normal.
Table D 12: Post mortem and histological findings following ultrasound-guided 
intraperitoneal injection of adenovirus vectors or colloidal carbon to early 
gestation sheep.
d: days; h: hours; m: months; Vol: volume o f  vector injected; *: twin fetuses; PM: postmortem; IP: 
intraperitoneal;
sheep sampling GA
(d)
Vector Vol
w
Dose
(p/kg)
PM findings Histological
findings
IP18 2d 52 carbon 200 — IP clot carbon
deposits
IP10 2d 40 adlacZ 100 1.1 x 10lj normal normal
IP3* 2d 52 adlacZ 500 1.5 x lO 12 bruised abdominal 
wall
normal
IP4* 2d 52 adlacZ 500 1.5 x lO 12 bruised abdominal 
wall
normal
IP11 died 24 h 55 adhFIX 100 1.5 x 1012 IP haemorrhage cocci in fetal 
tissues + 
placenta
IP14 died 24 h 54 adhFIX 100 2.7 x lO 12 IP haemorrhage bacterial 
colonization 
o f tissues
IP16 died 24 h 53 adhFIX 100 4.8 x 1011 normal bacilli in fetal 
tissues
IP9 2d 56 adhFIX 100 1.6 x 1012 IP clot focal fibrosis 
small bowel
IP17 2d 53 adhFIX 100 1.8 x 1012 normal normal
IP15 2d 53 adhFIX 100 8.2 x 1011 normal normal
IP12* 9d 55 adhFIX 100 1.0 x 1012 normal normal
IP13* 9d 55 adhFIX 100 1.0 x 1012 normal normal
IP6* 29d 54 adhFIX 100 l.O x 1012 normal oedematous 
small bowel 
serosa
IP7* 29d 54 adhFIX 100 1.0 x 1012 dense IP adhesions mild fibrosis 
over heart, 
bowel + heart
IP5 33 m 54 adhFIX 250 5.3 x 1012 dense peritoneal + 
moderate pleural 
adhesions
portal tract 
inflammation 
+ lung fibrosis
IP8 33 m 54 adhFIX 100 l.Ox 1012 mild perihepatic + 
pleural adhesions
liver fibrosis
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The two sheep that received intraperitoneal injection o f adhFIX were examined at post 
mortem nearly 3 years after birth. In one animal (IP5), dense peritoneal adhesions 
involving the omentum, bowel and liver made it difficult to identify the abdominal 
contents; in addition there were moderate pleural adhesions. Histological analysis 
showed mild chronic inflammation in the portal tract o f the liver, mild lung fibrosis, 
enlarged para-splenic lymph nodes and fibrous thickening o f the liver capsule which 
contained histologically foreign material that appeared to be o f plant origin (Figure D 
24 A -  E). There are two possible sources o f this material. It may have been introduced 
during postnatal life from a bowel perforation, however during postnatal life the lamb 
was well and showed no signs of peritonitis. Alternatively it may have been introduced 
into the fetal peritoneal cavity from the ewe’s abdomen during vector injection.
Post mortem examination of the other sheep that came to birth (IP8) showed moderate 
perihepatic and pleural adhesions and there was a chronic infiltrate in the portal tracts o f 
the liver on histological analysis. No plant material was identified in the fibrous tissue, 
although this may be due to sampling at the time o f post mortem. A liver biopsy, taken 
from this lamb at 2 years of age to investigate hepatocellular dysfunction that had been 
diagnosed on abnormal serum liver function tests and bile acid levels (see section D 5), 
showed a chronic infiltrate in the portal tracts (Figure D 24 F). It is unlikely that the 
liver biopsy caused the peritoneal adhesions since it was straightforward and the animal 
made an uneventful recovery.
Mild chronic portal tract inflammation was a common finding on histological analysis 
of the liver of ewes. It should be noted that intraperitoneal adhesions have never been 
seen in any of the ewes at post mortem examination, and pleural adhesions were 
observed in only one ewe that developed pneumonia following general anaesthesia.
In the fetuses that were examined 2 or 9 days after injection, a small intraperitoneal 
blood clot or bruising o f the anterior abdominal wall was found at post mortem analysis 
in four cases (27%). In conclusion intraperitoneal injection o f adlacZ vectors was 
associated with some peritoneal pathology but this may be related to the particular 
vector applied rather than the route o f injection itself.
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Figure D 24: Histological findings in adult sheep after early gestation 
intraperitoneal injection of adhFIX vector.
After intraperitoneal injection o f  adhFIX vector as fetuses, histological analysis (H & E stain) showed in 
one sheep (IP5) there was (A) chronic mild inflammation in the portal tract o f  the liver, (B) lung fibrosis 
surrounding a chronic abscess and (C) fibrous thickening o f  the liver capsule which contains foreign 
material (arrowed) that is o f  plant origin and shown enlarged in (D) and (E). (F) Liver biopsy from the 
other sheep (IP8) showed a mild chronic inflammatory infiltrate in the portal tracts. Original 
magnifications are as indicated.
D 3.3 Therapeutic levels of hFIX are observed after early gestation 
ultrasound-guided intraperitoneal injection
Therapeutic levels of hFIX were detected in the plasma of two fetuses sampled 2 days 
after injection (IP9 and IP17, 400 and 1900 ng/ml respectively, Table D 13, Figure D 
20). By 9 and 29 days after injection hFIX levels were still detectable (8.5 -  18 ng/ml)
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but below the therapeutic range (50 ng/ml). One animal showed a hFIX level of 16.5 
ng/ml at birth (Figure D 20) but this fell to undetectable levels from 5 months of age. In 
a second animal, allowed to deliver at term, no hFIX was observed 5 months after birth 
(the samples from birth until this time point were lost).
Table D 13: Transgene expression after ultrasound-guided intraperitoneal 
injection of adenovirus vectors in early gestation fetal sheep.
* denotes twin fetus; GA: gestational age; d: days; ++ to +++ indicates degree o f  transduction observed 
after X gal staining or (3-galactosidase immunohistochemistry; -  indicates no staining; nt: not tested
sheep PM GA
(d)
Vector Dose
(P/kg)
X gal staining or 
hFIX plasma level 
ng/ml (%)
P-gal or hFIX 
immuno­
histochemistry
IP10 2d 40 adlacZ 1.1 x 1013 nt +++
IP3* 2d 52 adlacZ 1.5 x lO 12 nt ++
IP4* 2d 52 adlacZ 1.5 x lO 12 nt —
IP9 2d 56 adhFIX 1.6 x 1012 400 (8%) nt
IP17 2d 53 adhFIX 1.8 x 1012 1900 (38%) nt
IP15 2d 53 adhFIX 8.2 x 10" 0 nt
IP12* 9d 55 adhFIX 1.0 x lO 12 9.5 (0.19%) nt
IP13* 9d 55 adhFIX l.Ox 1012 14.5 (0.29%) nt
IP6* 29d 54 adhFIX l.Ox 1012 18 (0.36%) nt
IP7* 29d 54 adhFIX l.Ox 1012 8.5 (0.17%) nt
IP5 33 m 54 adhFIX 5.3 x lO 12 16.5 (0.33%) nt
IP8 33 m 54 adhFIX l.Ox 1012 nt nt
D 3.4 Widespread transgene expression in serosa walls and 
adjacent tissue is observed after ultrasound guided intraperitoneal 
injection in early gestation
Immunohistochemistry for p-galactosidase 2 days after injection o f the adlacZ vector at 
52 days of gestation showed widespread expression in the subcapsular hepatocytes, the 
small bowel serosa and the surface o f the umbilical cord (Figure D 25).
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Figure D 25: p-galactosidase transgene expression after ultrasound-guided 
intraperitoneal delivery of adlacZ vector in early gestation.
Immunohistochemical analysis (haematoxylin counterstain) 2 days after IP injection o f  a fetal sheep (52  
days o f  gestation, IP3, 1.5 x 101 p/kg), positive staining is seen in the (A ) fetal small bowel serosa, (B) 
surface o f  the umbilical cord, (C) fetal liver and (D) bowel mesentery. Original magnifications are x 40.
Positive lacZ expression was also observed after intraperitoneal injection at 40 days of 
gestation with widespread expression in the subcapsular hepatocytes, the pleura and 
within the chest and abdominal wall (Figure D 26). During the injection procedures 
vector delivery was clearly seen by microbubble movement in the peritoneal cavity and 
the needle tip was visualized at all times, reducing the possibility that the needle 
penetrated the pleural cavity. The pleuroperitoneal canals that connect the peritoneal 
with the pleural cavity close with the formation of the pleuroperitoneal membranes at 
the end of the embryonic period. In humans this occurs at approximately 7 weeks of 
gestation (Noden DM and De Lahunta A, 1985) which approximates in sheep to 25 days 
of gestation, well before the time of our experiment and so it is unlikely that the vector 
entered the pleural cavity via these channels.
I
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Figure D 26: P-galactosidase transgene expression after ultrasound-guided 
intraperitoneal delivery of adlacZ vector to a fetal sheep at 40 days of gestation.
Immunohistochemical analysis (haematoxylin counterstain) 2 days after IP injection o f  adlacZ (IP 10, 1.1 
x 1013 p/kg), shows positive staining in the (A) fetal liver, m yocytes in (B) fetal chest wall and (C) 
anterior abdominal wall, and (D) fetal pleural epithelial cells. Original magnification x 50 except where 
indicated.
Another possibility is that the vector passed into the chest via lymphatic stomata 
connecting the pleural and peritoneal cavities. These appear early in gestation in the 
mammalian embryo (Shao XJ et al., 1998) and drain fluid from the peritoneal cavity to 
the lymphatic system (Nakatani T et al., 1996). Adenovirus particles (70nm in diameter) 
may pass through these stomata, enter the lymph glands and gain access to the systemic 
circulation. However this still would not explain the presence o f vector in the chest wall 
and we must assume that the needle inadvertently entered the chest cavity probably 
because of the small size of this fetus.
D 3.5 Broad haematogenic vector spread is observed after 
intraperitoneal injection in early gestation
We investigated the biodistribution of adenovirus vector after early gestation 
intraperitoneal injection in two fetuses, one receiving adlacZ vector at 54 days (IP3) and 
the other that received adhFIX vector at 56 days of gestation (IP9, Figure D 27).
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Figure D 27: AdhFIX vector spread after ultrasound-guided intraperitoneal 
injection in early gestation.
1st round PCR analysis in some fetal tissues 2 days after IP injection at 56 days o f  gestation (IP9). In this 
2% agarose gel transgenic hFIX cDNA was detected in genomic DNA extracted from the fetal liver, skin, 
adrenal and gonad after 1st round PCR. Positive adhFIX virus (+ve) and negative blank (dH20 -ve) and 
genomic DNA from a non-injected sheep fetus (sheep -ve) were used as controls, ladder: lOObp DNA  
ladder.
Widespread distribution of adlacZ vector to virtually all fetal tissues including the fetal 
gonads was detected by PCR analysis (Table D 11). This suggested that haematogenic 
vector spread occurred via this route of injection. Low level spread o f vector to the 
maternal liver and ovaries, but not to the maternal lung was detected by nested PCR.
In conclusion, ultrasound guided intraperitoneal delivery o f adenovirus vectors had a 
low morbidity and mortality and gave widespread and high levels o f transgene 
expression that were therapeutic in the case of the hFIX transgene.
D 4 Other routes o f vector adm inistration in early gestation: 
intramuscular injection
Intramuscular injection is an established route for vector administration by which in 
vivo expression of hFIX after injection of adenovirus and adeno-associated virus (AAV) 
hFIX vectors has been achieved in adult and fetal mice (Schneider H et al.,
2002,Mitchell M et al., 2000). We investigated this route of administration in early 
gestation fetal sheep to determine if striated muscle could be used as an alternative site 
of transgene expression. To maximize our chances of achieving therapeutic hFIX
A ,
A® A*
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expression in the fetal circulation we delivered a high adenovirus vector dose o f up to 3 
x 1013 p/kg.
We did not specifically investigate adenovirus mediated transfection of fetal sheep 
muscle in vitro. Gene transfer to fetal sheep muscle in vitro is achievable using 
retrovirus vectors (John HA, 1994) and comprehensive studies in the fetal mouse have 
shown adenovirus mediated transduction to be an efficient process, dependent on 
binding between the adenovirus fiber knob and the Coxsackie Adenovirus Receptor 
(Bilbao R et al., 2003b).
D 4.1 Ultrasound guided intramuscular injection can be achieved in 
early gestation
Both adlac Z and adhFIX vectors were administered to the quadriceps and hamstring 
thigh muscles and gluteal buttock muscles of sheep fetuses (n = 11, Figure D 28). The 
vector was delivered in a total volume of 150-450pl by 1-4 injections depending on the 
adenovirus titre (Table D 14).
Table D 14: Ultrasound-guided intramuscular injection of adenovirus vectors in 
early gestation fetal sheep.
GA: gestational age; d: days; Vol: volume o f  vector injected; Injection no.: number o f  injections.
Sheep GA
(d)
sampling Vector Vol
(Rl)
Dose
(P/kg)
Injection
no.
Injection
position
IM5 54 2d adlacZ 280 2.7 x 10'3 4 R buttock
IM1 50 2d adhFIX 150 9.9 x 10'Z 1 L buttock
IM2 55 2d adhFIX 450 3.0 x 10|J 4 L buttock + thigh
IM3 51 2d adhFIX 350 1.6 x 1013 4 L + R thigh
IM8 52 died 3d adhFIX 400 6.8 x 10’1 2 R buttock + thigh
IM4 61 9d adhFIX 400 2.7 x 1013 4 L buttock + thigh
IM11 54 9d adhFIX 400 6.8 x 101' 2 R buttock + thigh
IM7 52 28d adhFIX 400 2.7 x lO 13 4 L buttock + thigh
IM10 52 30d adhFIX 400 6.8 x 101’ 3 L buttock + thigh
IM6 54 birth adhFIX 320 2.1 x 1013 4 R buttock + thigh
IM9 52 birth adhFIX 400 6 .8 x 1 0 " 2 L buttock + thigh
Four fetuses received adenovirus vector doses o f 6.8 x 1011 p/kg rather than the higher 
dose of 1 x 1013 p/kg because o f low adenovirus titre in that vector preparation. The 
procedure at this early age was technically more difficult than intrahepatic or 
intraperitoneal injections. We chose to inject the fetal thigh and buttock muscle because 
this is the largest accessible muscle group at this gestational age in the sheep fetus 
(Joubert DM, 1956).
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Figure D 28: U ltrasound-guided in tram uscular injection in early gestation fetal 
sheep.
The ultrasonograms show injection o f  the thigh muscle o f  a sheep fetus aged 51 days o f  gestation. (A) A 
22 Gauge spinal needle enters the amniotic cavity and lines up with the fetal femur in longitudinal section 
prior to injection. (B ) The needle has now slid along the lateral side o f  the femur and is positioned within 
the thigh muscle parallel to the femur.
The cross-sectional diameter of the fetal thigh or buttock muscle on ultrasound 
measured only 2 - 3  mm while the bevel of the needle measured 2mm. Thus insertion of 
the needle tip into the muscle in a transverse section would have resulted in immediate 
loss of the vector into the amniotic fluid from the needle tip. To avoid this and to ensure 
a longer needle track, we placed the needle into the muscle parallel to the bone (Figure
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D 28 B) and injected the thigh and/or buttock at a number o f sites. Echogenic foci could 
be observed within the muscle parenchyma confirming vector placement. Despite these 
precautions, it is likely that only a proportion o f the administered dose remained in situ 
and we therefore applied a slightly higher dose initially.
The mean time to successful injection was 18 min 49 sec (± SD 5min 4 sec, range 14 
min -  25 min 40 sec). The reason for the long procedure time was the need to perform a 
number o f intramuscular injections on the same fetus to achieve a high enough vector 
dose. This occasionally required the fetus to be repositioned to be able to access the 
buttock as well as the thigh muscle.
D 4.2 Ultrasound guided intramuscular injection in early gestation 
has a low morbidity and mortality
Fetal survival was 91%; one ewe and fetus died as a result o f overwhelming sepsis 3 
days after injection secondary to chorioamnionitis and fetal abortion. Death was 
probably due to bacterial infection at the time o f injection since culture o f the viral 
vector was negative.
During post mortem examination of the remaining fetuses, slight bruising was observed 
at the site o f intramuscular injection in 3 fetuses (30%) and a 1cm haematoma was 
noted at the site of buttock injection 30 days after surgery (1M10, Table D 15). Some 
focal haemorrhage (2 fetuses, 7%) and inflammation in the muscle tissue (3 fetuses, 
10%) was detected by light microscopy (Figure D 30 A).
Table D 15: Post mortem and histological findings after ultrasound-guided 
intramuscular injection of adenovirus vectors in early gestation fetal sheep.
d: days; m: months; PM: post mortem.
Sheep sampling Vector Dose (p/kg) PM findings Histological findings
IM5 2d adlacZ 2.7 x 10 bruising normal
IM1 2d adhFIX 9.9 x 1012 normal muscle haemorrhage
IM2 2d adhFIX 3.0 x 1013 bruising muscle inflammation
IM3 2d adhFIX 1.6 x 1013 normal muscle haemorrhage
IM8 died 3d adhFIX 6.8 x 1011 aborted bacteria
IM4 9d adhFIX 2.7 x 1013 bruising muscle inflammation
IM11 9d adhFIX 6.8 x 10n normal muscle inflammation
IM7 28d adhFIX 2.7 x 1013 normal normal
IM10 30d adhFIX 6.8 x 1011 haematoma normal
IM6 41 m adhFIX 2.1 x lO 13 perihepatic peritoneal 
adhesions
mild portal tract 
inflammation
IM9 35 m adhFIX 6.8 x 1011 normal mild portal tract 
inflammation
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One o f two sheep bom after intramuscular injection o f  adhFIX had a misaligned jaw 
(IM9). This did not interfere with feeding, is a common finding in lambs (Dennis SM, 
1993) and is unlikely to have been a result o f the gene therapy treatment. Animals bom 
following in utero intramuscular injection were examined 3 years after birth. Dense 
perihepatic adhesions involving the diaphragm and omentum were observed in one 
animal (IM6) and histological analysis of the liver showed mild portal tract 
inflammation but no obvious cholestasis. Examination o f the other animal (IM9) 
similarly only found mild chronic portal inflammation that was also observed in the 
liver of many o f the ewes.
D 4.3 Therapeutic levels of hFIX are observed after early gestation 
ultrasound-guided intramuscular injection
Therapeutic levels of hFIX were detected in the plasma o f two fetuses sampled 2 days 
after injection (IM1 and IM2, 83 and 65.5 ng/ml respectively) and one fetus sampled 9 
days after injection (IM 4, 87.5 ng/ml, Table D 16, Figure D 20). Transgenic hFIX 
protein was detected in a further two fetuses at 9 and 30 days after injection although 
the levels were sub-therapeutic (IM11 and IM10, 23.5ng/ml and 19.5ng/ml 
respectively). O f the two animals that were bom, only one gave a measurable hFIX 
level of 5ng/ml that became undetectable after 20 weeks postnatally (Figure D 20).
Table D 16: Transgene expression after ultrasound-guided intramuscular injection 
of adenovirus vectors in early gestation fetal sheep.
* denotes twin fetus; GA: gestational age; d: days; ++ to +++ indicates degree o f  transduction observed 
after X gal staining or P-galactosidase immunohistochemistry; -  indicates no staining; nt: not tested
Sheep sampling Vector Dose
(p/kg)
X gal staining or hFIX 
plasma level 
ng/ml (%)
p-gal or hFIX 
immuno­
histochemistry
IM5 2d adlacZ 2.7 x 10° nt +++
IM1 2d adhFIX 9.9 x \ 0 li 83 (1.67%) ++
IM2 2d adhFIX 3.0 x lO 13 65.5 (1.31%) ++
IM3 2d adhFIX 1 .6 x 1 0 ° 0 ++
IM4 9d adhFIX 2.7 x 10b 87.5 (1.75) -hi­
IM11 9d adhFIX 6.8 x 1011 23.5 (0.47%) nt
IM7 28d adhFIX 2.7 x 10° 0 nt
IM10 30d adhFIX 6.8 x lO 11 19.5 (0.39%) nt
IM6 41 m adhFIX 2 .1 x 1 0 ° 5 (0.10%) nt
IM9 35 m adhFIX 6.8 x lO 11 0 nt
144
D. RESULTS: Haemophilia B
Positively stained myocytes were seen by immunohistochemical analysis for hFIX in 
four fetuses at 2 and 9 days after injection of the adhFIX vector (Table D 16, Figure D 
29 B and C). No positive staining was observed in any other fetal or maternal tissues.
Figure D 29: Histological analysis and hFIX transgene expression after 
ultrasound-guided intram uscular injection.
Nine days after injection at 61 days o f  gestation (IM4) there is (A ) focal haemorrhage and inflammation 
in the fetal quadriceps hamstring muscle tissue detected by light microscopy (H & E stain). Positively 
stained myocytes are seen on immunohistochemistry analysis for hFIX expression (haematoxylin 
counterstain) (B) and (C) in a fetus 2 days after injection o f  adhFIX vector at 51 days o f  gestation (1M3). 
Fetuses received 1.6 - 2.7 x 1013 p/kg adhFIX vector. Original magnifications are as indicated.
D 4.4 p-galactosidase transgene expression is observed in the fetal 
muscle and liver after intramuscular injection
Immunohistochemical analysis of fetal tissues 2 days after injection of adlacZ vector 
showed the presence of nuclear localised B-galactosidase expression in myocytes and 
the overlying skin with some spread to the liver as seen by staining of a few hepatocytes 
(Table D 16, Figure D 30).
 - - 3
Figure D 30: P-galactosidase transgene expression after ultrasound-guided 
intram uscular injection of adlacZ vector.
Immunohistochemistry (haematoxylin counterstain) two days after IM injection o f  adlacZ vector at 54 
days o f  gestation (IM5, 2.7 x 1013 p/kg) shows nuclear localised B-galactosidase expression (A) in 
m yocytes in the fetal gluteus muscle and (B) in the overlying skin with (C) spread to the liver as seen by 
staining o f  a single stained hepatocyte. Original magnifications are as indicated.
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D 4.5 Broad haematogenic vector spread is observed after 
intramuscular injection in early gestation
Widespread distribution of the adlacZ vector or hFIX transgene was found by PCR in 
almost all investigated fetal tissues albeit by the more sensitive nested PCR analysis 
(Table D l l ,  Figure D 31). First round PCR product was detected in the fetal muscle 
and liver in agreement with the results of (3-galactosidase immunohistochemical 
analysis. This suggests that low level haematogenic spread occurred following 
intramuscular injection. A representative gel showing nested PCR analysis for the 
presence of the adlacZ vector in fetal and maternal sheep tissues is shown in Figure D 
31. Low level spread to the fetal gonad was only detectable in the fetus injected with 
adlacZ vector.
In conclusion, we have shown that ultrasound guided intramuscular delivery of 
adenovirus vectors could be achieved in the early gestation sheep fetus with minimal 
morbidity or mortality, achieving haematogenous vector spread and therapeutic levels 
of transgene expression. This supports the concept that the muscle may be useful as an 
ectopic source of potentially therapeutic proteins in some systemic congenital disorders.
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Figure D 31: Vector spread after ultrasound-guided in tram uscular injection of 
adlacZ vector.
Nested PCR analysis in fetal and maternal tissues two days after IM injection o f  adlacZ vector at 54 days 
o f  gestation (1M5). In this 2% agarose gel transgenic adlacZ cDNA was detected in genomic DNA  
extracted from the fetal liver, ovary, lung, heart, spleen, adrenal, kidney, and right buttock muscle 
(injected side) after nested PCR. Positive adhFIX virus (+ve) and negative blank (dH20 -ve) were used as 
controls, ladder: lOObp DNA ladder.
146
D. RESULTS: Haemophilia B
D 4.6 Ultrasound-guided intramuscular injection of adenovirus 
vectors in late gestation gives only low level tissue transduction
We had previously shown that intravascular delivery o f adenovirus vectors in late 
gestation fetal sheep resulted in widespread tissue transduction and therapeutic 
transgene expression (Themis M et al., 1999). Initially one o f our aims was to perform a 
series of intramuscular injections in late gestation fetal sheep using the same adenovirus 
vector as a comparison with results from umbilical vein delivery at the same age 
(Themis M et al., 1999). However because o f time and resource constraints we decided 
to limit these experiments to 2 experiments in 4 twin fetuses.
Sheep fetuses at 125-137 days of gestation (n = 4, Table D 17) received an injection o f 
high or low dose adhFIX vector into the quadriceps and hamstring muscle. The 
procedure was straightforward because o f the much larger muscle bulk available, and in 
two fetuses up to 1ml of vector was injected with ease. Post mortem and histological 
analysis 2 days after injection in 2 fetuses showed no abnormality.
Levels of hFIX analysed by ELISA measured 23.5 and 16ng/ml 2 days after injection in 
one twin pair. One lamb bom after high dose in utero treatment had detectable hFIX 
levels of 7ng/ml at birth, falling to 5.5ng/ml at one week o f age and subsequently hFIX 
was undetectable; in the other lamb no hFIX expression was demonstrated.
Transgene expression was lower after intramuscular delivery o f adenovirus vectors than 
following umbilical vein delivery in late gestation probably because most o f the vector 
was confined to the muscle mass and only a small proportion spread into the fetal 
circulation. Because of the low level gene transfer observed we did not perform further 
intramuscular injection experiments using the adlacZ vector in late gestation fetal sheep. 
Nevertheless these results show that it is possible to achieve low level transduction of 
the fetal musculature at this late gestation.
Table D 17: Overview of late gestation in tram uscular injection experiments.
Sheep fetuses were injected with adenovirus vectors containing the human factor IX gene (adhFIX) by 
ultrasound guided intramuscular injection, d: days, *: twin fetus pairs, p/kg: particles/kg.
Sheep GA
(d)
sampling Vector Vol
(Pi)
Dose
(p/kg)
IM12* 125 2d adhFIX 1000 2.3 x 1014
IM13* 125 2d adhFIX 100 2.3 x 1013
IM14* 137 birth adhFIX 1000 l .Ox 1014
IM15* 137 birth adhFIX 100 2.7 x 1013
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D 5 Health of lambs born after early gestation adenovirus 
vector administration
All lambs bom following early gestation in utero injection o f adhFIX were examined at 
delivery and during postnatal development. Blood was analysed to investigate the effect 
o f fetal injection of adenovirus vectors on the long term health o f lambs. Blood was 
taken as soon after birth as possible and at regular intervals. Results from blood samples 
taken for blood count, serum biochemistry, liver function tests (LFTs) and bile acids 
were compared to international standards for adult sheep (International Sheep 
Information System, ISIS). Because the standard reference ranges were available only 
for adult sheep of Mouflon species we also examined blood from three normal Romney 
lambs aged 3 months old present on the farm for comparison. Serum from 10 adult non­
pregnant Romney ewes that had been on the farm for 6  months was also tested to 
provide an adult reference range for LFTs and bile acids.
D 5.1 Haematological analysis and serum biochemistry of sheep is 
normal
An increased platelet count was found in the blood from both injected and normal lambs 
that returned to the ISIS normal range by 6  months o f age. All other haematological 
values and serum biochemistry were within the normal range from birth.
D 5.2 Analysis of liver function tests suggests hepatocellullar injury 
in some sheep born after early gestation in utero adhFIX injection
The serum levels of liver enzymes can indicate whether hepatic disease is present and 
assess its functional impact. The diagnostic usefulness o f particular liver enzymes 
depends on the domestic animal species investigated and their age, and this must be 
considered when interpreting results (Meyer DJ, Harvey JW, 1998).
The serum level o f aspartate transaminase (AST) was above the upper limit o f normal 
(195 U/l) in one sheep at 6  and 7 months o f age (IM6 , 242 and 297 U/l) and another at 
18 months o f age (IP8 , 203 U/l). In both animals the level o f serum creatine kinase was 
normal, thus excluding muscular damage as the cause o f the raised AST.
While abnormal levels o f AST provide only a general indicator o f hepatic injury in 
ruminants, the serum concentration o f the liver enzyme glutamate dehydrogenase 
(GLDH) is the most specific for hepatocellular injury. In ruminants, GLDH is raised in 
hepatic necrosis and bile-duct obstruction (Kaneko JJ et al., 1997). The level of GLDH
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in 2 non-injected control lambs at 2-3 months of age (50 U/l) was higher than the 
normal range quoted for adult sheep (up to 20 U/l, Figure D 32) suggesting that the 
normal adult range cannot be applied to young lambs.
We observed similar levels o f GLDH initially in the serum o f almost all the sheep that 
had received early gestation in utero adenovirus injection. From 6  months of age 
however, very high levels o f GLDH were detected in one o f the sheep injected via the 
intramuscular route (IM6 ) that subsequently settled to within or just above the normal 
range by 18 months of age. One o f the two sheep that received intraperitoneal injection 
(IP8 ) had continuously raised levels o f serum GLDH significantly above the upper limit 
o f normal (33U/1). The sheep injected via the umbilical vein (UV12, UV15) and the 
sheep that received high dose intrahepatic adenovirus (HE5) had raised levels o f GLDH 
at 6  months that then normalised by 1 year o f age. Thus by a year after birth, serum 
GLDH levels were only significantly raised in one animal (IP8 ).
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Figure D 32: GLDH concentration in the serum of sheep born after in utero early 
gestation injection of adhFIX vector.
The dotted line represents the upper limit o f  normal in adult sheep (20 U/l). IM: intramuscular, HE: 
intrahepatic, IP: intraperitoneal, A: intra-amniotic, UV: umbilical vein injection; control: 2 and 3 month 
old normal Romney lambs.
Gamma-glutamyltransferase (GGT) and alkaline phosphatase (ALP) are markers of 
cholestasis, GGT being associated with epithelial cells comprising the bile ductular
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system and ALP associated with the canalicular membrane. Levels of GGT were high in 
the injected and non-experimental control lambs. GGT is present in colostrum and this 
may have resulted in the initial elevation up to 2 0  weeks o f age when the lamb is 
suckling. The raised GGT level remained however beyond 1 year o f age in the same 
animal that had a raised GLDH level (IP8 ), which suggested this animal may have a 
cholestatic problem (Figure D 33).
Serum levels o f ALP fluctuate widely in normal ruminants and are less valuable than 
GGT in the evaluation o f cholestatic disorders (Kaneko JJ et al., 1997). In addition, the 
bone isoenzyme would be elevated in neonates due to their rapid skeletal growth. ALP 
was not measured therefore in our sheep.
Bilirubin was not raised in the serum o f any o f the lambs. The levels o f alanine 
aminotransferase (ALT) were normal which is not unexpected. There is only low level 
ALT activity in the hepatocytes o f ruminants in contrast to rodent hepatocytes and 
therefore the level of this liver enzyme in the serum is not diagnostically useful.
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Figure D 33: GGT concentration in the serum of sheep born after in utero early 
gestation injection of adhFIX vector.
The dotted line represents the upper limit o f  normal in adult sheep (52 U/l). IM: intramuscular, HE: 
intrahepatic, IP: intraperitoneal, A: intra-amniotic, UV: umbilical vein injection; control: 2 and 3 month 
old normal Romney lambs.
D 5.3 Serum bile acids are raised
The level o f liver enzyme activity observed does not always correlate with the degree of 
functional impairment and serum bile acid level is considered to be a better indicator.
150
D. RESULTS: Haemophilia B
The measurement of the serum total bile acid level in ruminants is difficult due to the 
wide range of reported normal values, hourly fluctuations up to 60pmol/L during 
feeding and occasional high levels in apparently healthy animals. Reference ranges for 
normal levels o f serum bile acids in sheep have not yet been determined. The normal 
ranges quoted in the literature for studies investigating liver damage in sheep range 
from 20.2pmol/L (± SEM 1.78) (West HJ, 1987), 48 pmol/L (± SEM 3.3) (Anwer MS 
et al., 1976), to 74 pmol/L (± SEM 33pmol/L) (Sutherland RJ et al., 1992). In practice 
most veterinary biochemists use the normal range for adult cattle that has an upper limit 
of 60pmol/L (personal communication, Ms K Tennant, Department of Pathology & 
Infectious Diseases, Royal Veterinary College, UK).
To derive a normal range for our breed o f sheep, we investigated the bile acid 
concentration in the blood o f 10 normal adult non-pregnant Romney ewes (>1 year old) 
taken at the same time o f the day as blood from our fetally injected sheep. The mean 
bile acid concentration was 39.8 pmo/1 (± SEM 4.6, range 29.8 -  64.7 pmo/l).
From this data and published studies, nearly all the sheep injected in utero had 
abnormally high levels of serum total bile acids in the first year o f life but these settled 
to within normal ranges subsequently (Figure D 34)
jj
IS
1-4—>s=3u-dJ
C/D
-
200
180
160
140
120
100
80
60
40
20
0
A
X
o
n X  O± -------------- o -----------
9 •  •
▲
f k ________
o
X
A
-A-
A
A
O O
25 50 75 100
T im e after birth (w eek s)
125
♦ IM6
o IM9
X HE5
A IP 5
A IP8
+ A5
• UV12
O UV15
X control
X
150
Figure D 34: Total bile acid concentration in the serum of sheep born after early 
gestation injection of adhFIX vector.
IM: intramuscular, HE: intrahepatic, IP: intraperitoneal, A: intra-amniotic, UV: umbilical vein injection; 
control: 3 month old normal Romney lamb. The dotted line represents the upper limit o f  normal bile acid 
concentration used in clinical practice (60 pmol/1).
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The reason for this is unclear but generally there are low levels o f bile acids in the fetus, 
and increased synthesis after delivery leads to a rise in the serum bile acids up to adult 
levels (Hardy KJ et al., 1980). In particular serum total bile acids reached their highest 
levels in the animal that had abnormal GLDH and GGT (IP8 ) and suggested chronic 
hepatic pathology with a reduced hepatic functional capacity.
D 5.4 Liver biopsy from one sheep injected as a fetus shows chronic 
liver pathology
We performed a liver biopsy on one o f the sheep at 2 years o f age that had the most 
abnormal liver function tests (IP8 ) to investigate the type o f hepatocellular dysfunction 
observed. This showed chronic portal inflammation with cholestasis which was 
confirmed at post mortem examination a year later (Section D 3). These findings 
highlight the importance of long term follow up in any animal studies o f fetal gene 
therapy in the future combining haematological and biochemical assessment o f 
wellbeing with evidence from post mortem and histological examination.
In conclusion, the results suggest that all sheep bom following early gestation injection 
initially had mildly deranged liver function, although by 1 year o f age, this had resolved 
in all but one animal.
D 6. Adenovirus vector is not detectable in the sheep germline 
after early gestation administration
PCR analysis o f semen samples from three male lambs bom after early gestation 
intraperitoneal, intrahepatic or intramuscular injection o f adhFIX and ovarian tissue 
from one female lamb bom after intra-amniotic injection o f adhFIX was carried out to 
investigate gene transfer to the sheep germline. No hFIX cDNA sequences were 
detectable on first round or nested PCR analysis of semen or ovarian tissue samples. It 
was not possible to test the other lamb bom after intraperitoneal injection because it had 
bilateral undescended testes, a not uncommon finding in sheep flocks, and did not 
produce semen.
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D 7 Discussion
D 7.1 Fetal size limits the gestational age at which ultrasound guided 
umbilical vein and intracardiac injection can be reliably and safely 
performed in the sheep fetus
Experiments prior to this work had shown that ultrasound-guided intravascular delivery 
of gene therapy could be easily achieved in the late gestation sheep fetus by injecting 
the UV as it passed through the fetal liver in the abdomen (Themis M et al., 1999). We 
studied UV and intracardiac injection from early gestation to achieve systemic delivery 
of gene therapy at an age when the sheep fetus is believed to be pre-immune, before 65 
to 70 days of gestation.
D 7.1.1 Ultrasound guided injection of the umbilical vein
In clinical practice, injection o f the UV at the placental cord insertion is the original site 
described (Daffos F et al., 1983) and the most widely used. Studies report fetal loss 
rates o f up to 1.9% (Daffos F et al., 1985) although the risk o f fetal loss may vary 
according to the indication for fetal blood sampling (Maxwell DJ et al., 1991).
Our attempts to inject the UV in the early gestation sheep fetus at a gestational age 
when it is believed to be pre-immune, were hindered by the small size o f the fetus. A 
major obstacle to successful UV injection at 54 days o f gestation was that blood flow in 
the umbilical cord vessels or intrahepatic UV was not detected by Doppler measurement 
with our machine. A more advanced machine with better Doppler capability might have 
allowed visualisation of blood flow. Even at the later gestational age o f 60 days, it was 
not possible to visualise flow in the UV to confirm the correct injection site at the 
placental insertion.
We found that visualisation of the UV at the placental cord insertion in the fetal sheep 
was hampered by the short length of the umbilical cord, and division o f the UV into 
numerous small branches to supply the cotyledons. Even in those cases where the 
placental cord insertion was adequately visualised, attempts to inject the UV were 
unsuccessful and we concluded that this route o f intravascular injection should not be 
used in the fetal sheep. Newnham and colleagues had similar difficulties in the late 
gestation sheep and advocated intracardiac injection as an alternative route o f fetal 
blood sampling (Newnham JP and Kelly RW, 1993). We believed that injection o f the 
intrahepatic UV would be less traumatic than intracardiac injection at earlier gestations.
153
D. RESULTS: Haemophilia B
Injection of the intrahepatic UV in the fetal sheep also avoids the need to perform 
Doppler blood flow examination to confirm that an umbilical vein rather than an artery 
is being injected. This is important in the fetal sheep where there are normally two 
umbilical veins present.
Injection of the intrahepatic UV was attempted from 54 days o f gestation but was 
abandoned due to severe narrowing o f the UV, the difficulty with visualising the 
microbubble turbulence after vector injection and procedure related mortality. Injection 
at the slightly later gestation o f 60 days allowed for fetal survival. The major problem at 
this gestational age was narrowing o f the UV that occurred after the first injection 
attempt in almost every experiment. Even if the fetus was allowed to recover for a short 
time, the view of the UV was less good for subsequent injection attempts, reducing our 
success rate. More than one injection attempt was required in nearly half of the injected 
fetuses, and multiple injection attempts were associated with fetal death. A further 
problem was that intravascular delivery o f the vector could not always be confirmed by 
microbubble visualisation. This was probably caused by dislodgement o f the needle tip 
from the vessel when the syringe used to take fetal blood was switched to the syringe 
containing the viral vector. This could have been prevented by the use o f a 3-way tap as 
applied in clinical practice during fetal blood transfusions. However because o f the 
small circulatory volume of the fetus and small volumes o f fluid injected in our 
experiments, the dead space of even a short piece o f flexible tubing was believed to be 
too large. We considered instillation o f PBS and observation o f intravascular 
microbubbles as an alternative to withdrawal o f fetal blood, but this would compromise 
visualisation o f the UV should the needle tip not be correctly placed. While the ability 
to successfully inject the UV on the first attempt will improve with time as the operator 
becomes more experienced, the problems encountered if the first attempt fails and the 
difficulties with observing microbubbles, make this an unreliable route of vector 
delivery at this gestational age in fetal sheep.
Intrahepatic UV injection was more successful and reliable from 67 days of gestation. 
Although there were low numbers o f fetuses injected between 67 and 70 days of 
gestation, subjectively the procedure was technically easier and therefore more 
repeatable. There was minimal morbidity and low mortality, which is similar to that 
observed in clinical practice (Nicolini U et al., 1990). The narrowing o f the UV 
observed at 60 days was occasionally observed from 67 days o f gestation but was less 
severe.
It is unclear whether it was the adenovirus vector or the procedure itself that caused the
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hepatic necrosis observed nine days after intrahepatic UV injection at 60 days of 
gestation. Hepatic necrosis however, was not observed in one animal sampled 7 days 
after intrahepatic UV injection at 76 days o f gestation. We concluded that the necrosis 
was probably as a consequence o f UV narrowing seen at the earlier gestational age, that 
may have lead to hypoxia in the peripheral liver. A review o f the literature identified 
only one case report of fetal hepatic necrosis following intrahepatic UV blood sampling 
(Sturgiss SN et al., 1996). The fetus in this case had severe growth restriction and the 
procedure was difficult to perform requiring repeated attempts to access the UV that 
probably contributed to the poor outcome. No long term alterations in the concentration 
of liver enzymes in the fetal blood have been shown following intrahepatic UV 
sampling (Nicolini U et al., 1990). In clinical practice, narrowing o f the UV has not 
been documented and this may be because the placental cord insertion is preferentially 
sampled and intrahepatic UV injection is reserved for the 2nd trimester when the fetus is 
relatively larger.
Embryofetoscopy has been tested as an alternative technique for fetal blood sampling 
during the first trimester, in patients scheduled for termination o f pregnancy. Umbilical 
cord puncture was successful in two out of three attempts at 14 weeks o f gestation 
(Surbek DV et al., 2000) but was not achieved at 8  to 11 weeks of gestation (Surbek D 
et al., 1997). Early cordocentesis is not routinely used in clinical practice because it is 
associated with an increased risk o f complications such as fetal bradycardia and 
haemorrhage. Fetal loss rates are related to gestational age and ranged from 5.2% at 12- 
18 weeks to 2.5% at 19-21 weeks of gestation in one series o f cases o f sampling at the 
placental cord insertion (Orlandi F et al., 1990).
The use o f a needle guide has been advocated by some authors to reduce procedure- 
related losses during cordocentesis (Weiner and Okamura K, 1996) although most 
clinicians use the freehand technique which allows the needle to move with fetal or 
maternal movements and minimizes the risk o f dislodgement. Intravascular 
pancuronium can be given to prevent fetal movements (Weiner CP et al., 1991). This 
was not required in our investigations because the ewe was anaesthetized.
An alternative site o f UV injection in clinical practice is into a free loop o f cord. This 
route is usually advocated only in cases of oligohydramnios when the placental cord 
insertion is less accessible because of the specific complication of cord haematoma and 
tamponade. One recent series of cases found sampling at the free loop of cord to be 
associated with a fetal loss rate of 3.2% at mid gestation (Tongsong T et al., 2000). In
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our experience injection at the free loop o f cord was successful in one fetus but we 
observed cord haematoma, and did not attempt this route o f injection further.
In summary, delivery of gene therapy into the UV of the sheep fetus in mid-gestation is 
best performed using the intrahepatic UV route. In clinical practice, however, the 
placental cord insertion would be the route o f choice because o f the better visualisation 
o f the placental cord insertion in the human as compared to the sheep fetus.
D 7.1.2 Ultrasound guided intracardiac injection is not compatible with 
fetal survival in the early gestation sheep fetus
Our failure to achieve successful intracardiac injection in the early gestation fetal sheep 
is not unexpected. Aspiration o f blood from the left ventricle and vector injection was 
straightforward but the relatively large size o f the needle compared to the heart resulted 
in immediate life-threatening trauma and haemorrhage. Ultrasound-guided 
cardiocentesis (Jauniaux E et al., 1999a) and intracardiac injection o f radiolabelled fetal 
liver cells (Westgren M et al., 1997) has been performed on the human fetus at 12-17 
weeks of gestation, corresponding to day 43 - 61 o f gestation in sheep, prior to 
termination of pregnancy, but there is no data on the long-term complication rates. 
Intracardiac injection is rarely performed for clinical indications such as transfusion, 
and only later in pregnancy from 19 weeks o f gestation onwards because o f the high 
complication rate and associated mortality (Westgren M et al., 1988). Fetal intracardiac 
injection o f viral vectors has been successfully performed by laparotomy and 
microsurgical techniques in mouse embryos at 10 days postcoitum (Christensen G et al., 
2000). Ultrasound guided intracardiac injection using a 25 Gauge spinal needle in fetal 
rabbits in late gestation also had a high mortality rate o f 25 -  40% 3 days after injection 
(Wang G et al., 1998).
In the fetal sheep, direct cardiac access by operative fetoscopy in mid to late gestation 
had an unacceptable 30% failure rate with 80% mortality (Kohl T et al., 2000b). The 
fetal loss rate from ultrasound guided intracardiac fetal blood sampling from 1 0 0  days 
o f gestation can be reduced with operator experience to 4.5% (Newnham JP et al., 1989) 
(Newnham JP and Kelly RW, 1993). Pericardial haemorrhage was the cause o f death in 
only one o f seven fetuses that died, out o f 76 that were sampled. The technique was 
refined to approach the heart from the inferior aspect that avoids the cardiac conduction 
system and reduced the mortality rate.
We concluded that in the early gestation fetal sheep (up to 14 weeks gestation in
156
D. RESULTS: Haemophilia B
humans), intracardiac injection was not suitable for clinical application of fetal gene 
therapy and that other routes into the fetal circulation would be safer alternatives.
D 7.2 UV delivery of viral vectors to the early and mid gestation fetal 
sheep achieves gene transfer and haematogenic spread
From previous work in our laboratory performed in late gestation fetuses, we knew that 
UV injection of adenovirus vector resulted in strong transgene expression in the fetal 
liver, spleen and adrenal gland. Therefore we anticipated that gene transfer to these 
tissues would be observed after early gestation UV injection. We did not examine fetal 
sheep liver tissues for the presence o f Coxsackie Adenovirus Receptors but infection 
studies on the early gestation fetal liver ex vivo showed that adenovirus mediated gene 
transfer could be achieved. In the fetal mouse liver studies have shown homogeneous 
distribution o f the Coxsackie Adenovirus Receptor and P5 integrin, which are necessary 
for adenovirus binding and internalization respectively (Bilbao R et al., 2003a).
Because of the unreliability o f the UV injection procedure at 60 days o f gestation, we 
could only be sure that adenovirus vector had entered the fetal circulation in four 
fetuses. In two fetuses that were tested 2 and 9 days after injection, hFIX expression in 
the fetal plasma reached therapeutic levels and in the liver transgenic hFIX was detected 
by immunohistochemical analysis (Figures D9 and DIO respectively). The level o f fetal 
liver tissue transduction suggests that the fetal liver was a major site o f hFIX 
production. The remaining two fetuses were first tested for transgene expression at 
birth, 85 days after injection, and as expected from the short term nature o f adenovirus 
mediated gene expression, no hFIX activity could be detected at these time points.
PCR analysis of tissues from one fetus showed that the adhFIX vector had spread via 
the circulation to other fetal organs and expression in these ectopic locations may also 
have contributed to the hFIX levels observed. Human FIX sequences were detected on 
1st round PCR analysis in the fetal adrenal and spleen, but in the liver only on nested 
analysis and this could represent variation in the sampling sites o f tissue used for PCR 
analysis in this fetus. It is interesting to note however, that gene transfer to the adrenal 
gland was particularly evident in previous studies after UV injection in the fetal sheep at 
late gestation (Themis M et al., 1999) and at 60 days of gestation (Yang EY et al.,
1999). We were unable to distinguish between the adrenal cortex and medulla because 
o f the small fetal size, but in the late gestation study, p-galactosidase gene expression 
was mostly confined to the adrenal cortex (Themis M et al., 1999). Blood flow to the 
adrenal gland and particularly to the cortex increases at times o f fetal stress such as
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during haemorrhage (Toubas PL et al., 1981) or hypoxia (Richardson B et al., 1996), 
and needling o f the fetal UV may provoke a stress response. Our data show that 
injection of the UV at 60 days of gestation narrowed the vessel probably resulting in 
transient hypoxia, and we believe that this caused the peripheral necrosis present in the 
fetal liver 9 days after injection.
Injection o f the UV performed from 67 days o f gestation onwards was more reliable and 
we confirmed that the vector had entered the fetal circulation by visualisation of 
microbubbles during injection in all but two cases. We also demonstrated colloidal 
carbon distributed in many o f the fetal tissues after UV injection in one other case. 
Confident that we had achieved systemic delivery o f  the adenovirus vector, we expected 
to see gene expression particularly in the fetal liver, adrenal and spleen, but we were 
disappointed. In two experiments, we were concerned that the diluted vector used for 
the experiments may have degraded with time and a low dose was given inadvertently 
which may have lead to the negative results. It also became apparent that there was a 
problem with a fresh adlacZ vector preparation in use that failed to function in vivo 
despite good evidence of gene transfer to 293 human embryonic kidney cells in vitro. 
There did not appear to be any aggregation problem with viral particles in the 
preparation that can interfere with biological activity. Contamination o f the vector could 
have prevented activity in vivo that did not occur in vitro because contaminants were 
diluted by the cell culture supernatant. This problem highlights the importance o f testing 
vectors in vivo for biological activity as one o f the stringent quality controls that will 
need to be in place for clinical application of gene therapy. Presently all vectors are 
pretested in adult mice by tail vein injection before use in sheep experiments.
O f seven fetuses that received biologically active adlacZ vector and survived to 
analysis, four showed no evidence of gene transfer. These four fetuses were aged 
between 6 8  and 87 days of gestation at injection and the dose o f adenovirus received by 
these animals ranged from 2.5 x 1010 to 4.4 x 1011 p/kg. Positive p-galactosidase 
expression was only observed in one fetus aged 67 days o f gestation that received 
sodium caprate pretreatment and in the two oldest fetuses injected at 95 days of 
gestation. It is unlikely that there is a gestational age specific response to adenovirus 
infection after umbilical vein injection, since we had already observed transgene 
expression after umbilical vein injection o f adhFIX at 60 days o f gestation. The sodium 
caprate pretreatment may have enhanced gene transfer. Vector complexation with 
DEAE dextran was used in some experiments and although this increased transduction
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in general, it was not associated with positive transgene expression in these umbilical 
vein experiments.
It is more probable that there is a non-linear dose response to adenovirus infection. We 
observed strong transgene expression confirmed by positive immunohistochemical 
analysis for p-galactosidase in the fetal liver in one animal that received a high 
adenovirus dose o f 2.7 x 1012 p/kg. The other animal received a lower dose of 8.5 x 1010 
adenovirus p/kg and expression was low level and not confirmed by 
immunohistochemistry. There is evidence from studies in adult mice and primates of a 
non-linear dose response to intravenous adenovirus (Tao N et al., 2001). Temporary 
blockade of Kupffer cells by preadministration o f a non-reporter adenovirus or by 
Kupffer cell depletion dramatically enhanced reporter gene expression over a very 
narrow dose range. The authors proposed that the reticuloendothelial system acted as a 
‘biological filter’ to efficiently remove the majority o f low doses of intravenously 
injected adenovirus prior to transduction of hepatocytes. This could be the explanation 
for the poor transgene expression we observed at the lower doses o f adenovirus applied. 
One other group from the Children’s Hospital o f Philadelphia, USA has studied 
injection of adenovirus vectors (AdCMVlacZ) into the UV of fetal sheep (Yang EY et 
al., 1999). They injected a similar adlacZ vector at laparotomy into the UV in a free 
loop of cord at 60 days of gestation. Strong expression of p-galactosidase was observed 
in fetal hepatocytes, the adrenal glands, kidneys and endocardium three days after 
injection and a dose response was observed. Significant fetal demise occurred at doses 
higher than 1 x 1 0 11 pfu per fetus, equivalent to 1 x 1 0 12 pfu/kg or 1 x 1 0 13 p/kg, 
assuming each fetus weighs approximately lOOg. This is a log 10 dose higher than that 
used in our experiments, and although it is difficult to compare dosages from different 
studies because o f biological variation in viral vector batches, it is likely that the higher 
dose applied resulted in better gene transfer.
Adenovirus is known to be a highly toxic vector. There is an initial response 
characterized by cytokine production (Zhang Y et al., 2001) followed by immune- 
mediated inflammation that targets vector-transduced cells (Yang Y et al., 1994). In our 
study a twin fetus that received a high dose o f adenovirus (5 x 1012 p/kg) died shortly 
after injection, probably as a result o f adenovirus toxicity. The previous study o f UV 
injection in late gestation fetal sheep found that a dose o f up to 4.8 x 1011 pfu per fetus,
equivalent to 1-2 x 1011 pfu/kg was tolerated, but that 2.4 x 1012 pfu, equivalent to 1 x
1012 pfu/kg, led to intrauterine death. In that study, the adenovirus vector was titred by 
plaque assays on 293 cells that has now been superseded by the less variable optical
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density method that was used in this study. The titres o f adenovirus vector determined 
by optical density are assumed to be one order o f magnitude lower than that from 
plaque assays (personal communication, Dr M Themis, Imperial College).
All these results indicate that there is a narrow therapeutic range in the sheep fetus over 
which umbilical vein injection o f adenovirus results in gene transfer but without toxicity 
or fetal demise. This may be confined to the use o f adenovirus vectors for gene therapy 
but should be studied for other more clinically appropriate vectors when these become 
available. Repeating our umbilical vein injection experiments at higher adenovirus 
vector doses might have produced better gene transfer. It is probable that the gestational 
age of a fetus affects the efficiency o f vector infection and expression o f transgenic 
proteins. A limitation to this work is that because o f resource constraints associated with 
using a large animal model we were unable to demonstrate whether a gestation specific 
effect existed for umbilical vein injection. Early work with adenovirus vectors in mice 
showed that the gestational age of the fetal mouse at yolk sac vessel injection 
determined the pattern of organ expression (Schachtner SK et al., 1996). At 13 days 
post conception (dpc) the heart and liver were preferentially transduced and injection 2  
days later resulted in widespread transduction o f almost all organs, while at 18 dpc low 
levels o f gene transfer were seen in the liver and lung. Particular susceptibility o f cells 
to adenovirus infection appears to be an improbable explanation. In the fetal mouse, the 
pattern o f adenovirus mediated transgene expression is unrelated to the expression of 
the CAR receptor or integrins that are necessary for adenovirus binding and 
internalization respectively (Schachtner SK et al., 1996). There may be other yet 
unidentified receptors or perhaps variability in the activity o f promoters or transgene 
expression patterns through gestation that could be responsible for such development 
dependent variations in transgene expression. In the post-implantation mouse embryo, 
injection of adenovirus under the control o f the CMV promoter resulted largely in 
endothelial gene transfer, while the RSV promoter lead to expression within the 
myocardium (Baldwin HS et al., 1997). It will be important for clinical application of 
prenatal gene therapy to explore experimentally the gestational age that best allows 
minimally invasive delivery and maximal gene transfer.
A critical factor that could affect vector dose after intravascular delivery is the fetal 
blood volume that as expected, increases with advancing gestational age. Data from red 
cell label experiments however, has shown that the blood volume normalized for fetal 
weight remains relatively constant through gestation (Brace RA, 1993). Dilution o f the 
vector in the fetal circulation would thus be the same across gestational ages as long as
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the same dose per kg fetus was applied. The fetal circulation is fully formed and 
functional by the end of the embryonic period and there are no significant changes in 
the blood flow over the gestational ages we investigated. In the fetal sheep, about 50% 
of the umbilical venous flow passes through the liver with approximately equal 
distribution between the left and right lobes (Edelstone DI et al., 1978). The other 50% 
flows through the ductus venosus directly into the inferior vena cava and then to the 
heart, bypassing the fetal liver. Delivery o f gene therapy to the umbilical vein ensures 
its systemic distribution, as was borne out by the results o f vector spread from tissue 
PCR analysis.
In small animals such as the fetal mouse, UV injection has a high mortality, and 
injection o f the yolk sac vessel is used as an alternative route into the circulation. 
Indeed, yolk sac vessel injection o f adenovirus vectors containing the hFIX gene into 
fetal mice resulted in therapeutic levels o f hFIX expression (Waddington SN et al., 
2003b). Long-term transgene expression was observed in the liver, heart, brain and 
muscle up to a year after delivery o f lentivirus vectors containing the p-galactosidase 
gene into yolk sac vessels of fetal mice (Waddington SN et al., 2003c). This vector and 
route of injection was then used to achieve correction o f the haemophilic phenotype in 
factor IX deficient mice, without the development of immune reaction to the transgenic 
hFIX protein and provided one o f the first proofs o f principle for therapeutic prenatal 
gene transfer (Waddington SN et al., 2004b).
The sheep fetus is believed to be capable o f mounting an immune response between 65 
and 70 days of gestation. This is also the time in gestation at which we were able to 
inject the UV reliably. Although we were unable to demonstrate good gene transfer 
using the adlacZ vector, it is likely that an alternative and preferably integrating vector 
would be able to transfer genes efficiently to the fetal liver and adrenal gland in 
particular.
D 7.3 Ultrasound guided intrahepatic delivery of gene therapy can be 
achieved in early gestation fetal sheep
Studies in the fetal mouse show that intrahepatic delivery o f gene therapy vectors leads 
to transduction o f hepatocytes and so we investigated this route of application in the 
fetal sheep for the first time using ultrasound guidance. As a technique, ultrasound- 
guided intrahepatic injection was easy to perform in the fetal sheep and had a low rate 
of early and late morbidity and mortality. There is likely to be a limit to the volume of
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fluid that can be injected into the liver parenchyma before pathological damage is 
caused, although doubling the volume applied to 2 0 0 pl did not have a significant effect. 
Ultrasound guided intrahepatic injection has not been used for therapeutic indications in 
the clinical setting. Fetal liver biopsy has been reported for prenatal diagnosis o f inborn 
errors of metabolism such as ornithine transcarbamylase deficiency (Rodeck CH et al., 
1982) and glucose 6  phosphatase deficiency (Golbus MS et al., 1988b) in which a liver 
sample was required to test localised enzyme expression. The availability o f DNA 
analysis for some of these conditions has allowed prenatal diagnosis to be performed on 
chorion, fetal blood or amniocytes and has restricted the use o f liver biopsy to 
uninformative families. The procedure is usually performed from the early second 
trimester onwards. An outer 17G cannula is used to access the uterus and to allow 
placement o f an inner 19 Gauge needle into the fetal liver, where 10-25mg liver tissue is 
aspirated. The risk of complications such as haemorrhage is low and fetal loss is thought 
to be 1-2% (Vaughan JI and Rodeck CH, 2001).
Injection o f fluid into the liver parenchyma is likely to be a less invasive procedure than 
liver biopsy. Two studies have investigated ultrasound guided intrahepatic injection of 
gene therapy vectors in the late gestation fetal rabbit and Rhesus monkey when no fetal 
losses were observed (Baumgartner TL et al., 1999,Lai L et al., 2002) and in another 
study, two fetal Rhesus monkeys that received late first trimester intrahepatic injection 
o f retrovirus vectors survived to term (Tarantal AF et al., 2001c). We observed a fetal 
loss rate of 19%, which is likely to be due to the early gestational age at which 
procedures were performed. The necrosis observed within the liver parenchyma o f one 
fetus may be related to the injection procedure itself but a local hepatotoxic effect of 
adenovirus cannot be ruled out.
D 7.4 Direct injection of adenovirus vector into the liver of early 
gestation fetal sheep does not result in significant gene transfer
Because the fetal intravascular injection route was unsuccessful in early gestation, we 
attempted to reach the fetal liver by injection o f the liver parenchyma. This mode of 
injection, however, produced little or no hepatocyte gene expression as shown by 
immunohistochemistry and ELISA measurements for hFIX. Vector was present in the 
fetal and maternal liver and fetal heart only showing that very little haematogenic 
spread had occurred within the fetus. This was supported by the lack of systemic spread 
o f colloidal carbon after intrahepatic injection.
First generation adenovirus vectors are highly immunogenic and are known to have a
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tropism for hepatocytes. We observed haemorrhage and necrosis o f the liver with 
surrounding inflammation around the site o f vector injection in two fetuses. One 
possible reason for our findings may be that the strong tropism o f adenovirus for 
hepatocytes caused significant infection surrounding the injection site and the resulting 
cellular ‘over-load’ o f adenovirus infection and/or expression may have induced rapid 
cell death. Another explanation is that activation o f the humoral or innate immune 
systems by adenovirus destroyed hepatocytes that had been successfully infected. In all 
remaining fetuses we observed only very little inflammation although it cannot be ruled 
out that the sites o f vector injection might not have been analysed histologically in other 
fetuses due to sampling variations.
In the adult liver adenovirus gene therapy is limited by death o f hepatocytes expressing 
the gene therapy product (Yang Y and Wilson JM, 1995). This elimination is caused by 
both necrosis and apoptosis mediated via the innate and cell-mediated immune response 
to the adenovirus such as tumor necrPsis factor alpha and death domain receptors 
(Zhang H-G et al., 2002). Early induction o f chemokines in the liver within 24 hours of 
vector delivery has been observed and is thought to be directly responsible for hepatic 
injury (Muruve DA et al., 1999). Self-limited vector-induced hepatitis was found in a 
clinical trial of adenovirus gene therapy treatment o f partial ornithine transcarbamylase 
deficiency where the vector was infused into the right hepatic artery o f subjects (Raper 
SE et al., 2002). To achieve efficient hepatocyte transduction by systemic intravenous 
delivery, high doses are required but the dose o f adenovirus is o f critical importance for 
its ability to cause injury. In baboons, increasing the dose o f adenovirus vector delivered 
by intravascular infusion by a factor of 1 0  significantly increased transgene expression 
but resulted in severely abnormal blood, liver and biochemistry profiles and death 
within 48 hours (Morral N et al., 2002). A threshold effect was observed in mice for 
both transgene expression and hepatotoxicity but at a higher dose o f adenovirus.
An immune response to the adenovirus vector might explain the poor gene transfer we 
observed. There is evidence of a pre-thymic population o f immature lymphoid cells in 
the very early gestation fetal liver but these are no longer recognizable by 40 days of 
gestation, well before the age that fetuses in our study received intrahepatic injection. 
Lymphopoiesis occurs in the fetal thymus from 42 days o f gestation and lymphocytes 
first appear in the peripheral blood from 55 days of gestation. Subsequently 
lymphopoiesis occurs in the spleen, lymph nodes, bone marrow and Peyer’s patches as 
gestation advances (Al Salami M et al., 1985). Antibodies to the adenovirus vector were 
observed even 2 days after injection (see Section G), but they were at low level.
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Kupffer cells, the resident macrophages in the hepatic sinusoid, appear to play a major 
role in the adult immune response to adenovirus infection because their depletion before 
vector administration results in higher hepatocyte transduction and a nearly linear dose 
response (Tao N et al., 2001). Macrophages in fetal tissues including the fetal liver 
develop before the initiation o f bone marrow hematopoiesis. In the fetal mouse, 
macrophages capable of phagocytosis appear in the liver from 12 dpc (Naito M et al.,
1997) and from 13 weeks o f gestation human fetal Kupffer cells have the potential to 
respond to cytokines and lipopoly saccharide by increasing production o f tumor necrosis 
factor-alpha and interleukin-1 beta (Kutteh WH et al., 1991). Thus the response o f fetal 
Kupffer cells to the adenovirus vector may have contributed to the lack o f gene 
expression we observed.
In contrast to our findings, studies in the late gestation fetal mouse (15 dpc) show that 
intrahepatic injection o f adenovirus vectors resulted in high levels o f transgene 
expression in the liver and distant organs (Lipshutz GS et al., 1999b,Lipshutz GS et al., 
1999a) which declined over time (Lipshutz GS et al., 2000) in the absence o f an 
immune response. The fetal liver in the mouse may also be particularly sensitive to 
adenovirus. One study found the maximally tolerised dose o f adenovirus vector o f 1 x 
1 0 9 particles per fetus for intrahepatic injection to be at least one order o f magnitude 
lower than that for other routes o f delivery such as intramuscular or intra-amniotic 
injection (Mitchell M et al., 2000).
This is the only study of intrahepatic injection of viral vectors to the liver o f fetal sheep. 
Ultrasound guided intrahepatic injection has been performed in two other large animal 
models. In the late gestation fetal rabbit, X-gal staining of the fetal hepatocytes was seen 
2  days after ultrasound guided intrahepatic injection o f adenovirus vectors containing 
the p-galactosidase gene (Baumgartner TL et al., 1999). The dose o f vector applied, 2 x 
108 pfu per animal, equivalent to 5 x 109pfu per kg fetus assuming a fetal weight of 
40g, was similar to the low dose vector used in our experiments. On closer scrutiny the 
results are not so encouraging. O f 12 fetuses injected, only 6  had evidence o f p- 
galactosidase activity in the fetal liver, and in 2  o f these, it was confined to the liver 
serosa which the authors believed was probably due to erroneous intraperitoneal rather 
than intrahepatic delivery.
In the early gestation fetal primate, intrahepatic delivery o f HIV lentivirus vector 
resulted in lower levels o f transduced hematopoietic progenitors in the liver, bone 
marrow and blood when compared with intraperitoneal delivery (Tarantal AF et al., 
2001c). This is surprising since the fetal liver at this stage o f pregnancy is the main site
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of hematopoiesis. In addition, tissue distribution o f the vector as assessed by PCR 
analysis, was more restricted than following intraperitoneal administration. Together the 
data suggest that the poor gene transfer observed in our study was not simply due to the 
use o f adenovirus vector but the intrahepatic route itself may be an inhibitory factor.
It is likely that the gestational age at injection and the type o f vector applied are also 
factors influencing the gene transfer efficiency. In the late gestation rhesus monkey 
strong expression of transgenic enhanced green fluorescent protein was observed in 
hepatocytes one month after ultrasound-guided intrahepatic delivery of adeno- 
associated virus vectors (Lai L et al., 2002). Importantly vector genomes were detected 
throughout the fetal organs by PCR analysis supporting the concept that intrahepatic 
injection can achieve systemic spread. It is conceivable that delivery of a relatively large 
volume of fluid into the fetal liver in early gestation causes significantly more damage 
to the liver parenchyma than in late gestation. Delivery o f adenovirus that is known to 
be hepatotoxic, may compound the physical damage. We concluded that direct hepatic 
injection with either low or high dose adenovirus vector was unable to achieve 
significant tissue expression of reporter genes in the early gestation sheep fetus.
D 7.5 Ultrasound guided intraperitoneal injection is a low risk 
procedure to the early gestation sheep fetus
We applied ultrasound guided intraperitoneal injection in the fetal sheep as an 
alternative to intravascular injection at early gestations for systemic delivery o f gene 
therapy. The injection procedure was simple to perform, and an advantage o f the 
technique over intrahepatic injection was that it was easy to observe microbubbles in the 
peritoneal cavity to confirm correct needle placement. There were 3 fetal deaths out of 
15 fetal injections and the post mortem findings suggested these were probably related 
to the injection procedure or bacterial contamination o f the vector rather than a toxic 
effect o f the vector itself. The short term morbidity o f the procedure was moderately 
low, and the technique was even successfully applied at 40 days o f gestation in a few 
cases. In the medium to long-term there was significant intraperitoneal inflammation 
that could have been due to introduction o f adenovirus or the procedure itself. Certainly 
in one animal that came to birth, there appeared to be plant material in the fibrous 
peritoneal adhesions that was probably introduced during the procedure. Although the 
fleece o f the ewe is closely clipped over the abdomen before injection, it is extremely 
difficult to remove all the wool and the straw that is closely adherent to the fleece. 
Adenovirus is known to be highly immunogenic and its presence in the peritoneal cavity
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may have caused the chronic inflammatory process detected in the other fetuses. In the 
other animal that came to birth there was evidence o f hepatocellular dysfunction and 
cholestasis on serum biochemistry. Histological examination o f the liver showed mild 
chronic portal tract inflammation that was also present in many o f the ewes. There are a 
number of causes of hepatitis in ruminants including a wide variety o f plant toxins such 
as alkaloids and mycotoxins, viral and fluke infections (Kaneko JJ et al., 1997).
In clinical practice, intrauterine blood transfusion was first performed in the 1960s by 
intraperitoneal injection for fetuses affected by haemolytic disease (Liley AW, 1963). In 
the 1980s the mortality rate from intraperitoneal transfusion was found to depend on the 
presence of fetal hydrops, with the survival rate in hydropic versus non-hydropic fetuses 
o f 8 6 % and almost 100% respectively (Harman CR et al., 1990, Watts et al., 1988). This 
is because ascites reduces the absorption o f blood cells into the fetal circulation via the 
lymphatic drainage. Since then major advances in ultrasound technology have improved 
visualisation o f the fetus such that diriect intravascular transfusion is the route o f choice 
in most cases after 18 weeks o f gestation (Rodeck CH and Deans A, 2001,Harman CR 
et al., 1990). Intraperitoneal injection however, is still preferred for procedures before 
this gestational age when access to the fetal vasculature is hazardous or at any gestation 
if fetal positioning does not allow easy access to the fetal circulation. When 
intraperitoneal is combined with intravascular transfusion, an increased blood volume 
can be administered without overloading the fetal circulation, which allows a longer 
interval between transfusions (Nicolini U et al., 1989).
In the first trimester of pregnancy, ultrasound guided intraperitoneal injection has been 
used to apply in utero haematopoietic stem cell (HSC) transplantation for treatment of 
congenital disease in a number of cases (Westgren M et al., 2002,Flake AW et al., 
1996,Muench MO et al., 2001,Touraine, 1999). Early application was thought necessary 
to take advantage of the immunological immaturity o f the fetus and the space available 
in the developing bone marrow for engraftment of haematopoietic stem cells. One fetal 
death, due to graft versus host disease, has been reported 7 weeks after injection at 13 
weeks o f gestation (Bambach BJ et al., 1997), but no other fetal or neonatal 
complications have been observed.
In the fetal sheep, most studies of HSC transplantation or fetal gene therapy have been 
performed by intraperitoneal injection in the first trimester at laparotomy (Liechty KW 
et al., 2000,Zanjani ED et al., 1992,Westlake VJ et al., 1995,Porada CD et al., 1998).
One study o f HSC transplantation using ultrasound guided intraperitoneal injection 
between 45 and 60 days of gestation, found a fetal loss rate of 25% at term ( 6  out of 25
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fetuses), the majority occurring up to 14 days after the procedure (Young AJ et al., 
2003). The authors used a larger 20 Gauge needle which would be more traumatic and 
as anticipated, they observed a higher loss rate in twin pregnancies where both twins 
were injected. Survival in fetal primates was 100% following first or second trimester 
ultrasound guided intraperitoneal injection of HSCs or retrovirus vectors (Asano T et 
al., 2003,Shields LE et al., 1995,Tarantal AF et al., 2001c).
D 7.6 Intraperitoneal delivery of adenovirus vectors using 
ultrasound guided injection results in widespread gene transfer to 
the sheep fetus
Our poor results following intrahepatic delivery contrast those from intraperitoneal 
injection. We achieved therapeutic levels o f hFIX in the fetal plasma 2 days after 
injection and low level hFIX expression was evident at birth and 5 months o f age, over 
8  months after the fetal injection. This was probably because several tissues were 
successfully transduced as shown by the wide haematogenic spread observed on first 
round and nested PCR analysis for the hFIX transgene and adlacZ vector when 
compared with other routes o f adminstration at this early gestation. We localised p- 
galactosidase expression using immunohistochemical analysis to tissues that lined the 
peritoneal and pleural cavity and hepatocytes in the liver periphery. Many o f these 
tissues are epithelial cell surfaces that the vector would have made contact with after 
injection and which provide a large surface area for viral transduction.
As expected, the level o f hFIX gene expression fell significantly before birth. This was 
possibly due to the transient nature o f adenovirus expression since the transgene is not 
inserted into the genome but remains episomal. Transcriptional inactivation o f the CMV 
promoter driving hFIX expression may also be an important consideration for loss of 
gene expression (Loser P et al., 1998). Another likely contributor to the observed fall in 
hFIX concentration is the increase in the fetal blood volume over time as the fetus 
grows rapidly. Development o f an immune response to the adenovirus or transgene is 
also a possibility and this is discussed further later.
We detected the adlacZ vector and the hFIX transgene in the placenta and the maternal 
liver, ovary and lung on PCR analysis, although no transgene expression was detectable 
in these tissues. Gene transfer to the placenta is not an issue because the placenta is 
disconnected from the body following delivery. Transduction o f maternal tissues is a 
potential problem for integrating vectors when a route o f vector application results in 
haematogenic spread. In the mother the main issue is with inadvertent transduction of
167
D. RESULTS: Haemophilia B
the ovary that conceivably could lead to germline alteration and this is discussed further 
in Section D 7.9.
In small animals, intraperitoneal injection of adenovirus vectors has been used for 
successful gene transfer to multiple tissues including the heart and liver in fetal mice 
(Bouchard S et al., 2003,Lipshutz GS et al., 1999c) As we observed, transgene 
expression after adlacZ administration is primarily confined to the liver capsule, the 
intestine and peritoneal cavity (Lipshutz GS et al., 1999b). Therapeutic levels o f FVIII 
have been achieved after intraperitoneal injection o f hemophiliac mice with an 
adenovirus vector containing the FVIII gene (Lipshutz GS et al., 1999c) but only 
transient phenotypic correction was observed.
In rats, ecotropic retroviruses were able to infect the fetal liver after intraperitoneal 
administration but only temporary transgene expression occurred. Partial hepatectomy 
reactivated expression for over a year and this is believed to be mediated via DNA 
replication activating expression o f the viral promoter (Hatzoglou M et al., 1995).
When compared with adenovirus, intraperitoneal administration o f AAV produces 
lower levels of transgene expression but over a longer time period (Schneider H et al., 
2002,Bouchard S et al., 2003). Persistent peritoneal expression was observed 18 months 
after intraperitoneal injection o f adeno-associated virus serotype 2 (AAV2) vectors 
containing the luciferase gene in fetal mice (Lipshutz GS et al., 2001b) and altering the 
AAV serotype and the promoter can further increase transgene expression (Lipshutz GS 
et al., 2003). Intraperitoneal injection has also been shown to be an effective route for 
administration of non-viral vectors such as cationic liposome-DNA complexes 
(Gaensler KML, 1999) and plasmid DNA (Gallot D et al., 2002), resulting in 
widespread transgene expression in multiple fetal tissues and types.
In large animal models intraperitoneal injection is an effective route o f administration 
for integrating vectors although long-term transgene expression is still a concern 
Retrovirus vectors containing the a-L-iduronidase gene were delivered by ultrasound 
guided injection after exteriorisation of the uterus, into the peritoneal cavity or yolk sac 
o f mid-gestation fetal dogs with canine a-L-iduronidase deficiency (muco­
polysaccharidosis type 1). Widespread tissue transduction was seen and the fetal liver 
and kidney were targeted in particular (Meertens L et al., 2002). Surprisingly transgene 
expression did not persist beyond the neonatal period and this was thought to be due to 
the low dose o f virus applied.
In early gestation fetal primates, Tarantal et al delivered retrovirus vectors by ultrasound 
guided intraperitoneal injection (Tarantal AF et al., 2001c) with the aim o f gene transfer
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to hematopoietic progenitors. Haematogenic spread o f the vector was detected by PCR 
analysis o f fetal tissues but transgene expression fell significantly at birth and was not 
detectable by 3 months of age. The loss o f gene expression was probably due in part to 
methylation of the CMV-IE promoter element in the recombinant vectors. The finding 
that transgene expression in peripheral blood leukocytes in vitro could be reactivated by 
exposure to 5-azacytadine, a potent inhibitor o f DNA methylase, confirmed this. In 
contrast, Porada et al demonstrated persistent gene marking of hematopoietic stem cells 
in the bone marrow and blood 5 years following delivery o f Moloney murine leukemia 
viral vectors ( 2  x 1 0 5 -  1 x 1 0 6 particles) into the peritoneal cavity of early gestation 
fetal sheep at laparotomy (Porada CD et al., 1998). This was nevertheless low level with 
only 1% of peripheral blood leukocytes transduced and in 50% o f animals, no transgene 
expression was found. When the titre o f retrovirus was increased by 100 fold, the level 
of transduced peripheral blood leukocytes reached 6 % (Tran ND et al., 2000) suggesting 
that viral titre is an important factor influencing gene transfer.
The hFIX level and the widespread distibution o f the vector that we observed after 
intraperitoneal injection indicate that this is a universal and effective route for gene 
delivery in early gestation. The procedure is relatively straightforward, safe and reliable 
as compared with intravascular delivery and represents a useful therapeutic approach for 
in utero gene therapy in early gestation.
D 7.7 Ultrasound guided intramuscular injection is a low risk 
procedure in the early gestation sheep fetus
This is the first study to explore ultrasound guided intramuscular delivery of gene 
therapy in a large animal model at any gestational age. In small animals such as fetal 
mice, striated muscle can be used as an alternative site for transgene expression. We 
investigated this route of administration in early gestation when the fetal sheep is 
believed to be preimmune. At this age the volume of muscle present on the fetal thigh 
and buttocks was small and this initially presented difficulties at injection. We refined 
the procedure to place the needle in the muscle parallel to the fetal femur or pelvic bone 
to reduce backflow of the vector during injection. Despite this precaution, it is likely 
that some of the vector tracked from the injection site into the amniotic fluid. In 
addition, to increase the dose o f vector that each fetus received, we performed a number 
of injections on one fetus, injecting only small volumes o f vector at each injection site. 
Multiple injections will cause more trauma to the fetus but they are unavoidable at this 
early gestational age when the fetal muscle bulk is so small. Nevertheless, the morbidity
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and mortality of the procedure was low and it carried the lowest mortality rate of all 
early gestation routes of administration, making it a potentially clinically useful 
application method.
The muscle haemorrhage and inflammation observed histologically in many of the 
fetuses is likely to have resulted from the injection procedure itself, although the 
adenovirus vector may have contributed. Intramuscular injection in late gestation fetal 
sheep was very straightforward with no complications observed. In early gestation the 
only significant pathology we observed were the dense perihepatic adhesions in one of 
the lambs that delivered. It seems unlikely that injection o f the muscle could have lead 
to an inflammatory reaction in the peritoneal cavity and the adhesions might have been 
secondary to hepatitis that is common in ruminants (Kaneko JJ et al., 1997).
Ultrasound guided intramuscular injection has been used to deliver glucocorticoids to 
the mid - late gestation fetal sheep (from 104 days o f gestation) by single or repeated 
injection and has a low complication rate (Jobe AH et al., 1996,Willet KE et al., 2001). 
In clinical practice intramuscular injection is not used therapeutically, although two 
pilot studies of intramuscular vitamin K (Larsen JF et al., 1978) or glucocorticoid 
injection (Ljubic A et al., 1999) in late gestation found no complications. Fetal muscle 
biopsy is performed for prenatal diagnosis o f muscular dystrophies in families in which 
DNA studies are uninformative (Vaughan JI and Rodeck CH, 2001). Biopsies are 
usually performed from 18 weeks of gestation because o f the risk of biopsy failure, and 
the complication rate is low (Evans MI et al., 1994). The optimum gestational age for 
intramuscular delivery of gene therapy in the human fetus would need to be a 
compromise between the safety and reproducibility o f the procedure and the efficacy of 
gene transfer.
D 7.8 Therapeutic levels of hFIX transgene are detected in the fetal 
plasma after ultrasound-guided intramuscular injection of 
adenovirus vectors
Ultrasound guided intramuscular delivery o f gene therapy in the early gestation fetal 
sheep achieved low but nevertheless therapeutic levels o f hFIX transgenic protein in the 
plasma up to nine days after injection. Despite the large doses of adenovirus used, 
injection in the fetal muscle did not lead to major destructive or inflammatory reactions 
although a cellular infiltrate was observed in the muscle o f three animals up to 9 days 
after injection. Positive p-galactosidase staining restricted to a small region at the site of 
injection was detectable. This limited area o f expression may explain the rather low
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level of hFIX expression in the blood at the two day time point. Haematogenic spread 
was also less than that observed after intraperitoneal delivery as evidenced by the small 
amount of p-galactosidase expression in fetal hepatocytes and lower level spread 
detected by PCR analysis.
In adult mice, binding o f hFIX in the muscle may reduce its levels in the plasma. 
Experiments on intramuscular injection o f adhFIX suggested transgenic hFIX was 
bound not only in the muscle fibres but also in the interstitial spaces and colocalized 
with collagen IV protein using immunofluorescent staining (Herzog RW et al., 1997). 
Human factor IX binds specifically to collagen IV (Wolberg A et al., 1997) in the 
extracellular matrix o f endothelial cells in vitro (Cheung WF et al., 1996). In our study 
however, positive hFIX expression on immunohistochemistry was limited to the fetal 
myocytes only and not observed in the interstitial spaces. This could be due to the 
species difference or more likely the maturity o f fetal striated muscle at 50 -  60 days of 
gestation.
Developmental changes in the fetal muscle also may have reduced hFIX expression. In 
the human fetal quadriceps muscle, myoblasts fuse into primary myotubes from the 6 th 
week of gestation and by 11 -  16 weeks o f gestation, newly generated myoblasts 
surround and fuse with them to rapidly increase the number o f cells in the muscle and to 
form secondary myotubes (Barbet JP et al., 1987). At the same time, equivalent to 36 to 
58 days of gestation in the sheep fetus, numerous primary myotubes undergo 
degeneration and by 18 weeks of gestation, equivalent to 65 days in the sheep fetus, the 
first immature muscle fibers are observed (Fidzianska A and Goebel HH, 1991). Thus 
many transduced cells may undergo necrosis and death as a result o f the normal 
development of striated muscle.
Muscle tissue is a promising target for gene therapy. Because mature muscle is 
composed o f multi-nucleate post-mitotic myofibers, it might allow high-efficiency long­
term expression o f introduced genes. Muscle tissue is also highly vascularized and as 
such, may facilitate the systemic delivery o f potentially therapeutic non-muscle 
products such as growth factors, clotting factors or erythropoietin for example. 
Transduction o f mature as compared with immature muscle fibers is poor (Ascadi G et 
al., 1994,Acsadi G et al., 1994) and there appear to be a number of factors involved. The 
extracellular matrix acts as a physical barrier blocking the entrance o f viral particles 
such as Herpes Simplex Virus (HSV) into mature myofibers (Huard J et al., 1996). In 
contrast, HSV particles can penetrate myofibers isolated from neonatal mice that are 
immature, and from mature homozygous dystrophic mice that have an abnormal
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extracellular matrix. CAR expression is lower in adult compared with neonatal skeletal 
muscle. Increasing expression of the CAR receptor in adult muscle however, enhances 
susceptibility to adenovirus transduction (Nalbantoglu J et al., 2001). Fetal muscle may 
have advantages over adult muscle as a target for gene therapy. The basal lamina is 
immature (Borck C, 1977) facilitating access o f viral vectors and there is a high level of 
CAR expression in fetal striated muscle (Bilbao R et al., 2003b). There are large 
numbers of myoblasts that fiise with developing myofibers and these may serve as 
intermediate carriers o f genes, should integrating vectors be applied.
Studies of fetal gene transfer by intramuscular injection are confined to the mouse 
model. Injection of adenovirus vectors containing the p-galactosidase gene into the 
shoulder or hindlimb musculature resulted in persistent muscle transgene expression for 
up to 4 months and haematogenic spread to the liver was observed (Yang et al.,
1999a,Mitchell M et al., 2000). Previous work in our group achieved in vivo hFIX 
expression at therapeutic levels up to 6  months after injection o f adenovirus and AAV 
hFIX vectors in fetal mice (Schneider H et al., 2002). There were no antibodies to the 
hFIX transgene detectable in the serum at any time point after birth, which is similar to 
our findings in the fetal sheep (see Section G). In contrast to our results however, 
antibodies to the adenovirus vector were not detectable and there was no inflammatory 
reaction in the fetal muscle. This could be due to species differences or the relatively 
low dose of adenovirus vector applied. The absence o f antibodies in the mouse study 
may also explain the long-term transgene expression observed.
Intramuscular injection of lentivirus vectors in fetal mice leads to transduction o f the 
injected muscle groups with greatest efficiency from the Ebola and Mokola pseudotypes 
and expression persisted up to 10 weeks and 6  months respectively (MacKenzie TC et 
al., 2002). There was evidence of haematogenic or lymphatic spread from the injection 
site since cardiomyocytes and myocytes in the diaphragm were transduced after 
injection o f the left hindlimb. This is encouraging when considering that these are some 
of the muscle groups that would need to be targeted for successful gene therapy of the 
life-threatening muscle wasting disorders such as Duchenne muscular dystrophy 
(DMD). These congenital diseases are caused by mutations in the dystrophin gene, the 
protein product o f which aids membrane stabilization and force transduction from 
muscle fibres. A major problem with a gene therapy strategy for treatment of DMD is 
the very large size o f the dystrophin gene (2.4Mb) although progress has been made in 
constructing a micro- and mini-dystrophin (3.6 - 14 kb) cassette. When this was applied 
in an adeno-associated virus vector to the leg muscle o f neonatal and adult mdx mice it
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led to normal myofiber histology and protected membrane integrity (Wang B et al., 
2000). There is also a need to target this correct gene or sequence to most striated 
muscle groups in the body including the diaphragm, and cardiac muscle. A fetal 
approach offers a possible solution to this problem since correcting muscle precursor 
cells by gene transfer with a long term expressing vector would lead to continuous 
production o f dystrophin in the adult. A recent study using VSV-G pseudotyped EIAV 
lentivirus containing the lacZ gene, combined intrathoracic, supracostal, intraperitoneal 
and intramuscular injection o f three limbs and a single flank in the fetal mouse. This 
resulted in widespread gene expression in all injected muscles and also the diaphragm 
and heart (Gregory LG et al., 2004). Transgene expression was maintained for at least 5 
months and no cellular or humoral immune response was detected in this time. Our 
demonstration that ultrasound-guided intramuscular injection is feasible in a large 
animal model with a low morbidity and mortality rate is a step towards possible clinical 
application o f fetal gene therapy for treatment of muscular dystrophies.
D 7.9 Gene transfer to the germline
Vector spread is an important consideration when attempting in utero gene delivery. 
Ideally gene transfer should be restricted to the tissue o f interest for production o f the 
therapeutic protein. Although this is less significant for systemic production o f hFIX, it 
is more important for diseases such as cystic fibrosis, Duchenne muscular dystrophy 
and glycogen storage disorders. It is also central to avoiding inadvertent gene transfer to 
the germ line that currently is ethically unacceptable.
There is concern that prenatal vector administration may carry a higher risk of 
inadvertent gene delivery to germ cells (Billings PR, 1999). The adenovirus vectors we 
used reached the fetal gonads after intraperitoneal, intramuscular, intragastric and 
intratracheal injection, albeit detected only by sensitive PCR. However analysis o f the 
semen o f rams born after in utero early gestation intraperitoneal, intramuscular or 
intrahepatic treatment showed no detectable vector. It is likely therefore, that despite the 
virus reaching the gonad by these routes o f administration, it is either unable to reach or 
to infect the primordial germ cells. It is surprising that we did not detect transgenic 
DNA in the gonad following umbilical vein delivery at 60 days o f gestation, because 
this route gives systemic vector spread. In the previous study on late gestation fetuses 
there was evidence of adenovirus vector in the fetal gonads after intravascular gene 
delivery, but no gene expression was detected by RT-PCR analysis. In keeping with 
another study o f intra-amniotic delivery in fetal primates (Larson JE et al., 2000b), we
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did not detect transgenic DNA in the fetal sheep gonad following intra-amniotic 
delivery, even at the very early gestation we studied.
Germline transmission has also been studied after early gestation intraperitoneal 
delivery o f retrovirus vectors to fetal sheep (Porada CD et al., 1998,Tran ND et al.,
2000). Proviral DNA was detectable in the testes and whole ejaculate o f four fetally 
injected sheep. No sequences were present however in a pure population o f sperm cells 
isolated from the ejaculate on five separate occasions, and more importantly, there was 
no transmission o f the proviral DNA to the offspring o f these animals. A similar risk of 
germline transduction occurs with adeno-associated virus (AAV) that can integrate at 
low level into the genome. No AAV sequences were detectable in the germline tissues 
of fetal mice receiving injection of AAV vectors via the intraperitoneal route nor the 
tissues o f their progeny (Lipshutz GS et al., 2001b,Lipshutz GS et al., 2003). A clinical 
trial o f gene therapy for hemophilia B using AAV vector was briefly suspended when 
vector genomes were detected in the semen of participants, although this was shown to 
be only a temporary finding (Manno CS et al., 2003).
The chances of germline transduction occurring in the mother are low because there is a 
blood-follicle barrier present in the ovary and the eggs are held in meiotic metaphase 
arrest until fertilization. Results from evaluation o f maternal tissues in other studies o f 
large animal fetal gene therapy are reassuring. No vector sequences were detectable in 
maternal tissues following intraperitoneal delivery o f retro- and lentivirus vectors to 
early gestation Rhesus monkeys (Tarantal AF et al., 2001c). In the sheep, proviral DNA 
was present in the maternal ovary after early gestational intraperitoneal delivery of 
retrovirus vectors, but no vector sequences were detected in the tissues o f her later 
offspring (Tran ND et al., 2000).
Compartmentalisation o f the primordial germ cells in the gonads is complete by 7 
weeks o f gestation in humans and it is unlikely therefore that any therapy applied after 
this time would result in fetal germ-line transduction. Many o f these issues are not 
confined to in utero or even adult gene therapy and concerns regarding germ-line 
transmission can be raised in particular for chemotherapy treatment (Schneider H and 
Coutelle C, 1999). Further studies using appropriate vectors for long-term gene 
expression which are more relevant to the aims o f fetal gene therapy, such as integrative 
viruses, should be made on larger numbers o f animals to evaluate this risk. An 
important and more recent strategy for tissue restricted and therefore safer gene transfer 
may be the use o f tissue specific vector targeting (Engelstadter M et al., 2001).
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E Prenatal gene therapy for cystic fibrosis
Cystic fibrosis is a systemic disease o f most secretory epithelia and so the major 
affected organs are the lungs, pancreas, gut and liver. In these experiments we 
investigated minimally invasive methods o f targeting gene therapy to the airways and 
small bowel o f sheep fetuses since disease in the lungs and gut are leading causes of 
death from CF.
E 1. Ultrasound guided intra-amniotic delivery as a route to the 
fetal airways
In these experiments we were aiming to develop a minimally invasive ultrasound 
guided technique to deliver adenovirus vectors to the airways o f sheep fetuses as early 
as possible in gestation and we began by investigating intra-amniotic delivery. Delivery 
o f adenovirus vectors to the amniotic cavity results in transduction of the fetal skin 
(Schneider H et al., 1999). A number o f authors have also tried to target viral vectors to 
the fetal airways via intra-amniotic injection. In small animals such as the fetal mouse, 
transduction o f the airways can be achieved (Douar A-M et al., 1997), but the route is 
less successful in larger animals such as the fetal rabbit (Boyle MP et al., 2001) or fetal 
primate (Larson JE et al., 2000b) probably due to the dilution o f the vector by the large 
volume o f the amniotic fluid. We considered intra-amniotic injection to be the safest 
delivery technique and therefore we investigated its application earlier in gestation at 
33-39 days (0.23-0.26 term), equivalent to 8  - 10 weeks o f gestation in humans. 
Amniotic fluid from the early gestation fetal sheep had already been shown to have no 
effect on the ability o f adenovirus vector to infect cells in vitro (Mike Themis, personal 
communication).
E 1.1 Ultrasound guided intra-amniotic injection is possible in early 
gestation fetal sheep
We applied adlacZ and adhFIX vectors to the amniotic cavity o f fetal sheep at the 
earlier gestation o f 33-39 days (n = 14). Our first attempt at intra-amniotic injection was 
complicated by the presence of the larger allantoic cavity and the relative flaccidity of 
the amniotic membrane at this gestational age. We overcame this initial difficulty 
entering the amniotic cavity in the fetal sheep by directing the needle close to the fetus 
and flicking it through the amniotic membrane (Figure E 1). In the fetal sheep the 
allantois expands rapidly from 28 days o f gestation via the urachus to occupy both
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horns o f the uterus and contains fluid until term (Latshaw WK, 1987). The amnion 
begins to enlarge from 25 days but only stands away clearly from the fetus by 30 days 
o f gestation (Cloete JHL, 1939). In addition the allantoic fluid volume (45.7 ml) is 
approximately ten times that of the amniotic fluid (2.3 ml) at 31 days o f gestation but 
there is a rapid increase in the amniotic fluid volume, so that by 44 days o f gestation, 
there is only a two fold volume difference (95.3 ml versus 38.8 ml respectively) (Wales 
RG and Murdoch RN, 1973). Correct needle placement was confirmed by withdrawal 
o f amniotic fluid and by observing microbubbles around the fetus in the amniotic cavity 
on injection o f 0.9% sodium chloride solution and vector. Intra-amniotic injection was 
achieved at the first attempt in all fetuses and excluding the time taken to complete first 
procedure (26 minutes), the mean time to successful injection in all other cases was 3 
min 39 sec (± 3 min 11 sec, range 1-10 min).
tip o f 22 Gauge JM  
needle within 
amniotic cavity
fetus in 
longitudinal
Figure E 1: Ultrasound-guided intra-am niotic injection in early gestation.
The ultrasonogram shows intra-amniotic delivery o f  adhFIX vector to a fetal sheep aged 33 days o f  
gestation (A 14).
A small volume of amniotic fluid was withdrawn before injection o f the vector, and as 
can be seen in Table E 1, analysis o f the osmolality and electrolytes confirmed this was 
amniotic rather than allantoic fluid. At this stage o f gestation the composition of 
amniotic fluid is close to a dialysate o f fetal plasma, while allantoic fluid is hypotonic 
since it has been filtered by the mesonephros, the primitive kidney that is active in fetal 
sheep from 17 days until full regression by 57 days o f gestation.
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Table £  1: Amniotic and allantoic fluid osmolality and biochemistry in early 
gestation sheep fetuses.
Fluid was obtained from fetuses aged 33 -  39 days o f  gestation. Measurement o f  K+ concentration in 
amniotic fluid was inaccurate because at this gestation it is very high (normal range 17 ± 2 mmol/1) and 
the electrolyte analyser was unable to process the sample. For comparison, the osmolality and electrolytes 
in the allantoic fluid o f  one fetus removed at post mortem analysis is shown. *: denotes normal ranges 
from fetal sheep at 31 days o f  gestation (Wales RG and Murdoch RN, 1973).
Sheep Na+ (mmol/1) Cl (mmol/1) Osmolality 
(mOsm/kg w ater)
A2 140 142 292
A4 154 140 260
A5 147 135 292
A6 149 135 274
A l 159 145 2 0 1
A8 150 137 183
A9 155 142 288
A10 160 143 261
A ll 131 114 283
A12 1 21 1 1 1 293
A13 127 1 11 262
A14 159 141 290
A15 132 115 306
A15 (allantoic fluid post op) 6 6 64 229
Amniotic fluid* 136 ± 14 124 ± 10 293 + 3
Allantoic fluid* 89 ± 2 61 ± 5 214 ± 8
E 1.2 Ultrasound guided intra-amniotic injection has low morbidity 
and mortality
Fetal survival after intra-amniotic injection was 100% at 2 days following injection and 
8 6 % at term (Table E 1). One fetus of a twin pair that was still alive on day 5 after 
operation (ultrasound visible heart beat), was resorbed on day 9 at the time of post 
mortem sampling. This is a relatively common finding in normal early twin gestations 
in fetal sheep and may be unrelated to the procedure itself. Histological analysis o f all 
fetal and maternal tissues was normal apart from that o f the first fetus to be injected 
(A l), which showed evidence o f acute bacterial chorioamnionitis. This was probably 
procedure related and the difficulties encountered entering the amniotic cavity are likely 
to have been a contributing factor.
Two lambs were left to delivery. Because o f the foot and mouth epidemic it was not 
possible to access the ewes to assess fetal wellbeing by ultrasonography from mid­
gestation onwards. One lamb aborted at 136 days o f gestation as a fetus papyraceous
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although fetal measurements at post mortem investigation suggested fetal demise at 80 
days o f gestation. Although this is commonly associated with chlamydial infection in 
sheep, there was no evidence o f past or current infection in the maternal serum, or other 
causes o f miscarriage such as toxoplasma infection. The other lamb delivered at term 
with multiple congenital skeletal abnormalities including torticollis and the animal was 
euthanased because o f feeding difficulties and failure to thrive.
Table E 2: Ultrasound-guided intra-amniotic delivery of adenovirus vectors in the 
early gestation sheep fetus.
*: twin fetus pairs; d: days; Vol: volume o f  virus injected; p/kg: particles per kg; PM: post mortem.
Sheep GA (d) sampling Vector Vol (pi) Dose (p/kg)
Al 33 2d adlacZ 1000 4.4 x 1015
A2 39 2d adlacZ 300 1.8 x 1012
A9* 35 2d adhFIX 250 1.0 x 1013
A10* 35 2d adhFIX 250 1.2 x 10'3
A13 33 2d adhFIX 100 4.0 x 1013
A14 39 2d adhFIX 100 4.0 x 10U
A15 39 2d adhFIX 100 4.5 x 10l3
A7* 36 9d adhFIX 250 1.0 x 1013
A8* 36 resorbed at 9d adhFIX 250 1.0 x 1013
A12 36 l id adhFIX 250 1.0 x 1013
A4 36 28d adhFIX 250 1.0 x 10l3
A ll 36 28d adhFIX 250 1.0 x 10lj
A5 36 aborted at 1 OOd adhFIX 250 1.0 x 10lj
A6 36 birth adhFIX 250 1.0 x 10|J
E 1.3 Therapeutic levels of hFIX are detected after early gestation 
intra-amniotic delivery of adhFIX
Because o f their small size it was very difficult to take blood from fetuses 2 days after 
intra-amniotic injection, and plasma was only available from two o f the five fetuses 
sampled; no hFIX expression was detected in the plasma o f these fetuses. In those 
fetuses for which plasma was not available, hFIX was expressed in the amniotic fluid at 
levels o f 610, 66.5 and 39ng/ml on day 2 after injection and may have been produced by 
the fetal keratinocytes and/or amniotic membranes. Therapeutic levels o f hFIX were 
detected in the plasma of fetuses sampled on day 9 (103.5ng/ml), 11 (53.5ng/ml) and 
day 28 (49 ng/ml) after injection. Plasma from another fetus sampled 28 days after 
injection and a lamb sampled at birth had levels o f hFIX below the reliable detection 
level o f the assay (Figure D 20, Table E 3).
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Table £  3: Transgene expression after ultrasound-guided intra-am niotic injection 
of adenovirus vectors in early gestation fetal sheep.
* denotes twin fetus; GA: gestational age; d: days; +++ indicates degree o f  transduction observed after X  
gal staining or p-galactosidase immunohistochemistry; nt: not tested; t indicates testing o f  amniotic fluid.
sheep PM GA
(d)
Vector Dose
(P/kg)
X gal staining or 
hFIX level in plasm a 
and/or f  amniotic fluid 
ng/ml (% )
P-galactosidase
im m uno­
histochemistry
Al 2d 33 adlacZ 4.4 x 1012 +-H - +++
A2 2d 39 adlacZ 1.8 x 1012 +++ H—1—b
A9* 2d 35 adhFIX l.Ox 1013 1*66.5 (1.33%) nt
A10* 2d 35 adhFIX 1.2 x 1013 t39  (0.78%) nt
A13 2d 33 adhFIX 4.0 x 1013 1610(12.2%) nt
A14 2d 39 adhFIX 4.0 x 10l3 o, to nt
A15 2d 39 adhFIX 4.5 x 10l3 o, to nt
A7* 9d 36 adhFIX l.Ox 1013 103.5 (2.07%) nt
A12 l id 36 adhFIX l.Ox 1013 53.5 (1.07%) nt
A4 28d 36 adhFIX l.Ox 10'3 49 (0.98%) nt
A ll 28d 36 adhFIX l.Ox 1013 0 nt
A6 birth 36 adhFIX l.Ox 1013 0 nt
E 1.4 p-galactosidase expression is observed in those fetal tissues 
in contact with the amniotic fluid after intra-amniotic delivery
X gal staining o f fetal tissues 2 days after intra-amniotic adlacZ vector injection showed 
extensive expression in the fetal skin and amniotic membranes (Figure E 2 A-C). 
Immunohistochemistry showed positive p-galactosidase expression in fetal 
keratinocytes in the fetal skin, on the surface o f the cord and in the epithelial lining of 
the nasal cavities (Figure E 2 D-E).
In summary we observed significant gene transfer to those fetal tissues that are in 
contact with the amniotic fluid together with therapeutic levels o f the hFIX transgene in 
the circulation. This suggests that the amniotic route o f application may be useful for 
targeting genes to the very early gestation fetus.
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Figure E 2: p-galactosidase transgene expression after intra-am niotic delivery of 
adlacZ vector.
X gal staining (A-C) and immunohistochemical analysis (D-F, haematoxylin counterstain) 2 days after 
intra-amniotic delivery o f  adlacZ vector in early gestation. Positive transgene expression is seen in the 
fetal skin over the lower leg (A), thigh (B) and amniotic membranes (C) on X gal staining o f  one fetus 
(A l, 4.4 x 1012 p/kg), and in the keratinocytes o f  the fetal skin (D), surface o f  the umbilical cord (E) and 
epithelial lining o f  the nasal cavity (F) o f  another fetus (A2, 1.8 x 1012 p/kg). Original magnification o f  
immunohistochemistry sections x 20 except where indicated.
E 1.5 Attempts to stimulate fetal breathing movements in mid­
gestation fetal sheep
Transduction o f fetal airways using intra-amniotic delivery may be improved by 
stimulating fetal breathing movements (FBM). Spontaneous FBM are known to start in 
the fetal sheep from about 50 days (Cooke IRC and Berger PJ, 1990) and in humans at 
about 10 weeks o f gestation (de Vries JIP et al., 1986). In general animal studies have 
used fetal intravenous infusions of theophylline to study their effect on FBM. 
Intravenous theophylline administered to the ewe has been shown to increase FBM in 
the late gestation fetal sheep during normoxia or hypoxia (Moss IR and Scarpelli EM, 
1981). In humans, intravenous infusion of theophylline in the mother has been shown to 
stimulate FBM thereby increasing inhalation o f intra-amniotically injected surfactant 
(Cosmi EV et al., 1996).
Dr Suzy Buckley’s work in our laboratory investigated adlacZ transduction and/or 
colloidal carbon intake into the fetal mouse lungs. Subcutaneous theophylline injection 
to the pregnant mother (2mg) did not result in any significant increase in adlacZ 
transduction of the fetal airways. However, when intra-amniotic adlacZ and 
theophylline (dose 40-160pg per fetus) was co-administered with maternal hypercapnia
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(10% CO2), fetal airways transduction appeared to increase, and quantitative levels of p- 
galactosidase expression analysed by ELISA reached statistical significance (p=0.043). 
Intake o f intra-amniotic injected colloidal carbon was significantly increased (p<0.01) 
when co-administered with theophylline and maternal hypercapnia.
It was not known whether intra-amniotic administration o f theophylline might have a 
similar stimulatory effect on FBMs in the fetal sheep. We tested this therefore, on twin 
mid-gestation sheep fetuses in which we had failed to inject the trachea in the fetal neck 
(CC4, see Section E 2.6) during development o f the ultrasound-guided tracheal 
injection technique.
Theophylline (40mg) and colloidal carbon (500pl) were injected into the amniotic 
cavity o f twin fetuses at 81 days o f gestation. The dose o f theophylline applied was 
determined by extrapolation from the fetal mouse data. A day 16 post conception fetal 
mouse weighs lg  and a sheep fetus aged 80 days of gestation would weigh 
approximately 500g. Since the optimum theophylline dose in the fetal mouse amniotic 
cavity was 80pg this gave a dose o f 40mg theophylline into the fetal sheep amniotic 
cavity.
Both twins received an intra-amniotic injection since it was considered likely that 
theophylline would diffuse across the amniotic membranes. No FBM were seen in 
either twin, before or after theophylline injection. One twin that was alive 24 hours after 
operation was found dead at post-mortem 48 hours later. Histology o f this twin showed 
meconium and small amounts o f colloidal carbon in the airways, but none in the fetal 
gut; histology o f the other fetus that was alive at postmortem analysis was normal. 
Although acute hypoxia is known to depress FBMs in sheep (Boddy K et al., 1974), 
gasping has been observed before death in the sheep fetus (Patrick JE et al., 1976) and 
this is likely to have caused the histological findings. It is also possible that theophylline 
which is known to stimulate FBMs during hypoxia (Bissonnette JM et al., 1990) may 
have had an effect. However no colloidal carbon was found in the lungs o f the surviving 
twin fetus, suggesting that intra-amniotic theophylline at the dose applied in a normoxic 
fetus had no effect on FBMs. We had planned to perform further experiments in fetal 
sheep should we fail to achieve ultrasound-guided tracheal injection, but this was 
superseded by the successful development of this route o f injection.
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E 1.6 Haematogenic vector spread is observed after intra-amniotic 
injection in early gestation
We investigated the spread o f vector in the fetal and maternal tissues after intra- 
amniotic delivery by PCR analysis (Table E 4). Because o f the small size o f fetuses 
sampled 2 days after injection and the difficulty identifying organs, we also analysed 
vector spread in a wide range o f tissues from one animal sampled 28 days after vector 
delivery (A4). DNA from the vector or the transgene was detected in the fetal liver, 
skin, lung, heart, umbilical cord and membranes analysed by 1st round PCR analysis. 
Low levels o f vector were also found in the maternal liver and gonads.
Table E 4: Vector spread after intra-amniotic delivery of adenovirus vectors to 
fetal sheep in early gestation.
Transgenic hFIX (hFIX) or adenovirus lacZ vector (adlacZ,) was detected in fetal and maternal tissues (n 
= 3) by PCR analysis after intra-amniotic injection o f  3 fetal sheep sacrificed 2 days (A2, 1.8 x 1012 and 
A9, 1 x 1013 p/kg) or 28 days (A4, 1 x 1013 p/kg) after injection. Tissues that tested positive on 1st round 
PCR analysis (1st) were not generally subjected to nested PCR analysis (2nd). n: not available; m denotes 
maternal tissues; * indicates tissues tested from A4 fetus.
hFIX (A9 or A4*) AdlacZ (A2)
Tissue 1 st 2nd 1 st 2nd
Liver + + + +
+ m + m m + m
Gonad — - n
+ m T m m + m
Lung + + n
+ m m + m
Placenta + + + +
Umbilical cord + + +
Thymus _* _ * n
Heart + + n
Spleen _* _* n
Small bowel _ * _* n
Adrenal _ * _ * n
Skin + + + +
Fetal breathing and swallowing movements do not occur at this early stage in fetal 
sheep development and so it is not likely that the adenovirus vector accessed the lung or 
small bowel via this mechanism. In the fetal sheep the physiological hernia returns to 
the peritoneal cavity and the anterior abdominal wall closes by the 38th day o f gestation 
(Cloete JHL, 1939). It is possible therefore that the peritoneal contents were exposed to 
the adenovirus vector although a physiological hernia was only apparent in one fetus 
aged 33 days o f gestation at injection. The vector may also have crossed the fetal skin
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which is not keratinized at this stage o f development, and entered the lymphatic 
circulation and reached the heart and lung by this route.
E 1.7 The effect of adenovirus vectors on amniotic fluid 
biochemistry
We investigated whether intra-amniotic injection of adenovirus vector in early gestation 
fetal sheep affected the composition o f the amniotic fluid. At 30 - 41 days o f gestation 
the mesonephros is the main functioning kidney and the fetal urine drains into the 
allantoic cavity. The amniotic fluid on the other hand, is close to a dialysate o f fetal 
plasma and therefore its biochemistry and osmolality would provide us with some 
information about the effect o f the adenovirus vector on fetal well-being.
The concentration of sodium and chloride ions and the osmolality of amniotic fluid 
were compared before and after intra-amniotic adenovirus vector delivery in 4 fetuses. 
There was no significant difference detected between the two samples (paired Students 
rtest) indicating that the adenovirus vector had no significant effect on amniotic fluid 
biochemical composition.
E 2 Ultrasound guided tracheal injection to deliver gene therapy 
to the fetal airways
Having failed to achieve significant airways transduction by intra-amniotic delivery, we 
proceeded to develop a method o f injecting the fetal trachea directly. We also wanted to 
investigate how transduction o f the fetal airways might be improved since previous 
studies have shown poor epithelial airway cell gene transfer.
E 2.1 Tracheal fluid from the fetal sheep does not impair adenovirus 
transfection in vitro
Prior to in vivo experiments, we tested the adlacZ vector in vitro and ex vivo. The aim of 
these experiments was to determine whether fetal tracheal fluid affected adenovirus 
transfection o f an epithelial cell line. An initial experiment was done to determine the 
optimum dose range of the adenovirus vector. AdlacZ vector was incubated with 
tracheal fluid from a non-injected fetus aged 84, 97 or 116 days o f gestation, or with 
PBS, for 30 minutes at room temperature. Serial dilutions o f the vector in tracheal fluid 
were then made with PBS. These were applied to four 24-well plates containing human 
bronchial epithelial cells (HBE, 7 x 104 cells per well) cultured to 30% confluence to 
achieve 108, 107, 106, 105, 104 or 103 adenovirus particles per well. The plates were
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exposed to X-gal stain 48 hours after transfection and the number o f blue cells per well 
counted. At the two highest adenovirus concentrations it was not possible to accurately 
count the number o f blue cells per well. Examples of positively stained HBE cells at 
different virus concentrations are shown in Figure E 3.
Figure E 3: HBE cells expressing P-galactosidase after infection with adlacZ 
vector.
AdlacZ vector was pre-incubated with tracheal fluid from a fetal sheep aged 84 days o f  gestation for 30  
minutes and was then serially diluted with PBS and applied in the following concentrations (particles per 
w ell) (A) 107, (B ) 106 and (C) 105. X-gal solution was applied 48 hours after infection. Original 
magnification is x 4.
Having determined the optimum dose range of the adenovirus vector, the experiment 
was repeated in triplicate using the following concentrations of adenovirus particles per 
well: 107, 106, 5 x 105, 105, 104 or 103. At the two highest adenovirus concentrations it 
was not possible to accurately count the number o f blue cells per well. The results are 
displayed in Figure E 4 as mean ± SD. Preincubation o f the adlacZ vector with fetal 
tracheal fluid for 30 minutes significantly enhanced infection of HBE cells when 
compared with preincubation with PBS (two-way analysis o f variance, p = 0.004). As 
can be seen, tracheal fluid taken from a sheep fetus aged 84 days o f gestation had the 
most enhancing effect.
This enhancement effect is possibly due to factors in the fetal tracheal fluid that improve 
adenovirus infection of HBE cells in culture. The fetal tracheal fluid might contain 
growth factors that could enhance division o f the HBE cells in culture. The small 
volume of fetal tracheal fluid (1 pi at the highest concentration o f adenovirus vector) 
applied to each well however, makes this unlikely to be the cause o f the enhancement 
effect. We concluded that incubation of adlacZ vector with fetal tracheal fluid for 30 
minutes had no inhibitory effect on its ability to infect epithelial cells in culture.
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E 4: The effect of fetal tracheal fluid on adenovirus infection of epithelial 
vitro.
AdlacZ vector was pre-incubated for 30 minutes with tracheal fluid from fetal sheep aged 116, 97 or 84 
days o f  gestation, or with PBS. The adlacZ vector was serially diluted with PBS and applied to HBE cells 
in vitro. Cells were stained with X-gal solution 48 hours later and the number o f  blue cells per well 
counted, presented as mean ± SD.
E 2.2 Adenovirus vector efficiently transfects the fetal sheep airways 
ex vivo and gene transfer can be improved by sodium caprate and 
DEAE dextran
We then performed experiments ex vivo to investigate adenovirus mediated gene 
transfer to the fetal sheep trachea through gestation. Samples were taken from fetal 
sheep at 78-113 days of gestation that were either uninjected (n = 2) or had received 
intramuscular (n = 1), umbilical vein (n = 1) or intracranial (n = 1) injection with 
adenovirus vector. We determined the effect of sodium caprate and DEAE dextran, 
either singly or in combination, on adenovirus transfection. In the adult mouse, 
pretreatment o f the trachea with sodium caprate and complexation o f the adenovirus 
vector with DEAE dextran had been shown to significantly enhance gene transfer to the 
airway epithelium (Gregory LG et al., 2002). Sodium caprate acts by reversibly opening 
tight junctions allowing the adenovirus vector access to the coxsackie adenovirus 
receptor (CAR) that is situated on the basolateral surface o f the airway epithelial cells. 
The polycation DEAE dextran, complexes with the adenovirus vector, reducing its
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negative charge and improving CAR receptor binding. Samples o f the fetal trachea 
taken at post mortem examination were opened and cut into four sections that were 
randomly assigned to four different treatment groups. After 48 hours o f incubation with 
vector the tracheal samples were stained with X gal solution overnight and the results of 
transgene expression analysed quantitatively by p-galactosidase ELISA (Figure E 5, 
Table E 5).
Complexing the adlacZ vector with DEAE dextran enhanced levels o f gene transfer by 
41% on average. Pre-treatment o f the airways with sodium caprate before application o f 
uncomplexed adenovirus increased the level o f p-galactosidase expression significantly 
by 87% on average. The combination of sodium caprate pre-treatment and DEAE 
dextran complexed adenovirus further increased the levels o f gene expression observed 
by 90% on average when compared with adenovirus alone. All treatments with 
enhancers resulted in significantly higher transduction levels than that obtained with 
adenovirus alone.
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Figure E 5: Enhancement of adenovirus-mediated gene transfer to the fetal 
tracheal epithelium ex vivo.
Sections o f  the trachea from 5 sheep fetuses were pre-treated with 50mM Na-caprate (CIO) for lOmin 
prior to addition o f  either adenovirus alone (Ad) or com plexed with DEAE dextran (DEAE). 0- 
galactosidase transgene expression was analysed quantitatively using ELISA analysis. Results are 
expressed as averages ± SEM (n = 5). * p< 0.05 and ** p< 0.01 comparing each o f  the enhancers and 
combination o f  Na-caprate pre-treatment and DEAE dextran complexed virus with virus alone.
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Table E 5: Enhancement of adenovirus-mediated gene transfer to the fetal tracheal 
epithelium ex vivo.
Age
(days)
P-galactosidase enzyme concentration (pg/mg protein)
adlacZ alone adlacZ-DEAE CIO adlacZ CIO adlacZ - 
DEAE
78 268 298 1349 1873
78 196 374 983 2250
83 203 461 1532 2963
89 234 212 1864 1941
113 196 374 983 2250
E 2.3 Experiments investigating injection of the fetal sheep trachea 
at post mortem
The fetal airway epithelium can be more directly targeted for gene transfer by injection 
of the lung parenchyma or the trachea. Ultrasound-guided injection o f adlacZ vector 
through the uterine wall into the lung parenchyma was performed in a pilot experiment 
in a sheep fetus aged 98 days of gestation (personal communication Torvid Kiserud, 
Charles Coutelle). This resulted in low level p-galactosidase expression confined to the 
site o f injection assessed by X-gal staining o f the lungs. There was also significant 
haemorrhage present in the alveoli and small airways. Experiments delivering viral 
vectors to the fetal sheep trachea via catheters placed at laparotomy or fetoscopically 
result in gene transfer to the airway epithelium (Yang EY et al., 1999). We investigated 
the feasibility o f percutaneous ultrasound-guided injection o f the trachea in fetal sheep. 
Before attempting to inject the fetal sheep trachea in vivo we studied tracheal injection 
at post mortem in some fetal sheep available from other investigators. This allowed us 
to obtain measurements o f the fetal trachea and to determine the direction o f fluid flow 
in the trachea after injection. We believed that injecting the trachea in the fetal neck 
V ould be the best approach in vivo since a transthoracic approach might lead to damage 
to the large vessels in the fetal chest. As we were aiming to target the medium airways 
with a gene therapy vector for treatment o f cystic fibrosis, we decided to pass a catheter 
down a needle inserted into the trachea in the neck. We also wanted to determine 
whether a catheter passed down beyond the needle tip, would direct injected fluid 
distally down the fetal airways, rather than proximally towards the fetal larynx. 
Different sized catheters were tested by passage down a 16 or 17 Gauge needle. A
187
E. RESULTS: Cystic fibrosis
catheter measuring 1.02mm outer diameter and 0.58 inner diameter (Sims Portex, UK) 
fitted down a 17 Gauge needle into the trachea. A 23 Gauge needle could then be fitted 
into the non-injected end for instillation o f the vector. Narrower catheters were available 
to fit finer needles, however their small diameter meant fluid instillation took a 
significant length o f time; more than 10 minutes for 5ml fluid.
E 2.3.1 A catheter placed via the needle in the fetal trachea at post 
mortem passes down the airways and directs fluid distally to the 
peripheral airways
Four fetal sheep were examined (Table E 6). The lungs and trachea were exposed by 
removal of the anterior chest wall and neck and the trachea measured from the top of the 
larynx to the carina. With the fetus lying flat on its back, a 17 Gauge needle was 
inserted into the trachea 2cm distal to the larynx and a measured length o f catheter (ID 
0.58mm, OD 1.02mm, Sims Portex, UK) was passed down. Methylene blue dye 
solution was injected down the catheter and the volume injected was noted when it 
could be seen coming out o f the fetal mouth. This volume was a crude estimate o f the 
volume of the airways. The catheter was clamped in the trachea, the needle removed 
and the lungs and trachea dissected en bloc. The trachea and main bronchi were opened 
and the position o f the catheter noted. Tissue staining with methylene blue was 
observed at dissection.
Table E 6: Post mortem insertion of a catheter and needle into the trachea of late 
gestation fetal sheep.
Sheep
fetus
Age
(days)
Length of 
trachea 
(mm)
Volume of 
methylene blue 
injected (ml)
Catheter 
position at 
dissection
Tissue staining 
(methylene blue)
blue PM1 135 120 20 L main 
bronchus
pericardial and L 
pleural cavity
blue PM2 135 130 20 R main 
bronchus
all airways
blue PM3 140 130 20 20mm above 
carina
all airways
blue PM4 120 125 5 20mm above 
carina
large and medium 
airways
In the first fetus to be examined (blue PM1) we wanted to evaluate how easy it was to 
pass the catheter beyond the carina. An 18cm length o f catheter was passed with some 
difficulty down the needle and methylene blue dye was instilled. At dissection the
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catheter had passed down the L main bronchus, through the L upper lobe and perforated 
the visceral pleura. Methylene blue dye stained the pericardial and L pleural cavities but 
was not present in the fetal airways. This highlighted the potential danger o f passing a 
catheter too far into the fetal airways. Repeating this experiment (blue PM2), the 
catheter passed with ease beyond the carina into the R main bronchus and methylene 
blue dye was spread throughout the fetal airways. In two further experiments, the 
catheter was passed until the tip was estimated to be just above the carina. There was 
widespread staining of the airways in one animal (blue PM3) into which 20ml could be 
injected. In the other animal (blue PM 4) however, only 5ml volume of methylene blue 
dye fluid could be instillled before it came out o f the fetal mouth and staining was 
limited to the large and medium airways (Figure E 6). This was probably an 
underestimate o f the volume of the airways. It emphasized however, the importance of 
volume in delivery to the fetal airways.
Figure E 6: Spread of methylene blue dye after tracheal instillation ex vivo.
The lungs and trachea o f  fetal sheep after ex vivo instillation o f  methylene blue down a catheter placed in 
the fetal trachea. The position o f  the tip o f  the catheter above the carina is indicated by the yellow  needle 
in each case. (A) Widespread staining o f  the airways after instillation o f  20ml dye in a sheep fetus aged 
140 days o f  gestation (blue PM3). (B) Staining is limited to the large and som e medium airways after 
instillation o f  5ml dye in a sheep fetus aged 120 days o f  gestation (blue PM4).
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E 2.3.2 Removal of tracheal fluid at post mortem does not result in net 
movement of fluid into the fetal trachea
We considered that dilution o f the vector in the tracheal fluid was a potential problem 
for gene transfer. To avoid this, a large volume o f tracheal fluid could be removed prior 
to vector injection but we were concerned that this might lead to influx o f amniotic fluid 
through the fetal mouth. On the other hand it was possible that the epiglottis could close 
off the trachea by the creation o f a vacuum within the trachea.
We explored this at post-mortem on a fetal sheep (100 days o f gestation) from another 
investigator. Normally the late gestation fetus has breathing movements which allows 
tracheal fluid to efflux from the trachea. Findings at post mortem cannot be directly 
extrapolated to the in vivo situation because o f the lack o f muscular activity. Fetal 
breathing movements however, would be unlikely to happen while the fetus is 
anaesthetized. A 16 Gauge intravenous cannula (Becton Dickinson, Franklin Lakes, NJ, 
USA) was inserted through the fetal skin under ultrasound guidance into the fetal 
trachea just proximal to its entry into the chest and sutured in place. The fetus was 
submerged flat in a large sink o f water containing methylene blue dye and the fetal head 
tilted to the side so that the fetal mouth was underneath the water surface. Tracheal fluid 
was withdrawn slowly from the cannula, the end o f which was held above the surface o f 
the water. At this gestation the tracheal volume is 3.85ml and the lung liquid volume 
measures up to 40ml (Olver RE et al., 1981). Even after removal o f 30ml o f tracheal 
fluid, no methylene blue dye was seen in it, showing that the fluid bathing the fetus was 
not entering the trachea via the fetal mouth. We concluded that amniotic fluid was not 
likely to enter the fetal sheep trachea at times when fetal breathing movements were not 
occurring.
E 2.4 The fetal sheep trachea can be visualised from mid-gestation 
using ultrasound
To develop a method of injecting the fetal trachea directly we first investigated the 
dimensions o f the trachea in mid to late gestation fetal sheep, the gestational age at 
which we believed injection was most achievable and clinically relevant. Ultrasound 
visualisation and measurement o f the fetal trachea has been investigated in the sheep at 
70 days of gestation (Kalache KD et al., 2001). In this study with the animal awake, 
clear images of the trachea were possible in 14 out o f 16 ewes examined and results 
were correlated with measurements obtained stereoscopically at post mortem. The
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inner-to-inner diameter of the trachea in the distal third o f the fetal neck measured 1.3 ±
SD 0.28 mm (range 0.95 - 1.7 mm).
Measurements o f the trachea (inner-to-inner diameter) in the fetal chest and in the distal 
third o f the neck were taken in fetuses aged from 67 days o f gestation from animals 
used in umbilical vein gene therapy injection experiments and from animals used by 
colleagues (Figure E 7). Ewes were also scanned prior to surgery to detect fetal 
number, to confirm viability and gestational age and tracheal measurements were 
obtained where possible. From 80 days of gestation the tracheal diameter in the fetal 
chest or neck measured at least 3 mm, and by 100 days of gestation it had increased to 
5mm which we thought would be sufficiently large to permit ultrasound guided 
percutaneous injection.
60-69 70-79 80-89 90-99 100-109 110-119 120-129 130-139
n =1 n = 3 n = 7 n = l  n = 18 n = 6 n = 0 n = 4 
Gestational age (days)
Figure E 7: U ltrasound measurement of the fetal trachea in the mid to late 
gestation sheep.
The inner-to-inner diameter o f  the trachea was measured at the fetal chest and at the distal third o f  the
E 2.5 Ultrasound guided injection of the fetal sheep trachea is 
achieved in late gestation
The first ultrasound-guided experiments used 3 late gestation sheep fetuses to determine 
whether injection of the trachea, and insertion of a catheter into the fetal airways was 
possible. The trachea could be easily visualized in the fetal neck and thorax in
■  mean diameter of trachea in the neck
mean diameter of trachea in the chest
1.0
0.0
fetal neck.
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longitudinal section and Doppler flow was used to image the blood vessels in the neck 
and chest. Experimental details are given in Table E 7.
Table E 7: U ltrasound guided injection of the fetal trachea in late gestation sheep.
Sheep Age
(days)
Injection
site
Total no. 
attempts
Time to successful injection 
(minutes)
thorax neck
IT1 137 thorax 1 2 35:00
IT2 138 thorax 1 2 106:00
IT3 138 thorax 1 2 46:00
E 2.5.1 A transthoracic route of injection is successful in late gestation
In the first fetus (IT1), two attempts were made initially to inject the trachea within the 
fetal neck using a 17 Gauge needle (Cook, UK), both unsuccessful. Visualisation o f the 
fetal trachea during injection was difficult because o f shadowing from the fetal wool 
that was dragged with the needle into the subcutaneous tissues. The needle also tended 
to either glance off the trachea in the neck where it is relatively less supported by 
subcutaneous tissue, or tented the trachea due to the tough fully formed tracheal 
cartilage present at this gestation (Figure E 8 A). A transthoracic approach was used on 
the third attempt and the needle eventually passed between the 2nd and 3rd rib, 
penetrated the lung parenchyma and entered the trachea just proximal to the carina 
(Figure E 8 B). Tracheal fluid was drawn off to confirm correct positioning o f the 
needle and a catheter was passed down the needle into the right main bronchus (Figure 
E 8 C). Injection o f adlacZ vector was visualized on ultrasound as microbubbles 
passing distally down the trachea. Perflubron was then injected after which the lung 
parenchyma became very echogenic. On videotape review o f the procedure the trachea 
appeared to dilate slightly although no measurements were taken at the time of 
injection.
In the second fetus (IT2), injection o f the trachea in the neck met with similar problems. 
Attempts to penetrate the tracheal cartilage with an 18 and 20 Gauge needle resulted in 
displacement o f the trachea to the side. Following the attempt with an 18 Gauge needle, 
an intercostal vein was accidentally perforated and an echogenic area within the tracheal 
lumen thought to be a blood clot, was seen extending down from the site o f needle entry 
to the carina. The trachea was finally accessed through the fetal thorax using a 17 Gauge 
needle between the 2nd and 3rd rib but the catheter would not pass beyond the end o f the 
needle. The adlacZ vector complexed with DEAE dextran was instilled directly down 
the needle.
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Figure E 8: Ultrasound-guided injection of the trachea in late gestation fetal sheep.
Ultrasonongrams o f  a sheep fetus at 137 days o f  gestation (IT 1) during injection the fetal trachea. (A) 
shows tenting o f  the fetal trachea during an attempt to insert a 17 Gauge spinal needle into the trachea in 
the fetal neck. The successful transthoracic approach (B) passed the needle through the 2nd and 3rd ribs 
into fetal thorax and (C) a catheter was inserted through the needle down the trachea into the right main 
bronchus prior to delivery o f  adlacZ vector.
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In the third fetus (IT3) a 17 Gauge needle was injected into the trachea through the fetal 
upper thorax after two attempts to place it in the neck were unsuccessful. The catheter 
was successfully passed into the left main bronchus but became bent back on itself 
preventing fluid instillation. The catheter was removed but the sharp needle tip sliced 
off a section o f  catheter as it was pulled up. A second attempt to site the catheter was 
similarly unsuccessful and resulted in a second section o f catheter remaining in situ.
The adlacZ vector complexed with DEAE dextran was instilled down the needle itself 
followed by perflubron. Mild tracheal dilation was again noted on video review 
following the procedure.
The main difficulties encountered during this set o f experiments were probably related 
to the fetal gestation. The fetal skin, which at this gestation is covered with wool, was 
difficult to penetrate, obscured the view and distorted the fetal anatomy as it was 
dragged deep into the subcutaneous tissues by the needle tip. The tracheal cartilage was 
similarly difficult to penetrate. The trachea in these fetuses was accessed in the upper 
thorax via the transthoracic route between the 2nd and 3rd rib using a 17 Gauge needle on 
the first attempt.
E 2.5.2 Ultrasound guided transthoracic injection of the fetal trachea 
in the chest of late gestation sheep results in minimal trauma
Post mortem examination o f the second fetus (IT2) 48 hours after surgery showed a 
blood clot on the outer surface o f the upper 2/s of the oesophagus and within the tracheal 
lumen measuring 50mm long extending from the injection site in the fetal neck to the 
carina. There was no evidence o f the injection site in the chest on post-mortem analysis 
of all three fetuses. At dissection o f the third fetus (IT3), a cut section of catheter was 
found bent back on itself in the left main bronchus and a short piece was also found at 
the site o f  tracheal perforation (Figure E 9 A and B). The two fetuses injected with 
perflubron (IT1 and IT3) had a hyperaemic trachea and a fine fibrinous exudate on the 
posterior surface of both lungs (Figure E 9 A). Histology showed focal squamous 
metaplasia together with a small focus o f ulceration at the site of injection, and both 
fetuses had fibrinous thickening o f the pleura. Histological analysis o f the fetal lung, 
lower airways and other fetal and maternal organs of all these fetuses was normal.
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A piece of catheter tubing passes 
through the wall o f the trachea into 
the lumen indicating the site of 
tracheal injection
A second section o f catheter 
tubing enters the left main 
bronchus
Fine fibrinous exudate on the 
posterior surface o f the base 
of both lungs
A cut off piece of catheter tubing is 
in the left main bronchus bent back 
on itself
Figure E 9: Post mortem findings after ultrasound-guided tracheal injection of 
adlacZ vector via a catheter.
At post mortem analysis two days after placement o f  a fine catheter tube into the trachea and instillation 
o f  adlacZ vector and perflubron into the fetal trachea (138 days o f  gestation), (A) the tracheal epithelial 
lining was hyperaemic, and there was a fine fibrinous exudate on the lower posterior surface o f  both 
lungs. Two sections o f  catheter were cut o ff  on removal o f  the needle and can be seen within the tracheal 
lumen in (A) and (B).
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The use o f the catheter did not appear to improve vector distribution since virus was 
seen instilling the distal airways even in the fetus injected without the catheter. There 
were also difficulties with passing the catheter down the trachea, and catheter parts 
being cut off, which was a common observation in fetal balloon valvuloplasty (Kohl et 
al., 2000). We therefore abandoned the use o f a catheter while we determined the best 
route for tracheal injection at earlier gestations and explored the use o f enhancing agents 
further.
E 2.6 Ultrasound guided injection of the trachea in the neck is 
unsuccessful in mid-gestation fetal sheep
We believed that injection o f the trachea in mid-gestation would be easier at this stage 
o f fetal development because there was no fetal wool to obscure the view and the 
tracheal cartilage was less well developed. More importantly, this is a clinically more 
relevant gestation for therapeutic intervention.
We began our experiments in mid-gestation by attempting to inject the fetal trachea in 
the neck (n = 3, 82-103 days of gestation, Table E 8). Clear views o f the fetal trachea 
were obtained as it passed through the neck but despite this and easy passage o f the 
needle to the tracheal wall this route was not successful. In total, only one out o f 12 
attempts to inject the trachea in the fetal neck was successful, and there were three 
failed attempts at intrathoracic injection in this group of experiments. In one fetus (102 
days o f gestation, IT6) two attempts with an 18 Gauge needle from the anterior o f the 
neck were unsuccessful because o f lateral movement o f the trachea. A further two 
attempts were made using a 22 Gauge needle but this bent under the pressure applied to 
penetrate the trachea. A fifth attempt with an 18 Gauge needle from the side o f the fetal 
neck was successful. Post mortem and histological analysis 48 hours after injection 
showed no signs o f trauma or inflammation.
In two other fetuses (103 and 82 days o f gestation, IT5 and CC4) there were multiple 
attempts via the neck (3 attempts in one and 4 in the other) and thoracic routes (2 and 1 
attempt respectively) that were unsuccessful. After failing to inject the trachea of CC4, 
this fetus was used with its cotwin to study stimulation o f fetal breathing movements 
(see earlier). The fetuses that received tracheal injection however, were dead at 24 (IT5) 
and 48 hours (CC4) after the procedure. Death in one fetus (IT5) was probably related 
to haemorrhage following accidental needle insertion into the vena cava which occured 
with the fifth injection attempt. At post mortem analysis there was a large blood clot 
measuring 50 x 15 x 15mm in the right pleural cavity. In the second fetus (CC4), a
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small blood clot was observed in the fetal neck at the site o f an injection attempt but no 
cause o f death was found. Bacterial culture from both was negative.
Table E 8: U ltrasound guided injection of the trachea in the fetal neck of mid­
gestation sheep fetuses.
Sheep Age
(days)
Injection
site
Total no. attempts Time to successful injection 
(minutes)thorax neck
CC4 82 failed 1 4 failed
IT6 102 neck 0 5 68:20
IT5 103 failed 2 3 failed
The main reason for failing to access the fetal trachea using this route was the relative 
mobility o f the trachea within the neck that meant that it could slip sideways as soon as 
the needle tip was pressed against it. We decided therefore, to attempt a transthoracic 
approach in mid-gestation.
E 2.7 Ultrasound guided injection of the trachea in the chest is 
successful in mid-gestation fetal sheep
Having established that ultrasound-guided transthoracic injection o f the trachea was 
possible in late gestation fetal sheep, we performed experiments to develop this 
transthoracic injection technique at mid-gestation (n = 34, 81-116 days o f gestation).
We began by injecting adlacZ vector (n = 21) together with different combinations o f 
agents that we had shown in vitro and ex vivo to enhance adenovirus mediated gene 
transfer. In addition we applied the fluorocarbon perflubron that has been shown to 
enhance transduction in the lungs of adult rodents and monkeys (Weiss DJ et al.,
1999, Weiss DJ et al., 2002a) in the hope that this might flush the vector distally towards 
the peripheral airways.
Having determined the optimum combination on adenovirus transfection in vivo (see 
later) we performed experiments injecting adenovirus containing the human CFTR 
transgene (adhCFTR, n = 11, 1 x 1011 -  2 x 1012 p/kg). All fetuses injected with 
adhCFTR received pretreatment with sodium caprate and DEAE dextran complexation 
with the adenovirus. Finally we used a novel vector, Sendai virus containing the lacZ 
transgene (Sendai lacZ, n = 2). For the lacZ and hCFTR adenovirus vectors, post 
mortem analysis was performed at a few different time points after injection (Table E 
9). Data on the injection technique from all transthoracic injections are presented 
together.
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The results o f adenovirus vector mediated lacZ transgene expression and its 
enhancement with DEAE dextran and sodium caprate and the effect o f perflubron are 
described in Section E 2.8. Results of Sendai vector mediated lacZ transgene 
expression are described in Section H 4.2. Antibodies to detect human CFTR against a 
sheep background for hCFTR immunohistochemistry were not available at the time of 
this thesis. Testing o f a panel o f 9 antibodies to hCFTR on mixtures o f human and sheep 
nasal epithelial cell lines has revealed two that did not react to endogenous sheep CFTR 
(personal communication, Dr H Davidson, Medical Genetics, University o f Edinburgh) 
and this is the focus of ongoing studies.
Table E 9: An overview of transthoracic injection experiments in mid-gestation 
fetal sheep.
Vector Gestational age at injection 
(days)
Sampling (post 
mortem)
Fetal number
AdlacZ 81 2 days 4
AdlacZ 82 16 days 1
AdlacZ 100-115 2 days 14
AdlacZ 100-115 Birth 1
AdhCFTR 8 1 -8 2 Birth 2
AdhCFTR 100-115 2 days 2
AdhCFTR 100-115 17-21 days 3
AdhCFTR 100-115 Birth 2
Sendai lacZ 100-104 2 days 2
E 2.7.1 Transthoracic injection of the fetal trachea is reproducible and 
can be achieved in a short time
Injection of the trachea using the transthoracic route was achieved in 31 out o f 34 
fetuses (Table E 10). A 22 Gauge needle was used to inject one fetus aged 81 days of 
gestation (IT4) and an 18 Gauge needle was tested on two fetuses at 108 and 115 days 
o f gestation (IT9 and IT10). A 20 Gauge spinal needle however, provided the optimum 
combination o f flexibility to manoeuvre between the ribs in the thorax, stiffness to 
enable the needle to be ‘flicked’ through the tracheal wall and size to allow easy tissue 
penetration. The first mid-gestation fetus to be injected via the transthoracic route was 
aged 81 days o f gestation. Because o f the difficulties encountered we developed the 
technique further in fetuses aged at least 3 weeks older (102 days of gestation) and 
returned to the earlier gestation once the technique had been established.
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Table E 10: Ultrasound-guided injection of the fetal trachea in the chest in mid 
gestation fetal sheep.
Results are displayed in chronological order.*indicates twin fetuses; Time: time to successful injection; 
Poor view: poor ultrasound view  o f  fetal trachea due to fetal lie.
Sheep Age
(days)
No. attempts Time
(min)
Poor
view
Complications 
during procedure
thorax neck
IT4 co twin 81* 0 0 failed Y
IT4 81* 1 0 7:00
IT7 102 1 0 10:00
IT8 109 1 57:51
IT9 108 0 52:00 Y
IT10 115 1 0 3:42
IT11 116 1 0 37:00 needle dislodged
IT12 109 1 0 7:19
IT13 116 1 0 9:03
IT14 109 1 0 10:05
IT15 109 1 0 05:27
IT16 102 1 0 02:59
IT 17 cotwin 102* 1 1 failed Y
IT17 102* 1 1 12:30
IT18 102 1 0 12:00
IT19 102 1 0 03:59
IT20 102 1 0 04:13
IT21 81 0 68.19 tracheal collapse
IT22 81* 1 0 5:32
IT23 81* 1 0 4:17
IT24 82 1 0 9:30
IT25 102* 1 0 3:39
IT26 102* 1 0 3:36 blood vessel 
accident (chest)
IT27 102 1 0 19:55 blood vessel 
accident (chest)
IT28 102* 1 0 19:41 Y
IT29 102* 1 0 13:32
IT30 81 1 0 2:23
IT31 113 1 0 23:03 blood vessel 
accident (chest)
IT32 113 3 0 failed Y blood vessel 
accident (chest)
IT33 110 1 0 2:44
IT34 82 1 0 4:00
IT35 100 2 2 51:35 Y blood vessel 
accident (neck)
IT36 100 1 0 8:24
IT37 104 1 0 8:55
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Figure E 10: Ultrasound-guided injection of the trachea using the transthoracic 
route.
An ultrasonogram (A) and diagram (B) showing injection o f  the trachea using the transthoracic route in a 
sheep fetus (114 days o f  gestation). A 20 Gauge spinal needle is inserted into the fetal thorax between the 
3rd and 4th rib, penetrates the lung parenchyma and enters the fetal trachea just proximal to the carina.
The trachea in the fetal neck and chest was scanned in the coronal plane. Figure E 10 
shows an ultrasonogram of a typical injection using the transthoracic route. The fetus 
was lying right side up and the needle passed anterior to the fetal shoulder and arm, 
through the chest wall between the 3rd and 4th ribs, into the fetal trachea just superior to 
the carina avoiding the great vessels. In this fetus the pulmonary trunk was posterior to 
the trachea which made tracheal access more straightforward. In 6 fetuses (18%) there
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was a poor view of the trachea, defined as inability to visualize part or all o f the trachea 
from the distal third o f the neck to the carina. This fetal position was observed in nearly 
two-thirds o f cases (22 out o f 34 fetuses) and in only 2 fetuses was there a poor view of 
the trachea, which was caused by the fetal humerus obscuring it. Tilting the ewe on the 
theatre table and moving the humerus with the needle improved the view.
For the remaining experiments (12 out o f 34 fetuses), the fetus was lying so that the 
pulmonary trunk (n = 10) or aorta (n = 2) was anterior to the trachea and in these cases 
the needle was passed only between the 2nd and 3rd rib so as to penetrate the trachea 
superior to the arch o f the aorta. In this position there was a poor view o f the trachea in 
4 fetuses caused by the fetal scapula obscuring the trachea. Positioning of the great 
vessels anterior to the trachea was significantly associated with a poor view o f the fetal 
trachea (Chi-squared test, p<0.0025).
The gestational age at injection was also associated with the quality o f the ultrasound 
view of the trachea. In the younger age group (81 -  83 days o f gestation), there was 
only one case of a poor view out o f 8 injected fetuses that was in a twin pregnancy (IT4) 
and occurred early on in our series. All the other instances o f poor view (n = 5) occurred 
in the older age group (n = 26, 100 -  116 days o f gestation) and this was statistically 
significant (Chi-squared test, p<0.0005).
Once the needle was thought to be in the trachea, the trocar was removed and tracheal 
fluid was withdrawn into a 2ml syringe to confirm correct needle placement. 
Occasionally fluid could not be withdrawn because the needle tip was in the tracheal 
wall. While a vacuum was maintained in the 2ml syringe the needle tip was moved 
slightly, positioning the tip in the tracheal lumen which was confirmed by withdrawal of 
tracheal fluid. The gene therapy vector and transduction enhancing agents were instilled 
into the fetal trachea and could be seen flowing down the bronchii as microbubbles 
(Figure E 11). Following injection o f perflubron, the small airways and lung 
parenchyma became very echogenic and this obscured the ultrasound view. However 
there was no change in the fetal heart rate or in the breathing movements, which were 
absent while the ewe was under anaesthesia.
It was not possible to scan the fetal mouth during vector instillation to detect movement 
of fluid out o f the trachea. However only a small volume o f fluid was occasionally seen 
flowing proximally in the trachea towards the larynx, suggesting that very little, if any 
injected viral vector escaped from the trachea into the amniotic fluid.
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Figure E l l :  Ultrasound-guided delivery of adlacZ vector to the fetal trachea.
Microbubbles are visualised passing down a 20 Gauge needle, into the trachea and down the bronchii o f  a 
fetal sheep (109 days o f  gestation) on instillation o f  adlacZ vector.
There were three procedure failures (8.8%). Two occurred in fetuses from twin 
gestations in which fetal positioning prevented a good view of the trachea. In one fetus 
(IT4 cotwin) lying deeply with the back anterior, the trachea could not be adequately 
visualized and in the other fetus also positioned with its back anterior (IT17 cotwin) the 
procedure was abandoned after attempts to access the fetal trachea in the thorax and 
neck failed. The other procedure failure occurred in a singleton fetus (IT32) lying back 
up in which the right fetal scapula obscured the view of the trachea despite maximum 
tilting o f the ewe on the table and efforts to move the scapula with the needle. The 
pulmonary artery positioned anterior to the trachea was accidentally punctured and a 
large blood clot filled the trachea masking it from the surrounding soft tissues. The 
procedure was abandoned. Post mortem examination showed a large blood clot 
extending from the upper trachea to the medium airways, and 15ml blood in the right 
pleural cavity.
In 28 out o f 31 successful procedures (90%), transthoracic injection was achieved at the 
first attempt. The mean time taken to complete the injection procedure after a successful 
first attempt was 11 minutes 31 sec (SD 13 minutes 31 sec, range 2 minutes 40 sec -  68 
minutes 19 sec). In two fetuses complications following successful first injection 
prolonged the injection procedure to 37 minutes and 68 minutes 19 sec after needle 
dislodgement (IT11) and tracheal collapse (IT21) respectively. Excluding these cases,
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successful first attempts were straightforward in 26 out o f 28 fetuses and completed in a 
mean time o f 8 minutes 22 sec (SD 5 minutes 39 sec, range 2 minutes 40 sec -  23 
minutes 3 sec). O f three fetuses that failed transthoracic injection at the first attempt, a 
second attempt was successful in all three. There were attempts in two fetuses (IT8 and 
IT35) to inject the trachea in the fetal neck that failed before a second attempt to inject 
the trachea in the fetal chest was successful.
E 2.7.2 The transthoracic route to inject the fetal trachea has a low 
complication rate
Complications during the transthoracic tracheal injection procedure are listed in Table 
E 10 and can be classified into three main types: tracheal collapse during injection, 
needle dislodgement during vector instillation and blood vessel accident.
Tracheal collapse occurred in one fetus aged 81 days o f gestation. A 20 Gauge needle 
was passed with ease into the fetal chest and was thought to be in the tracheal lumen. 
Tracheal fluid was not aspirated however, and therefore the needle tip was repositioned 
while a vacuum was maintained using a 2ml syringe. Tracheal fluid was suddenly 
withdrawn (1.5ml) when the needle was correctly positioned in the trachea and the 
trachea collapsed, falling off the needle tip. Over the following hour three unsuccessful 
attempts to inject the trachea in the chest were made. As fluid reaccumulated, the 
trachea was more easily seen and the fifth injection attempt was successful. This was 
the first 81 day old fetus to be injected after the technique had been established in older 
fetuses. As can be seen from Table E l l ,  the volume o f the tracheal and lung fluid 
increases by almost five and ten fold respectively between 85 and 105 days o f gestation.
Table E l l :  The volume of the lung and tracheal liquid in fetal sheep through 
gestation.
Values are given as the mean ± standard error o f  the mean (Olver RE et al., 1981).
Gestational age (days) Lung liquid volume (ml) Tracheal volume (ml)
74.1 ±0.68 0.955 ± 0.220 0.295 ± 0.027
84.8 ±0.55 2.993 ± 0.368 0.831 ±0.079
96.1 ±0.93 9.298 ± 1.937 1.603 ±0.170
105.2 ± 1.6 34.57 ±4.92 3.85
113.4 ±0 .7 49.17 ±3.42 3.69
125.31 ±0.72 69.52 ± 7.09 5.07
134.9 ± 1.03 85.41 ± 16.47 5.37 ±0.64
126.4 ±0.42 76.23 ± 4.99 not available
140.0 ±0.19 122.6 ±3.75 not available
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The vacuum created by the syringe during the first injection attempt resulted in 
withdrawal o f approximately half the fluid volume o f the lungs and trachea, causing 
tracheal collapse. Following this complication, the plunger on the syringe was 
withdrawn enough so as to remove only 500pl fluid and this complication has not 
recurred.
There was one incidence o f needle dislodgement from the trachea in the middle of viral 
vector instillation. This occurred in a fetus aged 116 days o f gestation (IT11) during a 
straightforward transthoracic injection procedure. After instillation o f sodium caprate 
and viral vector the needle tip was observed in the subcutaneous tissues proximal to the 
trachea. The needle was reinserted into the trachea to allow delivery o f perflubron. 
Histological analysis o f tissues showed no evidence o f trauma in the subcutaneous 
tissue surrounding the fetal trachea and there was no positive X-gal staining or positive 
P-galactosidase immunohistochemical localization in the tissues around the trachea. 
Following this complication we reviewed our delivery procedure and considered 
attaching an extension set and three-way stopcock (Connecta™ Plus 3, Becton 
Dickinson, Helsingborg, Sweden) to the end of the needle for instillation o f gene 
therapy vectors as used in fetal blood transfusion procedures clinically. This would 
minimize movement o f the needle after correct placement. The dead space o f the 
extension set and three-way stopcock was large (500pl) in comparison to the total 
volume o f fluid injected into the trachea, especially in the earlier gestation fetal sheep. 
We were concerned that use o f an extension set could reduce the amount o f viral vector 
delivered and since we were already using large doses requiring a considerable 
preparation time, we did not believe their use in this context was justifiable. No further 
needle dislodgments occurred despite continuing to use individual syringes to deliver 
the viral vector and enhancing agents. For clinical application however, use o f an 
extension set and three-way stopcock would be a safer procedure.
Accidental damage to a blood vessel occurred in 5 fetuses (15%) but this lead to 
significant morbidity in only two cases (6%). Major vessel damage occured in one fetus 
(IT32) in which the pulmonary artery was punctured resulting in a large haematoma 
within the trachea and the procedure was abandoned. In one twin fetus (IT26, chest 
vessel puncture) a left sided pleural effusion measuring 27 x 36mm was noted on 
ultrasound scan the day after surgery; on the second day, large bilateral pleural effusions 
and ascites were present (Figure E 12 A and B).
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Figure E 12: Complications after ultrasound-guided transthoracic tracheal 
injection in mid-gestation.
Two days after ultrasound-guided transthoracic tracheal injection (102 days o f  gestation, IT26) during 
which a vessel was punctured in the fetal chest, ultrasonograms show (A) bilateral pleural effusions in the 
thoracic cavity in transverse section and (B) ascites and a pleural effusion either side o f  the fetal 
diaphragm in a transverse section o f  the upper peritoneal cavity. At post mortem examination there is (C) 
subcutaneous oedema in the skin over the abdomen and thorax and a large bilateral pleural effusion 
distending the diaphragm, and (D) an organised blood clot in the left pleural cavity with clear pleural 
fluid.
Post mortem analysis that day showed a severely hydropic fetus with right (50ml) and 
left pleural effusions (60ml) (Figure E 12 C). A small blood clot measuring 30 x 20 x 
5mm was present in the left pleural cavity (Figure E 12 D) although no vessel damage 
was visible. The pleural and ascitic fluid was of low protein content, very low 
cellularity with rare erythrocytes and occasional mononuclear cells which is consistent 
with it being a transudate. A full blood count taken at post mortem examination showed 
that the haemoglobin concentration was lower in this fetus (12 g/dl) than in o f its co­
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twin (14.7 g/dl) but still within the normal range. Overall these results suggest that the 
haemorrhage caused by the procedure was small, but was sufficient to compromise 
cardiac function causing heart failure.
In three cases there was damage to a minor vessel in the chest (2 fetuses, IT27, IT31) or 
neck (1 fetus, IT35). Post mortem examination o f these fetuses 2 days after surgery 
(neck vessel puncture) or 17 days after surgery and 1 day after birth (chest vessel 
puncture) showed no haematoma, inflammation or scar tissue. It is interesting to note 
that no blood vessel accidents occurred in fetuses aged 81 -  82 days of gestation.
E 2.7.3 Ultrasound guided transthoracic injection of adenovirus 
vectors and transduction enhancing agents into the fetal trachea 
results in some morbidity
Post mortem examination and histological analysis o f tissues was performed on all 
fetuses 2, 16 or 17 days after injection or 1 day to 1 week after birth (Table E 12). Post 
mortem and histological examination was completely normal in 15 (48%) and 8 (28%) 
out o f 29 injected fetuses respectively. The maternal and fetal organs other than the 
lungs and trachea were normal in all cases.
The most common abnormal findings at post mortem examination were pleural and/or 
pericardial adhesions (5 fetuses, 17%). These were generally small and all were situated 
at the upper lobes of the lung probably at the site o f injection through the pleura (Figure 
E 13 A). A visible injection site was seen in the fetal skin, chest wall or lung in 4 
fetuses (14%) and occurred only in fetuses aged 8 1 - 8 2  days o f gestation (Figure E 13 
B). This probably reflects the relative larger size o f the needle compared to the fetus at 
this earlier gestation. The mean fetal weight was 428 ± 57 g and 2100 ± 849 g at 81 -  82 
and 100 -  116 days of gestation respectively.
Clear pericardial fluid (1.5ml) and a thickened yellow pericardium was observed in one 
fetus (IT31) at post mortem analysis. Histological analysis o f the pericardium was 
normal, and Giemsa stain o f the pericardial fluid showed no evidence o f inflammatory 
cells, suggesting this was a transudate rather than an inflammatory exudate. 
Haemorrhagic lungs were observed at post mortem or histological analysis in 3 fetuses 
(10%) aged 8 1 - 8 2  days o f gestation (Figure E 13 C). These fetuses received large 
volumes of vector and enhancing agents: 10.5 ml (IT4), 7.5 ml (IT21) and 6 ml (IT22). 
Following this observation, the total volume delivered to the trachea o f younger fetuses 
was reduced to 1.2 ml and lung haemorrhage was not seen subsequently.
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Table E 12: Post mortem and histological analysis of mid-gestation fetal sheep 
after transthoracic injection of adenovirus vectors.
t: adhCFTR vector; h: hrs; d:days; wk: week; PN: postnatal, PM: time o f  post mortem after injection; C:
Sheep PM C D P GA (d) Post m ortem Histology
IT4 2 d - + - 81 visible injection site 
haemorrhagic lung
ulcerated focus in trachea, 
haemorrhagic lung focus
IT21 2 d + + - 81 visible injection sites 
pleural fluid + clot
haemorrhagic injection site, 
necrosis + lung haemorrhage
IT22 2 d + + - 81 visible injection site 
haemorrhagic lung
haemorrhagic injection site 
in lung
IT23 2 d + + + 81 visible injection site normal
IT24 16 d + + - 82 pleural adhesions, thick 
pericardium
thick pleura + pericardial 
lymphocyte infiltration
IT30t 12 h 
PN
+ + - 81 pleural -pericardial adhesion normal
IT34f 1 wk 
PN
+ + - 82 consolidation + mucus 
pasteurella pneumonia
confluent
bronchopneumonia
IT35f 2 d + + - 100 normal normal
IT7 2 d + + - 102 normal normal
IT16 2 d + - - 102 normal foamy material
IT17 2 d + + - 102 normal granular material
IT19 2 d + + - 102 normal normal
IT20 2 d + + - 102 normal granular material
IT25f 2 d + + - 102 normal normal
IT26f 2 d + + - 102 bilateral pleural effusions 
pleural clot
pigmented material
IT9 2 d + + + 108 white grainy patches focal acute inflammation 
small airways + mucosa
IT8 2 d + + - 109 normal mild focal neutrophilia
IT12 2 d + - + 109 white grainy patches pigmented material
IT14 2 d - + - 109 normal pigmented material
IT15 2 d - - - 109 normal pigmented material
IT10 2 d - + - 115 normal normal
IT11 2 d - + + 116 white grainy patches normal
IT13 2 d - - + 116 normal pigmented material
IT28f 17 d + + - 102 normal meconium in alveoli
IT29f 17 d + + - 102 pleural-pericardial adhesion meconium in alveoli
IT31 f 17 d + + - 113 pericardial fluid, 
thick pericardium
mild alveolar + bronchiolar 
neutrophilia
IT18 6 h PN + + - 102 small pleural adhesion pleural thickening
IT27f 1 dPN + + - 102 normal few alveolar neutrophils
IT33t 1 d PN + + - 110 normal few alveolar + bronchiolar 
neutrophils
207
E. RESULTS: Cystic fibrosis
Figure E 13: Post mortem findings after ultrasound-guided transthoracic tracheal 
injection of mid-gestation fetal sheep.
(A) A pleural-pericardial adhesion 17 days after injection at 102 days o f  gestation (IT29). (B) A visible 
injection site on the inner chest wall and (C) haemorrhage in the upper right lobes o f  the lung at the site o f  
injection 2 days after injection at 81 days o f  gestation (IT21).
Other findings were white grainy patches on the lung bases (3 fetuses, 10%) that were 
only seen in fetuses injected with perflubron as in the late gestation fetuses. A pleural 
clot was seen in two fetuses (7%), one complicated by tracheal collapse during injection 
and the other with an accidental blood vessel puncture in the chest. One of the five 
lambs born following tracheal injection o f adhCFTR vector developed pasteurella 
pneumonia 6 days after birth which was seen on post mortem analysis as lung 
consolidation (see below).
In two fetuses (7%, IT10 and IT22) there was X gal staining observed on the outer 
surface of the visceral pleura (Figure E 18). This suggested that the visceral pleura was 
perforated either during the tracheal injection procedure itself or during delivery o f the 
fluid. The injection procedure was straightforward in both cases and fluid was observed 
passing down the tracheal lumen. A large volume of aqueous fluid however, was 
delivered to both fetuses, 15 ml to IT10 (115 days of gestation) and 6ml to IT22 (81 
days of gestation) and we hypothesized that this was responsible for the pleural 
perforation. To prevent this occurring again, the total aqueous volume applied to the 
fetuses was reduced.
On histological examination, pigmented or foamy granular material was commonly seen 
within the lumen of the small and medium airways (8 fetuses, 28%, Figure E 14 A, B 
& C) but there was no associated inflammatory infiltrate. Four o f these fetuses had 
received a combination of sodium caprate and DEAE dextran complexed adenovirus.
The other four fetuses however, had received various combinations o f therapy (virus, 
perflubron or DEAE dextran alone or sodium caprate and perflubron combined). In two 
cases (IT15 and IT17) there was an uninjected cotwin available for comparison and
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small amounts of granular material were observed in the airways. Small amounts of 
meconium were occasionally observed in the alveoli without an inflammatory infiltrate 
(2 fetuses, 7%).
Figure E 14: Histological findings in the fetal airways after tracheal injection of 
adlacZ vector.
Light microscopy (H & E stain) o f  the trachea and airways shows in the lumen (A ) non-pigmented foamy 
material after injection o f  adlacZ and sodium caprate (IT 16), (B) pigmented material after injection o f  
adlacZ and perflubron (IT13), (C) pigmented and non-pigmented foamy material after injection o f  
adlacZ, sodium caprate and perflubron (IT12). Pigmented material was also present in the lumen o f  
airways after injection o f  adlacZ vector alone.
(D ) and (E) There is focal fluid in the alveoli and bronchioles with widespread focal acute inflammation 
in the mucosa o f  small airways following injection o f  sodium caprate, adlacZ DEAE dextran complex and 
perflubron (IT9). Original magnifications are as indicated. Fetal sheep were aged 102-116 days o f  
gestation at injection.
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A neutrophilia was seen in the alveoli and/or bronchioles o f 3 fetuses and 2 lambs 
(17%). This was mild in four animals all o f which had received sodium caprate and 
DEAE dextran complexed adenovirus. In the fifth animal that had received perflubron 
in addition to sodium caprate and DEAE dextran (IT9), histological analysis showed 
widespread focal acute inflammation in the mucosa o f the small airways (Figure E 14 
D & E ) .
E 2.7.4 Health of lambs following transthoracic injection in mid­
gestation
Lambs born following tracheal injection were examined after birth (Table E 13).
No signs o f respiratory distress were noted in any lamb immediately following birth. 
Blood was analysed for haematology, biochemistry, liver function and bile acids from 
all lambs 6 hours after delivery and results were normal.
Table E 13: Vital signs in lambs born after transthoracic injection of the trachea.
t: use o f  adhCFTR, PN: postnatal.
Sheep Time of 
examination
Resp rate (/min) Pulse rate (/min) Oxygen saturation
(% )
IT18 6 hrs PN 76 170 90
IT30f 12 hrs PN 78 190 92
IT27f 1 day PN 70 190 88
IT33t 1 day PN 64 160 92
IT34f 6 hrs PN 80 186 90
6 days PN 100 158 87
7 days PN 120 160 92
A non-injected twin (IT33 cotwin) was found dead in the morning 24 hours after a 
straightforward delivery. The lamb had been well and feeding normally in the 12 hours 
after birth and post mortem examination revealed a large retroperitoneal haematoma 
extending from the upper pole o f the kidney to the pelvis. There were no other 
abnormalities and microbiological culture o f tissues showed mixed bacterial growth 
including Pasteurella. The most likely cause o f death was thought to be crushing by the 
ewe, especially since she had retained the placenta that can lead to infection and 
unsteadiness (M Sheldon, personal communication).
One lamb (IT34) developed a tachypnoea 6 days after delivery but was otherwise well 
with no temperature and was feeding normally. Post mortem examination had been
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planned to take place 1 week after birth to allow for long term investigation o f antibody 
responses to the gene therapy. This showed dense consolidation o f the right lungs and 
the peripheral left lungs, with profuse thick green mucus in the large, medium and small 
airways (Figure E 15 A). There was confluent pneumonia on histological examination 
(Figure E 15 B) and microbiological analysis showed Pasteurella and Escherichia coli 
in 2 lungs lobes and a pure growth o f Pasteurella from the mucus.
Figure E 15: Evidence of pneumonia in a lamb that received fetal tracheal 
injection.
Post mortem and histological findings (H & E stain) in the lungs o f  a 1 week old lamb that had received 
tracheal injection o f  adhCFTR (2 x 1012 p/kg) and transduction enhancing agents at 82 days o f  gestation. 
(A) There is dense consolidation o f  the right lungs and (B) confluent bronchopneumonia with 
neutrophilia in the upper right lobe o f the lung (x 40).
Pasteurella haemolytica is a common cause o f pneumonia and death in lambs and is a 
commensal in domestic sheep. Ewes were routinely vaccinated a few weeks before they 
were due to deliver so that their colostrum can passively immunize the lamb when it 
starts to suckle. Factors such as stress and handling increase their susceptibility but 
more importantly, respiratory viruses such as adenovirus 6 and bovine adenovirus type 
2 predispose the lamb to secondary pasteurella infection (Brogden KA et al., 1998). It is 
possible that low level inflammation caused by the adenovirus vector predisposed the 
lamb to pneumonia despite maternal vaccination. In neonatal rats, tracheal instillation of 
adenovirus induced only mild non-significant inflammation, but airways morphometric
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analysis showed dose-dependent lung growth impairment (Waszak P et al., 2002). This 
highlights the importance o f long-term postnatal evaluation o f the effect o f prenatal 
gene therapy.
E 2.8 Adenovirus mediated transgene expression in late and mid­
gestation fetal airways can be enhanced
In adult rodents a significant stimulation o f adenovirus mediated gene transfer has been 
achieved in the airways, as already outlined in Section A 5.5, by complexing the virus 
with the polycation DEAE dextran, by pretreating the airways with sodium caprate 
(Gregory LG et al., 2002) or by application o f the inert fluorocarbon perflubron (Weiss 
DJ et al., 1999). In order to to improve adenovirus reporter gene transfer to the fetal 
sheep airway epithelium we therefore explored enhancement o f gene transfer in the late 
and mid-gestation fetal sheep.
£  2.8.1 Combinaton of DEAE dextran and perflubron enhances 
adenovirus mediated transgene expression in late gestation fetal 
airways
We first investigated the effect of DEAE dextran and perflubron in late gestation fetal 
sheep. After application o f 2 x 1010p/kg adlacZ vector to the trachea o f a late gestation 
fetal sheep (IT1, 137 days) and instillation o f 10ml perflubron to flush the vector 
distally, we did not observe any positive transgene expression with X-gal staining or p- 
galactosidase immunohistochemical analysis. Similarly complexing the adlacZ vector 
(IT2, 3.1 x 1010 p/kg, 137 days) with DEAE dextran (5pg/ml) did not result in any 
detectable transgene expression. Combination o f vector complexation with DEAE 
dextran (5pg/ml) followed by perflubron instillation (10ml) resulted in hazy light blue 
X-gal staining along the upper and medium airways and some stripey dark blue staining 
in the trachea (IT3, 138 days, 2.2 x 1010p/kg, Figure E 16). Immunohistochemical 
analysis for p-galactosidase expression demonstrated one positively stained nucleus in 
the trachea (data not shown).
Although the combination of DEAE dextran complexation and perflubron instillation 
resulted in detectable transgene expression, we believed that the large volume o f lung 
and tracheal fluid, approximately 100ml at this stage o f gestation, would have a large 
dilutional effect on the vector. We therefore performed further experiments in smaller 
fetuses in mid-gestation
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Figure E 16: P-galactosidase transgene expression after ultrasound-guided 
tracheal injection.
Two days after tracheal delivery o f  adlacZ vector complexed with DEAE dextran and perflubron (1T3, 
138 days o f  gestation), application o f  X-gal solution gives low level staining seen as stripey dark blue 
staining. Original magnification x 4.
E 2.8.2 Low level transgene expression in the mid-gestation fetal 
airway epithelium is observed following tracheal instillation of 
adenovirus vector alone
To determine the effect of adenovirus tranduction alone we applied a dose o f 1 x 1012 
adlacZ vector particles to the trachea o f one fetus (IT15) from a twin pregnancy in mid­
gestation. Low level and dispersed p-galactosidase expression that appeared to be 
limited to the peripheral airways or parenchyma was detected 48 hours after injection 
(Figure E 17 A).
Figure E 17: The effect of DEAE dextran on P-galactosidase expression in the fetal 
airways.
(A) A pale blue area o f  X-gal staining o f  the fetal trachea 2 days after instillation o f  adlacZ virus alone 
(IT15, 4.9 x 1011 p/kg) shows only low level P-galactosidase expression. (B) Complexing the adlacZ 
vector with DEAE dextran (IT14, 5.3 x 1011 p/kg) had very little effect on the visible transgene 
expression in the fetal trachea as seen by the patchy blue X-gal staining (arrowed). Original 
magnifications x 4.
Tissue samples taken from the right side o f the lung gave p-galactosidase enzyme 
concentrations of 55pg/mg protein, as determined by ELISA (Table E 14), but there
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was no detectable p-galactosidase protein in the left side o f the lung. There was no 
positive staining on immunohistochemistry for p-galactosidase.
E 2.8.3 The polycation DEAE dextran enhances adenovirus mediated 
transgene expression in the mid-gestation fetal sheep airways
Having shown that gene transfer to the airways could be improved in the late gestation 
fetal sheep, we devised a series o f experiments to evaluate the effects o f transduction 
enhancing agents on gene transfer in mid-gestation and to determine the optimum 
combination (Table E 14). We used the same dose o f adenovirus vector (1 x 1012 
particles) for each injection and the number o f particles per kg was calculated for each 
fetus from the weight at post mortem 2 days after injection. The p-galactosidase enzyme 
content o f the lung parenchyma was measured quantitatively using an ELISA assay.
One o f the fetuses (IT10) received an injection o f 5ml PBS, 5ml adlacZ complexed with 
DEAE dextran (5pg/ml) followed by 5ml PBS, a total aqueous fluid volume o f 15ml. 
X-gal histochemistry showed faint staining o f the large airways with stronger staining 
o f the left upper lobe small airways (Figure E 18 A and B). There was also strong 
staining o f the visceral pleura of the right upper lobe that suggested the injected fluid 
ruptured the lung and pleura leading to staining o f the visceral pleura (Figure E 18C 
and D). Immunohistochemistry for expression o f p-galactosidase was negative. The 
injection procedure itself was straightforward and the only feature o f this experiment 
different to others was the higher total volume o f aqueous fluid injected, 15ml versus 
10ml. Following this experiment it was decided to inject a maximal aqueous volume of 
10ml in subsequent animals aged 100 days o f gestation and above.
The volume o f fluid applied to fetuses aged 81-82 days o f gestation was initially 7.5 ml 
and this was subsequently reduced to 1.2 ml after haemorrhagic lungs were detected at 
post mortem examination. PBS was used where necessary to make up the total volume 
of fluid applied in place of sodium caprate or DEAE dextran.
Four fetuses received application o f adlacZ vector complexed with DEAE dextran 
(5pg/ml, IT4, IT6, IT10 and IT14). Some weak staining was observed in the fetal lungs 
(IT 14, Figure E 17 B) similar to that observed with adenovirus on its own and there 
was no macroscopically visible staining in the trachea or main bronchii. However, 
quantitative ELISA determination o f p-galactosidase was positive in each o f the 
samples taken from both the left and right sides o f the lungs showing an enzyme
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concentration ten fold increased above that achieved with the non-complexed virus (285 
pg/mg versus 28 pg/mg, Table E 14).
Table E 14: The effect of different enhancers on adenovirus infection of mid­
gestation fetal airways.
GA = gestational age o f  fetus (days). For transgene expression ,- indicates negative result. + to +++  
indicates degree o f  transduction observed after (3-gal staining or immunohistochemistry. (+) indicates 
single positive cells or sparse staining, d: days; h: hours; PN: postnatal; C: sodium caprate; D: DEAE  
dextran (5pg/ml); P: perflubron, T: trachea; PA: peripheral airways; L: left hand side; R: right hand side; 
mean: average; nt: not tested.
Sheep PM
(d)
GA
(d)
C D P p/kg 0-gal
staining
p-gal ELISA 
(pg/mg protein)
P-gal
immuno
T PA L R mean T PA
IT15 2 109 - - - 4 .9x  1011 - (+) 0 55 28 - -
IT13 2 116 - - + 3.8 x 10n - (+) 0 114 57 - -
IT4 2 81 - + - 2 x  1013 - (+) nt nt nt - -
IT6 2 102 - + - 3.8 x 1012 - - nt nt nt - -
IT10 2 115 - + - 8.3 x 1011 (+) + nt nt nt - -
IT14 2 109 - + - 5.3 x lO 11 - (+) 273 297 285 - -
IT11 2 116 - + + 3.7 x 1011 - (+) 108 184 196 - -
IT16 2 102 + - - 8 x 1011 ++ (+) 2576 3212 2894 - -
IT12 2 109 + - + 5.4 x 10n + (+) 3766 4038 3902 (+) (+)
IT7 2 102 + + - 7.5 x 1011 + + nt nt nt - -
IT8 2 109 + + - 4.8 x 1011 ++ ++ nt nt nt ++ ++
IT17 2 102 + + - 7.4 x 1011 (+) (+) 372 526 449 - (+)
IT19 2 102 + + - 8.3 x 1011 - - 0 0 0 - -
IT20 2 102 + + - 6.9 x 1012 - - 0 0 0 - -
IT21 2 81 + + - 2 x  1012 ++ +++ 17715 15750 16733 ++ ++
IT22 2 81 + + - 2.2 x 1012 + + 212 340 276 ++ +
IT9 2 108 + + + 4.2 x 1011 + +++ nt nt nt ++ +++
IT23 2 81 + + + 2.2 x 1012 + ++ 7235 4915 6075 ++ +++
IT24 16 82 + + - 2.2 x 1012 - - 584 688 636 nt nt
IT18 6h
PN
102 + + - 8 x  1011 - - 0 0 0 - -
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Figure E 18: p-galactosidase transgene expression in the airways after delivery of 
adlacZ vector complexed with DEAE dextran.
X-gal staining o f  the trachea and lungs after intratracheal injecton o f  adlacZ (9.3 x 1011 p/kg) and DEAE 
dextran complex in a fetal sheep (IT 10, 115 days o f  gestation). There is (A) faint staining o f  the large 
airways and (B) stronger staining o f  the left upper lobe small airways seen here in cut section. (C) 
Staining o f  the right upper lobe was confined to the visceral pleura when this was peeled o ff  the lung (D) 
which suggested that during tracheal injection the right upper lobe and visceral pleura had ruptured. 
Original magnifications x 4.
E 2.8.4 Sodium caprate enhances adenovirus mediated transgene 
expression in the mid-gestation fetal sheep airways
The optimal dose of sodium caprate (Na-caprate) for pre-treatment o f the airways was 
unknown to us. A dose o f 30mM has been shown to enhance adlacZ gene transfer in
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adult human airway epithelial cells in vitro (Coyne CB et al., 2000) and adult mouse 
airways in vivo (Gregory LG et al., 2002). We therefore compared the effect of 30mM 
(IT7) or lOOmM Na-caprate (IT8) used in combination with adlacZ complexed with 
DEAE dextran (5pg/ml) and showed the higher dose to be associated with enhanced 
levels of airway transduction (Figure E 19 A and B). The higher dose of lOOmM was 
used for all subsequent experiments.
Pre-treatment with Na-caprate followed by instillation o f adlacZ vector alone (IT16) 
produced clear macroscopic staining of the tracheal epithelium and main bronchi. 
Levels of transduction as shown by the P-galactosidase ELISA assay were 90 fold 
higher as compared with virus treatment alone and 10 fold higher than the combination 
o f adlacZ complexed with DEAE dextran (Table E 14).
Figure E 19: The effect of different concentrations of N a-caprate pre-treatm ent on 
adlacZ mediated tranduction of the tracheal epithelium.
Two fetuses received sodium caprate pre-treatment at (A) lOOmM sodium caprate (IT8) or (B) 30mM  
concentration (IT7) followed by adlacZ vector (4.8 and 7.5 x 1011 p/kg respectively) complexed with 
DEAE dextran. The higher dose o f  Na-caprate results in more widespread X-gal staining. Original 
magnifications x 4.
E 2.8.5 Sodium caprate pre-treatment and DEAE dextran 
complexation significantly improve adenovirus mediated transgene 
expression in the mid-gestation fetal airways
The combination o f Na-caprate pre-treatment and virus complexed with DEAE dextran 
was then investigated. Collectively, these transduction enhancing agents resulted in 
significant P-galactosidase staining o f the trachea and also marked transgene expression 
in the epithelial cells lining the large, medium and small airways observed both 
macroscopically and histologically in fetuses treated at both 109 (IT8, Figure E 20) and 
81 (IT21) days of gestation (data not shown).
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Figure E 20: The effect of pre-treatm ent with sodium caprate on DEAE dextran 
complexed adenovirus mediated p-galactosidase expression in the fetal sheep 
airways.
Panel 1 shows widespread gene expression on X-gal staining in the small (A), medium (B) and large (C) 
airways and also the main bronchi (D) and trachea (E).
Panel 2 shows widespread X-gal staining (A-C) and immunohistochemical localisation (D-F, 
haematoxylin counterstain) o f  P-galactosidase expression throughout the fetal airways. (A & D) show  
sections through the fetal trachea, (E) the bronchiolar epithelium and (B, C & F) the distal airway 
epithelium. Original magnifications x 40 except where indicated. The fetal sheep was 109 days o f  
gestation (IT8, 4.8 x 10n adlacZ p/kg).
The observable increase in marker gene expression using this combination of enhancers 
was reflected as a 600-fold increase in expression o f p-galactosidase protein, when
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determined by ELISA, compared with virus alone in the lungs. The combination of Na- 
caprate pre-treatment with DEAE dextran complexed adenovirus was repeated in five 
further fetuses. In one o f these cases (IT22) X gal staining o f the visceral pleura 
suggested pleural perforation and quantitative p-galactosidase analysis was o f low level. 
In three other cases (IT 17, IT 19 and IT20) there was a low level o f airways transduction 
observed probably due to use o f a frozen preparation o f adlacZ vector that was 
subsequently shown to have a low titre. A further fetus came to birth for investigation of 
perinatal morbidity and immune response and was analysed 6 hours after delivery 
(IT18). As anticipated, p-galactosidase expression was not detectable probably because 
o f the length o f time from injection procedure to tissue sampling.
In conclusion, we have shown that pre-treatment o f the airways with lOOmM sodium 
caprate combined with application o f adlacZ vector complexed with DEAE dextran, 
significantly enhances gene transfer to the mid-gestation fetal sheep airway epithelium.
E 2.8.6 Perflubron administration following adenovirus vector 
instillation results in redistribution of transgene expression from the 
proximal to the distal airways
We examined the effect o f perflubron on adlacZ mediated gene expression in the mid- 
gestaton fetal airways since we had shown this enhanced gene transfer in late gestation 
airway epithelia. For each of the combinations investigated, addition o f perflubron had 
little effect on the overall levels o f P-galactosidase expression in the lung tissue. As can 
be seen from Table E 14, in the presence of perflubron, p-galactosidase expression was 
low (IT13, 57 pg/mg) and levels were similar to adlacZ vector alone as measured by 
ELISA (IT15, 55 pg/mg). Instillation o f adlacZ/DEAE dextran complexes followed by 
perflubron (IT11, 196 pg/mg) was not observably different to that o f adlacZ/DEAE 
dextran alone (IT 14, 285 pg/mg). Equally perflubron did not appear to enhance gene 
expression further when used in combination with Na-caprate pre-treatment and 
uncomplexed adlacZ vector (IT12, 3902 pg/mg with perflubron and IT16, 2894 pg/mg 
without perflubron).
However, the addition of perflubron after Na-caprate pre-treatment and administration 
o f DEAE dextran complexed virus did alter the overall pattern o f gene expression.
There was reduced transduction in the trachea and larger bronchi while expression in 
the very peripheral airway epithelia was substantially enhanced (Figure E 21).
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Figure E 21: The effect of perflubron instillation on adenovirus-mediated p- 
galactosidase expression in the fetal airways.
The airways o f  a fetal sheep (108 days o f  gestation) were treated with lOOmM sodium caprate and DEAE 
dextran complexed adlacZ (IT9, 4.2 x 1011 p/kg).
Panel 1: X-gal staining o f  the peripheral airways in transverse sections (A & B) and longitudinal section 
(C) showing gene expression is limited to the terminal branches o f  the bronchial tree. Some staining o f  
the bronchioles was also observed (D).
Panel 2 shows X-gal staining (A-C) and immunohistochemical localisation (D-F, haematoxylin 
counterstain) o f  P-galactosidase expression in the peripheral airways. Original magnifications as 
indicated.
Macroscopically and histologically, intense blue staining could be seen in the small 
airways that exceeded the epithelial cell layer and spread into deeper tissues layers. We 
were concerned this might be an artefact of excessive chromogen production due to the
2 2 0
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high local enzyme activity, p-galactosidase immunohistochemistry was therefore used 
to subsequently determine the exact histological location o f transgene expression and 
showed a high density o f stained cells restricted to the epithelial layer. Perflubron 
effectively altered the distribution o f transgene expression, restricting it to the very 
peripheral airways resulting in intense transduction o f epithelial cells in this region. 
Addition o f perflubron did not further enhance total lung p-galactosidase levels using 
the combination o f Na-caprate pre-treatment and DEAE dextran complexed virus (IT23, 
6075 pg/mg with perflubron; IT21, 16733 pg/mg without perflubron, Table E 14).
E 2.8.7 Instillation of perflubron results in significant short-term  
dilatation of the mid-gestation fetal trachea
In the late gestation fetal sheep experiments, it was noted that perflubron instillation 
resulted in slight dilatation of the trachea. In the mid-gestation sheep fetus dilatation 
throughout the length o f the fetal trachea was seen immediately following injection of 
perflubron and persisted for at least 5 minutes after injection (Figure E 22).
The effect o f perflubron on the tracheal diameter was measured and compared with 
mid-gestation fetal sheep that did not receive perflubron injection. The maximal internal 
diameter (inner edge to inner edge) was measured using ultrasound with the fetal 
trachea viewed in longitudinal section (Table E 15). In the fetal neck the trachea was 
measured in the distal third, just proximal to the fetal thorax and in the chest it was 
measured at the site o f injection, just above the level o f the pulmonary artery.
In fetal sheep aged 108-116 days the tracheal diameter in the chest increased from a 
mean o f 6.2mm (SD 1.7) to 13.1mm (SD 1.4) significantly, (paired Students t test, p = 
0.016). In the fetal neck the diameter o f the trachea increased from a mean o f 6.8mm 
(SD 1.4) to 10.7mm (SD 1.0) but this change was not statistically significant. Perflubron 
had a similar dilatation effect on the trachea o f one fetal sheep aged 81 days o f gestation 
(IT23) that received perflubron injection.
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Figure E 22: The effect of perflubron instillation on the diam eter of the fetal 
trachea.
Injection o f  5ml perflubron (109 days o f  gestation, IT9) resulted in dilatation o f  the trachea in the fetal 
chest (A) from 6.0mm before to 12.2mm after injection and in the fetal neck (B) from 6.0mm before to 
14.0mm after injection
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Table E 15: The effect of perflubron on the d iam eter of the fetal trachea.
na = not available
Sheep Perflubron tracheal diam eter % tracheal diam eter %
volume in neck (cm) change in chest (cm) change
(ml) before after before after
100-116 days of gestation
IT9 5 6.0 14.0 133 6.0 12.2 105
IT11 5 na na - 4.5 13.4 198
IT12 5 5.8 9.0 55 5.8 14.8 155
IT13 5 8.6 9.0 5 8.6 11.7 36
IT10 0 na na 4.6 4.5 -2
IT14 0 5.1 5.3 4 4.2 4.0 -5
IT15 0 5.2 6.0 15 5.0 4.9 -2
IT16 0 5.0 5.1 2 4.6 5.6 22
IT17 0 3.5 3.9 11 3.9 4.0 3
IT18 0 na na - na na —
IT19 0 5.4 5.5 2 4.1 4.6 12
IT20 0 4.1 4.3 2 4.6 5.1 11
IT25 0 4.5 4.5 0 4.5 4.7 4
IT26 0 4.6 4.4 -4 4.2 4.7 12
IT27 0 3.9 3.4 -13 3.4 4.3 26
IT28 0 3.8 4.0 5 3.8 3.4 -11
IT29 0 3.9 4.0 3 3.6 4.0 11
IT31 0 5.8 5.8 0 5.8 5.8 0
IT33 0 5.5 5.5 0 5.2 5.5 6
IT35 0 4.1 4.8 22 4.0 4.4 10
IT36 0 4.7 4.7 0 4.4 4.5 3
IT37 5.3 5.0 -6 5.4 5.1 -6
81-82 days of gestation
IT23 1.5 2.5 3.2 28 2.5 3.3 32
IT21 0 2.9 2.8 -3 2.8 2.8 0
IT22 0 2.6 2.7 4 2.6 2.4 -8
IT24 0 3.2 3.0 7 3.3 3.1 -6
IT30 0 3.0 3.1 3 2.1 2.3 10
IT34 0 3.1 3.4 10 3.3 3.4 3
E 2.8.8 Dilatation of the fetal trachea at post mortem following 
instillation of liquids is related to the viscosity of the liquid
We explored the hypothesis that perflubron acted as a piston to push fluid distally down 
the airways because o f its high density. We compared tracheal instillation o f three fluids 
with different densities: PBS (1 g/ml), 5% glycerol (1.26 g/ml) and perflubron (1.92 
g/ml) in a non-injected sheep fetus (102 days of gestation) at post mortem. The fetal 
trachea was visualized in the chest using ultrasound. A 19 Gauge Venflon was inserted
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into the fetal trachea in the neck and the fluids were injected. The volume at which fluid 
was seen coming out o f the fetal mouth was noted and the diameter of the trachea was 
measured before and after injection o f each solution.
After injection o f 15ml PBS fluid was seen coming out o f the mouth and there was no 
change in the diameter o f the trachea in the chest. Injection o f 5ml 5% glycerol 
increased the tracheal diameter by a third (3.6mm to 5.0mm) and the trachea remained 
dilated for 30 seconds. Finally, administration o f 5ml perflubron resulted immediately 
in a tripling of the tracheal diameter (3.6mm to 9.1mm) that remained dilated for 90 
seconds. A second injection o f perflubron confirmed these findings. Although there was 
a small leakage o f perflubron (2ml) from the fetal mouth during the second injection, 
the majority o f fluid moved distally in a column down the airways. It appears therefore, 
that it is the density of perflubron that causes it to act as a piston and push fluid down 
the trachea to the distal airways. Although a balloon tipped catheter placed in the 
trachea would be able to prevent all injected fluid passing proximally, we saw very little 
movement o f injected fluid proximally. Variations in the volume o f perflubron used 
may thus allow targeting o f injected fluid to different areas o f the airways.
E 2.9 The effect of adenovirus and Sendai vectors and transduction 
enhancing agents on fetal tracheal fluid
£  2.9.1 Cytological analysis of fetal tracheal fluid
Fetal tracheal fluid was analysed for evidence o f an inflammatory reaction at post 
mortem examination and compared with samples obtained prior to injection o f vector. 
Broncho-alveolar lavage fluid (BAL) was also obtained at post mortem examination 
(Table E 16). The most florid inflammation was seen in two cases that were examined 
17 days after surgery (IT31) and one day after birth (IT27). In the remaining fetuses 
very little inflammatory reaction was observed, even when post mortem examination 
was delayed longer than two days after injection. Occasional epithelial cells were 
observed commonly in both the pre and post treatment samples and many o f these were 
pyknotic. Red blood cells (RBCs) were seen in one sample pre-op (IT33). In nine 
fetuses there were RBCs observed in post-op samples, in half o f which they were 
numerous (Figure E 23 A). Neutrophils were observed in post-op tracheal fluid or 
BALF o f four fetuses (Figure E 23 A and B) and this infiltrate was dense in the two 
animals that came to birth (IT31 and IT34), which correlated with histological findings 
of an alveolar neutrophilia.
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Figure E 23: Cytological analysis of bronchoalveolar lavage fluid after fetal 
tracheal injection.
Samples o f  BALF taken at post mortem examination were stained with Wright-Giemsa. (A) Red blood 
cells and neutrophils were seen 17 days after tracheal injection in one fetus (IT 31). (B) A monocyte 
(arrowed) and many neutrophils are seen 1 day after delivery o f  a lamb that was injected in mid-gestation 
(IT27).
Table E 16: Cytological analysis of tracheal and broncho-alveolar lavage fluid by 
W right-Giemsa stain.
GA: gestational age at injection; d: days; PN: postnatal; h: hours; C: sodium caprate; D: DEAE dextran; 
P: perflubron; E: epithelial cell; RBC: red blood cell; M: monocyte; N: neutrophil; (+) indicates few cells 
per high power field; + to +++ indicates occasional to many cells per high power field.
Sheep PM (d) GA
(d)
C D P Vector Tracheal fluid BAL fluid
Pre-op Post-op
IT21 2 81 + + - adlacZ E+ E+ E+; RBC(+)
IT22 2 81 + + — adlacZ E+ M+; RBC(+) RBC(+)
IT23 2 81 + + + adlacZ nt RBC+++; M(+) M(+); RBC(+)
IT24 16 82 + + — adlacZ nt E+ E+
IT35 2 100 + + - adhCFTR E+ E+ E+
IT25 2 102 + + — adhCFTR E+ E+; RBC+ E+; RBC+
IT26 2 102 + + - adhCFTR E+ M+; RBC+++; 
E++
N+; RBC+++; 
E++
IT28 17 102 + + - adhCFTR E(+) E+ E(+)
IT29 17 102 + + - adhCFTR E+ E+ E+
IT31 17 113 + + - adhCFTR nt E+; RBC +++; 
N+
RBC+-H-;
N+++
IT27 Id PN 102 + + - adhCFTR nt E+; RBC++; 
N+++
E+; RBC++; 
N+++; M+
IT33 Id PN 110 + + - adhCFTR E+;
RBC++
E++; RBC ++ E++; RBC ++
IT30 12h PN 81 + + - adhCFTR E+ E++ E++
IT34 7d PN 82 + + - adhCFTR E+ E+; M++; N+++ E+; M++; 
N+++
IT36 2 100 - - - Sendai lacZ E(+) E(+) E(+); RBC (+)
IT37 2 104 - - - Sendai lacZ M+ E++; M(+) E++; M(+)
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Monocytes were observed in the fluid from five fetuses (Figure E 23 B), in low 
numbers in four animals (2-3 per high power field), but there was a dense infiltrate in 
the remaining animal, in which post mortem and histological analysis demonstrated 
confluent bronchopneumonia. Tracheal and BALF fluid taken from a non-injected 
sheep fetus at 100 days o f gestation demonstrated numerous epithelial cells but no 
RBCs, neutrophils or monocytes were visible. Thus there appears to be a low grade 
inflammatory process associated with tracheal injection that could be due to the viral 
vectors or the procedure itself. We did not have access to tracheal or BALF fluid from a 
normal newborn lamb for comparison. Fluid from adult airways does not normally 
contain inflammatory cells but it is possible that neonatal airways contain low levels of 
inflammatory cells in response to antigenic stimuli. In two o f the animals that came to 
birth however, there were significant numbers o f inflammatory cells in the airways 
fluid.
E 2.9.2 Biochemical analysis of fetal tracheal fluid
The solute composition and osmolality o f fetal tracheal fluid before injecton and at post 
mortem examination was measured to determine whether adenovirus vectors had any 
effect. The concentration o f Na+, Cl' ions and the osmolality were not significantly 
different and were within the normal ranges for mid to late gestation ovine fetal tracheal 
fluids (Adamson TM et al., 1969). The K+ concentration was significantly higher after 
exposure to adenovirus vector than before (8.12 ± 1.5 versus 4.48 ± SD 0.26 mM/kg 
water respectively, paired Students rtest p<0.001, Table E 17).
Table E 17: The concentration of K+ ions in fetal tracheal fluid.
Sheep [K+] mM/kg water
before adenovirus at post mortem 
examination
IT24 4.29 6.06
IT25 4.52 8.62
IT26 4.17 10.22
IT28 4.7 8.89
IT29 4.5 6.27
IT31 4.92 8.09
IT35 4.27 8.74
This could reflect an increase in the secretion o f K+ ions into the tracheal fluid but was 
more likely due to the release o f K+ ions from dying cells. It is interesting to note
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however, that the normal range for K+ ions in mid to late gestation ovine fetal tracheal 
fluid is 6.3 ± SE 0.7 which is in between the measurements obtained before and after 
adenovirus injection (Adamson TM et al., 1969).
E 2.10 Spread of adenovirus vector in fetal and maternal tissues 
following intratracheal administration
We explored the spread o f transgene to the fetal and maternal organs by PCR analysis 
o f tissues in one late gestation fetus (Table E 18). The first fetus analysed (IT3) was 
one o f the first tracheal injection experiments in which there was very low-level 
transgene expression and we hoped that PCR analysis would provide a highly sensitive 
analysis of the spread of the vector. AdlacZ was detected in all tissues investigated but 
only after nested PCR analysis, indicating low levels o f vector spread.
Table E 18: Vector spread following adenovirus vector delivery to the airways of 
late gestation fetal sheep.
Transgenic adenovirus (3-galactosidase cDNA was detected by PCR analysis in fetal and maternal tissues 
2 days after ultrasound guided tracheal injection o f  adlacZ vector with or without transduction enhancing 
agents. IT3 (138 days o f  gestation) received 2.2 x 1010 pfu/kg adlacZ com plexed with DEAE dextran 
(5pg/m l) followed by 10ml perflubron.m denotes maternal tissues.
Tissue 1st round PCR Nested PCR
Gonad — +
m +m
Placenta - +
Upper trachea - +
Lower trachea - +
Lower bronchial tree — +
Soft palate - +
Upper oesophagus - +
The presence of vector, albeit at low level, in the placenta, fetal and maternal gonad 
suggests that haematogenic spread may have occured. It is possible that direct exposure 
of the placenta to the adenovirus vector occurred during withdrawal o f the needle from 
the uterus. This is unlikely however, since the vector was flushed through with 
perflubron or PBS prior to removal from the fetus, and it is doubtful that the placentome 
through which the needle passed was sampled at post mortem. The vector could have 
reached the fetal circulation during transthoracic injection in which trauma to minor 
blood vessels is inevitable. An alternative route into the fetal circulation is via the 
lymphatic drainage of the fetal airways.
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E 3 Placement of balloon-catheter systems and occlusive 
balloons in the trachea using ultrasound-guided injection
This series o f experiments was designed to explore placement o f balloon-catheter 
systems or occlusive balloons into the fetal trachea using the ultrasound-guided 
transthoracic injection technique. Using fetoscopy, tracheal obstruction with a 
detachable balloon has been shown to improve gene transfer to the fetal airway 
epithelium after tracheal instillation o f adenovirus vectors (Sylvester KG et al., 1997). 
Tracheal obstruction with fetoscopically placed detachable balloons is being used for 
the treatment o f congential diaphragmatic hernia (CDH) in the fetal sheep animal model 
(Deprest JA et al., 1997a) and clinically (Harrison MR et al., 1998). The morbidity from 
fetoscopy is significant however, because o f the relatively large diameter o f the 
puncture site in the fetal membranes that may lead to premature rupture o f the 
membranes and preterm labour and its associated problems. We wanted to investigate 
whether balloon-catheter systems or detachable balloons could be placed in the trachea 
using ultrasound-guidance alone. This might improve vector mediated gene transfer to 
the fetal airway epithelium and the technique might also be adapted for clinical use in 
the treatment of CDH.
E 3.1 Current balloon-tipped catheter systems are too wide for 
placement via a needle into the late gestation fetal sheep trachea at 
post mortem
Using a modified Seldinger technique we considered that it might be possible to pass a 
balloon-tipped catheter over a wire into the trachea. A 16 Gauge needle was thought to 
be the largest size suitable for ultrasound-guided injections. Larger needles could result 
in more trauma to the fetus and they would approach the diameter o f fetoscopes that are 
capable of placing a balloon with minimal fetal trauma down the trachea through the 
fetal mouth. Two balloon-tipped catheter systems were tested at post mortem in late 
gestation fetal sheep but were too large to fit a 16 Gauge needle (1.29mm). In addition, 
both systems had a maximal balloon diameter less than the tracheal diameter in mid­
gestation. For example, both a ureteropelvic junction occlusion balloon catheter and an 
overwire ureteroscopy balloon catheter (Cook Urological, IN, USA) measured 3.0 
French in diameter (1mm) and had balloons that could only inflate to 4mm, less than the 
diameter of the fetal trachea at 100 days o f gestation. Coronary artery balloon catheters 
have been successfully used in ultrasound-guided balloon valvuloplasty of human
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fetuses (Kohl T et al., 2000a). However the catheter diameter of one commonly used 
system (CrossSail™, Guidant, CA, USA) was 3.0 mm and had a maximal balloon 
diameter o f 4.0 mm.
E 3.2 A detachable occlusive balloon can be passed through a 15 or 
16 Gauge needle
We investigated whether a detachable balloon as used in the treatment o f congenital 
diaphragmatic hernia could be passed down a needle. The balloons tested were 
goldvalve embolisation balloons (GVB 16, CathNet-Science SA, Paris, France) that are 
used by Professor Jan Deprest’s group in Belgium for treatment o f CDH in the fetal 
sheep animal model and clinically (personal communication). The GVB 16 balloon 
inflates to a maximal length o f 21mm and a maximal diameter o f 8mm. This is 
sufficient to occlude the trachea o f a late gestation fetal sheep (Evrard VA et al., 1997). 
The deflated balloon is mounted on a 3 French catheter tapered to a 2.5 French tip 
containing a mandrel guidewire (Minitorquer detachable balloon catheter with teflon 
tip, CIFN35, CathNet-Science SA, Paris France). For fetoscopic application this is then 
passed down an 8 French (2.66mm) guiding catheter through the fetoscope. We tested 
whether the GVB 16 balloon attached to its mounting catheter alone would fit down a 
variety o f needles used in obstetrics and gynaecology (Table E 19).
As can be seen, the balloon could be backloaded up the bevel o f a 17 Gauge Chiba 
needle but would not pass down through it (Figure E 24 A and B). The balloon passed 
with some difficulty down the 16 Gauge needles, but easily passed down the 15 and 14 
Gauge needles. The mounting catheter fitted down all needles that were sized 17 Gauge 
or larger. We were concerned that the larger needles that had not been designed with a 
cutting bevel might have difficulty penetrating the fetus and we therefore tested out all 
the needles (17, 16 and 15 Gauge) that had fitted the balloon and catheter.
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Figure E 24: Testing a 17 Gauge Chiba needle (Cook USA Ltd).
(A) Diagram o f  a Chiba needle which has a bevelled stylet and needle cannula allowing good soft tissue 
penetration. (B) Backloading o f  a 17 Gauge Chiba needle. The mounting catheter is passed through the 
needle and a deflated GVB 16 balloon is placed on its tip, before being withdrawn into the bevel end o f  
the needle for ultrasound guided transthoracic injection.
Table E 19: Needles tested for placement of occlusive goldvalve embolisation 
balloons in the fetal trachea.
Needle
type
Needle
size
(Gauge)
M anufacturer Passage down needle
GVB16 balloon M ounting
catheter
Spinal 18 Cook Ob/Gyn, 
Spencer, Indiana, USA
No passage No passage
Chiba 17 Cook Ob/Gyn, 
Spencer, Indiana, USA
No passage down 
needle; balloon can 
be back loaded up 
the bevel
Passes easily
Epidural 16 Braun Melsunger AG, 
Germany
Balloon passes with 
difficulty; curved tip 
is a problem
Passes easily
IV
cannula
16 Becton Dickinson, 
Helsingborg, Sweden
Balloon passes with 
difficulty
Passes easily
Pencil tip 16 Somatex, Teltow, 
Germany
Balloon passes with 
difficulty
Passes easily
Pencil tip 15 Somatex, Teltow, 
Germany
Balloon passes 
easily
Passes easily
IV
cannula
14 Becton Dickinson, 
Helsingborg, Sweden
Balloon passes 
easily
Passes easily
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E 3.3 Attempts to place a detachable occlusive balloon and 
mounting catheter using ultrasound guided injection via a 17 Gauge 
Chiba needle fail in the late gestation fetal sheep trachea
We began in vivo experiments in a late gestation fetal sheep (137 days o f gestation) 
using the 17 Gauge Chiba needle (Cook Ireland Ltd, Limerick, Ireland) back loaded 
with the balloon mounted on its catheter. This needle has a sharp bevel point that makes 
it ideal for cutting through soft tissues. Unfortunately due to backloading o f the needle 
with the balloon, we would be unable to confirm correct positioning o f the needle 
within the fetal trachea by aspiration o f tracheal fluid. In addition, we wanted to test 
whether the bevel point might damage the balloon and/or the catheter during 
positioning.
Firstly we tested the mounting catheter and mandrel guidewire alone. The 17 Gauge 
Chiba needle containing its trocar was passed into the fetal trachea via the chest wall 
between the 2nd and 3rd ribs. The trocar was removed and tracheal fluid was aspirated to 
confirm correct positioning in the trachea. The mounting catheter and its mandrel 
guidewire were passed with ease into the fetal trachea as far as the carina. The catheter 
was flushed with PBS (5ml) and microbubbles were seen within the trachea. The 
catheter was then removed without damage, followed by the needle.
The 17 Gauge Chiba needle was backloaded with a deflated GVB 16 balloon on its 
mounting catheter and mandrel guidewire. The needle was reinserted through the fetal 
chest and appeared to be in the trachea, although it was not possible to confirm this by 
aspiration o f tracheal fluid. The balloon was advanced with some difficulty beyond the 
needle tip and inflated with 8ml fluid to its maximal dimensions measured on 
ultrasound (22.3mm long x 8.9mm diameter). The needle was removed from the trachea 
and the inflated balloon was detached by a sharp pull on the mounting catheter.
It was difficult to determine whether the balloon was within the fetal trachea or just 
alongside it on ultrasound examination o f the fetal chest (Figure E 25 A). The inner-to- 
inner diameter o f the trachea distal to the balloon measured 6.4 mm before surgery, 6.3 
mm immediately after surgery and 5.5 mm 24 hours after the procedure. We concluded 
that the balloon was positioned just outside the trachea and was probably compressing 
it. This was confirmed at post mortem examination 24 hours after surgery (Figure E 25 
B).
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Figure E 25: Failed attem pt to occlude the trachea with a detachable balloon.
After ultrasound-guided transthoracic injection, (A) an ultrasonogram shows the fetal trachea in 
longitudinal section with the inflated balloon that appears to be alongside. (B ) At post mortem 
examination 24 hours after injection the inflated balloon was actually positioned on the right side o f  the 
fetal trachea
Dissection o f the fetal neck showed the balloon was slightly posterior and to the right of 
the trachea with the oesophagus to its left. The upper part o f the balloon was at the level 
of the 1st rib. There was a small blood clot on the left side o f the trachea at the injection 
site but no other abnormal findings.
Although we failed to place the balloon in the fetal trachea, this experiment 
demonstrated that a detachable balloon could be passed down a needle without a 
guiding catheter, and inflated under ultrasound guidance.
E 3.4 Attempts to place a detachable occlusive balloon and 
mounting catheter using ultrasound guided injection via a 15 Gauge 
pencil tip needle fail in the mid gestation fetal sheep trachea
A second experiment was performed in a mid-gestation fetal sheep (102 days of 
gestation). Using a 15 Gauge pencil tip needle (Somatex, Teltow, Germany) we aimed 
to aspirate tracheal fluid to confirm correct needle placement before positioning the 
balloon in the trachea. The balloon passed with difficulty down a 16 Gauge pencil tip 
needle and we were concerned that it would be damaged, and therefore we chose to use 
the larger gauge instead.
There were three attempts to pass the 15 Gauge pencil tip needle into the fetal chest and 
all were complicated by excessive tenting o f the skin. On the second attempt, the needle 
was positioned superior to the 1st rib. A large haematoma developed posterior to the
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trachea which distorted the trachea anterior and obscured the view. A third attempt to 
place the needle between the 1st and 2nd rib failed.
We believed the pencil tip point o f the needle was not able to cut through the soft 
tissues. We decided therefore to place a 30cm long 18 Gauge spinal needle (Cook 
Ob/Gyn, Spencer, Indiana, USA) into the trachea and use it as a guide down which to 
pass the outside cannula o f the 15 Gauge pencil tip needle. The 18 Gauge spinal needle 
was positioned in the trachea and tracheal fluid withdrawn. It was not possible however, 
to pass the outside cannula o f the 15 Gauge pencil tip needle beyond the subcutaneous 
tissues o f the neck and the fetal anatomy was distorted significantly to obscure the view. 
This was because the outside cannula was not sharp enough to cut through the tissues.
£  3.4.1 A detachable occlusive balloon is successfully placed in the fetal 
trachea under ultrasound guidance
Having failed to access the fetal trachea using a 15 Gauge pencil tip needle in the mid­
gestation sheep fetus, we decided to have a further attempt in the same fetus using a 17 
Gauge Chiba needle, backloaded with the inflatable balloon and mounting catheter.
The needle passed through the 1st and 2nd rib into the fetal chest and once the tip was 
thought to be in the fetal trachea, the catheter and balloon were advanced into the 
trachea up to the carina. A good view o f the balloon within the trachea was obtained. 
The balloon was inflated with 8ml PBS and the needle was removed from the fetal chest 
but remained in the fetal subcutaneous tissues. A sharp pull was made to the catheter to 
detach it from the balloon but as this was done, the balloon deflated. The mounting 
catheter was removed with the deflated balloon still attached and on examination there 
was a small hole 3 cm from the distal end o f the mounting catheter. We believed it 
likely that during the sharp pull on the catheter to detach the balloon, the needle point 
had perforated the catheter causing the fluid to leak out of the balloon.
Using a new mounting catheter and after checking the integrity o f the balloon, the 
procedure was repeated with the 17 Gauge Chiba needle. The balloon was placed and 
inflated within the fetal trachea and the needle was removed completely from the ewe’s 
abdomen before the inflated balloon was detached from the mounting catheter, to avoid 
perforation. The inflated balloon measuring 18mm in length and 5.5mm in diameter 
completely occluded the fetal trachea (Figure E 26 A), which measured 5.1mm in the 
chest and neck prior to surgery. The time taken from needle insertion to successful 
insertion o f the inflated balloon, removal o f the needle and mounting catheter was 10
233
E. RESULTS: Cystic fibrosis
minutes 45 seconds. The previous attempt that failed due to catheter perforation took 21 
minutes 48 seconds from needle insertion to removal o f the deflated balloon.
inflated **
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within the 
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trachea --------►
-
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Figure E 26: Successul occlusion of the fetal trachea by ultrasound-guided 
injection.
A detachable inflated balloon was placed in the trachea o f  a mid-gestation fetal sheep using ultrasound- 
guided injection. (A) Ultrasonogram showing the inflated balloon within the fetal trachea superior to the 
carina. (B) At post mortem examination the inflated balloon is positioned 5mm from the carina.
Because of the trauma to the sheep fetus from multiple injection attempts, post mortem 
examination was performed immediately after successful balloon placement. There 
were multiple puncture sites visible on the right side o f the neck and posterior shoulder 
associated with small haematomas. In the fetal neck there was a large blood clot 
posterior and to the right of the trachea. On opening the chest there was a large amount 
of blood in the thoracic cavity and the root o f the neck. The inflated balloon measuring 
20mm long and 5.5 mm wide was positioned in the fetal trachea 5mm from the carina 
(Figure E 26 B).
This result confirmed that it was possible to place and inflate a detachable balloon 
within the trachea of mid-gestation fetal sheep by ultrasound-guided injection. For 
future clinical application, it was important to develop a needle and balloon catheter 
system that would allow confirmation that the needle tip had been correctly positioned 
in the trachea, before deploying the balloon. This could be achieved either by using a 
smaller balloon or a larger needle.
A balloon of smaller volume was tested in the needles (GVB 15, Figure E 27).
Although the manufacturer stated the deflated diameter was the same as the GVB 16
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balloon, it could be passed down a 17 Gauge Chiba needle after prelubrication with 
paraffin. Unfortunately the inflated length of the GVB 15 balloon is shorter than that of 
the GVB 16 (8mm compared with 21mm) and this results in more pressure damage on 
the tracheal epithelium limiting its use in the treatment o f CDH (personal 
communication, Professor Jan Deprest, Leuven University, Belgium). We concentrated 
our investigations therefore, on finding a more suitable needle.
Code Ref.
Deflated balloon 
Diam. length
Inflated balloon 
Diam. length
Max.
volume
Recommended guiding 
catheter size
1032828 GVB 15 1.5 mm 3.0 mm 6.0 mm 8.0 mm 0.1 ml GC 7F/95 cm
< 1032853 GVB 16 1,5 mm 6 5 mm B.O mm 21 0 mm 0.8 ml GC 8F/95 cm
Figure E 27: Gold valve balloons used for fetal tracheal occlusion.
The GVB 16 balloon (CathNet-Science SA, Paris, France) is used clinically for fetal tracheal occlusion  
and has an inflated length nearly 3 times that o f  the GVB 15 balloon.
E 3.4.2 Occlusion of the trachea is achieved by ultrasound guided
placement of a detachable balloon in the fetal sheep trachea
We investigated alternative needle systems used in other clinical specialities and tested 
a 16 Gauge Kellett needle (Rocket Medical pic, Watford, UK) that is used for liver 
biopsy in gastroenterology. This 3-way needle system included an outer flexible plastic 
catheter, an inner metal sleeve with a sharp tapered end and a diamond faceted stylet 
(Figure E 28). A locking mechanism allowed the needle parts to be secured as one unit 
during initial injection. The stylet could be retracted by twisting it back into the metal 
sleeve and then on removal of the stylet, the outer catheter and inner metal sleeve 
remained secured together. Prelubrication of the outer plastic catheter with perflubron 
allowed the balloon and catheter to pass with ease.
We tested this needle system in a fetal sheep aged 102 days of gestation using its cotwin 
as a control animal. The 16 Gauge Kellett needle was introduced into the fetal trachea 
under ultrasound guidance at the first attempt. The stylet was retracted 2mm and the 
needle then advanced a little further to ensure the tip of the outer plastic catheter was in 
the trachea before the stylet was removed. To confirm correct needle placement, 
tracheal fluid was withdrawn through the inner metal sleeve that was then removed
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leaving the flexible outer plastic catheter in place. The deflated balloon on its mounting 
catheter was passed down this into the trachea and was directed towards the carina.
outer flexible locking mechanism
plastic sleeve ^
Figure E 28: Diagram of a 16 Gauge Kellett needle.
Picture courtesy o f  Rocket Medical pic, Watford, UK.
Once in place, the balloon was inflated and the mounting catheter removed. The balloon 
measured 26.6mm long and 7.4mm in diameter (Figure E 29). The time taken from 
needle insertion, successful inflation o f the balloon to removal o f the needle and 
mounting catheter was 17 minutes. The ultrasound dimensions of the trachea and thorax 
at balloon insertion and at post mortem analysis are shown in Table E 20. The balloon 
dimensions did not change significantly during the post operative period but the trachea 
above the balloon narrowed and the trachea below the balloon widened.
Table E 20: Changes in the lungs and airways after tracheal occlusion.
(A) Ultrasound and (B) post mortem measurements o f  the fetal chest and trachea following ultrasound 
guided placement o f  an occlusive balloon in the fetal trachea.
A: Ultrasound measurements Injected fetus Control fetus
at surgery at PM at surgery at PM
Chest height (mm) 48.5 135 50.3 103
Chest circumference (mm) 165 246 164 218
Trachea below balloon (mm) 4.2 6.8 4.3 6.0
Trachea above balloon (mm) 4.1 4.0 4.7 6.5
B: Post m ortem  measurements Injected fetus Control fetus
Lung weight (g) 510 84
Lung-to-body-weight ratio 0.145 0.027
inner metal 
sleeve
diamond faceted 
stylet
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Figure E 29: Occluison of the fetal trachea by ultrasound-guided injection.
The ultrasonogram o f  the fetal chest shows the inflated detached balloon within the fetal trachea 
immediately after transthoracic tracheal injection.
Ultrasound scanning immediately prior to post mortem examination 21 days after 
surgery, showed ascites with a deepest pool of 23mm and bilateral pleural effusion. The 
injected fetus had lightly meconium stained liquor that was reduced in volume 
compared to the control animal. On opening the peritoneal cavity there was 100ml o f 
clear ascites and the diaphragm was distended into the abdominal cavity (Figure E 30 
A and B). There were pronounced rib markings on all surfaces o f the lungs (Figure E 
30 C). The lung weight and lung-to-body-weight ratios were over six and five times 
more in the injected fetus than the control fetus respectively, confirming that lung 
growth had occurred (Table E 20 B). Histological analysis of the lung parenchyma 
showed dilated small airways and alveoli when compared with control (Figure E 30D 
and E). There was no evidence of trauma, adhesions or inflammation.
These results confirmed that the balloon had been inflated correctly within the fetal 
trachea. We concluded that ultrasound guided balloon placement was technically 
feasible.
237
E. RESULTS: Cystic fibrosis
Figure E 30: Post mortem and histological findings after ultrasound guided fetal 
tracheal occlusion with a balloon.
At post mortem examination (A) the diaphragm was distended into the abdominal cavity in the injected 
fetus but not in the control fetus (B). (C) The lung o f  the injected fetus showing rib markings on all 
surfaces. Histological sections (H & E) o f  the lung showed dilated small airways and alveoli o f  the 
injected lung (D) when compared with the control lung (E); original magnification x 10.
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E 4 Ultrasound guided delivery to the fetal gut
As well as airways disease, cystic fibrosis leads to pathology in the gut that manifests as 
meconium ileus, a life-threatening condition that occurs in 10-15% of neonates with 
cystic fibrosis. Gene transfer to the fetal gut may be able to prevent this occurring. In 
the late gestation fetal sheep (112, 117, 120 and 125 days of gestation), previous 
experiments by our group had shown that ultrasound guided injection o f adenovirus 
vectors containing the p-galactosidase gene into the fetal stomach was possible, with 
minimal morbidity and no mortality (personal communication, Professor T Kiserud). X- 
gal staining of the fetal gut demonstrated very low level tissue transduction confined to 
the villi o f the small bowel, particularly the terminal ileum (personal communication, 
Professor T Cook). We considered that the relatively large size o f the fetal gut and its 
maturity may have contributed to these poor results. We also wanted to target the gut 
prior to the gestational age at which the fetus is thought to become immune competent. 
In the human fetus, tiny areas o f fluid can be seen within the small bowel lumen from 
13 weeks of gestation but ultrasound guided injection would not be possible because of 
their small size. By 25 - 30 weeks o f gestation the average diameter o f the small and 
large bowel lumen is 1.8 and 8.0 mm respectively which would permit ultrasound 
guided injection (Parulekar S, 1991), although widespread visualisation and peristalsis 
is typically only associated with bowel obstruction. The human fetal stomach may be 
visible on ultrasound examination o f the abdomen from 9 weeks, and usually by 14 
weeks o f gestation. Thus we designed a series of experiments to investigate ultrasound 
guided delivery o f adenovirus vectors to the fetal sheep stomach in early gestation.
We hypothesized that instillation o f the fluorocarbon perflubron into the fetal stomach 
after vector injection might flush the vector distally into the small and large bowel, in a 
similar way that perflubron acted in the fetal airways after tracheal injection. We aimed 
to transduce the cells in the intestinal crypts that are the site o f CFTR expression (Kalin 
N et al., 1999). Experiments on adult rat intestine have shown that lumenal distension of 
the small bowel with PBS results in shortening of the villi and widening o f the 
intervillus spaces (Sandberg J et al., 1994). Thus perflubron instillation might also aid 
vector delivery to the crypt spaces.
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E 4.1 Gastric fluid from the fetal sheep does not impair adenovirus 
transfection in vitro
The aim of these experiments was to determine whether fetal gastric fluid affected 
adenovirus transfection of an epithelial cell line in vitro. We used human bronchial 
epithelial (HBE) cells because there are no gastric epithelial cell lines available and our 
intention was to test the stability of the adenovirus vector in fetal sheep gastric fluid, 
rather than its ability to infect gastrointestinal epithelium per se.
An initial experiment was performed to determine the optimal dose range o f the 
adenovirus vector. AdlacZ vector was incubated with gastric fluid from a non-injected 
fetus aged 60, 83 or 113 days of gestation or PBS for 30 minutes at room temperature. 
Serial dilutions o f the vector in gastric fluid were then made with PBS. These were 
applied to four 24-well plates containing HBE cells (7 x 104 cells per well) cultured to 
30% confluence to achieve 108, 107, 106, 105, 104 or 103 adenovirus particles per well. 
The plates were exposed to X-gal stain 48 hours after transfection and the number o f 
blue cells per well counted.
JL
no fluid
Gestational age of fetal gastric fluid for adlacZ preincubation 
Figure E 31: The effect of fetal gastric fluid on adenovirus infection of epithelial 
cells in vitro.
AdlacZ vector was pre-incubated for 30 minutes with gastric fluid from fetal sheep aged 113, 83 or 60 
days o f  gestation, or with PBS. The adlacZ vector was serially diluted with PBS and applied to HBE cells 
in vitro. Cells were stained with X-gal solution 48 hours later and the number o f  blue cells per well 
counted, presented as mean ± SD.
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At the two highest adenovirus concentrations it was not possible to count the number of 
blue cells per well. There were no blue cells in the wells with the lowest concentration 
o f adenovirus vector (103 particles per well). The results are displayed in Figure E 31 
as mean ± SD. Having determined the optimum dose range o f the adenovirus vector, the 
experiment was repeated in triplicate using the following concentrations o f adenovirus 
particles per well: 107, 106, 5 x 105, 105, 104 or 103. Preincubation of the adlacZ vector 
with fetal gastric fluid for 30 minutes had no significant effect on adenovirus infection 
o f HBE cells when compared with preincubation with PBS (two-way analysis of 
variance).
E 4.2 Adenovirus vectors efficiently transfect the fetal sheep gut ex 
vivo
We performed experiments ex vivo to investigate adenovirus mediated gene transfer to 
the fetal sheep gut through gestation. For qualitiative analysis, small bowel samples 
were taken from fetal sheep at 59, 78, 83, 89 and 113 days o f gestation that were either 
uninjected (n = 2) or had received intramuscular (n = 1), umbilical vein (n = 1) or 
intracranial (n = 1) injection with adenovirus (Table E 21 A). For quantitative analysis 
we took small bowel samples from uninjected fetal sheep aged between 58 and 65 days 
of gestation (n = 5, Table E 21 B). We determined the effect o f Na-caprate and DEAE 
dextran, either singly or in combination, on adenovirus transfection. Samples o f the 
small bowel taken at post mortem examination were stripped o f their peritoneal 
covering, opened and cut into four sections which were randomly assigned to four 
different treatment groups (Figure E 32, Table E 21). After 48 hours o f incubation with 
vector, the small bowel samples were incubated overnight with X-gal and the results of 
transgene expression analysed qualitatively and quantitatively. It was not possible to 
culture the small bowel samples on a liquid-air interface and apply the vector to the 
luminal side as for the tracheal samples because o f their small size. It is likely therefore, 
that the final quantitative result reflects p-galactosidase expression from the serosal and 
the luminal surface o f the small bowel. Complexing the adenovirus vector with DEAE 
dextran enhanced gene transfer the most, whether alone (71% mean increase) or 
following Na-caprate pretreatment (78% mean increase). Na-caprate pretreatment only 
enhanced gene transfer by 28% on average, less than was seen in the fetal trachea.
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Figure E 32: Enhancement of adenovirus-mediated gene transfer to the fetal 
gastrointestinal epithelium ex vivo.
Sections o f  the small bowel from 5 sheep fetuses were pre-treated with 50mM Na-caprate (CIO) for 
lOmin prior to addition o f  either adenovirus alone (Ad) or com plexed with DEAE dextran (DEAE). |3- 
galactosidase transgene expression was analysed quantitatively using ELISA analysis. Results are 
expressed as averages ±  SEM (n = 5). * p< 0.02 and ** p< 0.0003 comparing each o f  the enhancers and 
combination o f  Na-caprate pre-treatment and DEAE dextran com plexed virus with virus alone, or virus 
and Na-caprate.
Table E 21: Enhancement of adenovirus-mediated gene transfer to fetal small 
bowel epithelium ex vivo.
(A) Qualitative analysis
Age (days) X-gal staining o f small bowel
adlacZ alone CIO adlacZ adlacZ-DEAE CIO adlacZ-DEAE
59 (+) + ++ +++
79 (+) + ++ +++
83 (+) + ++ +++
89 (+) + ++ +++
113 (+) + ++ +++
(B) Quantitative analysis
Age (days) P-galactosidase enzyme concentration (pg/mg protein)
adlacZ alone CIO adlacZ adlacZ-DEAE CIO adlacZ-DEAE
58 242.22 355.7 813.62 1254.64
61 364.44 496.5 1158.94 1583.59
62 315.87 512.04 1045.76 1362.83
62 287.68 389.56 980.55 1245.93
65 359.42 420.04 1365.9 1630.73
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A limitation to the quantitative analysis of transgene expression after ex vivo and in vivo 
application was that some o f the p-galactosidase expressing cells were on the serosal 
surface o f the stomach, small or large bowel. We can therefore not exclude that the 
different effect o f Na-caprate and DEAE dextran on transgene expression in the fetal 
gut ex vivo may be due to transduction o f the serosa. We tried to reduce this effect after 
in vivo application by removing the peritoneal covering on tissue samples prior to 
analysis. Nevertheless it is likely that the true level o f p-galactosidase protein expressed 
by the gut lumen is lower than we measured.
E 4.3 Measurement of the fetal sheep stomach through gestation 
using ultrasound
A literature search revealed there was no information about ultrasound visualisation of 
the stomach or its dimensions in the fetal sheep through gestation. We therefore used 
ultrasound to visualise and measure the fetal sheep stomach in early gestation.
Firstly video recordings from all fetal sheep experiments in early gestation were 
analysed. They recorded a general fetal anatomical survey, the fetal measurements 
including the abdominal circumference taken at the level o f the fetal stomach, and the 
injection procedure. Ewes were also scanned prior to surgery to detect fetal number, to 
confirm viability and gestational age. From these records we evaluated whether the fetal 
stomach was visualised by ultrasound (Figure E 33).
The fetal stomach was not visualized in any fetus aged 40 days o f gestation or less.
Only three fetuses aged between 40 and 50 days o f gestation were available for 
evaluation and so no conclusions can be drawn at this age range. From 50 days of 
gestation more data was available. Between 51 and 54 days o f gestation the fetal 
stomach was visualised in 35 out o f 43 fetuses (81%) but from 55 days o f gestation, the 
fetal stomach was always visible.
Secondly, the dimensions o f the fetal stomachs were measured prospectively in all early 
gestation fetal sheep experiments from November 2002 -  June 2003. The widest 
anteroposterior (AP) and transverse (Trans) diameters (inner-to-inner) were measured in 
the coronal plane and the widest longitudinal (Long) diameter was measured (inner-to- 
inner) in the sagittal plane. The rumen was seen in all fetuses as a prolate ellipsoid. The 
reticulum was also occasionally seen, situated caudal to the rumen in the longitudinal 
plane and medial to it in the coronal plane (Figure E 34). The omasum and abomasum 
were not visible. The measurements were grouped according to gestational age (Figure
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E 35). A description and diagram of the development and anatomy of the fetal sheep 
stomach is given in Section A 7.3.
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Figure E 33: Visualisation of the stomach in the early gestation sheep fetus by 
ultrasound.
Video recordings were reviewed from early gestation sheep experiments in which an anatomical survey 
o f the fetus was conducted. Ewes were also scanned prior to fetal surgery to detect fetal number, confirm 
viability and the gestational age. The fetal stomach was identified as a sonolucent area in the upper left 
quadrant o f  the fetal abdomen (see Figure E 34).
Figure E 34: M easurement of the early gestation fetal sheep stomach by 
ultrasound.
(A) With the fetal abdomen in coronal section the AP and Trans diameter are measured and (B) in the 
sagittal plane the Long diameter is measured.
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Figure E 35: The change in gastric dimensions in the fetal sheep with advancing 
gestational age.
The mean value ± 1.0 SD o f  the AP, Trans and Long diameter o f  the fetal stomach are illustrated. The 
number o f  fetuses measured at each time point is shown.
The fetal stomach dimensions increased linearly from 45 days to 69 days o f gestation 
and the largest diameter at any time point was the longitudinal diameter. From 55 -  60 
days of gestation all measurements were on average above 5 mm and from 60 days of 
gestation the mean AP diameter was approaching 10 mm.
We believed these findings would influence our ability to inject the fetal stomach by 
ultrasound guidance. The fetal stomach was reliably seen in fetuses aged from 55 days 
of gestation and the fetal stomach would need to be large enough to allow removal of a 
small amount o f gastric fluid to confirm correct needle placement. Thus we decided the 
first attempt to inject the fetal stomach should be from 55 days o f gestation.
E 4.4 Ultrasound guided intragastric injection is achievable in the 
early gestation fetal sheep
E 4.4.1 Gastric injection before 60 days of gestation is unsuccessful
The first attempt to inject the fetal sheep stomach was in a fetus aged 55 days of 
gestation. Only the rumen was visible and it measured 2.7 x 3 x 5 mm (AP x Trans x
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Long). With the fetal abdomen in transverse view a 22 Gauge needle was advanced 
through the anterior abdominal wall into the fetal stomach and the needle position was 
checked in the sagittal plane. It was not possible to withdraw any gastric fluid into a 
syringe although microbubbles were seen within the stomach lumen on instillation of 
100 pi saline, confirming that the needle was positioned correctly. The adenovirus 
vector (100 pi, 2 x 1011 p/kg) containing the lacZ gene was delivered into the stomach 
and microbubbles were visualised. The fetus was alive immediately following surgery 
but 12 hours later no fetal heart beat was detectable. At post mortem analysis there was 
a large peritoneal blood clot anterior to the liver, adjacent to the umbilical vein, and a 
smaller clot to the right o f the rumen. Bacteriological culture showed a moderate growth 
of Campylobacter jejuni in some o f the fetal tissues but not in the fetal liver or kidney 
and a mixed growth in the maternal tissues. These findings suggested that fetal demise 
was probably due to the procedure although infection could not be ruled out as a cause 
of death.
E 4.4.2 Gastric injection at or after 60 days of gestation is successful
Because o f the difficulty injecting the fetal stomach at 55 days gestation and our 
observation that the AP diameter was approaching 10 mm at 60 days we decided further 
stomach injections would be performed from this gestational age onwards. Injection 
was attempted in 11 fetuses from 7 ewes with success in 10 (91%, Figure E 36). In 
these fetuses the needle was confirmed to be correctly positioned within the fetal 
stomach by withdrawal o f lOOpl o f gastric fluid. The one injection failure was in a 
triplet pregnancy in which the other two fetuses were successfully injected. In this case 
visualisation o f the fetal stomach was inadequate due to fetal positioning. The needle 
was thought to be within the stomach lumen but attempts to withdraw gastric fluid 
failed. This suggested that the needle was not correctly positioned and we did not 
attempt to inject the vector. Occasionally it was difficult to see microbubbles on 
ultrasound following injection o f lOOpl fluid into the fetal stomach during early 
experiments, although review o f the video recordings confirmed their presence in all 
cases. In later experiments (G6 onwards) the volume o f Na-caprate and adenovirus 
vector administered was increased from lOOpl to 200pl which improved microbubble 
visualisation. In most cases (8 out o f 11 injections), the fetus was positioned so that the 
needle transgressed the abdominal cavity only a small distance before entering the 
stomach. In three cases, the fetus was lying on its left side and to reach the stomach, the
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needle had to pass through the fetal liver. These cases were not associated with failed 
injection, haemorrhage or infection.
Overall the mean time to successful gastric injection was 7 minutes 21 seconds (SD 6 
minutes 44 seconds, range 29 seconds to 13 minutes 34 seconds). In 2 twin fetuses the 
first attempt at gastric injection failed due to a combination o f fetal positioning and 
operator inexperience but a second attempt was successful in each case. In 8 fetuses the 
injection procedure was achieved at the first attempt in a mean time of four minutes 56 
seconds (SD 2 minutes 41 seconds, range 29 seconds to 8 minutes 18 seconds).
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Figure E 36: Ultrasonograms showing injection of the stomach in a fetal sheep 
aged 61 days of gestation.
With the fetal abdomen in coronal section, (A) the needle was inserted into the fetal stomach through the 
anterior abdominal wall and lOOpl gastric fluid was removed to confirm correct needle placement. (B) 
The vector was injected and microbubbles were observed in the stomach lumen (G3).
E 4.5 Effect of gastric injection on ultrasound visualisation of the 
fetal stomach
E 4.5.1 Fetal stomach volume
The fetal stomach was measured in three planes immediately before and after gastric 
injection. The stomach volume was calculated as that o f a prolate ellipsoid: 
4/37t(AP/2)*(Trans/2)*(Long/2), a figure generated by the revolution of an ellipse 
around its major axis (Zimmer EZ et al., 1992). This equation is used to calculate the 
volume of the human fetal stomach on ultrasound examination. We decided that it 
provided a good approximation to the fetal sheep stomach because at this gestational 
age only 2 stomach cavities were visible. The mean stomach volume before injection
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was 0.8ml (±SD 0.47). As expected, injection of the largest volume of perflubron 
(1500pl) resulted in the largest increase in stomach volume (Figure E 37). On average 
the stomach volume increased by 116%, 68%, 289% and 347% after injection of vector 
and Na-caprate alone, 300pl, lOOOpl and 1500pl perflubron respectively.
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Figure E 37: The change in stomach volume with gastric injection.
Fetuses (60 days o f  gestation) received intragastric adenovirus vector with or without DEAE dextran 
complexing and Na-caprate pretreatment, followed by injection o f  different volum es o f  perflubron.
E 4.5.2 Number of fetal stomach chambers visualised by ultrasound
The number o f stomach chambers visualized by ultrasound was determined before and 
after gastric injection. The sagittal view o f the fetus was found to be the best for 
determining which stomach chambers could be seen. Studies of the development of fetal 
sheep (Latshaw WK, 1987) and examination o f our early gestation sheep fetuses at post 
mortem confirmed our ultrasound finding that at 60 days gestation, the rumen was the 
largest stomach chamber and the reticulum was commonly visible.
Following injection of the rumen, in 6 out o f the 10 animals injected, there was an 
increase in the number of stomach chambers seen by ultrasound (Figure E 38). This 
was particularly observed in those fetuses that received perflubron after injection of the 
adenovirus vector and Na-caprate. In two fetuses that received 300pl and lOOOjul
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perflubron all four stomach chambers became visible (Figure E 39) and the dense 
perflubron could be seen lining the omasum and abomasum after injection. We 
concluded that injection o f perflubron into the rumen distended the fetal stomachs distal 
to the injection site.
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■  Stomach cavity seen 
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after injection
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Volume of perflubron (pi) injected into the rumen of sheep fetuses 
at 60 days o f gestation
Figure E 38: Changes in the visualisation of fetal sheep stomach cavities after 
intragastric injection.
Fetuses received intragastric adenovirus vector with or without DEAE dextran complexing and Na- 
caprate pretreatment, followed by injection o f  different volumes o f  perflubron.
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Figure E 39: The increase in the num ber of stomach cham bers visualised after 
gastric injection.
Ultrasonograms showing a sheep fetus (61 days o f  gestation) in coronal section. (A) Two stomach 
chambers can be visualised before surgery, and (B) four stomach chambers after surgery.
249
E. RESULTS: Cystic fibrosis
E 4.6 Gastric injection has a low morbidity and mortality
There was one fetal death of a twin fetus (G12) 24 hours after injection in which both 
twins received gastric injection (90% fetal survival). Post mortem analysis was 
performed 2 days after injection to allow sufficient time for maximal transgene 
expression in the surviving twin. This showed a large blood clot posterior to the right 
lobe of the liver and extending to the left o f the midline in the dead twin. Culture of 
fetal tissues showed no evidence of bacterial infection and we concluded that the cause 
of death was procedural rather than due to iatrogenic infection.
Clear ascitic fluid was present in all fetuses at post mortem examination 2 days after 
injection (Figure E 40). This was a larger volume than is usually present in non­
injected fetuses and those injected via alternative routes (50-1 OOpil). The protein content 
of samples o f ascitic fluid were analysed to determine whether they showed signs of 
inflammation. The protein levels from four fetuses, G5, G10, G9 and G 11 measured 3, 
3.2, 7.5 and 8.5 g/1 respectively. These results imply that the fluid was only a transudate, 
since protein levels must reach 25g/l to indicate an inflammatory process. In general the 
volume of the ascites was highest with the largest volume o f perflubron injected into the 
fetal stomach as shown in Table E 22.
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Figure E 40: Peritoneal fluid after intragastric injection of adlacZ vectors.
The peritoneal cavity o f  a sheep fetus aged 62 days o f  gestation at post mortem examination 2 days after 
ultrasound guided gastric injection o f  gene therapy vectors. The fetus received Na-caprate (100 pi, 100 
mM), adlacZ (100 pi, 9.5 x 101: p/kg) complexed with DEAE dextran (5pg/ml), and perflubron (300 pi). 
Clear straw-coloured fluid can be seen distending the omentum and also within the rumen and reticulum.
It is likely that the perflubron itself contributed to the ascitic volume by leaking out of 
the stomach after gastric injection. In two fetuses there were other significant findings at 
post mortem examination. In the fetus with the largest volume of ascites (8ml) a small
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pleural effusion was also observed. This may have occurred secondary to the 
compression effect o f the ascites on the venous return to the heart, leading to cardiac 
failure. In another fetus, fine peritoneal adhesions were seen. Culture of the fetal liver 
and ascites showed a pure growth o f coagulase negative staphylococcus that was most 
likely introduced during the injection procedure.
Table £  22: Post mortem findings after gastric injection of adenovirus vector and 
transduction enhancing agents.
Fetuses were examined 2 days after injection; dex (5pg/ml): DEAE dextran, cap (lOOmM): Na-caprate 
pretreatment, perf: perflubron, *denotes addition o f  colloidal carbon (1 :2 dilution) with adenovirus vector.
Sheep Age
(days)
Vector and enhancing agents Post mortem 
findings in addition 
to clear ascitic fluid
Ascites
(ml)adlacZ
(p/kg)
dex cap
(Ml)
perf
(pi)
G2 62 1 x 101U - 100 - - 1
G5 60 1.6x 1013 - - - - 2
G3 61 1 x 1013 - 100 300 - 2
G4 60 9.5 x 1012 + 100 300 - 2
G6 60 1.4 x 1013 + 200 1000 - 0.5
G8* 60
l.O x 1013 + 200 1000
Fine adhesions from 
liver to anterior 
abdominal wall
1
G il* 60 1.1 x 1013 + 200 1000 - 6.5
G9* 60 l.Ox 1013 + 200 1500 - 3
G10 60 8.8 x 1012 + 200 1500 Small pleural 
effusion (0.2ml)
8
E 4.7 Adenovirus vector transfects the villi but not the crypts in the 
fetal sheep intestine
Results o f ex vivo transfection experiments had shown us that adenovirus mediated gene 
transfer to the fetal sheep gut was possible at 60 days gestation. A series o f experiments 
were conducted to evaluate the effect of the fatty acid Na-caprate and the poly cation 
DEAE dextran on adenovirus transduction of the fetal gut. X-gal staining and f3- 
galactosidase immunohistochemical analysis o f tissues from the fetal gastrointestinal 
system was performed on fetuses 2 days after gastric injection (Table E 23 A). The 
amount o f p-galactosidase expression was also determined using ELISA analysis 
(Table E 23 B).
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Table E 23: p-galactosidase transgene expression after intragastric injection of 
adlacZ vectors.
(A) X-gal staining and p-galactosidase immunohistochemical analysis and (B) ELISA
analysis o f p-galactosidase expression (pg/mg protein) in the fetal gut.
Tissues were analysed 2 days after injection o f  Na-caprate (cap, lOOmM), adenovirus vectors (adlacZ) 
with or without DEAE dextran (dex, 5 |ig/m l) and different volum es o f  perflubron (perf) into the stomach 
o f  fetal sheep at 60 days o f  gestation. * denotes addition o f  colloidal carbon (100 pi, 1:2 dilution) with 
adenovirus vector. For transgene expression, + to +++ indicates degree o f  transduction observed after 0- 
gal staining or immunohistochemistry; (+) indicates single positive cell or sparse staining.
Table 
E23 A
Age
(days)
Vector and enhancing agents X-gal 
staining: 
small bowel
p-gal 
immuno: 
small bowelSheep adlacZ
(p/kg)
dex cap
(pi)
perf
(pi)
G5 60 1.6 x 10l3 - + ++
G2 62 1 x 101U - 100 - (+) +
G3 61 1 x 1013 - 100 300 (+) (+)
G4 60 9.5 x lO 12 + 100 300 + (+)
G6 60 1.4 x 10l3 + 200 1000 +++ +++
G8* 60 1 .0 x l0 lj + 200 1000 +++ +++
G il* 60 1.1 x 1013 + 200 1000 +++ +++
G9* 60 1.0 x 10lJ + 200 1500 +++ +++
G10 60 8.8 x lO 12 + 200 1500 +++ +++
Table E23 B G5 G3 G4 G6 G8* G il* G9* G10
dex (5pg/ml) - - + + + + + +
cap (pi) - 100 100 200 200 200 200 200
perf (pi) 0 300 300 1000 1000 1000 1500 1500
Oesophagus Upper 224 1129 11 41497 1124
Lower 722 629 20375 601
Stomach
Rumen 3496 373 714 1528 923 11318 8751
Reticulum 77 1584 3448 8864 2204
Omasum 1568 2138 10684 568
Abomasum 538 10322 13188 5984
Duodenum 518 1411 8394 174
Small bowel
Upper '/3 551 671 3091 174
Middle V 3 318 341 2601 104
Lower V 3 775 1378 578 4108 3818
Caecum 315 3654 811 2257
Transverse colon 498 3002 20375 2264
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In the first experiment (G2) only Na-caprate and the adenovirus vector were injected. X- 
gal staining showed weakly positive transgene expression in the villi of the small bowel 
that was not quantified by ELISA (data not shown). Immunohistochemical analysis of 
P-galactosidase expression (Figure E 41 A - E) showed scattered positive cells in the 
villi o f the distal small bowel, the spleen and the serosa surrounding the reticulum, 
small bowel and pancreas. There were many positive cells in the myocardium, and 
strong staining o f subcapsular hepatocytes. There was no transgene expression observed 
in the crypts o f the small bowel.
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Figure E 41: p-galactosidase transgene expression after intragastric injection.
Two days after injection o f  Na-caprate and adlacZ vector (G2, 1 x 1010 p/kg), immunohistochemical 
analysis (haematoxylin counterstain) shows scattered positively stained (A) villi o f  the distal small bowel 
(arrowed) and (B) serosa o f  the reticulum. Strong positive staining o f  (C) subcapsular hepatocytes, (D) 
the myocardium and (E) the spleen. Increasing the dose o f  adlacZ vector without Na-caprate pretreatment 
(G5, 1.6 x 1013 p/kg) resulted in a small improvement in p-galactosidase expression in the proximal small 
bowel villi (F) but no transduction o f  the epithelial cells in the crypts was observed (G). Original 
magnifications are as indicated.
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To improve adenovirus mediated transgene expression we decided to increase the dose 
o f vector applied. From our ultrasound measurement study, the fetal stomach volume 
measured between 0.5 -  1.5ml at 60 days o f gestation and the gastric fluid would dilute 
the vector considerably. Therefore we increased the adenovirus vector dose from 1 x 
1010p/kg to approximately 1 x 1013 p/kg, a similar dose to that applied by intramuscular 
injection.
Increasing the adenovirus vector dose alone (G5) without Na-caprate pretreatment 
resulted in a small improvement in the level o f transgene expression in the small bowel 
but positive staining was confined to the villi and was not observed in the epithelial 
cells lining the crypts (Figure E 41 F, G). Quantifying the level o f P-galactosidase by 
ELISA showed maximum transgene expression at the site o f injection (rumen) and there 
was low level expression in the small bowel up to the distal third (Table E 22 B).
E 4.8 Instillation of the fluorocarbon perflubron improves 
distribution of adenovirus mediated transgene expression to the 
distal intestine but does not affect transduction of the intestinal 
crypts
In this series o f experiments we wanted to evaluate the effect o f the fluorocarbon 
perflubron on spread o f the adenovirus vector distally beyond the gastric injection site 
through the small and large bowel. We considered that the lack o f crypt transduction 
might result from an inability o f the vector to reach the crypts, and that perflubron 
might distend the small bowel and improve crypt access. We therefore decided to inject 
increasing volumes o f perflubron into the fetal stomach after delivery o f the adenovirus 
vector. Because we did not know the maximum volume o f perflubron that the fetus 
would tolerate, we began by injecting 300pl which would increase the stomach volume 
by approximately a third (mean stomach volume before injection = 0.8ml). We then 
injected lOOOpl and 1500pl which would approximately double and triple the stomach 
volume respectively. To test whether this would improve crypt access we administered 
colloidal carbon (100 pi, 1:2 dilution) with the adenovirus vector in some fetuses. In all 
these experiments the volume o f Na-caprate and adenovirus vector administered was 
increased from lOOpl to 200pl to improve visualisation o f microbubbles during stomach 
injection. We considered it unlikely that this small increase in volume relative to the 
gastric volume would affect gene transfer results.
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Injection o f 300pl perflubron after pretreatment with Na-caprate and delivery of 
adenovirus vector alone (G3) resulted in only low level transgene expression (Figure E 
42) which had extended down to the level o f the transverse colon but was below the 
level o f detection by ELISA. Complexing the adenovirus vector with DEAE dextran 
(5pg/ml, G4) increased the amount o f gene transfer to a level o f 373 pg/mg protein by 
ELISA analysis but maximal expression was still local to the injection site at the fetal 
rumen. Immunohistochemical analysis for p-galactosidase expression was negative in 
both fetuses. These results were in agreement with the findings from ex vivo transfection 
experiments in which complexing the adenovirus vector with DEAE dextran improved 
gene transfer to the fetal gut. To achieve maximal gene transfer therefore, further 
experiments used DEAE dextran complexed adenovirus vector.
Figure E 42: p-galactosidase transgene expression after intragastric injection.
X-gal staining o f  the fetal sheep gastrointestinal tract 2 days after Na-caprate pretreatment and injection 
o f  adlacZ vector with perflubron (300pl) into the stomach at 61 days o f  gestation (G3, 1 x 1013 p/kg). 
There is low level staining in the (A ) oesophagus and (B) duodenum. Original magnification x 4.
Increasing the volume of perflubron substantially increased the spread and amount of 
adenovirus mediated gene transfer to the fetal gut. Administration o f lOOOpl perflubron 
to the stomach of two triplets (G6 and G8, Figure E 43, Panel 1 A and B) resulted in 
high levels of X-gal staining. Immunohistochemical analysis for p-galactosidase 
expression confirmed these results (Figure E 43, Panel 2 A -  C) and quantification by 
ELISA analysis showed positive expression throughout the length of the fetal gut that 
was maximal in the fetal reticulum of G6 (1584 pg/mg protein) and abomasum of G8 
(10322 pg/mg protein). Examination o f the non-injected co-triplet, G7 showed no 
positive X-gal staining and no p-galactosidase expression on ELISA analysis.
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Panel 1:
Panel 2
Figure E 43: The effect of perflubron instillation on adlacZ mediated gene transfer 
to the early gestation sheep gastrointestinal epithelium.
All fetuses received pretreatment with Na-caprate and adlacZ (8.8 x 1012-  1.4 x 1013 p/kg) complexed 
with DEAE dextran.
Panel 1: X-gal staining o f  the (A ) rumen (G6) and (B) abomasum (G8) after instillation o f  lOOOpl 
perflubron and o f  the (C) lower oesophagus, (D) rumen, (E) distal small bowel and (F) rectum after 
instillation o f  1500pl perflubron (G9). Original magnifications x 2 except where indicated.
Panel 2: P-galactosidase expression in the (A) serosa o f  the rumen (G6), (B) omasum and (C) proximal 
small bowel (G 8) after instillation o f  lOOOpl perflubron, and in the (D) rumen (G9) and (E) and (F) in the 
proximal small bowel (G 10) after instillation o f  1500pl perflubron. N o staining was observed in the 
epithelial cells lining the crypts (F). Original magnification x 40 except where indicated. Haematoxylin 
counterstain was used in all immunohistochemistry analysis.
Increasing the perflubron volume instilled to 1500pl in a set o f twins increased the level 
o f expression in one twin (G9) but had no effect on the other twin (G10). LacZ
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expression was seen throughout the gastrointestinal system, as for G6 and G8 in which 
lOOOpl perflubron was given (Figure E 43, Panel 1 C - F). Maximal expression in G10 
was observed in the rumen (8751 pg/mg protein). The highest level o f expression in G9 
was in the upper oesophagus (41497 pg/mg protein) suggesting that as well as being 
directed distally, the vector was also flushed proximally up the oesophagus, p- 
galactosidase expression detected by immunohistochemical analysis confirmed the 
findings from X-gal staining (Figure E 43, Panel 2 D-F), but staining was only 
observed in the epithelial cells of the villi and not in the crypts (Figure E 43, Panel 2 
F).
In addition there was positive staining in the nucleus and cytoplasm o f the endothelium 
and subendothelium lining the portal vein branches in the left lobe of the liver o f both 
fetuses (Figure E 44). This probably represents gene transfer to the portal vein 
endothelium and also uptake o f P-galactosidase expressed by transduced gastrointestinal 
epithelium.
Figure E 44: p-galactosidase transgene expression in the liver after intragastric 
injection.
Immunohistochemical analysis o f  P-galactosidase expression (haematoxylin counterstain) in the left lobe 
o f  the liver 2 days after ultrasound-guided injection o f  Na-caprate, DEAE dextran complexed adlacZ (8.8 
x 1012 -  1 x 1013 p/kg) and perflubron into the stomach o f  two early gestation fetal sheep. Strong 
transgene expression is seen in the nucleus and cytoplasm o f  the endothelium and subendothelium lining 
the portal vein branches in G9 (A and B) and G10 (C). Original magnification x 40.
Colloidal carbon was injected with the adenovirus vector (100 pi, 1:2 dilution) in one of 
the triplets (G8) and one o f the twins (G9). Low powered microscopic examination of 
the opened gut showed colloidal carbon in the lumen of the small and large bowel down 
to the rectum. On histological examination there were a few dots o f carbon in the crypt 
of the small bowel in one fetus (G8) but none in the other. This demonstrated that vector 
was able to reach the intestinal crypts but only in very small quantities. Colloidal carbon 
was seen within the lumen over the length o f the gastrointestinal system confirming that 
the vector spreads distally when large volumes o f perflubron are given.
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A small amount o f X-gal staining was seen on the serosal surface o f the stomachs and 
the small and large bowel o f the fetuses that received lOOOfal and 1500pl perflubron 
(G 6-G 11) suggesting that some o f the injected fluid escaped from the fetal rumen into 
the peritoneal cavity after injection. Although we did not observe microbubbles passing 
from the fetal rumen into the peritoneal cavity immediately after stomach injection, it 
was not unexpected because o f  the amount o f stomach distension we achieved that 
would increase intragastric pressure. The majority o f X-gal staining was seen within the 
lumen. Prior to X-gal staining and p-galactosidase ELISA the peritoneal covering was 
stripped from the small and large bowel. It cannot be ruled out however, that serosal 
transgene expression contributed to the total P-galactosidase expression observed on 
ELISA analysis o f  the fetal stomach cavities.
To conclude, sodium caprate pretreatment and DEAE dextran complexation improved 
adenovirus mediated gene transfer to the gastrointestinal epithelium in vivo but lacZ 
expression was limited to the intestinal villi. Flushing with perflubron gave transgene 
expression throughout the length o f the gut but did not result in gene transfer to the 
intestinal crypts.
E 4.9 Atropine, a suppressor of fetal gastrointestinal motility, is 
instilled with the adenovirus vector
We speculated that relaxation o f  the fetal small bowel smooth muscle might improve 
vector access to the intestinal crypts. Fetal hypoxia and intragastric atropine, an 
anticholinergic agent, have been shown to suppress upper gastrointestinal motility in 
late gestation fetal rabbits (Sase M et al., 2002,Acosta R et al., 2002). In adult humans 
atropine relaxes the gastrointestinal smooth muscle from stomach to colon and it is 
believed to act via muscarinic receptors. No data exists for the fetal sheep, but fetal 
gastric peristalsis appears as early as 14 weeks o f gestation in humans (Sase M et al., 
1999). This is approximately equivalent to 52 days gestation in the fetal sheep and we 
believed therefore, that atropine would have some effect on the fetal gut even at 60 days 
o f gestation.
We investigated the effect o f atropine on adenovirus mediated gene transfer to the gut o f 
twin fetal sheep (G 11 and G12). Both fetuses received an intragastric injection o f Na- 
caprate (lOOpl, lOOmM), colloidal carbon (1:2 dilution) and adenovirus vector 
complexed with DEAE dextran (5pg/ml), and lOOOpl perflubron. In addition, one fetus 
(G 11) received intragastric atropine (0.04pg/g estimated fetal body weight) with the Na-
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caprate pretreatment. The dose was the same as that used in the late gestation fetal 
rabbits (Acosta R et al., 2002).
Unfortunately the fetus that did not receive atropine died 24 hours after injection (G12) 
and it was not possible therefore, to compare the results o f the two fetuses. The fetus 
that received intragastric atropine (G 11) was analysed 48 hours after injection. On 
examination o f the opened bowel with low power microscopy, colloidal carbon could be 
seen within the lumen o f  the distal third o f the small bowel but not in the caecum or 
colon. These results can be compared with those o f the fetus that received the same 
volume o f Na-caprate, vector, perflubron and colloidal carbon (G8) in which colloidal 
carbon could be seen within the lumen o f the entire length o f the gastrointestinal 
system. X-gal staining and p-galactosidase immunohistochemical analysis was negative 
although p-galactosidase expression was detected in the rumen on ELISA analysis. We 
concluded that atropine probably had a small relaxant effect on gastrointestinal motility 
even at this early gestation but did not affect transgene expression in the intestinal 
crypts. Indeed, addition o f atropine may have reduced the efficiency o f adenovirus 
infection and gene transfer.
E 4.10 The effect of adenovirus vectors and transduction enhancing 
agents on fetal gastric fluid
E 4.10.1 Biochemical analysis of fetal gastric fluid
The concentration o f  solutes and the osmolality o f fetal gastric fluid before adenovirus 
delivery and at post mortem analysis were compared to determine whether the injection 
of the viral vector had any effect. There were no significant differences in values from 
samples before injection or those taken at post mortem. No normal ranges for ovine 
fetal gastric fluid were available at this early gestation (60 days) but all samples fell 
within the normal ranges for late gestation fetal ovine gastric fluid (Sherman DJ et al., 
1996).
E 4.10.2 Cytological analysis o f fetal gastric fluid
Fetal gastric fluid was analysed for evidence o f an inflammatory reaction at postmortem 
analysis and compared with samples obtained prior to injection o f vector. There were no 
epithelial or inflammatory cells observed in pre or post-injection gastric samples.
259
E. RESULTS: Cystic fibrosis
E 4.11 Spread of adenovirus vector in fetal and maternal tissues 
following intragastric administration
We explored the spread o f transgene to the fetal and maternal organs by PCR analysis 
of tissues from one fetus (G6). AdlacZ was detected throughout the gastrointestinal 
system and all fetal organs tested suggesting that systemic spread o f the vector had 
occured (Table E 24). This could have been via haematogenic or lymphatic spread.
Table E 24: Vector spread after in tragastric  injection of adlacZ vector to fetal 
sheep in early gestation.
AdlacZ vector was detected by PCR analysis o f  fetal and maternal tissues taken from a fetus aged 60 days 
o f  gestation sacrificed 48 hours after intragastric injection (G6, 1.4 x 1013 p/kg). Tissues that tested 
positive on 1st round PCR analysis (1st) were not generally subjected to nested PCR analysis (2nd).
Tissue 1st 2nd
Stomach
chamber
Rumen +
Reticulum +
Omasum +
Abomasum +
Duodenum - +
Small
bowel
Proximal lA +
Middle !4 +
Distal 'A +
Caecum +
Transverse colon +
Rectum +
Liver + +
Gonad + +
Lung + +
Heart - +
Spleen + +
Kidney +
Placenta - -
E 5 Discussion
E 5.1 Ultrasound guided intra-amniotic injection is safe at early 
gestation in the fetal sheep
In this study, we performed intra-amniotic injection o f the fetal sheep at 33 -  39 days of 
gestation equivalent to a human gestational age o f 8 -  10 weeks. This is the earliest 
gestational age that ultrasound-guided intra-amniotic injection has been conducted in 
the fetal sheep. Short-term survival after injection was excellent, suggesting that the 
procedure carries a low complication rate, in keeping with evidence from clinical
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studies performed at this gestation. From these experiments it was not possible to 
differentiate the effect o f the injection procedure from the effect o f early gestation intra- 
amniotic adenovirus vector on fetal morbidity and mortality. Our results however, are 
comparable to the only other study on ultrasound-guided intraamniotic injection in early 
gestation fetal sheep (aged 3 8 - 9 8  days o f gestation), in which retrovirus vectors or 
saline were delivered, resulting in the loss o f 5 out o f 18 fetuses (Galan HL et al., 2002). 
The long-term morbidity and mortality was more likely to be related to application o f 
the adenovirus vector. This is o f  concern since both fetuses that were left to deliver 
developed complications. No infective cause was identified for the fetus that aborted in 
late pregnancy and the other lamb had multiple congenital skeletal abnormalities. 
Congenital abnormalities are not uncommon in sheep and may be due to teratogenic 
agents in food or be genetic in origin. Akabane virus, an arthropod borne Bunyavirus is 
a major cause o f ruminant congenital malformations in Australia, the Middle and Far 
East. The congenital effects that include arthrogryposis, hydrocephalus, microencephaly 
or encephalomyelitis were not present in our lamb, and the infection is not found in the 
United Kingdom (Charles JA, 1994). Pestiviruses are the only infectious agents 
occurring in the United Kingdom that cause such congenital abnormalities (Nettleton PF 
and Entrican G, 1995) and they are not present in our flock. The possible role o f the 
adenovirus vector cannot be excluded, particularly since it was given before the 
completion o f organogenesis. In the fetal primate, ultrasound guided intraamniotic 
injection o f adenovirus vectors in mid-gestation resulted in one fetal death from Candida 
infection 10 days after injection. The remaining 5 animals analysed from 10 to 30 days 
after injection showed no developmental abnormalities (Larson JE et al., 2000b) but 
there is no data on long term follow-up in the fetal primate.
Adenovirus infection is associated with pathology in utero. Adenovirus vectors cause 
developmental delay and disorganised cleavage o f mouse embryos after the 2-cell stage 
(Gordon JW, 2002) and bovine adenovirus infection has been associated with 
unexplained fetal abortion in cows (Bartha A and Mate S, 1983). In the human, 
adenovirus is the most common viral pathogen identified in amniotic fluid and other 
fetal tissues from abnormal pregnancies (Wenstrom KD et al., 1998,Van den Veyver IB 
et al., 1998). Echogenic liver lesions with or without fetal hydrops have also been 
observed in patients with positive PCR results for adenovirus in the amniotic fluid 
(Baschat AA et al., 2003). Although it is unlikely that adenovirus would be the vector o f 
choice for prenatal gene therapy, our results and the evidence from the literature
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highlight the important concept that any vector used in clinical application must have an 
excellent safety profile in the fetus and mother.
In clinical practice, intra-amniotic injection has been used primarily to sample amniotic 
fluid to aspirate fetal cells for prenatal diagnosis. This procedure is performed between 
1 5 - 17  weeks o f gestation and most fetal medicine units quote a procedure-related 
additional risk o f spontaneous miscarriage o f 0.5 - 1%. Early amniocentesis at 11 -  13 
weeks o f gestation is technically straightforward but has a higher rate o f complications 
including miscarriage, amniotic fluid leakage, and orthopaedic deformity (CEMAT 
group, 1998). Intra-amniotic injection is also used to drain excess amniotic fluid that 
can occur for example, in twin to twin transfusion syndrome (TTTS). Amnioreduction 
is usually performed from 16 weeks o f gestation when severe TTTS may first present 
and even aggressive amniodrainage is associated with a low 1.5% complication rate 
(Wee LY and Fisk NM, 2002). Delivery o f therapeutic compounds into the amniotic 
cavity has been performed for a few fetal conditions in mid or late gestation, including 
thyroxine for the treatment o f fetal hypothyroidism (Collins FS and Watson JD, 2003) 
and surfactant for the prevention o f neonatal respiratory distress syndrome (Cosmi EV 
et al., 1996). Intra-amniotic injection at gestations earlier than 11 weeks has usually 
been performed to sample amniotic fluid for research purposes only, on women who 
subsequently underwent surgical termination o f pregnancy (Jauniaux E et al., 1999b) 
and the associated complication rate is therefore unknown.
The optimum gestational age for clinical application o f intra-amniotic fetal gene therapy 
must be a balance therefore between the risks o f an earlier procedure and targeting the 
fetus for the congenital disease to be treated. For gene therapy o f some genetic 
conditions for example skin diseases such as epidermolysis bullosa, earlier exposure of 
the fetus may result in better gene transfer because o f immaturity o f the developing 
skin. For cystic fibrosis gene therapy however, transport o f the vector into the airways 
relies on fetal breathing movements that only appear from the end o f the first trimester.
E 5.1.1 Alternative fluid compartments in the fetus: the 
extraembryonic coelom
The exocoelomic cavity or extraembryonic coelom surrounds the embryo and fetus 
during most o f the first trimester and could be used for delivery o f gene therapy. Intra- 
allantoic injection is straightforward in the fetal sheep. Indeed in our study, during intra­
amniotic injection, the needle first entered the allantoic cavity before passing through 
the amniotic membrane. Ultrasound-guided transabdominal coelomic injection has been
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studied in the sheep fetus at 40 -  45 days o f gestation for stem cell transplantation. Low 
level stem cell engraftment was achieved after delivery o f human haematopoietic stem 
cells but the procedure had a 33% miscarriage rate by mid-gestation (Noia G et al., 
2004). The relatively large fluid volume would reduce the efficacy of coelomic delivery 
for gene therapy. There would also be preferential transduction o f the placenta since 
there is no anatomical barrier between the mesenchyme o f the placental fetal plate and 
the extraembryonic coelom (Jones CPJ and Jauniaux E, 1995). This was observed after 
injection of adenovirus vectors into the extraembryonic coelom of the fetal rat (Laurema 
A et al., 2004). Giant cells o f Reichert’s membrane, the parietal lining o f the fetal rat 
yolk sac exhibited a high level o f transduction. No transgene expression however was 
detectable in the fetal or maternal liver, and PCR analysis confirmed that vector spread 
was restricted to Reichert’s membrane.
In the human embryo, the extraembryonic coelom can be visualised from 5 to 12 weeks 
of gestation and sampling o f coelomic fluid or coelocentesis can be performed by 
ultrasound guided transvaginal puncture with a 96% success rate between 6 and 10 
weeks of gestation (Jurkovic D et al., 1993). The high failure rate o f cell growth from 
coelomic fluid has limited its use in prenatal diagnosis to DNA analysis (Jauniaux E et 
al., 2003). In addition, a study o f short-term safety o f coelocentesis in women 
undergoing elective termination o f pregnancy for psychosocial reasons found a 
miscarriage rate of 25%, 2 to 13 days after the procedure (Ross J et al., 1997). Long­
term safety has not been assessed in the human fetus, but a study in the baboon showed 
a loss rate o f one out o f 9 fetuses up to the third trimester after ultrasound-guided 
transvaginal coelocentesis at 40 days o f gestation (equivalent to 8 weeks of gestation in 
the human) (Santolaya-Forgas J et al., 1998). For these reasons, coelocentesis is not 
used currently for routine prenatal diagnosis. Coelomic delivery may be suitable for 
targeting gene transfer to the placenta in early gestation, but it is unlikely to be a 
suitable route for fetal gene therapy.
E 5.2 Ultrasound guided intra-amniotic injection in early gestation 
fetal sheep does not transfer genes to the airways
We investigated intra-amniotic application o f adenovirus vectors because this route has 
been shown to allow gene transfer to the fetal airways (Douar A-M et al., 1997,Larson 
JE et al., 2000b,Boyle MP et al., 2001). In addition we wanted to test whether tissues 
transduced via this route of injection could act as an ectopic source o f hFIX production. 
Therapeutic plasma concentrations of hFIX were detectable up to 11 days after injection
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and immunohistochemical analysis showed positive expression of p-galactosidase in the 
fetal skin and nasal cavities. This suggests that transduction of keratinocytes in utero 
may be able to deliver proteins to the circulation as well as to treat hereditary skin 
disease such as epidermolysis bullosa.
At the gestational age that we chose for injection, the abdominal wall is still open prior 
to the return o f the herniated intestinal loops to the peritoneal cavity which occurs in 
fetal sheep between 32 and 40 days of gestation (Cloete JHL, 1939). We hypothesised 
this would allow vector entry into the peritoneal cavity and although not observed by 
immunohistochemistry, PCR analysis showed vector presence in the fetal liver. We did 
not however detect vector in any o f the other intraperitoneal organs even by sensitive 
nested PCR analysis.
We did not see any significant airway or gastrointestinal tissue transduction after 
ultrasound-guided intra-amniotic delivery o f adenovirus vectors to early gestation fetal 
sheep. Studies o f intra-amniotic delivery in other large animal models have had more 
promising results. Ultrasound-guided injection o f adenovirus vectors in mid-trimester 
rhesus macaque fetuses resulted in significant transgene spread to tissues coming into 
contact with amniotic fluid but low level transgene expression in the fetal airways and 
intestine (Larson JE et al., 2000b). Application o f a retrovirus producer cell line had 
similar results (Bennett M et al., 2001). Short-term gene transfer to the fetal trachea and 
pulmonary epithelium was found after intra-amniotic injection o f AAV in late gestation 
fetal rabbits (Boyle MP et al., 2001). At its peak however, transgene expression was 
only detected in 1 in 500 cells and most of these were in the alveoli that are not the site 
of CFTR expression. Long-term low level gene expression in the lung, intestines and 
kidney was seen 16 months after delivery o f AAV containing the GFP reporter gene to a 
mid-gestation rhesus macaque (Garrett DJ et al., 2003).
The different result we observed is most likely due to the early stage o f gestation in our 
study. At this early gestation we were unable to take advantage o f fetal breathing 
movements or swallowing to distribute the vector to the airways or gut since these first 
occur at around 50 days of gestation (Cooke IRC and Berger PJ, 1990) and are only 
common in the last third of gestation (Ross MG and Nijland MJ, 1998). The dilution of 
the vector in the relatively larger volume o f amniotic fluid is probably responsible in 
general for the low transfection levels that are achieved. In fetal sheep the amniotic fluid 
volume increases ten-fold from 2mls at 31 days to 20mls at 38 days of gestation (Cloete 
JHL, 1939), thus the gestational age o f vector delivery is o f critical importance.
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We did nevertheless observe p-galactosidase expression in the nasal cavity, and 
transduction o f the fetal skin was most likely responsible for blood levels o f hFIX, 
which reached about 2% of normal human adults. At this stage o f development in the 
human fetus, the immature epidermis undergoes remodelling by programmed cell death 
to be replaced by mature keratinocytes to form the definitive four-layer arrangement by 
mid-gestation (Polakowska RR et al., 1994). This remodelling could explain some of 
the lower values o f hFIX at later investigation points in spite o f the lack o f anti-hFIX 
antibodies. It may also be due to the dilution o f the protein in the blood volume o f the 
growing fetus that increases rapidly by 10 fold between day 31-38 o f gestation (Cloete 
JHL, 1939). In therapeutic terms 1% of the normal hFIX level would be sufficient to 
convert a severe form o f Haemophilia B into a mild condition. However the transient 
nature of expression from the adenovirus would require re-application in late gestation, 
where delivery to the liver by intra-umbilical injection would be more effective in 
achieving high enough hFIX levels to avoid perinatal haemorrhagic complications. 
Intra-amniotic application o f adenovirus vectors has been investigated extensively in 
small animal models such as the fetal rat (Sekhon HS and Larson JE, 1995,Garrett DJ et 
al., 2003), mouse (Douar A-M et al., 1997,Holzinger A et al., 1995,Larson JE et al., 
1997,Larson JE et al., 2000a,Mitchell M et al., 2000,Sekhon HS and Larson JE,
1995,Mitchell M et al., 2000,Larson JE et al., 1997,Larson JE et al., 2000a,Sekhon HS 
and Larson JE, 1995,Holzinger A et al., 1995) and guinea pig (Senoo M et al., 2000). 
Therapeutic plasma concentrations o f hFIX have also been achieved in fetal mice after 
intra-amniotic injection o f adenovirus vectors carrying the hFIX gene (Schneider H et 
al., 1999). In general, transgene expression is maximal in those tissues that are in 
contact with the amniotic fluid, namely the amniotic membranes and the fetal skin with 
less transduction o f the gut and the mucosae. In larger animals, intra-amniotic 
application o f adenovirus vectors has generally been performed in mid to late gestation, 
using highly invasive laparotomy techniques (Holzinger A et al., 1995,Iwamoto HS et 
al., 1999) but has only achieved limited gene transfer. The only other study o f intra­
amniotic prenatal gene therapy to be performed at a comparable gestational age applied 
an amphotropic retrovirus producer cell line to fetal sheep (Galan HL et al., 2002) but 
no gene transfer could be demonstrated. The authors concluded this was specific to fetal 
sheep since the same vector produced limited gene transfer to mid-gestation fetal 
macaques (Bennett M et al., 2001). However the gestational age differences in these two 
studies is an important factor to consider.
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The low level transgene expression that we and others observe in the lungs shows that 
intra-amniotic injection is not a suitable route to target gene transfer to the airways for 
prenatal gene therapy o f cystic fibrosis, even in early gestation. In 1997 Larson et al 
claimed that the CF-phenotype in CFTR-knockout mice could be cured by short-term 
prenatal expression o f CFTR from an adenovirus vector (Larson JE et al., 1997). Recent 
work in our laboratory aimed to reproduce this report but could not substantiate this 
claim (Buckley SMK et al., 2003). Intra-amniotic delivery however, may be suitable for 
prenatal gene therapy of skin disorders such as dystrophic epidermolysis bullosa (Horn 
HM and Tidman MJ, 2002). We have also shown that this route o f injection results in 
transduction o f tissues that can be used as an ectopic source o f proteins such as hFIX for 
treatment o f congenital diseases requiring systemic correction.
E 5.3 The trachea can be reached by a minimally invasive ultrasound 
guided injection technique
Results o f gene transfer to the fetal airways are poor following gene delivery to the 
amniotic cavity (Boyle MP et al., 2001) or injection o f the lung parenchyma (Tarantal 
AF et al., 2001a). Direct instillation o f viral vectors into the trachea has been more 
successful. This has been attempted in fetal sheep using highly invasive surgery such as 
hysterotomy and placement of catheters down the fetal airway or fetal tracheotomy 
(Vincent MC et al., 1995,McCray PB et al., 1995). Another group used fetoscopic 
bronchoscopy in fetal sheep at laparotomy (Sylvester KG et al., 1997,Yang EY et al., 
1999) and although this technique could be developed for percutaneous use, endoscopic 
procedures are known to have a significant complication rate (Deprest JA et al., 1997b). 
To target the fetal trachea using an ultrasound guided percutaneous injection method we 
firstly studied its sonographic appearance from mid to late gestation. At 100 days of 
gestation the tracheal diameter was wide enough to permit injection and the fetus was 
not too large that fetal parts obscured the view. Injection before 70 days o f gestation is 
most likely not achievable because o f the small size o f the trachea and therefore 
targeting of gene therapy to the preimmune fetal sheep trachea is probably not possible 
via this route.
We first believed that injection o f the trachea would be more easily achieved in the fetal 
neck than in the thorax, and might be associated with fewer complications. In late 
gestation sheep, attempts to inject the trachea in the fetal neck were hampered by the 
fleece and the tracheal cartilage and we eventually successfully injected the trachea via 
a transthoracic route. To our surprise however, injection o f the trachea in the fetal neck
266
E. RESULTS: Cystic fibrosis
was also unsuccessful in the mid-gestation sheep. Despite being clearly visualized, the 
trachea was extremely mobile and slipped sideways from the needle as it approached. 
Altering the needle dimensions did not improve our success rate. The trachea within the 
fetal neck is superficial and relatively unsupported with the oesophagus placed posterior 
and fatty subcutaneous tissue placed laterally. The sheep neck is longer than that in the 
human and so the sheep trachea may be relatively more mobile. This approach would 
probably also be more difficult in the human fetus because o f the more flexed attitude 
adopted by the human fetus.
The best route to the trachea in the mid-gestation sheep fetus was found to be via the 
thoracic cavity. The procedure was reproducible and o f short enough duration for 
application in a clinical setting. As anticipated, fetal position was important for access 
to the trachea and was made easier when the fetus was lying with its right side anterior 
so that the great vessels were positioned posterior to the trachea. The gestational age 
was also a determining factor and there appeared to be a window of access in gestation, 
from approximately 80 days when the trachea was wide enough for injection, up to 120 
days o f gestation when it became increasingly obscured by the fetal humerus and 
scapula as the fetal head entered the pelvis.
The most common complication during the procedure was accidental vessel perforation 
leading to haemorrhage, although this caused significant morbidity in only 6% o f cases. 
Poor visualisation o f the trachea was a major factor and could be improved by careful 
selection of the gestational age for injection, and during the procedure, by tilting the 
mother on the table. Perforation o f a major vessel within the chest can lead to 
catastrophic haemorrhage as we observed in one fetus, and may be severe enough to 
cause death. Even damage to a minor vessel can have serious consequences. In our 
series, one fetus developed bilateral pleural effusions that in the long term might have 
required drainage with all its attendant complications. Although uncommon, vessel 
perforation is associated with serious morbidity and therefore transthoracic injection of 
the trachea should only be performed on fetuses that are suffering from a life- 
threatening condition.
The other complication was needle dislodgement during fluid injection that could be 
prevented in clinical practice by an extension set and three-way stopcock. Passing a 
catheter down the needle into the trachea would also prevent needle dislodgement but 
was associated with other complications such as tracheal perforation and damage to the 
catheter on the needle tip. The importance of tracheal volume was highlighted in one 
case when too much fluid was removed from the trachea leading to its collapse. This
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becomes most important in earlier gestations when the volume o f the trachea is small. 
We considered that removal o f tracheal fluid might improve airways transduction by 
reducing dilution o f the vector in tracheal fluid. The problems caused by the tracheal 
collapse however, lead us to abandon this technique.
It is noteworthy that the injection site was not identifable forty-eight hours after the 
procedure either macroscopically or microscopically in fetuses aged 100 days of 
gestation or older. This illustrates that the fetus is able to heal rapidly without scarring 
following minor trauma. At the younger gestation o f 80 days the injection site was 
always visualised but use of a smaller gauge needle may prevent this.
E 5.3.1 An occlusive balloon can be placed in the fetal sheep trachea by 
percutaneous ultrasound guided injection
With the aim o f improving gene transfer to the fetal airway epithelium, we adapted our 
transthoracic injection technique to place and inflate an occlusive balloon within the 
fetal trachea. None o f the balloon tipped catheter systems available would fit down a 
needle suitable for intratracheal injection. We considered whether a modified Seldinger 
technique used in interventional radiology, could be used to place a guide wire along a 
needle that had been injected into the fetal trachea under ultrasound guidance. After 
removal o f the needle, a balloon-tipped catheter would then pass over the guide wire 
into the fetal trachea. However it was thought unlikely that this system would succeed 
because o f the distance to the trachea and the tough tissues involved, and we could not 
locate a suitable catheter. We therefore investigated a detachable balloon system that 
has been used in the fetus for the treatment o f CDH.
Studies in animal models of CDH have used a variety o f occlusive devices in the fetal 
trachea including a polymeric foam insert (Skarsgard ED et al., 1996), a foam filled 
endotracheal tube (Bealer JF et al., 1995), and detachable silicone (Harrison MR et al., 
2001) or latex balloons (Flageole H et al., 1997). The detachable balloon systems that 
were developed for interventional neurovascular treatments (Higashida RT et al., 1991) 
proved the best for maintaining tracheal occlusion with minimal damage to the fetal 
trachea.
We showed that a detachable inflated balloon could be placed within the fetal trachea by 
ultrasound-guided injection alone. Whether the percutaneous technique is adopted for 
use in treatment o f CDH depends on a risk benefit analysis comparing it with the 
currently used fetoscopic technique. With improvements in balloon technology it may 
be possible to use a smaller gauge needle that would be less traumatic to the fetus.
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A randomized trial concluded that fetoscopic tracheal occlusion did not improve 
survival or morbidity rates in fetuses with CDH when compared with standard care 
(Harrison MR et al., 2003). Premature rupture o f the membranes and preterm delivery 
were more common in the group receiving the fetoscopic intervention, and the benefits 
o f tracheal occlusion on pulmonary function were probably outweighed by the adverse 
effects o f earlier delivery. Recent data from the Eurofoetus Consortium suggest that the 
use o f a narrower fetoscope may reduce the complication rate (Jan Deprest, personal 
communication). A wholly percutaneous approach might further reduce the risk of 
preterm delivery such that intervention in CDH may prove beneficial overall.
A feasibility study published in 2002 has shown that occlusion o f the fetal trachea might 
be achieved through the mouth using an ultrasound guided guidewire and detachable 
balloon system in the fetal sheep (Fauza DO et al., 2002). After exteriorisation o f the 
uterus at laparotomy, a catheter was introduced into the amniotic cavity and under 
ultrasound guidance, a remotely steerable guide wire was fed past the vocal cords into 
the trachea. Using the Seldinger technique, a catheter and an occlusive detachable 
balloon were placed in the trachea. Further developments in catheter steering 
technology may allow this to be achieved without the need for laparotomy.
The transthoracic tracheal injection technique may be o f further use in the treatment o f 
CDH. Reversible tracheal occlusion has been found to improve type II pneumocyte 
density in fetuses with CDH while maintaining the beneficial effect on lung growth. 
Unplugging of the balloon by puncture has been performed in fetal sheep under 
tracheoscopic vision (Flageole H et al., 1998). Recently it has been performed clinically 
in a few fetuses with CDH treated by balloon occlusion using the transthoracic 
ultrasound guided technique developed here (Deprest J et al., 2004).
E 5.4 Adenovirus mediated gene transfer to the fetal airway 
epithelium is enhanced by Na-caprate and the polycation DEAE 
dextran
In keeping with other studies, we found that the sheep airway epithelia is very resistant 
to adenovirus transduction in utero (Vincent MC et al., 1995,Yang EY et al., 
1999,Iwamoto HS et al., 1999). We believed that this was due to the lack o f adenovirus 
receptors on the apical side of the airway epithelia and we used two strategies to 
enhance virus transduction. Initially we applied the virus with the polycation DEAE 
dextran that forms complexes with the negatively charged adenovirus. This reduces the 
repulsive charge interaction between the virus and the anionic sialylated glycoproteins
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and glycolipids on the epithelial cell surface, which present a barrier to luminal vector 
delivery (Arcasoy SM et al., 1997a). We did not observe any macroscopically visible 
transduction in the trachea or main bronchi, although the quantitative measurement of 
total lung p-galactosidase expression did show a ten-fold increase over that of 
adenovirus-only administration. Our second approach was to expose the airways to Na- 
caprate prior to virus application to allow virus penetration to the basolateral surface of 
the epithelial cells, where the CAR and adenovirus binding integrins are present in 
higher abundance (Walters RW et al., 1999). This pharmacological pre-treatment, that 
temporarily and reversibly opens the epithelial tight-junctions, resulted in widespread 
staining o f the trachea and main bronchi and increased virus mediated transgene 
expression in the lungs by more than 90-fold. The combination o f virus and DEAE 
dextran complexing and Na-caprate pretreatment resulted in significantly enhanced 
gene transfer to the trachea and main bronchi as well as the large, small and medium 
airways. The synergy we observed between DEAE dextran and Na-caprate is 
presumably due to facilitated attachment and cellular uptake o f the complexed 
adenovirus at the basolateral versus the apical cell surface.
Our findings were validated quantitatively using an ex vivo tracheal culture system. The 
enhancement we observed was independent o f gestational age since the results were 
similar from each o f the five experiments performed on tracheal tissues from fetuses 
aged between 72 and 106 days o f gestation. Indeed, tight junctions are present and 
functional in the lung o f the fetal sheep aged 69 days of gestation (Olver RE et al., 
1981). We did not examine fetal sheep airways for the presence o f adenovirus receptors 
because it was beyond the scope o f this thesis. Studies in the fetal mouse lung however, 
have shown expression o f the Coxsackie Adenovirus Receptor and 05 integrin 
particularly by the airway epithelial cells (Bilbao R et al., 2003a).
E 5.5 Perflubron administration following adenovirus vector 
instillation alters the pattern of transgene expression in the fetal 
airways
In an attempt to increase gene delivery further we also applied the fluorocarbon 
perflubron, Overall we saw redistribution from the upper to the peripheral airways, 
where expression was enhanced at the expense o f tracheal and the large and medium 
airway epithelia. This redistribution of expression is most likely due to flushing o f the 
vector solution further down the airways by the water immiscible perflubron that 
increases the virus concentration locally in the peripheral airways. It has also been
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proposed that perflubron transiently increases the permeability o f epithelial tight 
junctions which could explain the high intensity o f local transgene expression in the 
extreme periphery (Weiss DJ et al., 2003).
The finding that perflubron did not affect levels o f p-galactosidase expression in each 
combination was not that surprising when considering the difference between fetal and 
adult airways. In one study on gene transfer to adult rodent airways where there is an 
air-tissue interface, instillation o f perflubron following adlacZ vector delivery increased 
levels o f p-galactosidase activity by 5 to 6 fold and more uniform distribution o f p- 
galactosidase expression was observed (Weiss DJ et al., 1999). The low surface tension 
o f  the fluorocarbon allows it to spread through communicating small airways and over 
alveolar walls (Shaffer TH et al., 1992) resulting in a less patchy distribution o f tissue 
transduction when compared to virus alone. This is particularly effective where there is 
lung damage already present (Weiss DJ et al., 2001). In the fetus however, a liquid- 
tissue interface exists already and therefore this effect o f perflubron is likely to play a 
smaller part.
Perflubron administration may not provide an advantage to the potential treatment o f CF 
in utero that requires predominantly upper and medium airway gene transfer. The 
pathological process in cystic fibrosis starts in the distal airways where a combination of 
abnormally thick mucus and chronic bacterial infections lead to damage. The main site 
o f CFTR expression in the adult lung however, is in the serous tubules o f the 
submucosal glands (Engelhardt JF et al., 1992) with only low level expression in the 
surface epithelium. One o f the major difficulties facing cystic fibrosis gene therapy in 
adults is targeting o f these glands which are more proximal. In the human fetal lung 
submucosal glands develop from around 15 weeks o f gestation and successful 
transduction o f submucosal glands using AAV in a mid-trimester human fetal tracheal 
organ culture system have shown proof o f principle (Lim F-Y et al., 2002). Variations 
in the volume o f perflubron may allow targeting o f injected fluid to different areas of 
the airways necessary for CF gene therapy.
The gestational age at vector delivery is likely to be critical to the efficiency of airways 
gene transfer and to targeting o f cells in the epithelium. In this study we administered 
the adenovirus vector during the late pseudoglandular phase, up to 90 days o f gestation 
and the early canalicular phase o f lung development, from 90 to 125 days o f gestation. 
From quantitative measurement o f p-galactosidase expression, transgene expression 
was higher at the earlier than at later gestation. This may simply reflect the higher local
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concentration o f vector that can be achieved at the younger age but also suggests that 
gene transfer may be more efficient at the earlier pseudoglandular stage. Similarly 
lentivirus mediated gene transfer was found to be more efficient at the pseudoglandular 
stage when compared with the earlier embryonic stage after lung parenchyma injection 
o f fetal macaques (Tarantal AF et al., 2001a). Application o f adenovirus vectors to late 
gestation fetal sheep results in gene transfer to type II alveolar pneumocytes as would be 
expected (Sylvester KG et al., 1997).
The gestational age is probably also critical for targeting an integrating vector to the 
stem cells o f the airway epithelium for permanent transgene expression. Although the 
common epithelial airway stem cell has not yet been identified there are several stem 
cell subsets which are capable o f reconstituting a fully differentiated tracheobronchial 
epithelium (Zepeda ML et al., 1995,Engelhardt JF et al., 1995). In the fetal sheep 
submucosal glands begin as gland buds during the pseudoglandular stage o f lung 
development (Smolich JJ et al., 1978) similar to humans (Thurlbeck WM et al., 1961).
It is not until the saccular stage that tubules are found, after the stage o f gestation o f our 
experiments. Targeting o f submucosal gland bud progenitors may be possible using the 
lymphoid enhancing factor 1 (LEF1) o f which expression has been shown to be 
important for submucosal gland development (Duan et al., 1998).
Transgene expression may be limited by the fetal immune response to it. In the fetal 
sheep lung, adenovirus mediated gene transfer faded coincident with the development of 
cellular inflammation and serologic evidence of antiadenovirus antibody production 
over a few weeks (McCray PB et al., 1995,Vincent MC et al., 1995). In our experiments 
the sampling time point o f two days after injection is insufficient time for them to 
mount an effective immune response and long term studies are required to evaluate this. 
An important area to investigate is the effect o f this potential treatment on the fetal 
airways and other organs. The pigmented material seen in the airway lumen is thought 
to be epithelial slough since it was seen in both injected and uninjected fetuses. There 
was evidence o f inflammation in the pleura and the pericardium on post mortem or 
histological examination in some fetuses. Injection o f a needle is traumatic and will 
have caused much o f the inflammation observed but the adenovirus vector used in these 
experiments is highly inflammatory and probably contributed largely to these findings. 
Significant pulmonary inflammation consisting o f cellular infiltrates and fibrous tissue 
was observed after tracheal administration o f adenovirus (McCray PB et al.,
1995,Vincent MC et al., 1995) and retrovirus (Pitt BR et al., 1995) vectors to late 
gestation fetal sheep. In all these studies however, the vector was applied using highly
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invasive laparotomy and catheter techniques that will be associated with more 
inflammation.
Whitened plaques identified microscopically as fibrous thickening o f the pleura, were 
seen on the posterior surface o f the lungs o f fetuses that received perflubron. Focal 
inflammation in the lumen o f the airways was also more evident in these fetuses. This 
may be due to impurites such as hydrogen fluoride that are present in non-clinical grade 
perflubron that we used (Weiss DJ et al., 2002b). Perflubron which is used in liquid 
ventilation o f neonates, is unlikely to cause any long-term damage o f the airways 
(Shaffer TH et al., 1992) and it has been shown to reduce inflammation in acutely 
damaged lungs (Younger JG et al., 1997). Transient inflammation however, has been 
observed after combination o f  perflubron with adenovirus vectors in normal and 
damaged adult lungs (Weiss DJ et al., 2001). In adults, perflubron is quickly cleared 
from the airways although it may persist for a few weeks following liquid ventilation of 
premature infants (Leach CL et al., 1996). There are no studies on its use in fetal 
airways although it is likely that very little will remain in situ because o f the net efflux 
o f fluid from the fetal airways. Na-caprate has been used to enhance delivery of 
antibiotics to the rectal mucosa in humans with no ill effects (Lindmark T et al., 1997) 
although there are as yet no long-term studies on its use in fetal or adult airways.
It has been suggested that gene transfer to between 5 and 10% o f airway epithelia may 
be sufficient to achieve therapeutic correction o f the defective chloride channel function 
in cystic fibrosis (Johnson LG et al., 1992). Given the widespread gene transfer 
throughout the airways under optimal conditions and the density o f transduced cells in 
the individual airways the achieved level o f gene expression may be sufficient to 
provide a therapeutic effect when applying a CFTR expressing vector. Ovine CFTR has 
a similar pattern o f expression during development to the human gene and there is 90% 
sequence identity within the coding region, making detection o f human CFTR on an 
ovine background potentially difficult. Using antibodies specific to hCFTR on a sheep 
background we are currently developing a protocol to analyse hCFTR expression in our 
fetal sheep samples.
E 5.6 Ultrasound guided intragastric injection is achievable in the 
early gestation fetal sheep with low short term morbidity and 
mortality
The aim o f intragastric delivery o f viral vectors was to target the gene therapy to the 
small and large bowel in early gestation, at an age when the fetus is considered to be
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preimmune. Ultrasound examination o f  the fetal sheep abdomen from 31 days of 
gestation showed that the stomach could be visualized from 40 days but it was always 
observed from 55 days o f  gestation. In one study in the human using transabdominal 
scanning, the stomach could be seen in 98% o f fetuses from 14 weeks o f gestation; 
indeed, non visualisation o f  the stomach at this age was associated with an abnormal 
pregnancy outcome (Pretorius DH et al., 1988). Transvaginal sonography (TVS) in the 
human fetus permits earlier visualisation o f the stomach from 9 weeks, and it was seen 
in almost all cases at 12 weeks o f  gestation, equivalent to 46 days o f gestation in the 
fetal sheep (Bronshtein M et al., 1992). TVS has not been used in the fetal sheep but it 
is likely that fetal anatomy would be visible earlier in gestation by this method. 
Transrectal sonography has been used to detect pregnancy in sheep but has a lower 
accuracy than transabdominal scanning (Watt BR et al., 1984) and is associated with 
rectal perforation.
The development and anatomy o f the sheep stomach is very different to that o f the 
human because o f  its more specialized function. By ultrasonography the human 
stomach is elliptical in its longitudinal section and spherical on transverse section. 
Although there is a wide variation in stomach volume due to dynamic filling and 
emptying (Zimmer EZ et al., 1992), over long periods o f evaluation the dimensions 
remain relatively constant (Goldstein I et al., 1987). Using three dimensional 
reconstruction from two dimensional ultrasound measurement, the stomach volume has 
been shown to increase linearly in the latter half o f pregnancy (Nagata S et al., 1994). 
The four chambers o f the sheep stomach develop at different rates through gestation. In 
early pregnancy at the stage o f  gestation we studied, the rumen is the most prominent 
chamber and it was observed in all fetuses where the stomach was visible. The 
reticulum was the next chamber most likely to be visualised, but the other two chambers 
were not seen routinely. Because o f this, we approximated the shape o f the stomach by 
ultrasonography to be a prolate ellipsoid, as in the human fetus. The largest diameter o f 
the stomach was also found to be the longitudinal measurement, and the dimensions 
increased linearly over the gestational ages that were measured.
This is the first report o f ultrasound guided intragastric injection in a large animal model 
in early gestation. From the stomach measurements obtained, we decided that 
intragastric injection should be possible from 55 days o f gestation since the AP and 
transverse diameters measured on average 5mm. We considered however, that the small 
stomach size might not permit withdrawal o f some gastric fluid to confirm correct 
needle placement and this was our experience in one fetus at this age. To improve our
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chance o f success, we moved forward in gestation to 60 days, when the AP diameter 
was approaching 10mm on average and reached our goal. Intragastric injection was 
achieved in all but one case and in a relatively short time. Despite differences in the 
stomach anatomy, the shape o f the fetal sheep rumen is very similar to that o f  the whole 
stomach in the human fetus. We expect therefore, that injection of the stomach in the 
human fetus would be just as straightforward.
An advantage of the procedure over other routes such as intramuscular or intrahepatic 
injection, was that the needle position could be confirmed prior to injection by 
withdrawal o f a small volume o f gastric fluid. The stomach could be seen expanding 
during instillation o f viral vectors and transduction enhancing agents. As would be 
anticipated, the volume and the number o f stomach chambers visualized rose with 
increasing volumes of fluid instillation, although there was very little difference 
between instillation of 1000 and 1500 pi fluid.
The short term morbidity and mortality from the procedure was low. Measurement of 
the protein levels in the ascitic fluid demonstrated that it was most likely due simply to 
leakage o f the fluid after gastric instillation into the peritoneal cavity rather than 
inflammation. As anticipated, we observed haemorrhagic and infective complications 
but further experiments are needed for a more accurate assessment. In a clinical setting 
the risk o f trauma to intraperitoneal organs might be reduced by injecting the fetal 
stomach only when it was positioned uppermost, and closest to the uterine wall. It is 
likely that procedures would be done without maternal general anaesthetic or sedation, 
and therefore the injection could be performed when the fetus had moved into the 
optimum position. We performed post mortem and histological analysis 2 days after 
injection but longer term follow up, including allowing some lambs to deliver, is 
necessary to evaluate the effect o f intragastric injection on the development o f the fetal 
stomach and its function in postnatal life. Peritonitis and intraperitoneal adhesions are 
likely to be the most common complications.
There is one published study of ultrasound guided intragastric injection o f late gestation 
fetal rabbits (Brandt et al., 1997b). The authors successfully injected the stomach in 
70% o f cases (18 out o f 26 cases). This was lower than our success rate o f 91% (10 out 
o f 11 cases) and may be due to the double needle technique that the authors used in 
which they placed a 20 Gauge spinal needle into the fetal abdominal cavity and then 
advanced a 26 Gauge needle through this into the fetal stomach. Air (100pl) was 
injected to confirm correct needle placement before barium (500jul) was instilled. The
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presence o f barium in the peritoneal cavity o f injection failures suggested that 
inadvertent intraperitoneal injection had occcurred, although it might also have leaked 
out o f the stomach after intragastric delivery. Their survival rate four hours after 
injection was 100% and and there was no histological evidence o f trauma or 
haemorrhage. Thus, in the short term, ultrasound guided intragastric injection appears to 
be o f  low risk to the fetus and mother, although further work is needed to determine 
longer term outcomes.
E 5.7 Gene transfer to the small and large bowel of fetal sheep can 
be achieved by ultrasound-guided intragastric injection
Genetic diseases affecting the gastrointestinal tract are rare but in the case o f cystic 
fibrosis, can have severe consequences, and treatment before birth may eliminate 
intestinal obstruction and its deleterious effect on nutritional status. The intestine could 
also be used as an alternative site for expression o f critical genes in somatic gene 
therapy treatment o f liver disorders. As a first step towards gastrointestinal fetal gene 
therapy, we have shown that the gut epithelium can be targeted in early gestation for 
gene transfer by a minimally invasive injection procedure in the fetal sheep.
Prior to our research, very little work had been done on gene transfer to the fetal gut. 
Gene therapy studies targeting the adult gut epithelium use various methods such as 
intraluminal (Foreman PK et al., 1998) or transrectal injection (Arenas et al., 1996) to 
deliver vectors to the small or large bowel epithelium respectively. Such methods 
bypass the stomach and involve flushing o f the bowel with saline to prevent exposure o f 
the vector to gastric acid and proteases that affect vector stability (Shao G et al., 2003). 
Our preliminary in vitro studies showed that gastric fluid from early and mid gestation 
fetal sheep did not inhibit adenovirus mediated gene transfer to an epithelial cell line. 
This is in agreement with studies on the ontogeny o f gastric acidity which show that 
acid secretion begins in the fetal sheep stomach from 120 days o f gestation (Shulkes A 
et al., 1985) and in the human fetus, gastric acid, intrinsic factor and gastrin can be 
secreted only from the middle o f the second trimester (Kelly EJ and Brownlee KG,
1993).
Before administering adenovirus in vivo we analysed the effect o f enhancers using an ex 
vivo small bowel culture system, similar to that used in the fetal trachea. The best gene 
transfer was obtained when both Na-caprate pretreatment and complexation o f the 
adenovirus with DEAE dextran were applied successively. DEAE dextran appeared to 
enhance gene transfer more to the fetal small bowel than to the fetal tracheal epithelium.
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Conversely Na-caprate, either alone or in combination with DEAE dextran, had less o f 
an enhancing effect on transduction o f the fetal small bowel. This is an interesting 
finding, since much o f the work on the mechanism o f action o f Na-caprate has been 
done on human intestinal epithelial (Caco-2) cells (Anderberg EK et al., 1993,Lindmark 
T et al., 1998) (Chao AC et al., 1999). In addition, Na-caprate can be used clinically to 
promote intestinal absorption o f hydrophilic drugs such as ampicillin across the 
gastrointestinal mucosa (Lindmark T et al., 1997). The different effects o f Na-caprate 
and DEAE dextran on fetal small bowel and airway epithelial cells that we observed 
may be due to the maturity o f  the epithelium at the time o f application, since the agents 
were applied at 60 and 80-110 days o f  gestation respectively. In our ex vivo fetal small 
bowel experiments, we quantified the enhancement o f adenovirus mediated gene 
transfer at around 60 days o f gestation. Although we only subjectively assessed gene 
transfer in older samples, we did not observe any major differences. The gut epithelial 
surface has a similar negatively charged glycocalyx with sialic acid residues in the adult 
and during fetal development (Hill RR and de Bruyn G, 1991) and this may explain the 
enhancing effect we observed with DEAE dextran.
Our findings also suggest that even at 60 days o f gestation, tight junctions are functional 
in the fetal sheep gut epithelium. This is supported by research in the human fetal colon 
showing that the structural components o f  tight junctions are already present by 10 
weeks o f gestation (Polak-Charcon S et al., 1980) and functional tight junctions can be 
observed in fetal rat small bowel epithelium at 16 days o f gestation (term = 22 days) 
(Colony PC and Neutra MR, 1985). It is possible that tight junctions in the small bowel 
epithelium at 60 days o f  gestation may be more leaky than those in the airway 
epithelium o f older sheep fetuses.
Delivery o f adenovirus vector alone resulted in gene transfer to the fetal gut epithelium 
in vivo at the site o f  injection. We showed that flushing the vector and enhancing agents 
with the fluorocarbon perflubron improved gene transfer to the small and large bowel 
epithelium. Increasing the volume o f perflubron applied led to transduction o f the gut 
more distal to the site o f  injection, and application o f 1ml was sufficient to reach the 
transverse colon. The small intestine is the area o f the adult human gut where maximum 
CFTR expression occurs, with lower levels in the colon (Strong TV et al., 1994,Trezise 
AE and Buchwald M, 1991). A similar pattern o f  CFTR expression is seen in the gut o f 
second trimester human fetuses (Trezise AE et al., 1993). Thus intragastric injection o f 
viral vectors can target CFTR gene transfer to the relevant tissues with the aim to 
prevent meconium ileus in cystic fibrosis.
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Throughout the fetal gut, adenovirus mediated transgene expression was seen only in 
the epithelial cells o f the villi and not in the cells lining the crypts. This is important for 
transduction o f  stem cells and in cystic fibrosis gene therapy. In the adult mouse, 
multipotent stem cells residing in the base o f the crypts o f  Lieberkiihn give rise to the 
four cell lineages in the small intestine (Winton and Ponder, 1990). Stem cell 
transduction is the ‘holy grail’ in gene therapy, since this would ensure that all progeny 
were corrected for a congenital disease. There is a decreasing gradient o f CFTR 
expression along the crypt to villous tip axis in the adult and fetal gut, with the highest 
levels o f expression in the crypts and only weak or undetectable expression in the top 
one-third o f the villi (Trezise AE et al., 1993,Strong TV et al., 1994). Gene expression 
in the villi but not in the crypts was observed after oropharyngeal application o f 
adenovirus to late gestation fetal rabbits (Wu Y et al., 1999). Similar results were also 
found in the adult gut epithelium after application o f adenovirus (Foreman PK et al.,
1998). Intestinal mucus present in the adult bowel, may prevent vector access to the 
crypts and flushing the bowel with mucolytics improves crypt transduction (Cheng et 
al., 1997b). We did not consider mucus to be a problem in the fetal sheep gut at the 
gestational age used in our experiments. Mucous cells are only seen in the small 
intestine o f  small animals in late gestation (Smith T et al., 1985,Trier and Moxey PC, 
1979) and in human fetuses from 17 weeks o f  gestation (Verma KB, 1979).
We hypothesized that the crypts might be inaccessible to the adenovirus vector because 
o f their deep location. The presence o f  colloidal carbon in the small bowel crypts o f  one 
animal after co-injection with the vector suggested that the vector was able to reach the 
crypts but only in low amounts. Attempts to relax the smooth muscle in the bowel wall 
using intragastric atropine resulted in gene transfer closer to the site o f injection 
suggesting that bowel peristalsis was slowed, but no expression was detected in the 
crypts. Subcutaneous injection o f  glucagon, which is known to reduce small intestine 
contractility, was not successful in targeting adenovirus mediated gene transfer to the 
crypt cells in the adult mouse (Cheng et al., 1997a).
Physical distension o f the bowel lumen should improve access to the crypts, since it 
causes shortening o f the villi and widening o f the intervillus space (Sandberg J et al.,
1994). When sufficient adenovirus vector was instilled into clamped off sections o f 
adult rodent small bowel to distend the lumen, gene expression was observed in the 
crypts (Hamilton TE, 1997). Transgene expression was also seen in the crypts after 
rectal instillation o f  plasmids but the method involved extensive flushing o f the colon 
before vector delivery which may have dilated the bowel sufficiently to allow the vector
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to penetrate the crypts (Westbrook et al., 1994). We hoped that perflubron instillation 
would have the same distending effect but it was probably applied at too high a level to 
have any effect on the small bowel. The increase in the stomach volume and the number 
o f cavities observed showed that we did distend the fetal stomach.
Adenoviruses are not able to infect immature cells such as stem cells efficiently and this 
may have resulted in the expression pattern we observed in the fetal gut. In the adult 
mouse, modifications to first generation adenovirus by covalently attaching activated 
monomethoxypoly (ethylene) glycols (MPEGs) that stabilize the vector during oral 
administration, led to improved levels o f gene transfer throughout the gut when 
compared with the unmodified vector. Notably, gene expression was observed in the 
crypts o f the small bowel (Cheng X et al., 2003). In another study, the same group 
showed that coadministration o f adenovirus with beta cyclodextrins, that enhance the 
transport o f macromolecules across the intestinal epithelium, lead to concentrated 
expression in the crypts (Croyle MA et al., 1998). Application o f lentivirus vectors that 
are capable o f transducing stem cells may reveal whether the lack o f  crypt expression 
we observed is due to a failure o f viral infection or an inability o f fetal stem cells to 
express the transgene.
In the adult mouse a single multipotent stem cell maintained in the crypts o f Lieberkiihn 
gives rise to absorptive enterocytes and to the three types o f secretory cells: goblet, 
enteroendocrine and Paneth, that are resident in the gut (Winton and Ponder, 1990). The 
descendants o f the multipotent stem cell undergo several rounds o f  cell division in the 
midportion o f the crypt. Members o f the Paneth cell lineage differentiate and remain in 
the base o f each crypt for approximately 20 days (Cheng H, 1974). The remaining cell 
lineages differentiate as they translocate from a crypt to the apex o f  a surrounding villus 
where they exfoliate and this sequence takes between 2 to 5 days depending on the type 
o f  cell (Cheng H and Leblond CP, 1974). In fetal mice the crypt stem cells are initially 
polyclonal and become monoclonal by the third week o f  postnatal life (Ponder BA et 
al., 1985). This could be a problem for fetal gene therapy if  the efficiency o f crypt stem 
cell transduction is poor. There is no data on the kinetics o f cell movement up the villus 
from the crypt in the fetal gut. Studies o f the human fetus shows that cell proliferation in 
the crypt-villus axis peaks at 8 -10  weeks and falls to a plateau by 18 weeks o f  gestation 
(Arsenault P and Menard D, 1987,Arsenault P and Menard D, 1989). Although growth 
o f the crypt-villus axis also occurs at this stage o f  development, the data suggest that the 
transit time o f cells from crypt to villus is at least as fast as in the adult gut. Therefore it
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is possible that the gene expression we observed in the villi o f the fetal sheep intestine 
resulted from migration o f epithelial cell daughters o f a transduced crypt stem cell.
Our finding o f significant transgene expression in the endothelium and subendothelial 
lining o f portal vein branches in the fetal liver probably represents transduction o f the 
portal vein endothelium. PCR analysis following intragastric injection showed 
widespread distribution o f the vector in the majority o f fetal tissues that probably 
occurred via lymphatic drainage o f the intestine. The intestine has been suggested as an 
alternative site for expression o f critical genes. In vitro studies show that intestinal 
epithelial cells infected with retrovirus vectors can secrete significant levels o f 
transgenic factor VIII and IX (Lozier JN et al., 1997) and transgenic secreted alkaline 
phosphatase was detected in the circulation o f adult rats after luminal instillation of 
adenovirus (Foreman PK et al., 1998). Intragastric injection is therefore a potential route 
o f administration o f fetal gene therapy to achieve systemic correction o f congenital 
disease.
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F Prenatal gene therapy for mucopolysaccharidoses
In utero gene delivery to the fetal brain may be useful for the treatment o f congenital 
diseases that affect the brain such as storage disorders eg mucopolysaccharidosis type 
VII and Tay-Sachs disease, or to prevent hypoxic-ischaemic brain damage in fetuses. 
Some congenital diseases may affect the brain from early in fetal development (Burlet P 
et al., 1998). Studies in the fetal sheep from 60 days o f gestation show that the 
permeability o f  the blood brain barrier, which prevents larger molecules from entering 
the neurocortex, decreases through gestation (Stonestreet BS et al., 1996,Dziegielewska 
KM et al., 1979). We therefore used early gestation fetal sheep for these experiments to 
take advantage o f the immaturity o f the blood brain barrier. The fetal skull sutures 
would be wider and the fetal skull would be softer and more easily penetrated if it 
proved difficult to place the needle directly through a skull suture. Any damage due to 
passing the needle through the parenchyma might be more easily repaired at early 
gestation. We chose to inject the vector into the lateral ventricle rather than into the 
brain parenchyma, since this would reduce the effect o f pressure damage on the 
developing neurons. Also we believed that it would be easier to see the needle tip in the 
sonolucent ventricle and could visualise microbubbles confirming it was correctly 
positioned. Therefore we investigated gene delivery to the fetal brain by injection o f 
adenovirus vectors containing the lacZ gene into the lateral ventricles o f  the early 
gestation fetal sheep.
F 1 Adenovirus efficiently transfects the neurocortex of early 
gestation fetal sheep ex vivo
Before applying our vector to fetal sheep in vivo, we tested whether adenovirus was able 
to transfer genes to the fetal sheep neurocortex ex vivo. The fetal neurocortex o f one 
non-injected animal (55 days o f gestation) was taken at post mortem examination, 
sectioned and infected with 1 x 108 particles adlacZ vector. X-gal staining 48 hours after 
application showed scanty p-galactosidase expression (data not shown).
F 2 Visualisation of the fetal brain in early gestation fetal sheep
A search o f  the literature revealed two studies on ultrasound visualisation o f the fetal 
brain in late gestation sheep. One group had developed an experimental model o f 
hydrocephalus in fetal sheep by ultrasound-guided injection o f kaolin into the cistema 
magna (Cambria S et al., 1979). In another study, blood flow velocity in the cerebral
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circulation was evaluated by Doppler ultrasound examination o f fetal sheep during 
maternal hypoxia (Gunnarsson GO et al., 1998). However no studies had been done on 
ultrasound visualisation or injection o f the early gestation sheep fetal brain. We began 
these experiments therefore, by evaluating the ultrasound view and measurements o f the 
fetal brain in early gestation.
We retrospectively reviewed ultrasound examinations o f  the fetal brain including 
measurements o f the biparietal diameter and occipito-snout length in a series of 
experiments recorded on videotape (n = 95) to decide whether the lateral ventricles 
could be clearly seen (Figure F 1). The axial view o f the brain at the level where the 
biparietal diameter is measured gives a good view o f the lateral ventricles in the human 
fetus and is also the view in which ventricular size is measured (Griffin D, 2002).
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Figure F 1: Visualisation of the lateral ventricles in the early gestation sheep fetus 
by ultrasound.
Videotape recordings were reviewed from early gestation sheep experiments in which an anatomical 
survey o f  the fetus was conducted and fetal biometry was performed. The lateral ventricles were 
identified as two translucent areas in an axial scan o f  the fetal head.
The lateral ventricles could not be identified in fetuses aged 40 days o f gestation or less. 
There was no data available for the age range 41 to 49 days o f gestation because no fetal 
experiments had been performed at these gestational ages. We attempted to visualise the 
lateral ventricles in fetuses aged between 41 and 49 days o f gestation by sonography o f 
awake ewes a week prior to surgery, but because o f difficulties restraining the ewes 
visualisation o f the fetal head was not adequate and no conclusions could be drawn. The
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lateral ventricle was seen in all fetuses aged 50 days o f gestation and older, equivalent 
to 13 weeks gestation in humans. The coronal and lamdoidal skull sutures were 
visualised with the skull in coronal section.
Measurements o f the cerebral hemisphere and the posterior horn o f the lateral ventricle 
were performed in 10 fetuses between 52 and 60 days o f gestation (Figure F 2).
25
20
15
u
u
E
5  10
B
+ +
X
•  Biparietal diameter 
+  Hemisphere 
X  Posterior horn
+
x
51 52 53 54 55 56 57 58
Gestational age (days)
59
4=
+
x
60 61
Figure F 2: Skull and  b ra in  m easurem ents in the early gestation sheep fetus by 
ultrasound.
(A) The distal hem isphere diameter (inner to inner) and the posterior horn o f  the lateral ventricle were 
measured as indicated in a fetus aged 57 days o f  gestation ( B l ,  Table FI) and (B ) plotted with gestational 
age, together with the biparietal diameter.
As in the human fetus, the distal hemisphere was chosen for measurement because o f 
disturbance o f the ultrasound beam as it passes through the convex proximal skull bone.
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The fetal skull and brain were assessed for the best possible route o f injection. The fetal 
orbits and eyes in the sheep are more prominent and laterally placed than in the human. 
To avoid damaging the eyes it was thought best to direct the needle through the coronal 
suture in a posterior direction into the posterior horn o f the lateral ventricle. In addition 
visualisation o f the anterior horn o f the lateral ventricle was difficult in early gestation 
due to the prominance o f the fetal orbits. The posterior horn measured on average 3.7 
mm that was considered to be adequate for ultrasound-guided injection.
F 3 Ultrasound guided injection of the fetal lateral ventricle is 
achievable in early gestation but technically difficult
In these experiments we aimed to pass the needle through a skull suture line so as to 
cause minimal trauma and to deliver adenovirus vectors into the lateral ventricle. 
Experimental details are shown in Table F 1
Table F 1: Ultrasound-guided injection of adlacZ vectors into the lateral ventricle 
of early gestation fetal sheep.
L: left; R: right.
Sheep Age(days)
AdlacZ
(p/kg)
Volume
(pi)
Injection
site
Time to 
injection 
(min.sec)
Posterior horn 
diameter o f injected 
ventricle (mm)
Pre-op Post-op
Bl 57 1.67x 10" 100 L
ventricle
5:08 3.5 3.6
B2 60 1 x 1012 200 L & R
ventricle
56:09 3.4 3.4
B3 54 2.3 x 1011 100 R
ventricle
5:02 3.5 3.5
The first injection was o f  a fetus aged 57 days o f gestation (B l), since this was in the 
middle o f the age range in which we had measurements. The fetal head was very 
superficially situated close to the maternal anterior abdominal wall, left side anterior 
and the lateral ventricles were clearly seen and measured. At this gestation the choroid 
plexus was prominently sited within the lateral ventricle. Under ultrasound guidance, a 
22 Gauge spinal needle was advanced into the uterus, passed with ease through the left 
coronal suture posterior to the left eye, and entered the posterior horn o f the left 
ventricle (Figure F 3). AdlacZ vector was injected through the needle which was then 
flushed with 40pl PBS and removed. Microbubbles were seen within the posterior horn 
on injection o f the vector and PBS.
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Figure F 3: U ltrasound-guided injection of the lateral ventricle in a sheep fetus 
aged 57 days of gestation (B l).
Ultrasonograms o f  a sheep fetus (57 days o f  gestation, B l)  showing (A) with the fetal skull in transverse 
section, a 22 Gauge needle positioned in line with the left coronal suture and (B) inserted into the 
posterior horn o f  the left lateral ventricle.
We repeated the intraventricular injection successfully in two more fetuses, although in 
both cases this was technically more demanding. Although the first fetus (B2, 60 days 
o f gestation) was well positioned with the head superficially placed and the left side 
anterior, the first two injection attempts via the left coronal suture flexed the head on the 
neck laterally and then forward (Figure F 4 A). It appeared that the skull was thicker 
and the coronal suture was more difficult to enter. There were three further unsuccessful 
attempts in which the needle entered the scalp but skimmed over the skull because o f 
the shallow angle o f inclination o f the needle. Efforts to move the fetal head into the 
correct position with the needle tip resulted in it drifting around in the amniotic fluid. At 
the sixth attempt the needle passed through the left coronal suture and into the left 
lateral ventricle (Figure F 4 B).
AdlacZ vector (lOOpl) was injected but appeared to leak back out o f the needle track. 
The needle was therefore advanced across the midline into the right lateral ventricle and 
a further dose o f vector was given (1 OOjul) that did not leak. Microbubbles were 
observed after each injection. During the procedure fetal blood was seen coming from 
the scalp at the site o f failed injection attempts.
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Figure F 4: Flexion of the fetal head during ultrasound-guided injection of the 
lateral ventricle.
Ultrasonograms o f  a sheep fetus aged 60 days o f  gestation (B2). (A ) The first two attempts to inject the 
fetal skull failed but resulted in severe lateral flexion o f  the fetal head. (B) On the sixth attempt the needle 
successfully passed through the left coronal suture into the left lateral ventricle.
Because o f the difficulty injecting the second fetus, our third injection attempt was in a 
younger animal (B3, 54 days o f gestation) in which we expected the skull to be thinner. 
The fetal head was positioned right side up with the face slightly anterior which resulted 
in difficulty lining up the coronal suture with the needle. We were reluctant to 
reposition the head because o f our previous experience and therefore the needle was 
injected into the skull, through which it passed with ease, into the posterior horn o f the 
right ventricle where the vector was delivered. Bleeding from the scalp was seen at the 
site o f injection.
In all fetuses the posterior horn was more translucent after injection probably as a result 
o f displacement o f the choroid plexus with fluid. The diameter o f the posterior horn did 
not increase significantly (Table F 1) although this is probably a reflection o f the small 
volume of fluid given.
F 4 U ltrasound gu ided  injection o f the fetal lateral ventricle  
resu lts in minimal short-term  m orbidity
All three fetuses survived the injection procedure and post mortem analysis was 
performed 2 days after injection. In two fetuses (B2 and B3) the injection site(s) could 
be seen as small petechial haemorrhages in the scalp (Figure F 5A). A moderate 
amount of haemorrhage lined the skull o f B2 and the meninges were adherent to the 
underlying neurocortex. This probably reflected the technical difficulties encountered 
during injection. Histological analysis o f the skull o f this fetus showed thickened
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meninges with reactive fibroblastic tissue but few inflammatory cells (Figure F 5B). 
Histological examination of the brain in all fetuses showed no inflammatory infiltrate or 
other abnormalities (Table F 2).
haemorrhage
Figure F 5: Post m ortem  and histological findings after ultrasound-guided 
injection of the lateral ventricle.
T w o days after injection o f  the lateral ventricle (60 days o f  gestation, B2), (A ) small petechial 
haemorrhages and a skin laceration are seen in the left scalp at the site o f  injection. (B) On light 
microscopy (H & E staining) the meninges is thickened with reactive fibroblastic tissue but few  
inflammatory cells.
Table F 2: U ltrasound-guided injection of adlacZ vectors into the lateral ventricle 
of early gestation fetal sheep.
Post mortem and histological findings, and |3-galactosidase transgene expression 2 days after injection.
Sheep Post mortem findings
Histological
analysis
p-galactosidase expression
X-gal staining immuno
Bl normal normal choroid plexus, lateral 
ventricle ependyma & cortex
negative
B2 scalp & skull 
haemorrhage, 
adherent meninges
meningeal
fibroblasts
choroid plexus negative
B3 scalp petechial 
haemorrhages
thickened
meninges
negative negative
F 5 S u ccessfu l transgene expression  is o b served  in the fetal 
brain after ultrasound-guided injection o f the fetal lateral 
ventricle in early gesta tion
X-gal staining performed on frozen sections o f the fetal cortex, cerebellum and upper 
thorax was positive in two fetuses (Bl and B2, Figure F 6).
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Figure F 6: (3-galactosidase transgene expression after ultrasound-guided adlacZ 
injection into the lateral ventricle of early gestation fetal sheep.
X-gal staining o f  the fetal brain 2 days after injection o f  a fetus (57 days o f  gestation, B l ), positive 
staining is seen in the choroid plexus o f  (A ) the anterior, (B) the middle and (C) the posterior lateral 
ventricle. There is also staining o f  the ependymal lining o f  the lateral ventricle (D and E) and (F) o f  the 
cortex o f  the occipital region o f  the brain which may represent the needle track. (G) In a fetus aged 60 
days o f  gestation (B 2) there is staining o f  the choroid plexus in the posterior third o f  the lateral ventricle 
near the site o f  injection. Original magnifications as indicated.
In Bl there was extensive staining o f the choroid plexus throughout the fetal cortex 
(Figure F 6 A-C), and positive transgene expression in the ependymal cells lining the 
lateral ventricles (Figure F 6 D and E). There was also staining o f developing cortical 
neurones in the occipital cortex probably along the needle track (Figure F 6 F).
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In B2 positive X-gal staining was confined to the choroid plexus in the posterior third of 
the left lateral ventricle (Figure F 6 G). X gal staining o f the fetal spinal cord and (3- 
galactosidase immunohistochemical analysis o f the brain and spinal cord were negative.
F 6 Discussion
F 6.1 Ultrasound guided intraventricular injection is achievable in 
the early gestation sheep fetus
This is the first study o f percutaneous intraventricular injection in the early gestation 
fetal sheep. Ultrasound examination o f the fetal sheep head showed that the lateral 
ventricles were consistently visualised from 50 days o f gestation, equivalent to 13 
weeks gestation in humans. At this gestation, one study showed that complete 
visualisation o f  the head and brain structures was achieved in 80% and 82% o f human 
fetuses scanned transabdominally and transvaginally respectively (Braithwaite JM et al., 
1996). In clinical practice however, transvaginal sonography allows better visualisation 
o f  the fetal brain in the first trimester and is recommended for patients at risk o f 
congenital brain abnormalities (van Zalen-Sprock RM et al., 1995). The coronal skull 
suture, through which we hoped to direct our needle, was visible in the sheep fetus at 
this gestation and the diameter o f the posterior horn o f the lateral ventricle was adequate 
to permit needle injection.
Our results showed that ultrasound guided placement o f a needle within the lateral 
ventricle was achievable in early gestation but was technically demanding. The major 
problem was flexion o f the fetal skull on the neck as an attempt was made to pass the 
needle through the coronal suture or skull. In the first case, the fetal head in coronal 
section was positioned perpendicular to the ewe’s abdomen so that the needle passed 
directly through the coronal suture into the lateral ventricle with no flexion. In the 
subsequent two fetuses, the fetal head was not so well positioned and attempts to 
reposition one fetus using the needle was unsuccessful. Injection through the skull 
rather than the coronal suture however, was relatively straightforward. The morbidity 
observed at post mortem examination 2 days after injection probably reflected the 
difficulties encountered during injection and further experiments are needed to evaluate 
the mortality and long term morbidity o f the procedure 
In clinical practice intracranial or intraventricular injection is rarely performed. 
Therapeutic drainage o f fetal hydrocephalus was first attempted in 1981 when repeated 
ultrasound guided cephalocentesis was performed in a fetus aged 25 weeks o f gestation
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(Birnholz JC and Frigoletto FD, 1981). Ventriculo-amniotic shunting was then 
developed, but the results o f the “International Fetal Surgery Registry” were very poor 
and since then, most medical centres have discontinued the practice (Manning FA et al.,
1986). In Brazil, where termination o f pregnancy is not permitted, repeated 
cephalocentesis is still performed to reduce the intracranial pressure to within normal 
limits which some believe is o f benefit to neurological development (Cavalheiro S et al., 
2003). The only complication observed in this study was a small haemorrhage in the 
needle track in a few cases and there were no procedure related deaths.
There is one other study in the fetal sheep in which ultrasound guided brain injection 
has been performed (Cambria S et al., 1979). The authors injected kaolin into the 
cisterna magna under ultrasound guidance at laparotomy in late gestation to create an 
experimental hydrocephalus with low morbidity and mortality. In the mid-trimester fetal 
Rhesus monkey, ultrasound guidance has been used to place a thermocouple into the 
tentorium through the posterior fontanelle via a 20 Gauge needle for measurement o f 
brain temperature (Tarantal AF et al., 1993). Ultrasound guided intraventricular 
injection o f lentivirus vectors has also been performed in the first trimester but no 
information about the morbidity or mortality o f the technique is available (Tarantal AF 
et al., 2001b). Ultrasound backscatter microscopy (UBM) provides excellent 
visualisation o f the brain in the fetal mouse (Cheng H and Bjerknes M, 1984) and has 
been used to guide injection o f the brain parenchyma at laparotomy with 34% survival 
(Olsson M et al., 1997).
In our hands, intraventricular injection was achievable but too technically demanding in 
early gestation to consider clinical application. Injection in mid-gestation may be easier 
to perform because there is less liquor and therefore less passive fetal movement on the 
needle tip. However, it would be more important to place the needle through a suture 
line because o f the bone density and there might be difficulty gaining an adequate view 
o f the fetal brain because the fetus is usually in cephalic presentation at this gestation.
F 6.2 Gene transfer to the early gestation fetal sheep brain can be 
performed using ultrasound guided intraventricular injecton
Many life-threatening congenital diseases considered as candidates for fetal gene 
therapy affect the fetal brain from early in development. Targeting genes to the brain 
however, is difficult because the blood brain barrier effectively prevents access to the 
brain after intravascular injection. Indeed, we were unable to show any gene transfer to 
the early gestation fetal sheep neurocortex after intraperitoneal or intramuscular
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injection in which haematogenic spread o f vector was observed. Injection o f  adenovirus 
vectors into the lateral ventricle resulted in significant transgene expression in the 
choroid plexus and low level expression in the ependymal cells lining the lateral 
ventricles. There was limited gene transfer to the neurocortex at the site o f the needle 
track but in effect, only those tissues in direct contact with the vector were transduced. 
We had already shown that early gestation fetal neurocortex could be infected by the 
adenovirus vector and express transgenic protein ex vivo. In adult brain the capacity o f 
adenovirus vectors to penetrate through cell layers is limited. After intraventricular 
injection in the adult rodent brain, only ependymal cells expressed transgenic protein 
and, in contrast to our findings, no transduction o f the choroid plexus was observed 
(Akli S et al., 1993,Bajocchi G et al., 1993). It has been postulated that the limited 
spread o f  vector after parenchymal injection is affected by cellular organization and the 
degree o f myelinization o f the injection area (Hermens WTJMC et al., 1997).
In the fetal mouse, preliminary data on delivery o f adenovirus and AAV vectors to the
th4 ventricle via intracranial injection o f the fetal mouse gave good gene expression with 
no morbidity and good survival (American Society o f Gene Therapy conference abstract 
2001 (Lipshutz GS et al., 2001a)). In our case, the lack o f adenovirus expression in the 
neurocortex is probably partly due to the dilution o f the vector in the cerebrospinal fluid 
and the large surface area o f cells lining the ventricles that will have ‘mopped up’ the 
vector. In addition, there appears to be a CSF-brain barrier present specifically during 
early fetal but not in adult life that may have prevented adenovirus penetration. This 
barrier o f ‘strap junctions’ has a tight junction-like appearance o f close and continuous 
contact between neighbouring cells that spirals from the ventricular pole o f  the cells 
towards the subependymal zone (Mollgard K and Saunders JM, 1986). In the fetal sheep 
it functions in early gestation at 60 days and has prevented the movement o f protein and 
horseradish peroxidase across the neuroependyma after ventricular perfusion (Balslev Y 
et al., 1997,Fossan G et al., 1985). By 125 days o f gestation however, ependymal 
permeability reaches adult levels (Fossan G et al., 1985) and the strap junctions are 
replaced by mature gap junctions that are present in adult brains (Mollgard K et al.,
1987). Thus we might expect to see more extensive penetration o f the neurocortex after 
ventricular injection o f adenovirus vectors in late gestation.
Targeting genes to the brain via systemic administration is difficult because the blood 
brain barrier effectively prevents access to the brain. There was until recently a widely 
held belief that the fetal blood brain barrier is immature and therefore should be 
relatively permeable to proteins and other small molecules. It is however now accepted
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that the barrier between the blood and the brain develops from very early stages o f brain 
vascularisation and it is made up o f tight junctions (Saunders NR et al., 2000). In the 
fetal sheep, even at 30 -  40 days o f gestation, very little intravenous plasma protein 
penetrates the lateral ventricular CSF (Cavanagh ME et al., 1983). At 12 weeks of 
gestation there is evidence o f tight junction formation in the endothelium of human 
brain microvessels (Virgintino D et al., 2004) and permeability studies also support the 
concept that the human fetal blood brain barrier matures early (Bell JE et al., 1991). A 
number o f agents are able to increase the permeability o f the blood brain barrier 
including sodium caprate (Awazu S et al., 1999), hyperosmotic mannitol (Muldoon LL 
et al., 1995) and VEGF (Young PP et al., 2004) but there are concerns about their 
toxicity.
We did not observe any toxicity or inflammation within the injected neurocortex or 
lateral ventricle although there was an inflammatory reaction localized to the skin and 
meninges at the site o f the injection. This lack o f response is probably because the two 
day time point to sample the brain was too soon for an inflammatory reaction to 
develop. Although it is generally believed that the brain is an immunoprivileged site, 
delivery o f adenovirus vectors into the adult rat brain parenchyma lead to invasion by 
macrophages and cytotoxic T cells from four and eight days respectively after injection 
(Hermens WT and Verhaagen J, 1997). A humoral immune response to the transgenic 
protein and to adenovirus was also seen (Kajiwara K et al., 2000). In our study there 
was no evidence o f cytotoxicity o f the adenovirus on the fetal brain tissue even at doses 
o f 2 x 1012 p/kg (1 x 1011 particles). Injection o f 107 pfu adenovirus vector into the brain 
parenchyma o f chicken embryos similarly had no toxic effect at 24 hours (Thakur A et 
al., 2001). By contrast, in the adult mouse brain cytotoxicity has been observed when 
doses o f 107 pfu, equivalent to 108 particles or higher have been applied to the 
parenchyma (Akli S et al., 1993). The lack o f cytotoxicity we observed probably reflects 
the dilutional effect o f the cerebrospinal fluid on the vector although it is possible that 
the fetal neurons are less susceptible to the cytotoxic effect o f adenovirus.
This is the only study to investigate delivery o f adenovirus vectors into the brain o f a 
large animal fetal model. Gene transfer assessed using PCR analysis o f transgenic 
protein in the fetal brain tissue was low level after intraventricular delivery o f lentivirus 
vectors into the early gestation fetal rhesus monkey lateral ventricle (American Society 
of Gene Therapy conference abstract (Tarantal AF et al., 2001b)). Most o f the research 
on gene transfer to the fetal brain has used injection o f retrovirus vectors to analyze cell 
lineage and migration o f neural progenitors. Vectors have been delivered to the neural
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tube o f chicken embryos (Golden JA et al., 1997) or into the lateral ventricle o f fetal rats 
(Walsh C and Cepko CL, 1988) and mice (Luskin MB et al., 1988). This results in gene 
transfer to dividing cells and allows them and their progeny to be followed along 
migration pathways. Thus application o f integrating vectors, especially lentiviruses that 
are able to infect non-dividing cells, should result in more widespread gene transfer. 
Interestingly retrovirus mediated gene transfer to brain cells from fetal sheep aged 60 to 
80 days o f gestation in vitro was shown to be at least an order o f magnitude more 
efficient than gene transfer to kidney, muscle, lung or skin cultures (John HA, 1994). 
The author suggested this may be due to areas o f active genome transcription in brain 
cells into which retrovirus vectors might preferentially integrate, rather than an effect of 
cell proliferation.
Early treatment o f lysosomal storage diseases with early and severe CNS involvement 
may be o f critical importance, and this is one o f the rationales behind fetal as opposed to 
neonatal gene therapy. Evidence from studies o f gene therapy to neonatal mouse models 
o f lysosomal storage diseases supports this concept. In neonatal twitcher mice, a model 
o f Krabbe disease, intraventricular delivery o f adenovirus vectors containing the 
therapeutic gene to newborn animals was more effective at correcting neurological 
symptoms and the enzyme defect at the cellular level than injection two weeks after 
birth (Eto Y et al., 2004). Adeno-associated vectors have also proved capable o f long­
term prevention o f pathology in beta-glucuronidase-deficient mice (Passini MA et al., 
2003).
It is unlikely that delivery o f gene therapy to the fetal ventricle will become clinically 
acceptable in early or even late gestation because o f technical difficulties with the 
procedure. Techniques to transfer genes to the fetal brain may prove useful however for 
investigating the mechanism and possible treatment o f conditions such as perinatal brain 
injury (Peebles DM and Wyatt JS, 2002).
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G The fetal humoral immune response to ultrasound- 
guided injection of adenovirus gene therapy
The rationale that fetal gene therapy may avoid the development o f immune reactions to 
the vector or transgene product depends critically on the timing o f  gene delivery and the 
route o f administration. Some authors propose that there is a ‘window o f opportunity’ in 
the first third to half o f pregnancy during which time introduction o f foreign genetic 
material may not produce an immune response but may allow development o f tolerance 
(Billingham RE et al., 1956,Binns R, 1967). This time is thought to be up to 60 -  75 
days o f gestation in the fetal sheep although the immune response depends on the type 
o f antigen used and there is also wide variation between individual fetuses (Fahey KJ 
and Morris B, 1978,Fahey KJ and Morris B, 1974).
We investigated the humoral immune response o f fetal sheep that had received 
ultrasound-guided adenovirus vector injection. We studied the levels o f antibodies in 
the fetal serum to the transgene (hFIX or p-galactosidase) and to the adenovirus vector. 
In many cases, fetuses were sampled 2 days after exposure to the antigen. This is not 
generally thought to be a sufficiently long time interval to allow development o f a full 
immune response and therefore some fetuses injected with adhFIX in early gestation 
were sampled at later time intervals from exposure (9 and 28 days and birth).
Permanent tolerance is believed to take place if antigens are consistently maintained 
(Ramsdell F and Fowlkes B, 1992). This could occur following gene transfer mediated 
by integrating vectors such as retrovirus or lentivirus vectors. Long term expression has 
been seen in mice up to a year after adenovirus injection as fetuses. In sheep however, 
adenovirus mediated gene transfer is only short term, maximally up to one month after 
fetal injection. We did not perform experiments therefore to test for immune tolerance 
in lambs born after fetal injection o f adenovirus vectors.
G 1 Fetal sheep receiving umbilical vein injection of adenovirus 
vectors at 60 days of gestation can mount a humoral immune 
response to the transgenic protein and adenovirus
We analysed the sera o f fetal sheep injected with adlacZ (n = 2) and adhFIX (n = 9, 7 
survivors) vectors via the umbilical vein at 60 days o f gestation for the presence o f 
antibodies to the P-galactosidase or hFIX transgenic protein and to adenovirus. Fetuses
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injected with adhFIX were sampled at several time points following injection to 
investigate the time course o f antibody production.
G 1.1 Antibodies to the transgenic protein
There was a marked variation in the humoral immune response o f individual fetuses to 
the transgene that did not depend on either the time o f sampling after injection or the 
presence o f transgene expression (Table G 1). By 9 and 29 days after injection, two o f 
three fetuses injected with adhFIX vector had detectable levels o f anti-hFIX antibodies, 
albeit at low levels. In two o f these fetuses, hFIX was detectable in their plasma.
Table G 1: Fetal humoral immune response after umbilical vein injection of 
adenovirus vectors at 60 days of gestation.
Antibody level was determined by comparing the sample ratio with an internal standard; d: days;
Sheep Vector Time o f 
sampling
(d)
Antibody to 
transgenic protein 
(Hg/ml)
Expression of 
transgenic 
protein (ng)
Antibody to 
adenovirus 
(pg/ml)
hFIX lacZ
UV5 adlacZ 2 d - 0 0 0.34
UV16 adlacZ 2 d - 0 0 0.68
UV6 adhFIX 2 d 0 - 581 0.91
UV10 adhFIX 2 d 0.13 — 0 0.93
UV7 adhFIX 9 d 0.203 — 199.5 0.85
UV8 adhFIX 9 d 0 — 145 0
UV11 adhFIX 29 d 0.041 — 0 0.42
UV12 adhFIX birth 0 — 0 0.54
UV15 adhFIX birth 0 — 0 0.58
UV15 control birth 0 - 0 0
We analysed the levels o f antibody to hFIX transgenic protein over time in the sera of 
the lambs that came to birth after adhFIX injection (Figure G 1). Antibodies to hFIX 
were detected at birth at low levels and were found at later days o f analysis on day 10 in 
one lamb and repeatedly up to 70 days after delivery in the second lamb, although no 
antibody was detected in the serum o f the control animal.
G 1.2 Antibodies to adenovirus
Analysis o f fetal sera at 9 days or later after fetal injection revealed antibodies to the 
adenovirus were detectable in all but one fetus (Table G 1). Similarly antibodies to 
adenovirus were detected in the sera o f both injected lambs but not in the serum from 
the control lamb (Figure G 2).
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Figure G 1: The humoral immune response to transgenic hFIX protein in lambs 
born after ultrasound-guided umbilical vein injection at 60 days of gestation.
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Figure G 2: The humoral immune response to adenovirus vector in lambs born 
after ultrasound-guided umbilical vein injection at 60 days of gestation
The antibody to the adenovirus was measured at a higher level than the antibody to the 
transgenic hFIX in sera from fetuses and lambs. In this study we used a standard
296
G. RESULTS: Immune response
calibration curve to determine the antibody level rather than titration methods because 
o f the low levels o f antibody we detected. If higher levels o f  antibody had been 
detected, titration would have been the more accurate method o f quantifying the 
antibody response.
G 2 The humoral immune response of fetal sheep to umbilical 
vein injection of adenovirus vectors from 67 days of gestation
We analysed the sera o f fetal sheep injected with adlacZ (n = 11,9 survivors) and 
adhFIX (n = 1) vectors via the umbilical vein from 67 -  95 days o f gestation for the 
presence o f antibodies to the p-galactosidase or hFIX transgenic protein and to 
adenovirus. All fetuses were sampled 2 days after injection.
G 2.1 Antibodies to the transgenic protein
In three fetuses an antibody response to the transgenic protein was detectable. As can be 
seen, the presence o f antibody to the transgenic protein was not related to detectable 
transgene expression (Table G 2). Antibody detection did appear to be related to the 
gestational age o f the fetus, with antibody only detected in older fetuses.
Table G 2: Fetal humoral immune response after umbilical vein injection of 
adenovirus vectors from 67 days of gestation.
GA: gestational age at injection; -  to +: level o f transgene expression; na: not available
Sheep GA
(d)
Vector Antibody level 
(pg/ml, sample ratio vs internal 
standard)
Transgene
expression
hFIX P-galactosidase adenovirus
UV20 67 adlacZ 0 na (+)
UV17 68 adlacZ 0 0
UV18 68 adlacZ 0 0.37 —
UV21 71 adlacZ 0 na —
UV22 71 adlacZ 0 na —
UV23 74 adlacZ 0 0.01 (+)
UV14 83 adhFIX 0.158 0.01
UV28 87 adlacZ 0 0 —
UV26 95 adlacZ 0.041 0 +
UV27 95 adlacZ 0.026 0 +
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G 2.2 Antibodies to adenovirus
There was a similar individual variability in the fetal humoral immune response to the 
adenovirus (Table G 2) although this did not appear to depend on the gestational age o f 
the fetus at which the injection was performed.
Since all fetuses were sampled only 2 days after injection it is difficult to draw 
conclusions from these results. It is unlikely that the protein detected in the fetal serum 
2 days after injection was a true antibody response to the applied antigen since there is 
usually a lag period o f at least 5 days before the first immunoglobulins, in the form o f 
IgM, are detected in the serum. It is more likely that there was some cross-reactivity in 
the assay or that it detected naturally occurring antibody that we know to be present in 
fetal sheep (Reynaud CA et al., 1995) and pigs (Cukrowska B et al., 1996) from early 
gestation.
G 3 Fetal sheep injected with adenovirus vectors before 61 
days of gestation mount a humoral immune response to 
adenovirus but not to the transgenic protein
The sera o f fetal sheep receiving ultrasound-guided intraperitoneal, intrahepatic, 
intramuscular or intra-amniotic injection o f adhFIX vector were analysed for anti­
adenovirus and anti-hFIX antibodies by ELISA assays. Sera from fetuses injected with 
adlacZ vector were not analysed (IM5, HE2, HE8, HE 11, IP 10) since they were 
sampled at 2 days after injection and we did not expect to observe a humoral immune 
response so rapidly.
G 3.1 Antibodies to the transgenic protein
No antibodies against hFIX were detected in any o f the treated animals at 2, 9 - 11 or 28 
- 30 days following injection or at birth. Even when there was strong expression o f the 
transgene, for example following intraperitoneal delivery, no anti-hFIX antibodies were 
detectable.
G 3.2 Antibodies to adenovirus
Antibodies to the adenovirus vector however, were present following all routes o f 
vector application (Figure G 3). Even at two days after injection, low levels o f antibody 
were detected in almost all (6 out o f 8) fetuses sampled. Because o f  the small numbers 
o f fetuses examined at later time points we cannot draw any conclusions as to the effect 
o f gestational age on antibody response. It should be noted however that adenovirus
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antibodies were detected in almost all (12 out o f 13) fetuses sampled 9 or 28 days after 
injection.
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Figure G 3: The humoral immune response to adhFIX vector after ultrasound- 
guided early gestation delivery.
Five lambs, one for each route o f injection (intraperitoneal, intrahepatic, intra-amniotic and intramuscular, 
were followed and sampled at regular time intervals after birth.
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As can be seen, the presence o f antibodies to adenovirus was not associated with any 
particular route o f injection and antibody levels varied considerably between fetuses.
We did not observe any relation between the extent o f procedure related necrosis and 
inflammation on histological analysis and the level o f adenovirus antibody in the fetal 
serum.
The different findings following umbilical vein injection and other routes o f injection in 
early gestation is interesting. A direct comparison between the routes o f injection cannot 
be made however, since in all but one case (IM4 injected at 61 days o f gestation), the 
intraperitoneal, intrahepatic, intra-amniotic and intramuscular injection procedures were 
performed on or before 57 days o f gestation. It is possible that this earlier time o f 
injection is responsible for the differences in humoral immune responses observed.
G 4 Late gestation fetal sheep receiving intramuscular injection 
of adenovirus vectors do not mount a detectable humoral 
immune response to the transgenic protein
The sera o f fetal sheep receiving intramuscular injection o f adlacZ vector (n = 4) in late 
gestation (125 -137 days o f gestation) were analysed for a humoral immune response. 
There were no antibodies detectable to the hFIX transgenic protein in any o f the 
animals, even at this late gestation although adenovirus antibodies were detected in all 
fetuses and lambs (Table G 3).
Table G 3: Fetal humoral immune response after intramuscular injection of 
adenovirus vectors in late-gestation fetal sheep.
GA: gestational age at injection; d: days
Sheep GA (d) Time o f 
sampling
(d)
Expression o f 
transgenic hFIX 
protein (ng)
Antibody level (pg/ml, sample 
ratio vs internal standard)
hFIX adenovirus
IM12 125 2 d 23.5 0 0.54
IM13 125 2 d 16 0 0.21
IM14 137 birth 7 0 0.07
IM15 137 birth 0 0 0.16
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G 5 The humoral immune response of mid and late-gestation 
fetal sheep to intratracheal injection of adenovirus vectors
The sera o f fetal sheep receiving ultrasound-guided intratracheal injection o f adlacZ (n 
= 23) or adhCFTR vectors (n = 10) were analysed for antibodies to p-galactosidase and 
adenovirus by ELISA assays. There is no sheep specific anti-hCFTR antibody currently 
available to allow calibration o f an ELISA assay and we therefore did not analyse fetal 
sera from sheep injected with adhCFTR vector for anti-hCFTR antibodies.
G 5.1 Antibodies to the lacZ transgene
The majority o f fetuses injected with adlacZ vector were sampled 2 days after injection 
(n = 21) but two were analysed at later time points, at 16 days after injection (IT24) and 
6 hours after birth (IT18). Antibodies to p-galactosidase were detectable in the serum of 
the lamb that delivered but not in the fetus sampled 16 days after injection (Table G 4). 
No antibodies to p-galactosidase were detectable in the sera o f fetuses analysed 2 days 
after injection.
Table G 4: Fetal humoral immune response after intratracheal injection of 
adenovirus vectors in fetal sheep.
GA: gestational age at injection; d: days; nt: not tested.
GA (d) No. of 
fetuses
Vector Time o f 
sampling
(d)
Antibody level (pg/ml, sample 
ratio vs internal standard)
p-galactosidase adenovirus
137 -1 3 8 3 adlacZ 2 d 0 0
8 1 -8 2 4 adlacZ 2 d 0 0
102-116 13 adlacZ 2 d 0 0
116 1 adlacZ 2 d 0 0.24
82 1 adlacZ 16 d 0 0.008
102 1 adlacZ birth 49 0.563
100- 102 3 adhCFTR 2 d nt 0
102-113 3 adhCFTR 17 d nt 0
1 0 2 -1 1 0 2 adhCFTR birth nt 0
81 -82 2 adhCFTR birth nt 0
A time interval o f 2 days from injection to sampling o f fetal serum is probably not 
sufficiently long enough for the fetus to be able to mount a true humoral immune 
response. The lack o f immune response to the transgenic lacZ protein in the fetus 
sampled 16 days after injection however, is unexpected, especially since there was
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evidence o f transgene expression in the fetal lung on p-galactosidase ELISA analysis. 
The lamb that came to birth after tracheal injection was sampled 43 days after injection 
and showed a substantial anti-adenovirus response. As anticipated from the short-term 
nature o f adenovirus mediated gene transfer, no transgene expression was detectable in 
the lung o f this lamb. It is possible that the delivery o f gene therapy vectors to the fetal 
airways rather than systemically influenced the ability o f the sheep fetus to mount an 
immune response 16 days after injection.
G 5.2 Antibodies to adenovirus
Antibodies to adenovirus were only detectable in 3 out o f 23 fetuses that received 
intratracheal injection o f adenovirus vectors, all o f which were injected with the adlacZ 
vector (Table G 4). As might be anticipated, the fetuses sampled later than 2 days after 
injection (16 days after injection or at birth) both had antibodies. In contrast there were 
seven fetuses injected with the adhCFTR vector that were sampled later than 2 days 
after injection (17 days after injection or at birth) and none had detectable levels of 
antibody to the adenovirus. Results o f hCFTR transgene expression are not available 
currently and we cannot confirm therefore that the adhCFTR vector is able to mediate 
gene transfer in fetal sheep. It is possible that there is a different humoral response o f 
the fetal sheep to the adlacZ and adhCFTR vector although the viral backbone o f the 
vectors was the same. The results could also reflect individual variation in the fetal 
response to adenovirus.
G 6 The humoral immune response of fetal sheep to 
intragastric injection of adenovirus vectors at 60-62 days of 
gestation
The sera o f fetal sheep receiving ultrasound-guided intragastric injection o f adlacZ 
vector (n = 11,9 survivors) were analysed for antibodies to p-galactosidase and 
adenovirus by ELISA assays. No antibodies were detectable. All fetuses however, were 
sampled 2 days after injection and it is likely this is not sufficient time from exposure to 
the antigen for the fetus to mount a humoral immune response.
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G 7 Discussion
One o f the main caveats in adult gene therapy is the immune response to vector and/or 
transgene. In utero application, on the other hand, aims to circumvent this by treatment 
before maturity o f the functional immune system. The sheep is a particularly good 
animal model to use for investigation o f the fetal immune response to antigen because 
the synepitheliochorial placenta does not permit passage o f gammaglobulin from 
mother to fetus (Morris B, 1986) and we can therefore be sure that all antibodies in the 
fetal serum are derived from the fetus and not from the mother. Classic experiments in 
fetal sheep have demonstrated that the fetal response to antigenic stimulus varies 
according to the type o f antigen and with gestational age (Silverstein AM et al.,
1963b,Fahey KJ and Morris B, 1978).
The effect o f gestational age on antibody response can be seen in our results after 
umbilical vein injection. After umbilical vein delivery at 60 days o f gestation, 
antibodies to the hFIX transgenic protein were detected in some but not all o f the 
fetuses that expressed the transgene. The fetus receiving adhFIX at 83 days o f injection 
mounted a robust immune response to the hFIX protein. Antibody to the lacZ protein 
was not detected until adlacZ injection was performed at 95 days o f gestation although 
this could reflect a lack o f protein expression by this route o f administration. The 
previous study with late gestation sheep (day 102-140 o f gestation) using the same 
adenovirus vector construct, showed the presence o f antibodies to the adenovirus vector 
and hFIX protein in all fetuses (Themis M et al., 1999). These findings support other 
studies showing that most fetuses acquire a capacity to respond to several antigens 
between 60 to 75 days o f gestation although there is considerable variation in the 
response between individual fetuses (Silverstein AM et al., 1963b,Fahey KJ and Morris 
B, 1978).
In contrast, fetuses receiving adenovirus vector by each o f the intraperitoneal, 
intramuscular, intrahepatic or intra-amniotic routes, most o f which were injected by 57 
days o f gestation, did not produce measurable levels o f antibodies to the hFIX or lacZ 
protein. This was despite good levels o f expression o f both proteins that was detectable 
in the case o f hFIX, for longer than two days. Our data would suggest that at the time o f 
injection, these fetuses were pre-immune to the proteins they were exposed to.
It cannot be ruled out that alternative therapeutic proteins may generate an immune 
response and that these observations were not specific for hFIX or lacZ. In contrast to 
the adenovirus and lacZ protein, these normal sheep fetuses produce their own factor IX
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protein that may be similar to the human protein. It is possible but unlikely that 
injection by these routes leads to tolerance to the antigen we applied.
Recently, studies have shown that the development o f tolerance to self-antigens appears 
to depend on the presence o f T-regulatory cells (Schwartz RH, 2005,Sakaguchi S,
2005). These naturally occurring T cells are specialized for a suppressive function and 
their depletion can lead to tumour rejection and the development o f autoimmunity. 
Thymic and extra-thymic T regulatory cells are detectable in the human fetus from 13 
and 14 weeks o f gestation respectively (Darrasse-Jeze G et al., 2005) and function 
similarly to those found in adults. It is possible that they also may play a role in the 
development o f tolerance to exogenous antigens.
The levels o f adenovirus antibodies after early gestation umbilical vein, intraperitoneal, 
intramuscular and intrahepatic injection varied considerably between fetuses. We 
investigated whether in these particular animals there was more procedure related 
necrosis and inflammation which might have an adjuvant effect on the generation and 
prolongation o f the antiviral immune reaction. However there was no indication o f 
particular trauma in those fetuses that did show antibodies. Individual variation in the 
fetal sheep response to antigenic stimulus is well known and our findings could simply 
reflect this.
Antibodies to the adenovirus vector were detected following umbilical vein, 
intraperitoneal, intramuscular and intrahepatic delivery to fetal sheep at any gestational 
age investigated. By comparison, another group showed a fetal immune response to 
adenovirus vector at 90 and 125 days o f gestation, after umbilical vein injection at 60 
days (Yang EY et al., 1999). The different assays used in this study and ours may be 
responsible for the observations. Yang et al used a neutralizing antibody assay to test for 
the presence o f antibodies that block adenovirus infection o f HeLa cells. In contrast our 
ELISA assay detected all adenovirus specific immunoglobulins except IgE, whether 
they be neutralizing or non-neutralizing. It is possible that the fetus produces non­
neutralizing antibodies that can bind to parts o f the virus but that are unable to prevent 
infection. Certainly in adult humans, antibodies to adenovirus 5 were detectable in all 
subjects in one study, but only 55% o f the antibodies neutralized the virus (Chirmule N 
et al., 1999).
After intratracheal delivery o f adenovirus vector, antibodies to lacZ transgenic protein 
were detected at 43 days but not at 16 days after injection. It is difficult to draw 
conclusions with such a few number o f experimental animals. However, this could 
again signify variation in the individual fetal response to antigens, may represent
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maturation in the ability o f the animal to produce antibody specific to the lacZ protein 
or reflect the more local delivery achieved by intratracheal delivery o f adenovirus. 
Studies in adult humans have shown that the route o f administration o f adenovirus 
vectors alters the humoral (Harvey BG et al., 1999) and innate immune response to the 
vector, local delivery evoking a smaller response than systemic methods. Vincent et al 
observed that intratracheal delivery o f adenovirus to mid gestation fetal sheep did not 
elicit a neutralizing antibody response to adenovirus at 3 or 14 days after injection 
(Vincent MC et al., 1995). After repeated injection o f the vector in late gestation 
however, neutralizing antibodies were detectable, showing that the fetus was not 
tolerant to the vector (Iwamoto HS et al., 1999).
The immune response to adenovirus following intra-amniotic delivery o f vector was 
interesting, since after injection at 33 days o f gestation, anti-adenovirus antibodies were 
detectable at day 42, within the time period that the sheep fetus is still believed to be 
pre-immune. Evidence from studies o f fetal pigs show that they are able to develop 
preimmune natural antibodies from 30 days o f gestation (term =114  days) (Sun J et al.,
1998) and can mount an immune response to viruses from 38 days o f gestation (Butler 
JE et al., 2001). Our data suggests that a highly immunogenic agent can elicit a humoral 
immune response and that the hFIX protein is probably less immunogenic. This has 
important implications for therapeutic gene transfer in utero since at present, little is 
known about the immunogenicity o f alternative therapeutic proteins to be used in gene 
therapy applications.
Late gestation intramuscular injection o f adhFIX vector was unable to evoke an 
antibody response to the hFIX transgenic protein. This was surprising because we 
anticipated there would be an immune response similar to that observed following late 
gestation umbilical vein injections (Themis M et al., 1999). In particular, the 
intramuscular route o f injection is known to induce a strong immune response and has 
been applied in the fetal sheep for immunization against a number o f newborn 
pathogens (Gerdts V et al., 2004). The lack o f antibody response to the transgenic 
protein may reflect the low level transduction we achieved, although similar levels of 
hFIX expression were detected in one o f the lambs bom after late gestation umbilical 
vein injection in which anti-hFIX antibodies were detected.
Our hypothesis that expression o f a foreign antigen during early fetal development 
could result in its recognition as “se lf’ has been based on previous observations by 
others in a murine system where exposure o f the fetus to foreign antigen was 
maintained (Billingham RE et al., 1953). Although we did not detect antibodies to
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transgenic hFIX after early gestation injections, it is not possible to determine tolerance 
by repeat injection o f adhFIX vector due to the presence o f anti-adenovirus antibodies 
and the relatively short-term gene expression provided by this vector. Attempts by 
others to induce tolerance to adenovirus following fetal delivery via intratracheal 
(Iwamoto HS et al., 1999), umbilical vein (Yang EY et al., 1999) and intra-amniotic, 
intrahepatic or intramuscular injection (Jerebtsova M et al., 2002) have been 
unsuccessful. Nevertheless, evidence to support induced tolerance has been reported 
from experiments performed in the fetal sheep (Tran ND et al., 2001). Following 
intraperitoneal injection o f retrovirus vectors containing the p-galactosidase gene into 
the preimmune sheep fetus via laparotomy at 60 days o f gestation, there was a reduced 
cellular and humoral response to postnatal injection o f the transgene in lambs when 
compared with uninjected lambs. We investigated the feasibility o f injecting hFIX 
protein into sheep but the prohibitive costs o f this in a large animal precluded its use in 
this study using adenovirus vector. However we hope that future studies that deliver an 
integrating vector to the fetal sheep may result in long-term expression o f transgenic 
hFIX and allow us to test for tolerance using exogenous hFIX.
In fetal MF1 mice, yolk sac vessel injection o f adhFIX vector lead to the animals being 
tolerant to exogenous hFIX as adults (Waddington SN et al., 2003b). No tolerance was 
demonstrated to the adenovirus vector however, and the fetally injected mice developed 
high levels o f antibody to adenovirus after injection o f adhFIX as adults. In both these 
studies, the transgenic protein was maintained, albeit at low levels in the circulation and 
this may have acted to reinforce tolerance to the antigen. This concurs with the theory 
that tolerance may be induced by the continual exposure o f anergic T cells to antigen 
(Ramsdell F and Fowlkes B, 1992) or by the maintenance o f a T-regulatory population 
(Schwartz RH, 2005).
Adenovirus is known to be a highly immunogenic virus. Indeed, a systemic 
inflammatory response to a first generation adenovirus vector resulted in the death o f  a 
participant in a phase 1 clinical trial towards gene therapy o f the inherited metabolic 
disorder, ornithine transcarbamylase deficiency (Lehrman S, 1999). Attempts to reduce 
the immunogenicity and toxicity o f the vector and prolong gene expression have led to 
the generation o f the so called ‘gutless vectors’ in which essentially all adenovirus 
coding sequences have been eliminated (Chen HH et al., 1997,Schiedner G et al., 
1998,Schiedner G et al., 1998). These vectors will be more appropriate for clinical 
application o f prenatal gene therapy.
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Fetal application o f oncoretrovirus vectors such as lentivirus that integrate into the 
genome and provide long term transgene expression, may provide tolerance in the adult 
animal. Certainly, a recent report demonstrated long term hFIX expression and 
tolerance to exogenous hFIX in adult haemophiliac and immune competent mice that 
had received yolk sac vessel injection o f lentivirus containing the hFIX transgene as 
fetuses (Waddington SN et al., 2004b). Only by application o f integrative vectors that 
produce good levels o f gene transfer in the sheep fetus and testing for tolerance to the 
transgenic protein after birth o f the animal will we be able to determine whether 
immune tolerance can be reliably achieved in a large animal fetal model.
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H The future: experiments with alternative vectors in 
fetal sheep
Retrovirus and lentivirus vectors offer the advantage o f being able to integrate into the 
genome and therefore provide long-term gene expression. In utero application of 
lentivirus vectors to the mouse showed widespread and sustained gene expression 
particularly in the liver and musculature (Waddington SN et al., 2003c). Pilot 
experiments were performed in fetal sheep in early and late gestation using amphotropic 
retrovirus vectors (Moloney Leukemia Virus, CMV promoter) that have a general 
tropism for mammalian cells. There are difficulties in preparing sufficient quantities o f 
lentivirus vectors and experiments using these vectors were confined to early gestation 
fetal sheep.
Recombinant Sendai virus has shown a tropism for respiratory epithelium in a number 
o f small animal models (Yonemitsu Y et al., 2000) and a broad range o f tissues were 
transduced in the fetal mouse including the airway epithelium (Waddington SN et al., 
2003a). We therefore performed some pilot experiments in the fetal sheep airways both 
ex vivo and in vivo.
H 1 A high rate of cell division is observed in early gestation 
fetal sheep tissues
Retrovirus vectors only integrate into the genome o f actively dividing cells. As a 
preliminary step to injection o f retrovirus vectors into early gestation fetal sheep we 
wanted to assess cell division in the sheep fetus at this gestational age. Ultrasound 
guided intraperitoneal injection has been used in mid-gestation fetal sheep to 
successfully administer the DNA synthesis marker 5-bromo2’-deoxy-uridine (BrDU) 
(Greenwood PL et al., 1999). To determine the correct dose o f DNA label, we 
extrapolated from this study on the basis o f fetal weight, and 250 pi BrDU was 
delivered into the peritoneal cavity of a fetus at 60 days o f gestation by ultrasound- 
guided injection. Extensive tissue sampling o f the fetus was performed at post mortem 
analysis one hour later and immunohistochemical analysis for BrDU staining showed 
high cell proliferation in all tissues apart from the adrenal gland (Figure H 1). This 
suggests that retrovirus vectors should be capable o f transducing a broad range o f early 
gestation fetal sheep tissues.
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Figure H 1: Cell proliferation in the early gestation fetal sheep.
Immunohistochemistry for BrDU in early gestation fetal sheep tissues after ultrasound-guided 
intraperitoneal injection o f  a fetal sheep aged 60 days o f  gestation. There is strongly positive BrDU  
staining suggesting a high rate o f  cell division in the following tissues: (A) lung, (B) myocardium, (C) 
small bowel, (D) kidney, (E) liver, (F) spleen, (G) thymus, (H) gonad, (I) skin, (J) neurocortex and (K) 
muscle. In the adrenal (L) however, there is very little positive staining. Original magnifications x 40 
except where indicated.
H 2 Retrovirus vector m ediated gene transfer to fetal sh eep  is  
poor
H 2.1 Fetal sheep liver can be transduced ex vivo by retrovirus 
vectors
Amphotropic retrovirus vectors (Moloney Leukemia Virus, MLV, 1 x 108 particles) 
containing the lacZ gene were applied to the liver o f fetal sheep aged 55 and 100 days 
o f gestation ex vivo. The vector was applied alone or in complex with DOGS (5pg/ml) 
or DEAE dextran (5pg/ml). Widespread scanty p-galactosidase expression in
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subcapsular cells was observed on X-gal staining 24 hours after transfection, when the 
vector was complexed with either of the polycations (Figure H 2); DEAE dextran 
enhanced transduction more than DOGS.
Figure H 2: Retrovirus-m ediated p-galactosidase transgene expression in the fetal 
sheep liver.
The liver o f  a fetal sheep aged 55 days o f  gestation was incubated ex vivo with MLV vector containing 
lacZ complexed with DEAE dextran (5pg/ml). Positive X-gal staining o f  subcapsular cells is seen.
H 2.2 Ultrasound-guided intraperitoneal or intrahepatic injection of 
retrovirus vectors to early gestation fetal sheep does not result in 
transgene expression
Amphotropic retrovirus vectors (MLV, 2 x 107 particles) containing the lacZ gene were 
delivered to early gestation fetal sheep by ultrasound-guided intrahepatic (n = 2) or 
intraperitoneal (n = 1) injection (Table H 1). Post mortem and histological examination 
was normal 9 - 1 0  days after surgery apart from mild vascular congestion in the liver of 
one fetus (HE 16). Transgene expression was not detectable by X-gal staining or p- 
galactosidase immunohistochemistry. Assuming that this negative result might be due to 
the immaturity of the fetal liver at this young gestational age, we performed retrovirus 
injections in later gestation fetal sheep.
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Table H 1: U ltrasound-guided in trahepatic or in traperitoneal retrovirus vector 
injection.
Post mortem and histological findings, and transgene expression after ultrasound-guided intrahepatic 
(HE) or intraperitoneal (IP) injection o f  retrovirus vectors (M LV) into early gestation fetal sheep, t  
indicates the vector was complexed with DEAE dextran (5pg/m l); PM: post mortem; d: days; p/kg: 
particles per kg.
Sheep Age
(d)
Vector PM PM
findings
Histological
findings
p-galactosidase
expression
Vol
(pi)
Dose
(P^g)
X-gal
staining
immuno
HE15t 53 200 4 x  108 9d normal normal - —
HE16t 53 200 4 x  108 9d normal vascular 
congestion in liver
— —
IP18f 53 300 6 x  108 lOd normal normal - -
H 2.3 Low level transgene expression is observed after ultrasound- 
guided umbilical vein injection of retrovirus vectors in mid and late 
gestation fetal sheep
We delivered retrovirus vectors to mid and late gestation fetal sheep by umbilical vein 
injection similar to previous experiments using adenovirus vectors (Table H 2). Sheep 
fetuses aged 76 days o f gestation (n = 1, 8 x 108 particles) and 137 days o f gestation (n 
= 2, 1 x 108 particles) received MLV vector containing the lacZ gene via the intrahepatic 
umbilical vein. There was no data available on the toxicity o f polycation administration 
into the circulation o f fetal sheep and we therefore complexed the retrovirus with the 
polycations DOGS (UV24) or DEAE dextran (RV1) in only two o f the three 
experiments in an attempt to improve tissue transduction.
Only low level transgene expression was observed in the fetal tissues from the mid­
gestation sheep on X-gal staining with one positively stained area on the umbilical cord, 
occasional stained villi in the distal small bowel, and pale diffuse staining o f the 
neurocortex (data not shown). X-Gal staining o f tissues from the late gestation fetuses 
showed moderate expression in the fetal heart but only low level expression in the fetal 
liver and kidney (Figure H 3). Vector complexation with DEAE dextran did not 
significantly improve transgene expression. X-gal staining was very faint on 
histological section (data not shown) and immunohistochemistry for p-galactosidase 
expression was negative in all three fetuses.
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Table H 2: U ltrasound-guided umbilical vein injection of retrovirus vector.
Post mortem and histological findings, and transgene expression after ultrasound-guided injection o f  
retrovirus (MLV) vectors into the intrahepatic umbilical vein o f  mid and late gestation fetal sheep.
* indicates the vector was complexed with DOGS (5pg/ml); + indicates the vector was complexed with 
DEAE dextran (5pg/ml); PM: post mortem; d: days; p/kg: particles per kg
Sheep Age
(d)
Vector PM Post mortem 
findings
Histological
findings
P-galactosidase
expression
Vol
(ml)
Dose
(p/kg)
X-gal
staining
immuno
UV24* 76 4 3.2 x 10“ 7d small
peritoneal
adhesion
normal (+)
R V lf 137 20 1.6 x 107 3d normal normal + —
RV2 137 20 1.7 x 107 3d normal normal + —
Figure H 3: p-galactosidase transgene expression after ultrasound guided
umbilical vein delivery of retrovirus vectors.
Three days after UV injection o f  MLV vector in late gestation fetal sheep, low-level positive X-gal 
staining is seen in the fetal heart (A) and (B), liver (C), and kidney (D). All magnifications x 4.
312
H. RESULTS: Alternative vectors
Despite these disappointing results, these preliminary studies have shown that retrovirus 
transduction o f fetal sheep tissues with MLV vectors is possible, albeit at low levels. 
Increasing titres may therefore allow better transduction.
H 3 Lentivirus vector m ediated  gene transfer to fetal sh eep  is 
poor
H 3.1 Early gestation fetal sheep liver can be transduced ex vivo by 
Equine Immune Anaemia Virus lentivirus vectors
The lentivirus vector, Equine Immune Anaemia Virus, (EIAV, 1 x 107 particles) 
containing the lacZ gene and pseudotyped with VSV-G protein was applied to the liver 
of a fetal sheep aged 53 days o f gestation ex vivo. We also investigated the effect of 
complexing the vector with the polycations DEAE dextran (5pg/ml) or DOGS (5pg/ml) 
on liver transfection. Widespread scanty p-galactosidase expression was observed in 
subcapsular hepatocytes on X-gal staining 24 hours later, but only when the vector was 
complexed with DEAE dextran (Figure H 4).
Figure H 4: Lentivirus-mediated P-galactosidase transgene expression in the early 
gestation fetal sheep liver.
Two days after ex vivo infection o f  a fetal sheep liver (55 days o f  gestation) with EIAV lacZ vector 
complexed with DEAE dextran (5pg/m l), positive X-gal staining o f  subcapsular hepatocytes is seen.
313
H. RESULTS: Alternative vectors
H 3.2 Ultrasound-guided injection of Equine Immune Anaemia and 
Human Immunodeficiency Virus lentivirus vectors to early gestation 
fetal sheep did not achieve transgene expression
We applied lentivirus vectors to early gestation fetal sheep by ultrasound guided 
intrahepatic (n = 2), intraperitoneal (n = 1) or intramuscular injection (n = 4, Table H 
3).
Table H 3: U ltrasound-guided delivery of lentivirus vectors to early gestation fetal 
sheep.
HE: intrahepatic, IP: intraperitoneal, IM: intramuscular injection; t  indicates the vector was complexed  
with DEAE dextran (5pg/m l); PM: post mortem; d: days; p/kg: particles per kg; nt: not tested
(A) Experim ental details and transgene expression
Sheep Age
(d)
Vector PM P-galactosidase
expression
Type Pseudo
type
Trans
gene
Vol
(Hi)
Dose
(p/kg)
X-gal
staining
P-gal
immuno
HE13t 55 EIAV VSV-G lacZ 100 2x10^ 9d — —
HE14t 53 EIAV VSV-G hFIX 100 2x10^ 3d — —
IP19t 53 EIAV VSV-G hFIX 200 6 x 10y lOd — —
IM16 64 HIV VSV-G lacZ 100 9 x  107 lOd — —
IM17 64 EIAV VSV-G lacZ 100 2 x  108 Id nt nt
IM18 60 EIAV VSV-G lacZ 200 1 x 108 l id — —
IM19 64 EIAV Mokola lacZ 300 4 x  107 13d - -
(B) U ltrasound, post m ortem  and histological findings
Sheep Vector PM USS findings 
postop
PM findings Histological findings
HE13t EIAV 9d ascites (+) 8d 
postop
abdominal wall oedema, 
10ml ascites, mottled 
liver
normal
HE14t EIAV 3d alive Id, dead 
3d postop
abdominal wall oedema, 
2ml ascites, no blood 
clot; Campylobacter 
jejuni cultured
fetal liver necrosis, 
acute inflammation 
uterus
IP191* EIAV lOd ascites +++ 6d 
postop
abdominal wall oedema, 
10ml ascites, mottled 
liver
normal; normal fetal 
blood profile; culture 
negative
IM16 HIV lOd normal normal normal
IM17 EIAV Id dead fetus macerated fetus; Bacillus 
cereus cultured
necrosis, haemorrhage 
+ bacteria
IM18 EIAV lid normal normal normal
IM19 EIAV 13d normal normal normal
The Equine Immune Anaemia Virus (EIAV) vector was used in all but one experiment; 
we applied the Human Immunodeficiency Virus (HIV) vector in this case (IM16). The
314
H. RESULTS: Alternative vectors
vectors were pseudotyped with the VSV-G envelope apart from one experiment (IM19) 
in which the Mokola envelope was used.
Injection o f EIAV VSV-G pseudotyped vector into the liver parenchyma or peritoneal 
cavity of early gestation fetal sheep resulted in significant fetal morbidity. In one case 
(HEM) the fetus was alive and well the day following surgery, but on the third postop 
day the ewe had vaginal bleeding and fetal death was confirmed by ultrasound scanning. 
This was an unusual finding, since in all other cases o f fetal mortality that we observed 
in this research, death occurred within 24 hours of surgery. At post mortem examination 
there was skin oedema and a small amount o f ascites, but no evidence o f intrahepatic or 
intraperitoneal bleeding. Histological analysis showed acute inflammation o f the uterus 
and Campylobacter jejuni was cultured in some fetal and maternal tissues. We 
considered this most likely to have been due to ascending infection o f the genital tract 
after fetal death.
In the other two cases, ascites was noted on ultrasound examination 6 days (IP 19,
Figure H 5 A) and 8 days (HE13) after surgery respectively. In both cases the volume 
of ascites increased over the ensuing days and one experiment was terminated early 
because of its severity (HE 13). Extensive subcutaneous oedema and ascites was found 
at post mortem examination o f both fetuses and the liver was mottled (Figure H 5 B 
and C).
Figure H 5: Fetal m orbidity following intraperitoneal or intrahepatic ultrasound 
guided injection of EIAV vector into early gestation sheep fetuses.
(A ) An ultrasonogram o f  the fetus in transverse section 6 days after intraperitoneal injection (IP19) 
showing severe ascites, deepest pool o f  8.5mm. (B) Subcutaneous oedema o f  the anterior abdominal wall 
and abdominal distension with ascites at post mortem examination 10 days after intraperitoneal injection 
(IP 19). (C) Mottled liver and subcutaneous oedema o f  the anterior abdominal wall at post mortem 
examination 9 days after intrahepatic injection (HE 13).
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Histological examination however, showed no abnormality. Fetal blood sent from IP 19 
showed a normal blood film, blood count, biochemistry and liver function; the ascites 
was a transudate with low cellularity; culture o f fetal blood and ascites was negative. 
The coagulation profile showed slightly prolonged Prothrombin Time and Activated 
Partial Thromboplastin Time that can be associated with inflammation. These results 
suggested that the vector was causing a severe inflammatory reaction that did not result 
in fetal haemolysis. In view o f the delayed onset, the reaction might be immune 
mediated. No transgene expression was observed in any fetal tissues. This could be due 
to an inability o f the vector to infect fetal cells in vivo or perhaps destruction o f the 
vector by an inflammatory process.
In contrast to these findings, intramuscular injection o f lentivirus vectors was associated 
with no fetal morbidity. One fetus (IM17) died within 24 hours o f  injection due to 
iatrogenic infection. Post mortem examination showed severe necrosis and haemorrhage 
o f the skin and muscle o f the injected left leg that extended in a line up across the 
abdomen. On histological analysis there was extensive haemorrhage and necrosis in the 
injected muscle, and bacilli on the surface o f the femur. Culture o f the fetal tissues 
showed a pure growth o f Bacillus cereus, a known fleece commensal o f sheep. This 
bacteria produces a haemolytic toxin which results in severe necrosis, and clinical 
infection is associated with immune suppression (Drobniewski FA, 1993).
There were no abnormalities detected on post mortem or histological analysis o f the 
other three fetuses that received intramuscular injection. It is interesting to note that one 
fetus (IM18) received exactly the same vector as those fetuses that developed oedema 
and ascites after intrahepatic or intraperitoneal injection. The other two either received a 
vector with a different backbone (HIV, IM16) or pseudotype (Mokola, IM19). The 
intramuscular injection route therefore, may not have resulted in the same degree o f 
systemic exposure to the vector, either because the myocytes were not infected or 
because there was local sequestration o f the vector.
Although there was no inflammatory reaction to intramuscular injection o f lentivirus 
vectors, no transgene expression was observed. We did not test infection o f fetal 
myocytes ex vivo and it is possible that the vector is unable to infect these cells.
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H 4 Sendai vector can m ediate gene transfer to the airway 
epithelium o f fetal sh eep
H 4.1 Sendai viral vector efficiently transfects the fetal sheep 
airways ex vivo
The trachea from a non-injected sheep fetus aged 83 days o f gestation was used to test 
Sendai vector mediated gene transfer ex vivo. Sendai lacZ vector (F-deficient, 5pl 
containing 5 x 105 particles) was applied to the epithelial airway surface o f 2cm long 
sections o f fetal trachea in culture medium and incubated for 24 hours. The tracheal 
sections were fixed in 100% ethanol and stained with X-gal solution for a further 24 
hours. There was extensive staining of the epithelial cell surface (Figure H 6).
Figure H 6: P-galactosidase transgene expression in the fetal trachea after Sendai 
virus application ex vivo.
X-gal histochemistry 24 hours after application o f  Sendai lacZ vector ex vivo shows strongly positive 
staining. Original magnification x 6.5.
H 4.2 Sendai virus mediated transgene expression in the fetal sheep 
airways
We next applied Sendai lacZ vector to the tracheal airway epithelium o f fetal sheep at 
mid-gestation (n = 2) using the ultrasound-guided transthoracic injection technique 
(Table H 4). The injection procedure was straightforward in both cases and details of 
the procedure are described in Section D 2.8.1.
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Table H 4: U ltrasound-guided delivery of Sendai virus to the fetal sheep trachea.
Post mortem and histological analysis o f  mid-gestation fetal sheep lungs and trachea 2 days after 
transthoracic injection o f  Sendai lacZ vector, h: hrs; d:days; PM: time o f  post mortem after injection; GA: 
gestational age at injection; p/kg: particles per kg;
Sheep GA
(d)
PM Vector
dose
(p/kg)
Post m ortem  
findings
Histology findings
IT36 100 2 d 3 x 106 in 
5ml PBS
200pl clear pleural 
fluid, thickened 
pericardium
normal lungs, trachea and 
pericardium; normal fetal 
blood profile
IT37 104 alive 24 h, 
dead 2 d
1.5 x 106 
in 5ml 
PBS
no evidence o f trauma, 
haemorrhage; cloudy, 
smelly amniotic fluid
bronchopneumonia + 
bacteria; scanty mixed 
growth on culture
Examination o f the first fetus (IT36) two days after injection showed no abnormality 
apart from a small volume o f clear pleural fluid. X-gal staining and 
immunohistochemical analysis for p-galactosidase showed no positive transgene 
expression. The batch o f vector applied in this fetus had been frozen and thawed twice 
and its infection efficiency consequently may have reduced.
The experiment was repeated with a fresh batch o f virus (IT37). Ultrasound 
examination o f the fetus the day after injection showed no abnormality but at post 
mortem examination a day later the fetus was dead. There was no evidence that the 
injection procedure had caused fetal death. The findings o f smelly and cloudy amniotic 
and tracheal fluids suggested infection that was confirmed as mixed growth on culture. 
Histological analysis of fetal tissues showed bronchopneumonia and numerous bacteria 
in the airways; only inflammation was present in the alveoli. We concluded that fetal 
death had probably been due to infection present in the vector or introduced during the 
procedure. No positive transgene expression was detectable on X-gal staining. It is 
likely however, that bacterial infection prevented gene transfer or resulted in the death 
o f transduced cells.
H 4.3 Tracheal fluid does not affect ex vivo Sendai virus mediated 
transgene expression in the fetal sheep airways
With a limit on the amount o f Sendai lacZ vector left available, we decided to 
investigate whether fetal tracheal fluid might affect Sendai vector mediated gene 
transfer to the fetal sheep trachea ex vivo. Sendai lacZ vector (FI deficient, 5 x 105 
particles) was incubated overnight at room temperature with tracheal fluid taken from a 
non-injected sheep fetus aged 83 days o f gestation. Sections o f the trachea from the
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same fetus were then infected with this vector or with the same concentration of 
unincubated vector for 24 hours. After fixation with 100% ethanol, X-gal solution was 
applied for a further 24 hours. There was no difference in the level o f lacZ expression 
observed and we concluded that fetal tracheal fluid did not affect ex vivo Sendai vector 
mediated gene transfer.
H 5 Discussion
Retrovirus and lentivirus vectors offer the advantage o f being able to integrate into the 
genome and therefore can provide long-term gene expression. We hoped that 
application o f an integrative vector to the fetal sheep would allow us to show proof of 
principle for tolerance after prenatal gene transfer. Studies in the fetal mouse and non­
human primate have shown widespread and long-term gene transfer after application o f 
both these vector groups. In the fetal sheep however, only studies o f retrovirus mediated 
gene transfer have been reported.
We were unable to demonstrate gene transfer after intrahepatic or intraperitoneal 
application o f amphotropic Moloney Leukemia Virus (MLV) retrovirus vectors to early 
gestation fetal sheep. Even in mid and late-gestation fetal sheep, umbilical vein delivery 
resulted in low level transgene expression that was not confirmed by 
immunohistochemistry. These results should be compared with the strong and 
widespread expression observed following umbilical vein application o f adenovirus 
vectors (Themis M et al., 1999). Vector complexing with DOGS or DEAE dextran 
improved gene transfer in vitro but not in vivo.
Other investigators have similarly observed no evidence o f gene transfer after 
instillation o f MLV retrovirus producer cells into the amniotic cavity o f early and mid­
gestation fetal sheep (Galan HL et al., 2002). Low level gene transfer to the respiratory 
epithelium has been achieved after direct delivery o f amphotrophic MLV vectors to the 
trachea o f fetal sheep (Pitt BR et al., 1995). In addition low level gene transfer into 
hematopoietic cells was detected in 6 out o f 8 early gestation fetal sheep that received 
an intraperitoneal injection o f amphotrophic MLV vector supernatant containing the 
neox transgene at 57 -  67 days o f gestation (Porada CD et al., 1998). The dose o f vector 
that we applied (2 x 107 particles per fetus) was between one to three logs higher than 
the highest vector dose used in Porada’s study and should have lead to widespread gene 
transfer. Furthermore Porada’s group subsequently reported that application o f higher 
doses o f their MLV vector supernatant to the same dose as we used, resulted in 
improved levels o f gene expression (Tran ND et al., 2000). Differences in the
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experimental technique such as the route o f injection or the gestational age at 
application, might account for the lack o f transduction we observed.
Application o f EIAV lentivirus vectors to early gestation fetal sheep did not achieve any 
gene transfer and was associated with significant morbidity and mortality. Post mortem, 
histological and biochemical analysis o f fetuses suggested that the vectors caused a 
severe inflammatory reaction when they were applied directly to the liver or 
systemically by intraperitoneal injection. Intramuscular injection did not lead to fetal 
morbidity but this route o f application results in more local delivery to the tissues. The 
lack o f gene transfer we observed in vivo probably resulted from destruction o f the 
vector and/or infected cells. Only one experiment was performed using HIV vector and 
it is therefore difficult to draw any conclusions.
We were surprised by our negative results following EIAV application, since in vitro 
studies in the fetal sheep liver demonstrated gene expression. Furthermore lentivirus 
application in other fetal animal models has achieved excellent gene tranfer. In the fetal 
mouse, long term transgene expression is seen up to a year after yolk sac vessel 
injection o f the same EIAV vector we applied to the fetal sheep (Waddington SN et al., 
2003c,Waddington SN et al., 2004b,Gregory LG et al., 2004), and intrahepatic or 
intramuscular injection o f HIV vectors efficiently transduces hepatocytes and myocytes 
respectively (MacKenzie TC et al., 2002). Direct injection o f HIV vectors into the lung 
parenchyma o f fetal Rhesus monkeys leads to local gene transfer, with no evidence o f 
toxicity or inflammation (Tarantal AF et al., 2001a). The different results highlight the 
difficulties in extrapolating between species and from small to larger animal models. 
EIAV causes a self-limiting and lifelong but rarely fatal infection o f all equidae 
resulting in plasma viraemia and recurrent thrombocytopenia (Rohll JB et al., 2003). 
The VSV-G envelope that was used to pseudotype the vector gives it a broad tropism 
permitting transduction o f a wide range o f tissue types (Mitrophanous K et al., 1999). 
The VSV-G protein is toxic to producer cells and it is possible that the toxicity we 
observed was due to the envelope rather than the vector itself.
Preliminary ex vivo results from application o f a second-generation Sendai lacZ vector 
to the fetal sheep trachea were encouraging. Unfortunately this was not reflected by our 
in vivo experimental data, probably resulting from the use o f a batch o f poor quality 
vector. In the fetal mouse, this vector has been shown to achieve high levels o f gene 
transfer to the respiratory epithelium after intra-amniotic application, and to the 
endothelium after intravascular administration (Waddington SN et al., 2004a). Further 
experiments with newer vector batches may give better results.
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I Discussion
I I  Fetal gene transfer can be achieved using minimally 
invasive clinically applicable delivery of gene therapy to the 
sheep fetus
For fetal gene therapy to be applied in clinical practice, delivery o f the vector to the 
fetus will need to be acceptable to both patient and clinician, with a low morbidity and 
mortality. In this thesis we have used the fetal sheep as an animal model to explore 
ultrasound-guided delivery o f fetal gene therapy. To target therapy to some fetal organ 
systems, we used existing techniques applied in current fetal medicine practice. For 
other organ systems, for example to reach the fetal airways, small bowel and brain 
however, we developed novel routes o f application.
For many reasons the fetal sheep is a highly suitable animal model in which to explore 
ultrasound-guided injection techniques. Unlike in the majority o f fetal medicine 
procedures, the animals were anaesthetized during injections, but it was possible to 
assess and follow fetal growth longitudinally with the ewes awake and sitting up. In 
addition, a lighter touch on the probe is required in sheep to prevent compression o f the 
uterus and its contents because they have a thinner anterior abdominal wall musculature 
than humans. Maternal morbidity and mortality was almost negligible, similar to 
findings from ultrasound-guided procedures in clinical practice (Elchalal U et al., 2004). 
Fetal morbidity and mortality was dependent on the injection route applied, for example 
a higher rate o f fetal loss was observed with the more invasive routes such as 
intraperitoneal and intrahepatic injection (80% and 81 % respectively) which are more 
likely to cause life-threatening fetal trauma, than with less invasive routes such as intra- 
amniotic and intramuscular injection (86% and 91% fetal loss rate respectively). This is 
also observed in clinical practice (Alfirevic Z et al., 2003).
The placenta o f the sheep and human are very different and this results in a different 
approach towards ultrasound-guided procedures. In the human fetus which has one 
discoid placenta, transplacental needling is avoided if  at all possible because it is 
associated with a higher rate o f complications, such as haemorrhage and miscarriage 
(Tabor A et al., 1986). In the fetal sheep, the cotyledons o f the synepitheliochorial 
placenta cover the entire uterine wall so that there is no window through which to avoid 
transplacental needling. In one study o f  ultrasound-guided amniocentesis and
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allantocentesis in the first trimester fetal goat that has a similar placental structure, 
penetration o f a cotyledon in one o f 13 injection procedures resulted in a bloody tap 
with subsequent fetal abortion (Lovell KL et al., 1995). During our ultrasound-guided 
injection procedures we avoided passing the needle through a cotyledon if  at all possible 
to prevent associated complications. This was simple to achieve in early gestation when 
the amount o f amniotic fluid relative to the fetus was higher. From 80 days o f gestation 
onwards however, the cotyledons are at their maximum diameter (Kelly RW et al.,
1987) and this, combined with the larger fetal size and low amniotic fluid volume 
resulted in the fetus being positioned directly against the anterior abdominal wall, 
making it occasionally impossible to avoid transgressing a cotyledon during needling. 
We did not observe any fetal or maternal complications associated with 
transplacentomal needling in these cases and concluded that transgressing a cotyledon 
probably did not significantly affect fetal survival.
Direct translation from the sheep to the human situation should be possible for most o f 
the injection routes that we investigated, and in particular for the intragastric, 
intramuscular and intrahepatic injection routes that were developed in this thesis. For 
the transthoracic route into the trachea further data is needed on tracheal views in the 
human fetus. Obviously long term outcome data is not available for any o f  the routes 
that were developed and this is necessary prior to human application. The robustness o f 
the fetal sheep for development o f ultrasound guided procedures is supported by the 
recent translation of the transthoracic tracheal injection technique developed in fetal 
sheep into the human clinic. This was successfully used to puncture an occlusive 
balloon in the fetal trachea that had been placed fetoscopically a few weeks earlier for 
treatment o f CDH (Deprest J et al., 2004).
There are few sheep models o f human genetic disease and this lessens their usefulness 
in the development of fetal gene therapy. Efforts to produce transgenic sheep are 
progressing (Piedrahita JA, 2000). Taking cystic fibrosis as an example, there is close 
homology between ovine and human CFTR o f almost 91%, which is significantly 
higher than that between murine and human CFTR (Harris A, 1997) and steps have 
begun to generate a CF sheep (Williams SH et al., 2003). In addition one group in New 
Zealand is looking for naturally occurring CFTR mutants that exist in heterozygote 
form for breeding programs and a potential CFTR mutation has been identified (Tebbutt 
SJ et al., 1996).
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I 2 Delivery of gene therapy to the sheep fetus achieves levels 
of gene transfer that are useful for prenatal treatment of 
congenital disease
Adenovirus proved to be useful a pathfinder vector in this thesis, having a broad tissue 
tropism and efficiency of infection. In addition we were able to improve gene transfer to 
epithelia significantly by sodium caprate pretreatment and DEAE dextran complexation. 
Although it is unlikely that 1st generation adenovirus will be the vector o f choice for 
clinical application o f fetal gene therapy, it is important to know that barriers to gene 
transfer, for example the tight junctions in the epithelia, can be reversibly and safely 
overcome by coapplication o f other agents. The safety o f these agents must also be 
scrutinized rigorously before clinical application.
A major drawback o f the fetal sheep animal model was the toxicity and lack o f gene 
transfer following delivery o f integrating vectors. We had hoped that long term 
transgene expression mediated by retrovirus or lentivirus vectors would allow us to test 
for immune tolerance to transgenic protein in lambs born after in utero injections. The 
reason for the lack o f gene transfer is unclear but is very likely due in part to the toxicity 
observed. We are conducting further studies looking for evidence o f integration o f  the 
viral backbone into the DNA from injected fetal sheep tissues.
13 Alternative fetal animal models for investigating ultrasound- 
guided delivery of fetal gene therapy
I 3.1 The fetal nonhuman primate
Nonhuman primates are, strictly speaking, the most appropriate animal model for 
comparison with the human because o f the many similarities in developmental biology. 
They are close physiologically to humans with menstrual cycles o f similar length and 
hormonal control, comparable cellular and endocrine processes o f implantation, and 
similar timetables o f prenatal and immune system development. The placental structure 
in some nonhuman primates is also the same, for example in the rhesus monkey the 
placenta is hemomonochorial and bidiscoidal (Benirschke K and Kaufmann P, 1990). 
For this reason they are used as an animal model in studies o f teratology, developmental 
biology, infertility and contraception (Hendrickx AG and Peterson PE, 1997).
Ultrasound guided injection techniques as used in fetal medicine have also been applied 
extensively in the fetal nonhuman primate with comparable results (Tarantal AF, 1990).
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Currently available lentivirus and retrovirus vectors are effective at mediating gene 
transfer into fetal non-human primates and in this at present they have an advantage 
over fetal sheep.
However nonhuman primates are significantly more costly than sheep and are difficult 
to maintain because o f the need for appropriate environments and intensive husbandry. 
There are also no non-human primate models o f disease that would be suitable 
candidates for fetal gene therapy. More importantly perhaps, there are ethical concerns 
associated with experimentation on nonhuman primates that preclude all but the most 
necessary investigations. Prenatal gene therapy will require particularly stringent safety 
assessments. Non-human primates are the most appropriate animal model for this and 
for the monitoring of long-term efficiency o f gene transfer.
I 3.2 The fetal mouse
Transgenic mouse models have proved extremely valuable for studying the efficacy of 
gene therapy in congenital diseases, for example cystic fibrosis and thalassaemia, where 
there are no natural animal models. Mice are small and are therefore easy and 
reasonably cheap to house. They breed quickly with large litters (6-20 pups) and 
consequently allow study o f the effect o f prenatal gene therapy on the adult animal, and 
analysis o f  trans-generational effects in a reasonably short time-frame. Integrating 
vectors provide long term gene expression in the fetal mouse and it is for this reason 
that mice are being used in our laboratory for initial studies into the effectiveness o f in 
vivo gene transfer from novel vectors.
There are obvious differences in the size o f mice and men that precludes their use for 
the development o f minimally invasive techniques for future clinical application o f  gene 
therapy. There are major differences in placentation and in the development o f the fetal 
immune system that in the neonatal mouse is relatively immature as compared with the 
human neonate. In the case o f cystic fibrosis gene therapy, mice are not the ideal animal 
model. Submucosal glands, which are the site o f the highest levels o f CFTR expression 
in the human airways, are only present in very low numbers in the mouse and the main 
secretory cell type is the Clara cell (Pack RJ et al., 1981). Despite these reservations, 
fetal mice will continue to be used for first-line in vivo gene therapy experiments before 
moving on to larger animal models that are closer to the human situation.
I 3.3 Other fetal animal models
The rabbit has been studied in some prenatal gene therapy studies. Minimally-invasive
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percutaneous ultrasound guided injection and fetoscopic procedures are being 
developed (Brandt et al., 1997a,Papadopulos NA et al., 1999,Papadopulos NA et al.,
1999). Because o f the small size o f the fetus and litter number however, technically this 
is only possible from late gestation and the rabbit does not generally provide much 
advantage over the sheep. The guinea pig has the same placental structure as humans 
but these animals are not commonly used in prenatal gene therapy studies because o f the 
small fetal size and lack o f transgenic models o f disease.
The dog is suitable for some minimally invasive delivery techniques and prenatal gene 
transfer has been attempted using ultrasound guided intraperitoneal or yolk sac injection 
through the exposed uterus (Lutzko C et al., 1999,Meertens L et al., 2002,Meertens L et 
al., 2002). In addition there are dog models o f a few human congenital diseases 
including mucopolysaccharidosis type VII, Duchenne muscular dystrophy and 
haemophilia B, which are useful for investigating the therapeutic effect o f gene therapy. 
Such colonies are costly to maintain however and probably do not provide much 
advantage over transgenic mice for proof o f principle studies.
I 4 Ethical issues and the future of fetal gene therapy
Congenital disease places a huge burden on the community and the health service. A 
population based study found nearly 12% of pediatric hospitalizations in two US states 
were related to birth defects and congenital disease. The children stayed longer in 
hospital, incurred 184% higher charges and had a 4lA  times higher rate o f mortality than 
that o f children hospitalized for other causes. In a narrower setting a study o f pediatric 
inpatient admissions in 1996 in a US children’s hospital found that wholly genetic 
conditions accounted for one-third o f hospital admissions and for 50% of the total 
hospital charges for that year (McCandless SE et al., 2004). Thus a preventative strategy 
such as prenatal gene therapy will have an important social and economic impact.
A criticism levelled at fetal gene therapy is that gene transfer to an individual after it is 
born may be as effective and probably safer than prenatal treatment. Indeed current 
conventional treatment o f some genetic disease is highly effective. One o f the most 
successful examples is that o f the metabolic disorder phenylketonuria, in which dietary 
restriction o f phenylalanine prevents the brain damage associated with this condition. 
However the diet is unpalatable, rigid and must be lifelong, since discontinuation o f it in 
adult life is accompanied by progressive loss o f intellectual function and behavioural 
disturbance (Ding Z et al., 2003). For many genetic diseases treatment is palliative 
rather than curative, resulting in patients living longer but with a reduced quality o f life.
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This has been particularly seen in cystic fibrosis, in which life expectancy has risen 
from school age in 1955 to the mid thirties today (Cystic Fibrosis Foundation). To 
achieve this however, patients require daily chest physiotherapy, antibiotic treatment, 
dietary supplementation, insulin for diabetes mellitus and in many cases, lung 
transplants which require immunosuppressive therapy in addition. Effective treatment in 
utero could cure genetic disease, or at least provide partial correction that may have a 
huge impact on disease progression.
There are various ethical issues in relation to in utero gene therapy that need to be 
addressed before such therapy could be applied clinically (Fletcher JC and Richter G,
1996,Recombinant DNA Advisory Committee, 2000,Fletcher JC and Richter G, 1996). 
There is a theoretical risk that the therapeutic gene product or vector that is required at a 
certain stage during fetal development could cause developmental aberrations to occur. 
The problem of insertional mutagenesis as a potential risk o f retrovirus gene therapy has 
been debated for some years. This serious adverse event has now been identified in a 
trial o f gene therapy for X-linked severe combined immunodeficiency syndrome in 
which CD34+ haemopoietic stem cells were transduced ex vivo with the yc gene using 
retrovirus vectors. Two patients out o f fifteen treated developed acute lymphoblastic 
leukemia (ALL) three years after successful gene therapy treatment. Analysis o f the 
lymphocytes showed that the transgene had been inserted adjacent to a potential 
oncogene, LM 02, the product o f which has been implicated in the pathogenesis o f ALL 
(Juengst ET, 2003). Further work is needed to address this issue and to devise strategies 
to determine and possibly direct integration sites.
While one o f the aims o f prenatal gene therapy is to achieve immune tolerance to the 
transgene and delivery system, vectors must be designed to be sufficiently different to 
the wild type so that the immune system remains able to mount an effective immune 
response against wildtype virus infection. Germline transmission is another risk that 
raises ethical concerns and has been addressed previously.
Any fetal therapy or procedure poses risks o f infection, immune reactions and the 
induction o f  preterm labour for the fetus. An additional challenge for procedures 
performed on the fetus is that there is the potential to harm the mother. A conflict o f 
interest can arise since treating the fetus may not be in the mother’s best interest and in 
law a fetus has no rights per se. Attempts have made to resolve this moral ambiguity 
using the concept o f ‘the fetus as a patient’. This aims to provide a moral framework 
within which the fetus is reliably expected later to achieve the status o f becoming a 
child and eventually a person. ‘The fetus as a patient’ relies on the mother’s decision to
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continue with the pregnancy and to present the fetus for medical care (Chervenak FA 
and McCullough LB, 2002). However it should be emphasised that in many societies, 
presently the prospective mother has a right to abortion, even o f a non-affected fetus, as 
well as the decision to abort an affected fetus or subject it to fetal gene therapy. The 
availability o f fetal gene therapy should not in any way infringe her autonomy in these 
decisions. Currently used fetal treatments such as fetal blood transfusion for anaemia 
are effective and carry a low risk for the mother such that the risk-benefit analysis falls 
heavily on the side o f treatment. For experimental fetal procedures the risk-benefit 
analysis is uncertain and it is therefore especially important that the mother gives 
informed consent (Burger IM and Wilfond BS, 2000). This can be difficult since the 
decision to participate in a fetal gene therapy trial will occur close to the time o f 
prenatal diagnosis o f the condition. The professionals involved in counselling the 
parents must present the information in a non-biased way and ensure that resources are 
set aside for long-term surveillance o f the mother and fetus after birth. The parents must 
also consider that fetal treatment in this pregnancy may pose risks for a future 
pregnancy by potentially affecting the mother’s health.
Currently many parents when faced with a baby with a genetic disease decide to 
terminate the pregnancy in a procedure that is very safe for the mother and totally 
effective. A prenatal gene therapy strategy will have to be extremely safe, reliable and 
effective at treating the disease (Coutelle C and Rodeck C, 2002). For parents who 
would not have continued with an affected pregnancy, a partial cure o f an affected child 
resulting in a poor quality o f life would be the worst case scenario, and we must not 
forget the first rule o f medicine to ‘do no harm’. It is possible that there would be an 
opportunity to test the fetus after gene therapy treatment to evaluate its effectiveness 
and to terminate should the prenatal gene therapy have failed. This presents a risk to the 
pregnancy but allows termination o f pregnancy if  no effective gene expression can be 
detected. Such a strategy was used recently in a case report o f in utero stem cell 
transplanation for X-linked SCID in which a couple insisted on evaluation o f stem cell 
engraftment following transplantation (Westgren M et al., 2002). Following 
intraperitoneal injection o f fetal liver cells at 14 weeks o f gestation, analysis o f fetal 
blood at 24 and 33 weeks o f gestation showed 10% and 50% chimerism confirming 
engraftment.
Assuming that a safe and effective prenatal gene therapy approach were to be possible, 
how might it work in practice? We could consider a hypothetical syndrome X, an 
autosomal recessive metabolic condition that results in certain brain damage in an
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affected child with death by school age. Without an effective screening strategy with 
accurate prenatal diagnosis for syndrome X, many families would not know that they 
were at risk until an affected child was born. For the next pregnancy the parents would 
have five options: (1) take a 1:4 chance o f having an affected baby, (2) prenatal 
diagnosis and continuation o f or (3) termination o f an affected child, (4) prenatal gene 
therapy o f an affected child and (5) preimplantation genetic diagnosis (PGD) resulting 
in a pregnancy with an unaffected child. Option (4) would require diagnosis of 
syndrome X in the fetus prior to the gestational age for optimum gene therapy treatment 
probably by chorionic villus sampling. The mother would undergo the invasive 
procedure to treat the fetus and might have further invasive testing to confirm gene 
transfer later in the pregnancy. For the more common genetic disorders such as cystic 
fibrosis an effective and comprehensive prenatal screening policy would need to be 
implemented. Preimplantation genetic diagnosis (option 5) is often proposed as the most 
sensible option for parents at risk o f having an affected fetus. This would require in 
vitro fertilization (IVF) to generate a number o f embryos to the blastocyst stage when 
one or two cells (blastomeres) would be removed and tested for syndrome X. Only 
unaffected embyros would then be transferred back to the mother resulting in a 
pregnancy in which the fetus is not affected. The main limitations o f IVF and PGD are 
the ovulation induction and invasive procedures that the woman is required to have, that 
only 20-30% o f couples achieve a pregnancy per cycle (Wells D and Delhanty JD,
2001) and that some embryos will be disposed of which for some individuals is of 
concern (Snowdon C and Green JM, 1997).
One criticism levelled at prenatal gene therapy is a belief that couples pregnant with an 
affected child would be unlikely to proceed with prenatal gene therapy and would opt 
for a termination instead. There is almost no research in this area however and the views 
o f the general public and patient groups need to be solicited as this technology comes 
closer to the clinic. The general public remains concerned that ethical discussion about 
issues such as gene therapy, cloning and the Human Genome Project are falling behind 
the technology (Brown P, 2000). It is therefore important to provide adequate 
information that will allow the public to understand the risks and benefits o f these novel 
techniques and to enable an educated involvement in the decision-making process along 
with health professionals. This will also help individuals to give informed consent as 
these procedures become used in clinical practice.
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/ 5 Future work
This work has clearly demonstrated the value o f the fetal sheep model for investigation 
o f ultrasound guided delivery o f prenatal gene therapy. We adapted and applied many 
techniques used in clinical fetal medicine practise, and for these routes such as umbilical 
vein, intraperitoneal, intrahepatic and intramuscular injection, further experiments will 
be performed when a suitable long-term integrative vector becomes available.
We also developed new injection methods to target organ systems that had previously 
not been reached using ultrasound guidance and more evaluation o f these procedures is 
required. For the intraventricular route further work is needed to ascertain the 
reproducibility o f this injection technique as well as to study its long term effect on the 
fetus and neonate. For the intragastric and intratracheal routes, the long term morbidity 
and mortality o f the injection procedures should be studied, together with the effects of 
DEAE dextran, sodium caprate and perflubron. The earliest gestational age limit for 
safe intratracheal injection also needs to be better defined. The ultrasound view o f the 
stomach in the sheep and human fetus is very similar so that it is likely that intragastric 
injection in the human fetus will be technically comparable. For intratracheal injection 
however, the shape and structure o f the thorax and trachea in the sheep and human fetus 
differ considerably. Before clinical application can be considered the dimensions o f the 
human fetal trachea and its relations to the great vessels need to be evaluated further in 
longitudinal section. We are currently undertaking such a study in the Fetal Medicine 
Unit at University College London and assessing how feasible transthoracic injection of 
the trachea would be. Having placed a balloon in the fetal trachea, future experiments 
are planned to ascertain whether occluding the trachea enhances adenovirus gene 
transfer further.
The lack o f  stem cell transduction in the intestinal crypts requires further investigation. 
Firstly to detect vector presence in the crypts and to determine whether the stem cells 
are transduced but unable to express the transgenic protein, we have sourced an 
adenovirus vector labelled with a fluorescent protein (EGFP) in its capsid (Le LP et al., 
2004). We are also planning some ex vivo small bowel experiments to quantify the 
effect o f luminal distension on gene transfer to the intestinal crypts.
Long term gene transfer by application o f an integrative vector to the fetal sheep would 
allow us to show proof o f principle for tolerance after prenatal gene transfer. Our results 
clearly show that EIAV lentivirus vectors pseudotyped with VSV-G protein are unable 
to mediate gene transfer in the early gestation sheep fetus. We are currently
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investigating integration o f the viral backbone in fetal tissues to determine whether the 
lack o f gene transfer was related to viral infection o f tissues. Pseudotyping with other 
envelope proteins such as those from the rhabdoviruses rabies and Mokola may be less 
toxic to the fetal sheep (Rohll JB et al., 2003). Retrovirus vectors have been 
successfully applied in the fetal sheep (Porada CD et al., 1998) but their use is limited 
by their inability to transduce non-dividing cells. Alternative lentivirus vectors based on 
feline, simian or bovine immunodeficiency viruses are available. In addition vectors 
based on Visna lentivirus (Berkowitz RD et al., 2001) or Jaagsiekte retrovirus (Liu SL 
et al., 2004) that are both naturally occuring sheep viral infections, are being developed 
and may be more suitable for use in the fetal sheep, although it should not be forgotten 
that the overall aim is for long-term integration into human cells for clinical application. 
Another strategy is to combine the high infectivity o f adenovirus with the longer 
duration o f expression from lentivirus in a hybrid vector. The adenovirus particles are 
used to infect cells and deliver the genes necessary to produce a lentivirus vector 
containing the required transgene for a short time, that can then transduce the 
surrounding cells (Kubo S and Mitani K, 2003). Such adeno-lentivirus hybrid vectors 
are being constructed by our team and may be available for use in the fetal sheep after 
testing in the fetal mouse.
330
APPENDICES
Appendix 1: General Chemicals and Reagents
acetic acid BDH Laboratory Supplies, Poole, UK
agarose low melting point (LMP) Gibco BRL, Life Technologies, Paisley, 
Scotland
agarose ultrapure electrophoresis grade Gibco Gibco BRL, Life Technologies, 
Paisley, Scotland
amoxycillin trihydrate Norbrook Laboratories Ltd, Newry, NI
benzylalcohol Sigma Chemical Co, St Louis, MD, USA
benzyl benzoate Sigma Chemical Co, St Louis, MD, USA
bromophenol blue Sigma Chemical Co, St Louis, MD, USA
caesium chloride Sigma Chemical Co, St Louis, MD, USA
calcium chloride BDH Laboratory Supplies, Poole, UK
chloroform BDH Laboratory Supplies, Poole, UK
Chronogest® (flugestone acetate) Intervet UK Ltd, Milton Keynes, UK
dexamethasone Sigma Chemical Co, St Louis, MD, USA
dimethylsulfoxide (DMSO) Sigma Chemical Co, St Louis, MD, USA
dithiothreitol (DTT) Sigma Chemical Co, St Louis, MD, USA
100 bp DNA ladder Gibco BRL, Life Technologies, Paisley, 
Scotland
1Kb DNA ladder Gibco BRL, Life Technologies, Paisley, 
Scotland
DNase Gibco BRL, Life Technologies, Paisley, 
Scotland
ethanol BDH Laboratory Supplies, Poole, UK
ethidium bromide Sigma Chemical Co, St Louis, MD, USA
ethylenediaminetetraacetic acid (EDTA) BDH Laboratory Supplies, Poole, UK
Folligon® (Pregnant Mares Serum 
Gonadotrophin)
Intervet UK Ltd, Milton Keynes, UK
formaldehyde BDH Laboratory Supplies, Poole, UK
gelatine Merck KGaA, Darmstadt, Germany
glutaraldehyde Sigma Chemical Co, St Louis, MD, USA
glycerol BDH Laboratory Supplies, Poole, UK
halothane Merial, Essex UK
Heptavac-P plus® Hoechst Roussel Vet Limited, Dublin
human Factor IX Haematologic Technologies Inc, Vermont, 
USA
hydrochloric acid BDH Laboratory Supplies, Poole, UK
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hydrogen peroxide Fluka, Sigma Aldrich, Switzerland
insulin Sigma Chemical Co, St Louis, MD, USA
isopropranol BDH Laboratory Supplies, Poole, UK
L-glutamine (tracheal culture Lisa) Gibco BRL, Life Technologies, Paisley, 
Scotland
magnesium chloride Sigma Chemical Co, St Louis, MD, USA
methanol BDH Laboratory Supplies, Poole, UK
mineral oil Sigma Chemical Co, St Louis, MD, USA
NCTC-135 Sigma Chemical Co, St Louis, MD, USA
dNTPs set (ultrapure) Amersham Pharmacia Biotech Inc
orange G dye BDH Laboratory Supplies, Poole, UK
ortho-phenylenediamine Sigma Chemical Co, St Louis, MD, USA
paraformaldehyde BDH Laboratory Supplies, Poole, UK
pentobarbitone Rhone Merieux, Essex UK
PCR primers o f the AdRSVGgal virus 
(first round and nested)
Genosys Biotechnologies Ltd, Pampisford
PCR primers o f the human factor IX 
transgene (first round and nested)
Genosys Biotechnologies Ltd, Pampisford
PCR primers o f the endogenous sheep 
sequence 3'UT o f scavenger receptor 
class B type 1 (SRB1)
originally provided by Dr Jill Maddox, Centre 
for Animal Biotechnology, University of 
Melbourne, Australia
phenol (equilibrated to pH 7.9) Sigma Chemical Co, St Louis, MD, USA
potassium ferricyanide Sigma Chemical Co, St Louis, MD, USA
potassium ferrocyanide Sigma Chemical Co, St Louis, MD, USA
povidone iodine antiseptic solution Grampian Pharmaceuticals Ltd, UK
procaine hydrochloride Arnolds Veterinary Products Ltd, UK
progesterone sponges Intervet UK Ltd, Milton Keynes, UK
proteinase K Gibco BRL, Life Technologies, Paisley, 
Scotland
Ram Raddle® Net Tex Agricultural Ltd, Kent, UK
Rnase Gibco BRL, Life Technologies, Paisley, 
Scotland
normal saline (0.9% w/v) sodium 
chloride
Martindale Pharmaceuticals, Essex UK
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sodium acetate BDH Laboratory Supplies, Poole, UK
sodium chloride BDH Laboratory Supplies, Poole, UK
sodium hydroxide BDH Laboratory Supplies, Poole, UK
sodium thiopentone Merial, Essex UK
sodium dodecyl sulphate (SDS) Sigma Chemical Co, St Louis, MD, USA
sodium phosphate (anhydrous and 
monohydrate)
Sigma Chemical Co, St Louis, MD, USA
sucrose BDH Laboratory Supplies, Poole, UK
sucrose buffer Sigma Chemical Co, St Louis, MD, USA
sulphuric acid Sigma Chemical Co, St Louis, MD, USA
Super Ewe & Lamb UFAS compound 
feed
J & W Atlee Ltd, Dorking, Surrey, UK
Taq DNA polymerase Sigma Chemical Co, St Louis, MD, USA
Transfectam® Reagent (DOGS, 
dioctadecylamidoglycyl spermine)
Promega Corp., San Luis Obispo, CA, USA
tris (hydroxymethyl) methylamine BDH Laboratory Supplies, Poole, UK
trypsin Difco Laboratories, Detroit, USA
ultrasound coupling medium Electro Medical Supplies Ltd, Oxon UK
X-gal (5-bromo-4-chloro-3-indoyl-p-D- 
(galactopyranoside)
Melford Laboratories Ltd, Ipswich, UK
xylene Genta Medical, York, UK
Mammalian cell lines
293 cells human embryonic kidney
NIH 3T3 cells mouse fibroblast
HeLa cells human cervical epithelial
HT 1080 cells human fibrosarcoma
HBE human bronchial epithelial
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Tissue culture media and equipment
100mm x 20mm cell culture dishes Coming Inc, New York, USA
Nunclon™ 75 cm3 triple flasks Nalge Nunc International, Denmark
75 cms cell culture flask Corning Inc, New York, USA
6 well cell culture cluster plates Coming Inc, New York, USA
24 well cell culture cluster plate Coming Inc, New York, USA
bovine serum albumin Sigma Chemical Co, St Louis, MD, USA
Dulbecco’s Modified eagle media 
(D-Mem) with glutamax-1, glucose and 
pyridoxine
Gibco, Invitrogen Corporation, Paisley, 
Scotland
fetal calf serum (FCS) Gibco, Invitrogen Corporation, Paisley, 
Scotland
penicillin/streptomycin (10,000 Units/ml 
penicillin G sodium and 10,000 pg/ml 
streptomycin sulfate in 0.85% saline
Gibco, Invitrogen Corporation, Paisley, 
Scotland
cell culture dish 100mm x 20mm Coming Inc, New York, USA
1 x phosphate buffered saline (PBS) 
without calcium, magnesium and sodium 
bicarbonate
Gibco, Invitrogen Corporation, Paisley, 
Scotland
trypsin-EDTA Gibco, Invitrogen Corporation, Paisley, 
Scotland
Commercial kits:
P-galactosidase ELISA kit Roche Diagnostics GmBH, Mannheim, 
Germany
First-Strand cDNA synthesis kit Amersham Pharmacia Biotech Inc, Bucks
Asserachrom IX ELISA kit Diagnostica Stago, Asnieres-sur-Seine, 
France
Wright-Giemsa stain Shandon Inc, Pittsburgh, PA
bicinchoninic acid (BCA) protein assay kit Pierce, Rockford, USA
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Histology and immunohistochemistry reagents and equipment
mouse anti-pgalactosidase antibody 
(primary antibody for (3-gal immuno)
Promega, Madison, USA
biotinylated goat anti-mouse antibody 
(secondary antibody for P-gal immuno)
Dako, Cambridge, UK
rabbit anti-human factor IX antibody 
(primary antibody for human FIX immuno)
Dako, Cambridge, UK
swine anti-rabbit antibody (secondary 
antibody for human FIX immuno)
Dako, Cambridge, UK
mouse anti-BrdU antibody (primary 
antibody for BrdU immuno)
Dako, Denmark
rabbit anti-mouse antibody (secondary 
antibody for BrdU immuno)
Dako, Denmark
5% non-immune serum Dako, Cambridge, UK
avidin egg white
biotin skimmed milk
peroxidase-labelled streptavidin Roche, Mannheim, Germany
diaminobenzidine tetrahydrochloride Sigma Chemical Co, St Louis, MD, USA
Enzyme-linked immunosorbent assay (ELISA) equipment and reagents
cross-reactive goat anti-adenovirus antibody Skybio, Bedford, UK
horseradish peroxidase labelled rabbit anti­
sheep IgG
DAKO, Cambs, UK
cross-reactive goat anti-human factor IX 
antibody
Skybio, Bedford, UK
cross-reactive sheep anti-P-galactosidase 
antibody
Biogenesis, Poole, UK
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Appendix 2: Solutions
1 litre 0.5 M EDTA (pH 8.0)
186.1 g 186.1gNa2EDTA.2H20
approximately 50ml adjust pH to 8.0 with 10 M sodium hydroxide
make up to 1 litre total volume distilled water
1 litre 0.1 M Tris HC1 (pH 8.0)
12.lg tris base
58.4ml hydrochloric acid
make up to 1 litre total volume distilled water
Tris-EDTA (TE) buffer pH 8.0 (100ml)
200pl 0.5 M EDTA (pH 8.0)
10ml 0.1 M Tris HC1 (pH 8.0)
make up to 100ml total volume distilled water
Proteinase K Buffer (500ml)
25ml 1 M Tris pH 8.0
100ml 5 M EDTA
10ml 5 M NaCl
5ml 10% SDS
360ml distilled water
500ml 50x Electrophoresis (TAE) buffer pH 8.0
121 g Tris
50ml 0.5M EDTA
28.5ml acetic acid
make up to 500ml total volume Distilled water
DNA gel loading buffer
30% v/v glycerol
0.25% w/v bromophenol blue
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PCR gel loading buffer
30% v/v glycerol
0.25% w/v orange G
Fix solution for cell culture
400ml PBS
10ml formaldehyde
32ml glutaraldehyde
Caesium chloride solutions for adenovirus purification
Heavy solution (density = 1.40g/ml) 62 g CsCl in 100ml lOmM Tris pH 8.0
Medium solution (density = 1.34g/ml) 51.20g CsCl in 100ml lOmM Tris pH 8.0
Light solution (density = 1.25g/ml) 36.16g CsCl in 100ml lOmM Tris pH 8.0
2x sucrose buffer (100ml) for adenovirus purification
0.24g Tris
200pl IM M gC h
1.75g NaCl
68.46g sucrose
Sucrose buffer (51) for adenovirus purification
6g Tris
0.5g MgCl2
43.8g NaCl
1711.5g Sucrose
250mg 10% Tween-80
4% paraformaldehyde in PBS pH 7.4 (500ml)
0.71g Anhydrous Na2H P04
0.69g Monohydrate Na2H P04
4.5g NaCl
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Appendix 3: Post mortem form
Date: Animal No:
Fetal measurements:
Crown Rump Length: 
Biparietal Diameter: 
Occipito-snout Length: 
Post mortem findings:
Code:
Fetal Weight:
Femur Length:
Abdominal Circumference:
Photographs taken: 
Bloods taken:
Fetal Blood Count 
Fluids taken:
Other tissues taken:
Maternal Serum 
Fetal Serum
Fetal Biochemistry/LFT 
Gastric fluid (GC) 
Tracheal fluid (TF)
Maternal Plasma 
Fetal Plasma 
Fetal Clotting (RVC) 
Frozen Fresh
Frozen Fresh
Bronchoalveolar lavage (BALF) Fresh
Tissue samples to be collected from the MOTHER:
code frozen/formalin
Blood E-B
Lung E-AU
Heart E-H
Ovary E-G
Brain E-NC
Liver E-L
Adrenal E-D
Kidney E-K
Spleen E-X
Thymus E-T
Tissue samples to be collected from the FETUS:
code frozen/formalin
0.) Placenta P
Umbilical cord U
Amniotic Fluid F
1 ) Blood (serum & plasma) B
Bone Marrow W
2.) Buccal Cavity/Oesophagus
Soft palate O-P
Tongue, lower part O-T
Oesophagus, upper part O-U
at diaphragm O-L
3.) Airways and Neighbouring Organs wt: (trachea <
Thyroid wt: Y
Thymus wt: T
Epiglottis A-E
Vocal cords A-L
Trachea at 3 levels towards bifurcation A -Tl A-T2 A-T3
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Pleura visceralis A-A
Bronchial tree, samples from both sides A-BR1 A-BL1
Blocks from each lobe o f the lung A-UR1 A-UR2 A-UR3
(upper = 1, middle = 2, lower = 3) A-UL1 A-UL3
Diaphragm I
4.) C ardiovascular System
Aorta H-A
Pericardium H-C
Pulmonary artery H -P l
Blocks from each chamber o f the heart H-LA H-LV
(atrium = 1, ventricle = 2) H-RA H-RV:
wt:
5.) G astro  Intestinal System and Neighbouring O rgans
Pancreas C-P
Stomach, Rumen C-A
Reticulum C-BI
Abomasum C-B2
Omasum C-B3
Duodenum C-D
Jejunum C -J
Small Bowel at 3 levels CS-1 CS-2 CS-3
Caecum C-C
Colon transversum C-T
Rectum C-R
Spleen wt: X
6.) Liver wt:
Portal system L-P
Area where hepatic vein joins vena cava L-H
Gall Bladder wt: L-G
Blocks from each lobe o f the liver L-R L-C L-L
7.) G onads wt: G Female M ale
8.) U rinary  T rac t & Neighbouring O rgans
Adrenal glands wt: D-L D-R
Kidney wt: K
Bladder Z
9.) Muscle M
or where muscle taken in parts M u-R l M u-R2
M u-L l M u-L2
10.) Skin S
Abdominal wall AW
11.) B rain &  Neighbouring Organs
Cortex N-C
Medulla oblongata N-M
Basal ganglia N-B
Pituitary gland N-P
Nasal sinuses A-N
Skull S-K
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Appendix 4: Publications 
Original Papers
Peebles D, Gregory LG, David A. Themis M, Waddington SN, Knapton HJ, Miah M, 
Cook T, Lawrence L, Nivsarkar M, Rodeck C, Coutelle C
Widespread and efficient marker gene expression in the airway epithelia o f fetal sheep 
after minimally invasive tracheal application o f recombinant adenovirus in utero.
Gene Therapy 2004;11:70-8
David AL. Peebles DM, Gregory L, Themis M, Cook T, Coutelle C, Rodeck CH 
Percutaneous ultrasound-guided injection o f the trachea in fetal sheep: a novel 
technique to target the fetal airways.
Fetal Diagnosis and Therapy 2003;18:385-390
David A. Cook T, Waddington S, Peebles D, Nivsarkar M, Knapton H, Miah M, Dahse 
T, Noakes D, Schneider H, Rodeck C, Coutelle C, Themis M 
Ultrasound guided percutaneous delivery o f adenovirus vectors encoding the 0- 
galactosidase and human factor IX genes to early gestation fetal sheep in utero.
Human Gene Therapy 2003;14:353-364
David AL. Peebles DM, Gregory L, Waddington SN, Themis M, Weisz B, Ruthe A, 
Perocheau D, Lawrence L, Cook T, Rodeck CH and Coutelle C Reporter gene delivery 
to the fetal gut by ultrasound-guided gastric injection towards prenatal prevention o f 
cystic fibrosis intestinal pathology.
Submitted
David AL. Weisz B, Roubilova X, Perocheau D, Themis M, Cook T, Coutelle C, 
Deprest J, Rodeck CH and Peebles DM
Ultrasound-guided tracheal occlusion using a detachable inflatable balloon in the fetal 
sheep model.
Submitted
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Review Articles
David AL. Themis, Rodeck C
Fetal gene therapy: the present and the prospects.
Yearbook o f  Obstetrics and Gynaecology 2004, RCOG Press, London
David AL. Themis M, Waddington SN, Gregory L, Buckley SMK, Nivsarkar M, Cook
T, Peebles D, Rodeck CH, Coutelle C
The current status and future direction o f fetal gene therapy.
Gene Therapy and Molecular Biology 2003 ;7:181 -209
Coutelle C, Themis M, Waddington S, Gregory L, Nivsarkar M, Buckley S, Cook T, 
Rodeck C, Peebles D, David A
The hopes and fears o f in utero gene therapy for genetic diseases -  a review.
Placenta 2003;24:S114-S121
David AL. Themis M, Cook T, Coutelle C, Rodeck C 
Fetal gene therapy.
The Ultrasound Review o f  Obstetrics & Gynaecology 2001; 1:14-27
341
REFERENCES
References
Acosta R, Lee JJ, Oyachi N, Buchmiller-Crair TL, Atkinson JB, Ross MG. 
Anticholinergic suppression o f fetal rabbit upper gastrointestinal motility. Journal of 
Maternal Fetal and Neonatal Medicine 2002; (11): 153-157.
Acsadi G, Jani A, Massie B, Simoneau M, Holland P, Blaschuk K, Karpati G. A 
differential efficiency o f adenovirus-mediated in vivo gene transfer into skeletal muscle 
cells o f different maturity. Human Molecular Genetics 1994; (3): 579-584.
Adamson TM, Boyd RDH, Platt HS, Strang LB. Composition o f alveolar liquid in the 
fetal lamb. Journal o f Physiology 1969; (204): 159-168.
Aiumlamai S, Fredriksson G, Nilsfors L. Real-time ultrasonography for determining the 
gestational age o f ewes. The Veterinary Record 1992; (131): 560-562.
Akli S, Caillaud C, Vigne E, Stratford-Perricaudet LD, Poenaru L, Perricaudet M, Kahn
A, Peschanski MR. Transfer o f a foreign gene into the brain using adenovirus vectors. 
Nature Genetics 1993; (3): 224-228.
Al Salami M, Simpson-Morgan MW, Morris B. Haemopoiesis and the development o f 
immunological reactivity in the sheep foetus. In: Immunology o f the sheep. (Eds.Morris
B, M iyasakaM). Basel: Roche, 1985; 1st: 19-36.
Alfirevic Z, Sundberg K, Brigham S. Amniocentesis and chorionic villus sampling for 
prenatal diagnosis. Cochrane Database o f Systematic Reviews 2003;CD003252.
Alsalami MT, Filippich LJ. Haematology o f foetal sheep. Australian Veterinary Journal 
1999; (77): 588-594.
Anderberg EK, Lindmark T, Artursson P. Sodium caprate elicits dilatations in human 
intestinal tight junctions and enhances drug absorption by the paracellular route. 
Pharmacological Research 1993; (10): 857-864.
Anwer MS, Engelking LR, Gronwall R, Klentz RD. Plasma bile acid elevation 
following carbon tetrachloride induced liver damage in dogs, sheep, calves and ponies. 
Research in Veterinary Science 1976; (20): 127-130.
Arcasoy SM, Latoche J, Gondor M, Watkins SC, Henderson RA, Hughey R, Finn OJ, 
Pilewski JM. MUC1 and other sialoglycoconjugates inhibit adenovirus-mediated gene 
transfer to epithelial cells. Am J Respir Cell Mol Biol 1997a; (17): 422-435.
Arcasoy SM, Latoche JD, Gondor M, Pitt BR, Pilewski JM. Polycations increase the 
efficiency o f  adenovirus-mediated gene transfer to epithelial and endothelial cells in 
vitro. Gene Therapy 1997b; (4): 32-38.
Arenas R B, Fichera A, Mok P, Blanco M C, Michelassi F. Introduction o f human 
adenomatous polyposis coli gene into Min mice via cationic liposomes. Surgery 1996; 
(120): 712-717.
342
REFERENCES
References
Ultrasound in obstetrics and gynaecology. Churchill Livingstone, London 2002.
Acosta R, Lee JJ, Oyachi N, Buchmiller-Crair TL, Atkinson JB, Ross MG. 
Anticholinergic suppression o f fetal rabbit upper gastrointestinal motility. Journal of 
Maternal Fetal and Neonatal Medicine 2002; (11): 153-157.
Acsadi G, Jani A, Massie B, Simoneau M, Holland P, Blaschuk K, Karpati G. A 
differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle 
cells o f different maturity. Human Molecular Genetics 1994; (3): 579-584.
Adamson TM, Boyd RDH, Platt HS, Strang LB. Composition o f alveolar liquid in the 
fetal lamb. Journal o f Physiology 1969; (204): 159-168.
Aiumlamai S, Fredriksson G, Nilsfors L. Real-time ultrasonography for determining the 
gestational age o f ewes. The Veterinary Record 1992; (131): 560-562.
Akli S, Caillaud C, Vigne E, Stratford-Perricaudet LD, Poenaru L, Perricaudet M, Kahn
A, Peschanski MR. Transfer o f a foreign gene into the brain using adenovirus vectors. 
Nature Genetics 1993; (3): 224-228.
Al Salami M, Simpson-Morgan MW, Morris B. Haemopoiesis and the development o f 
immunological reactivity in the sheep foetus. In: Immunology o f the sheep. (Eds.Morris
B, Miyasaka M). Basel: Roche, 1985; 1st: 19-36.
Alfirevic Z, Sundberg K, Brigham S. Amniocentesis and chorionic villus sampling for 
prenatal diagnosis. Cochrane Database o f Systematic Reviews 2003;CD003252.
Alsalami MT, Filippich LJ. Haematology o f foetal sheep. Australian Veterinary Journal 
1999; (77): 588-594.
Anderberg EK, Lindmark T, Artursson P. Sodium caprate elicits dilatations in human 
intestinal tight junctions and enhances drug absorption by the paracellular route. 
Pharmacological Research 1993; (10): 857-864.
Anwer MS, Engelking LR, Gronwall R, Klentz RD. Plasma bile acid elevation 
following carbon tetrachloride induced liver damage in dogs, sheep, calves and ponies. 
Research in Veterinary Science 1976; (20): 127-130.
Arcasoy SM, Latoche J, Gondor M, Watkins SC, Henderson RA, Hughey R, Finn OJ, 
Pilewski JM. MUC1 and other sialoglycoconjugates inhibit adenovirus-mediated gene 
transfer to epithelial cells. Am J Respir Cell Mol Biol 1997a; (17): 422-435.
Arcasoy SM, Latoche JD, Gondor M, Pitt BR, Pilewski JM. Polycations increase the 
efficiency o f adenovirus-mediated gene transfer to epithelial and endothelial cells in 
vitro. Gene Therapy 1997b; (4): 32-38.
Arenas R B, Fichera A, Mok P, Blanco M C, Michelassi F. Introduction o f human 
adenomatous polyposis coli gene into Min mice via cationic liposomes. Surgery 1996; 
(120): 712-717.
342
REFERENCES
Arsenault P, Menard D. Cell proliferation in developing human jejunum. Biology o f the 
Neonate 1987; (51): 297-304.
Arsenault P, Menard D. Cell proliferation during morphogenesis o f the human colon. 
Biology o f the Neonate 1989; (55): 137-142.
Asano T, Ageyama N, Takeuchi K, Momoeda M, Kitano Y, Sasaki K, Ueda Y, Suzuki 
Y, Kondo Y, Torii R, Hasegawa M, Ookawara S, Harii K, Terao K, Ozawa K,
Hanazono Y. Engraftment and tumor formation after allogeneic in utero transplantation 
o f primate embryonic stem cells. Transplantation 2003; (76): 1061-1067.
Ascadi G, Jani A, Huard J, Blaschuk K, Massie B, Holland P, Lochmuller H, Karpati G. 
Cultured human myoblasts and myotubes show markedly different transducibility by 
replication-defective adenovirus recombinants. Gene Therapy 1994; (1): 338-340.
Awazu S, Ohnishi T, Aida K, Awaz. Enhancement o f blood-brain barrier permeability 
by sodium caprate. Journal o f Pharm Pharmacology 1999; (51): 1015-1018.
Baconnais S, Tirouvanziam R, Zahm JM, de Bentzmann S, Peault B, Balossier G, 
Puchelle E. Ion composition and rheology of airway liquid from cystic fibrosis fetal 
tracheal xenografts. Am J Respir Cell Mol Biol 1999; (20): 605-611.
Badalian SS, Chao CR, Fox HE, Timor TI. Fetal breathing-related nasal fluid flow 
velocity in uncomplicated pregnancies. American Journal o f Obstetrics and Gynecology 
1993; (169): 563-567.
Bajocchi G, Feldman SH, Crystal RG, Mastrangeli A. Direct in vivo gene transfer to 
ependymal cells in the central nervous system using recombinant adenovirus vectors. 
Nature Genetics 1993; (3): 229-234.
Baldwin HS, Mickanin C, Buck C. Adenovirus-mediated gene transfer during initial 
organogenesis in the mammalian embryo is promoter-dependent and tissue-specific. 
Gene Therapy 1997; (4): 1142-1149.
Balslev Y, Dziegielewska KM, Mollgard K, Saunders NR. Intercellular barriers to and 
transcellular transfer o f albumin in the fetal sheep brain. Anatomy and Embryology 
1997; (195): 229-236.
Bambach BJ, Moser HW, Blakemore K, Corson VL, Griffin CA, Noga SJ, Perlman EJ, 
Zuckerman R, Wenger DA, Jones RA. Engraftment following in utero bone marrow 
transplantation for globoid cell leukodystrophy. Bone Marrow Transplantation 1997; 
(19): 399-402.
Barbera A, Jones OW, Zerbe GO, Hobbins JC, Battaglia FC, Meschia G. 
Ultrasonographic assessment o f fetal growth: Comparison between human and ovine 
fetus. American Journal o f Obstetrics and Gynecology 1995; (173): 1765-1769.
Barbet JP, Labbe S, Maillet M, Schramm B. Scanning electron microscopy o f human 
prenatal muscle development. Bulletin de l'Association des Anatomistes 1987; (71): 15- 
2 1 .
Barcroft J, Barron DH. Observations upon the form and relations o f the maternal and 
fetal vessels in the placenta o f the sheep. Anatomical Record 1946; (94): 569-595.
343
REFERENCES
Bartha A, Mate S. Transplacental transmission o f bovine adenoviruses. Comparative 
Immunology Microbiology and Infectious Diseases 1983; (6): 189-192.
Baschat AA, Towbin J, Bowles NE, Harman CR, Weiner CP. Is adenovirus a fetal 
pathogen? American Journal of Obstetrics and Gynecology 2003; (189): 758-763.
Baumgartner TL, Baumgartner BJ, Hudon L, Moise KJ. Ultrasonographically guided 
direct gene transfer in utero: Successful induction o f p-galactosidase in a rabbit model. 
American Journal of Obstetrics and Gynecology 1999; (181): 848-852.
Bealer JF, Skarsgard ED, Hedrick MH, Meuli M, VanderWall KJ, Flake AW, Adzick 
NS, Harrison MR. The 'PLUG' odyssey: adventures in experimental fetal tracheal 
occlusion. Journal of Pediatric Surgery 1995; (30): 361-364.
Bell JE, Fryer AA, Collins M, Marshall T, Jones PW, Strange R, Hume R. 
Developmental profile of plasma proteins in human fetal cerebrospinal fluid and blood. 
Neuropathology and Applied Neurobiology 1991; (17): 441-456.
Benirschke K, Kaufmann P. Placental types. In: Pathology o f the human placenta. New 
York: Springer-Verlag, 1990.
Bennett M, Galan H, Owens G, Dewey R, Banks R, Hobbins J, Accurso F, Schaack J. 
In utero gene delivery by intraamniotic injection o f a retroviral vector producer cell line 
in a nonhuman primate model. Human Gene Therapy 2001; (12): 1857-1865.
Berkowitz RD, lives H, Plavec I, Veres G. Gene transfer systems derived from Visna 
virus: analysis o f virus production and infectivity. Virology 2001; (279): 116-129.
Bigger B, Coutelle C. Perspectives on gene therapy for cystic fibrosis airway disease. 
Biodrugs 2001; (15): 615-634.
Bilbao R, Reay DP, Hughes T, Biermann V, Volpers C, Goldberg L, Bergelson J, 
Kochanek S, Clemens PR. Fetal muscle gene transfer is not enhanced by an RGD 
capsid modification to high-capacity adenoviral vectors. Gene Therapy 2003a; (10): 
1821-1829.
Bilbao R, Srinivasan S, Reay D, Goldberg L, Hughes T, Roelvink PW, Einfeld DA, 
Wickham TJ, Clemens PR. Binding o f adenoviral fiber knob to the coxsackie- 
adenovirus receptor is crucial for transduction o f fetal muscle. Human Gene Therapy 
2003b; (14): 645-649.
Billingham RE, Brent L, Medawar PB. Actively acquired tolerance o f foreign cells. 
Nature 1953; (172): 603-606.
Billingham RE, Brent L, Medawar PB. Quantitative studies on tissue transplantation 
immunity III Actively acquired tolerance. Philosophical Transactions o f the Royal 
Society: Biological Sciences (London) 1956; (B239): 357-369.
Billings PR. In utero gene therapy. Nature Medicine 1999; (5): 255-256.
Binns R. Bone marrow and lymphoid cell injection o f the pig fetus resulting in 
transplantation tolerance or immunity, and immunoglobulin production. Nature 1967; 
(214): 179-180.
344
REFERENCES
Bimholz JC, Frigoletto FD. Antenatal treatment o f hydrocephalus. New England 
Journal o f Medicine 1981; (304): 1021-1023.
Bissonnette JM, Hohimer AR, Chao CR, Knopp SJ, Notoroberto NF. Theophylline 
stimulates fetal breathing movements during hypoxia. Pediatric Research 1990; (28): 
83-86.
Boddy K, Dawes GS, Fisher R, Pinter S, Robinson JS. Foetal respiratory movements, 
electrocortical and cardiovascular responses to hypoxemia and hypercapnia in sheep. 
Journal o f Physiology 1974; (243): 599-618.
Borck C. The development o f the myo-tendinous junction in the upper extremity of 
mouse embryos (days 15 p.c. - 1 p.p.). Zeitschrift fuer Mikroskopisch-Anatomsiche 
Forschung 1977; (91): 229-240.
Bouchard S, MacKenzie TC, Radu AP, Hayashi S, Peranteau WH, Chirmule N, Flake 
AW. Long-term transgene expression in cardiac and skeletal muscle following fetal 
administration o f adenoviral or adeno-associated viral vectors in mice. Journal o f Gene 
Medicine 2003; (5): 941-950.
Boue A, Muller F, Nezelof C, Oury JF, Duchatel F, Dumez Y, Aubry MC, Boue J. 
Prenatal diagnosis in 200 pregnancies with a 1 -in-4 risk o f cystic fibrosis. Human 
Genetics 1986; (74): 288-297.
Boyle MP, Enke RA, Adams RJ, Guggino WB, Zeitlin PL. In utero AAV-mediated 
gene transfer to rabbit pulmonary epithelium. Molecular Therapy 2001; (4): 115-121.
Brace RA. Regulation o f blood volume in utero. In: The circulation. (Eds.Hanson MA, 
Spencer JAD, Rodeck CH). Cambridge University Press, 1993; 1st: 75-99.
Braithwaite JM, Armstrong MA, Economides DL. Assessment o f fetal anatomy at 12 to 
13 weeks o f gestation by transabdominal and transvaginal sonography. British Journal 
o f  Obstetrics & Gynaecology 1996; (103): 82-85.
Brandt M L, Moise K J J, Eckert J W, Johnson L, Waltrip T, Saade G, Wu Y, Finegold 
M J. Transuterine puncture o f the fetal stomach provides access to the small bowel in 
the rabbit. Journal o f Investigative Surgery 1997c; (10): 41-46.
Brandt M L, Moise K J J, Eckert J W, Johnson L, Waltrip T, Saade G, Wu Y, Finegold 
M J. Transuterine puncture o f the fetal stomach provides access to the small bowel in 
the rabbit. Journal o f Investigative Surgery 1997b; (10): 41-46.
Brandt M L, Moise K J J, Eckert J W, Johnson L, Waltrip T, Saade G, Wu Y, Finegold 
M J. Transuterine puncture o f the fetal stomach provides access to the small bowel in 
the rabbit. Journal o f Investigative Surgery 1997a; (10): 41-46.
Broackes-Carter FC, Mouchel N, Gill D, Hyde S, Bassett J, Harris A. Temporal 
regulation o f CFTR expression during ovine lung development: implications for CF 
gene therapy. Human Molecular Genetics 2002; (11): 125-131.
Brogden KA, Lehmkuhl HD, Cutlip RC. Pasteurella haemolytica complicated 
respiratory infections in sheep and goats. Veterinaiy Research 1998; (29): 233-254.
345
REFERENCES
Bronshtein M, Yoffe N, Zimmer EZ. Transvaginal sonography at 5 to 14 weeks' 
gestation: fetal stomach, abnormal cord insertion, and yolk sac. American Journal of 
Perinatology 1992; (9): 344-347.
Brooks Al, Stein CS, Hughes SM, Heth J, McCray PM, Sauter SL, Johnston JC, Cory- 
Slectha DA, Federoff HJ, Davidson BL. Functional correction o f established central 
nervous system deficits in an animal model o f lysosomal storage disease with feline 
immunodeficiency virus-based vectors. Proceedings o f the National Academy of 
Science o f America 2002; (99): 6216-6221.
Brown P. Regulations not keeping up with developments in genetics, says poll. British 
Medical Journal 2000; (321): 1369.
Buckley SMK, Waddington SN, Jezzard S, Themis M, Colledge WH, Coutelle C. Intra- 
amniotic application o f CFTR-expressing adenovirus does not reverse cystic fibrosis 
phenotype in inbred C//r-knockout mice. Molecular Therapy 2003; (7): S200.
Burger IM, Wilfond BS. Limitations o f informed consent for in utero gene transfer 
research: implications for investigators and institutional review boards. Human Gene 
Therapy 2000; (11): 1057-1063.
Burlet P, Huber C, Bertrandy S, Ludosky MA, Zwaenepoel I, Clermont O, Roume J, 
Delezoide AL, Cartaud J, Munnich A, Lefebvre S. The distribution o f SMN protein 
complex in human fetal tissues and its alteration in spinal muscular atrophy. Human 
Molecular Genetics 1998; (7): 1927-1933.
Bums JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis virus 
G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and 
efficient gene transfer into mammalian and nonmammalian cells. Proceedings o f the 
National Academy o f Science o f America 1993; (90): 8033-8037.
Butler JE, Sun J, Weber P, Ford SP, Rehakova Z, Sinkora J, Lager K. Antibody 
repertoire development in fetal and neonatal piglets. IV. Switch recombination, 
primarily in fetal thymus, occurs independent o f environmental antigen and is only 
weakly associated with repertoire diversification. Journal o f Immunology 2001; (167): 
3239-3249.
Calvin HL, Bedford JM. Formation o f disulphide bonds in the nucleus and accessory 
structures o f mammalian spermatozoa during maturation in the epididymis. Journal o f 
Reproduction and Fertility: Supplement 1971; (13): 65-67.
Cambria S, Gambardella G, Cardia E, Cambria M, Labianca M. Experimental 
hydrocephalus in the fetus in utero I-IV. Chirurgia Patologia Sperimentale 1979; (27): 
256-272.
Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, 
Naldini L, Kohn DB, Crooks GM. Stable transduction o f quiescent CD34(+)CD38(-) 
human hematopoietic cells by HIV-1-based lentiviral vectors. Proceedings o f the 
National Academy o f Science o f America 1999; (96): 2988-2993.
Cavalheiro S, Moron AF, Zymberg ST, Dastoli P. Fetal hydrocephalus - prenatal 
treatment. Child's Nervous System 2003; (19): 561-573.
346
REFERENCES
Cavanagh ME, Cornelis ME, Dziegielewska KM, Evans CA, Lorscheider FL, Mollgard 
K, Reynolds ML, Saunders NR. Comparison o f proteins in CSF o f lateral and IVth 
ventricles during early development o f fetal sheep. Brain Research 1983; (313): 159- 
167.
CEMAT group. Randomised trial to assess safety and fetal outcome o f early and 
midtrimester amniocentesis. The Canadian Early and Mid-trimester Amniocentesis Trial 
(CEMAT) Group. Lancet 1998; (351): 242-247.
Challita PM, Kohn DB. Lack o f expression from a retroviral vector after transduction of 
murine hematopoietic stem cells is associated with methylation in vivo. Proceedings o f 
the National Academy o f Science o f America 1994; (91): 2567-2571.
Chao AC, Nguyen JV, Broughall M, Griffin A, Fix JA, Daddona PE. In vitro and in 
vivo evaluation o f effects o f sodium caprate on enteral peptide absorption and on 
mucosal morphology. International Journal o f Pharmaceutics 1999; (191): 15-24.
Chao H, Samulski RJ, Bellinger D, Monahan PE, Nichols T, Walsh CE. Persistent 
expression o f canine factor IX in hemophilia B canines. Gene Therapy 1999; (6): 1695- 
1704.
Charles JA. Akabane virus. Veterinary Clinics o f North America Food Animal Practice 
1994; (10): 525-546.
Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR. Persistence in 
muscle o f an adenoviral vector that lacks all viral genes. Proceedings o f the National 
Academy o f Science o f America 1997; (94): 1645-1650.
Cheng H. Origin, differentiation and renewal o f the four main epithelial cell types in the 
mouse small intestine. IV. Paneth cells. American Journal o f Anatomy 1974; (141): 
521-535.
Cheng H, Bjerknes M. Whole population cell kinetics and postnatal development o f the 
mouse intestinal epithelium. Anatomical Record 1984; (211): 420-426.
Cheng H, Leblond CP. Origin, differentiation and renewal o f the four main epithelial 
cell types in the mouse small intestine. I - III. American Journal o f Anatomy 1974; 
(141): 461-520.
Cheng SH, Smith AE. Gene therapy progress and prospects: gene therapy o f lysosomal 
storage disorders. Gene Therapy 2003; (10): 1275-1281.
Cheng X, Ming X, Croyle MA. PEGylated adenoviruses for gene delivery to the 
intestinal epithelium by the oral route. Pharmaceutical Research 2003; (20): 1444-1451.
Cheng D Y, Kolls J K, Lei D, Noel R A. In vivo and in vitro gene transfer and 
expression in rat intestinal epithelial cells by El-deleted adenoviral vector. Human Gene 
Therapy 1997a; (8): 755-764.
Cheng D Y, Kolls J K, Lei D, Noel R A. In vivo and in vitro gene transfer and 
expression in rat intestinal epithelial cells by El-deleted adenoviral vector. Human Gene 
Therapy 1997b; (8): 755-764.
347
REFERENCES
Chervenak FA, McCullough LB. A comprehensive ethical framework for fetal research 
and its application to fetal surgery for spina bifida. American Journal o f Obstetrics and 
Gynecology 2002; (187): 10-14.
Cheung WF, van den Bom J, Kuhn K, Kjellen L, Hudson BG, Stafford DW. 
Identification o f the endothelial cell binding site for factor IX. Proceedings o f the 
National Academy o f Science o f America 1996; (93): 11068-11073.
Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to 
adenovirus and adeno-associated virus in humans. Gene Therapy 1999; (6): 1574-1583.
Christensen G, Minamisawa S, Gruber PJ, Wang Y, Chien KR. High-efficiency, long­
term cardiac expression o f foreign genes in living mouse embryos and neonates. 
Circulation 2000; (101): 178-184.
Cloete JHL. Prenatal growth in the merino sheep. Onderstepoort Journal o f Veterinary 
Science and Animal Industry 1939; (13): 417-557.
Collins FS, Watson JD. Genetic discrimination: time to act. Science 2003; (302): 745.
Colony PC, Neutra MR. Macromolecular transport in the fetal rat intestine. 
Gastroenterology 1985; (89): 294-306.
Cooke IRC, Berger PJ. Precursor o f respiratory pattern in the early gestation 
mammalian fetus. Brain Research 1990; (522): 333-336.
Cosmi EV, La Torre R, Di Iorio R, Anceschi MM. Surfactant administration to the 
human fetus in utero: a new approach to prevention o f neonatal respiratory distress 
syndrome (RDS). Journal o f Perinatal Medicine 1996; (24): 191-193.
Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. High-titer packaging cells 
producing recombinant retroviruses resistant to human serum. Journal o f Virology 
1995; (69): 7430-7436.
Coutelle C, Rodeck C. On the scientific and ethical issues o f fetal somatic gene therapy. 
Gene Therapy 2002; (9): 670-673.
Coyne CB, Kelly MM, Boucher RC, Johnson LG. Enhanced epithelial gene transfer by 
modulation o f tight junctions with sodium caprate. Am J Respir Cell Mol Biol 2000; 
(23): 602-609.
Crawford I, maloney PC, Zeitlin PL, Guggino WB, Hyde SC, Turley H, Gatter KC, 
Harris A, Higgins CF. Immunocytochemical localization o f the cystic fibrosis gene 
product CFTR. Proceedings o f the National Academy o f Science o f  America 1991;
(88): 9262-9266.
Croyle MA, Roessler BJ, Hsu CP, Sun R, Amidon GL. Beta cyclodextrins enhance 
adenoviral-mediated gene delivery to the intestine. Pharmaceutical Research 1998; (15): 
1348-1355.
Cukrowska B, Sinkora J, Rehakova Z, Sinkora M, Splichal I, Tuckova L, Avrameas S, 
Barot-Ciorbaru R, Tlaskalova-Hogenova H. Isotype and antibody specificity o f 
spontaneously formed immunoglobulins in pig fetuses and germ-free piglets: production 
by CD5- B cells. Immunology 1996; (88): 611-617.
348
REFERENCES
Daffos F, Capella-Pavlovsky M, Forestier F. A new procedure for fetal blood sampling 
in utero: preliminary results of 53 cases. American Journal o f Obstetrics and 
Gynecology 1983; (146): 985-987.
Daffos F, Capella-Pavlovsky M, Forestier F. Fetal blood sampling during pregnancy 
with use o f a needle guided by ultrasound: a study o f 606 consecutive cases. American 
Journal o f Obstetrics and Gynecology 1985; (153): 655-660.
Daly TM, Vogler C, Levy B, Haskins ME, Sands MS. Neonatal gene transfer leads to 
widespread correction o f pathology in a murine model o f lysosomal storage disease. 
Proceedings o f the National Academy o f Science o f America 1999; (96): 2296-2300.
Darrasse-Jeze G, Marodon G, Salomon BL, Catala M, Klatzmann D. Ontogeny of 
CD4+CD25+ regulatory/suppressor T cells in human fetus. Blood 2005; (105): 4715- 
4721.
de Vries JIP, Visser GHA, Prechtl HFR. Fetal behaviour in early pregnancy. European 
Journal o f Obstetrics, Gynecology and Reproductive Medicine 1986; (21): 271-276.
Denker BM, Nigam SK. Molecular structure and assembly o f the tight junction. 
American Journal o f Physiology 1998; (274): F1-F9.
Dennis SM. Congenital defects o f sheep. Veterinary Clinics o f  North America Food 
Animal Practice 1993; (9): 203-217.
Deprest J, Gratacos E, Nicolaides K. Fetoscopic tracheal occlusion (FETO) for severe 
congenital diaphragmatic hernia: evolution o f a technique. Ultrasound in Obstetrics and 
Gynaecology 2004; (24): 121-126.
Deprest JA, Evrard VE, Van Ballaer PP, Verbeken E, Vandenberghe K, Lerut TE, 
Flageole H. Tracheoscopic endoluminal plugging using an inflatable device in the fetal 
lamb model. European Journal o f Obstetrics, Gynecology and Reproductive Medicine 
1997a; (81): 165-169.
Deprest JA, Lerut TE, Vandenberghe K. Operative fetoscopy: new perspective in fetal 
therapy? Prenatal Diagnosis 1997b; (17): 1247-1260.
Ding Z, Harding CO, Thony B. State-of-the-art 2003 on PKU gene therapy. Molecular 
Genetics and Metabolism 2003; (81): 3-8.
Douar A-M, Adebakin S, Themis M, Pavirani A, Cook T, Coutelle C. Foetal gene 
delivery in mice by intra-amniotic administration o f retroviral producer cells and 
adenovirus. Gene Therapy 1997; (4): 883-890.
Douar A-M, Themis M, Sandig V, Friedmann T, Coutelle C. Effect o f amniotic fluid on 
cationic lipid mediated transfection and viral infection. Gene Therapy 1996; (3): 789- 
796.
Driskell RA, Engelhardt J. Current status o f gene therapy for inherited lung diseases. 
Annual Review o f Physiology 2003; (65): 585-612.
Drobniewski FA. Bacillus cereus and related species. Clinical Microbiological Reviews 
1993; (6): 324-338.
349
REFERENCES
Duan D, Sehgal A, Yao J, Engelhardt J F. Lefl Transcription Factor Expression Defines 
Airway Progenitor Cell Targets for In Utero Gene Therapy o f Submucosal Gland in 
Cystic Fibrosis. American Journal o f Respiratory Cell and Molecular Biology 1998; 
(18): 750-758.
Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A third- 
generation lentivirus vector with a conditional packaging system. Journal o f Virology 
1998; (72): 8463-8471.
Dyce KM, Sack WO, Wensing CJG. Textbook o f veterinary anatomy. Saunders, 
Philadelphia 2002.
Dziegielewska KM, Evans CA, Malinowska DH, Mollgard K, Reynolds JM, Reynolds 
ML, Saunders NR. Studies o f the development o f brain barrier systems to lipid 
insoluble molecules in fetal sheep. Journal o f Physiology 1979; (292): 207-231.
Edelstone DI, Rudolph AM, Heymann MA. Liver and ductus venosus blood flows in 
fetal lambs in utero. Circulation Research 1978; (42): 426-433.
Ekhterae D, Crumbleholme T, Karson E, Harrison MR, Anderson WF, Zanjani ED. 
Retroviral vector-mediated transfer o f the bacterial neomycin resistance gene into fetal 
and adult sheep and human hematopoietic progenitors in vitro. Blood 1990; (75): 365- 
369.
Elchalal U, Shachar IB, Peleg D, Schenker JG. Maternal mortality following diagnostic 
2nd-trimester amniocentesis. Fetal Diagnosis and Therapy 2004; (19): 195-198.
Engelhardt JF, Schlossberg H, Yankaskas JR, Dudus L. Progenitor cells o f the adult 
human airway involved in submucosal gland development. Development 1995; (121): 
2031-2046.
Engelhardt JF, Yankaskas JR, Ernst SA, Yang Y, Marino CR, Boucher RC, Cohn JA, 
Wilson JM. Submucosal glands are the predominant site o f CFTR expression in the 
human bronchus. Nature Genetics 1992; (2): 240-248.
Engelstadter M, Buchholz CJ, Bobkova M, Steidl S, Merget-Millitzer H, Willemsen 
RA, Stitz J, Cichutek K. Targeted gene transfer to lymphocytes using murine leukaemia 
virus vectors pseudotyped with spleen necrosis virus envelope proteins. Gene Therapy 
2001; (8): 1202-1206.
Eto Y, Shen J, Meng X, Ohashi T. Treatment o f lysosomal storage disorders: cell 
therapy and gene therapy. Journal o f Inherited Metabolic Disease 2004; (27): 411-415.
Evans MI, Hoffman EP, Cadrin C, Johnson MP, Quintero RA, Golbus MS. Fetal muscle 
biopsy: collaborative experience with varied indications. Obstetrics and Gynaecology 
1994; (84): 913-917.
Evrard VA, Flageole H, Deprest JA, Vandenberghe K, Verhaeghe J, Lerut TE. 
Intrauterine tracheal obstruction, a new treatment for congenital diaphragmatic hernia, 
decreases amniotic fluid sodium and chloride concentrations in the fetal lamb. Annals o f 
Surgery 1997; (226): 753-758.
350
REFERENCES
Fahey K.J, Morris B. Lymphopoiesis and immune reactivity in the fetal lamb. Series 
Haematologica 1974; (7): 548-567.
Fahey K.J, Morris B. Humoral immune responses in foetal sheep. Immunology 1978;
(35): 651-661.
Fauza DO, Bamewolt C, Brown SD, Jennings RW. Ultrasound-guided fetal tracheal 
occlusion. Journal o f  Pediatric Surgery 2002; (37): 300-302.
Fidzianska A, Goebel HH. Human ontogenesis. 3. Cell death in fetal muscle. Acta 
Neuropathologica 1991; (81): 572-577.
Flageole H, Evrard VA, Piedboeuf B, Laberge JM, Lerut TE, Deprest JA. The plug- 
unplug sequence: an important step to achieve type II pneumocyte maturation in the 
fetal lamb model. Journal o f  Pediatric Surgery 1998; (33): 299-303.
Flageole H, Evrard VE, Vandenberghe K, Lerut TE, Deprest JA. Tracheoscopic 
endotracheal occlusion in the ovine model: technique and pulmonary effects. Journal o f 
Pediatric Surgery 1997; (32): 1328-1331.
Flake AW, Roncarolo MG, Puck JM, Almeida-Porada G, Evans MI, Johnson MP, 
Abella EM, Harrison DD, Zanjani ED. Treatment o f  X-linked severe combined 
immunodeficiency by in utero transplantation o f  paternal bone marrow. New England 
Journal o f  Medicine 1996; (335): 1806-1810.
Fletcher JC, Richter G. Human fetal gene therapy: moral and ethical questions. Human 
Gene Therapy 1996; (7): 1605-1614.
Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, Conrad CK, Brass- 
Emst L, Humphries M, Sullivan K, Wetzel R, Taylor G, Carter BJ, Guggino WB. Phase 
I trial o f intranasal and endobronchial administration o f  a recombinant adeno-associated 
virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part 
clinical study. Human Gene Therapy 2003; (14): 1079-1088.
Food and Drug Administration. Guidance for human somatic cell therapy and gene 
therapy. 1998. US Department o f  Health and Human Services, Food and Drug 
Administration .
Ref Type: Report
Foreman PK, W ainwright MJ, Alicke B, Kovesdi I, Wickham TJ, Smith JG, Meier- 
Davis S, Fix JA, Daddona P, G ardner P, Huang MT. Adenovirus-mediated transduction 
o f intestinal cells in vivo. Human Gene Therapy 1998; (9): 1313-1321.
Fossan G, Cavanagh ME, Evans CA, M alinowska DH, Mollgard K, Reynolds ML, 
Saunders NR. CSF-brain permeability in the immature sheep fetus: a CSF-brain barrier. 
Brain Research 1985; (350): 113-124.
Fowden AL. Nutrient requirements for normal fetal growth and metabolism. In: 
Growth. (Eds.Hanson MA, Spencer JAD, Rodeck CH). Cambridge: Cambridge 
University Press, 1995; 31-56.
351
REFERENCES
Frisella WA, O'Connor LH, Vogler CA, Roberts M, Walkley S, Levy B, Daly TM,
Sands MS. Intracranial injection o f  recombinant adeno-associated virus improves 
cognitive function in a murine model o f  mucopolysaccharidosis Type VII. Molecular 
Therapy 2001; (3): 351-358.
Furie B, Limentani SA, Rosenfield CG. A practical guide to the evaluation and 
treatment o f hemophilia. Blood 1994; (84): 3-9.
Gaensler KML. Fetal gene transfer by transuterine injection o f  cationic liposome-DNA 
complexes. Nature Biotechnology 1999; (17): 1188-1192.
Gaillard D, Ruocco S, Lallemand A, Dalemans W, Hinnrasky J, Puchelle E. 
Immunohistochemical localization o f cystic fibrosis transmembrane conductance 
regulator in human fetal airway and digestive mucosa. Pediatric Research 1994; (36): 
137-143.
Galan HL, Bennett ML, Tyson RW, Owens G, Ragnault TR, Accurso F, Robbins JC, 
Schaack J. Inefficient transduction o f sheep in utero after intra-amniotic injection o f 
retroviral producer cells. American Journal o f  Obstetrics and Gynecology 2002; (187): 
469-474.
Gallot D, Seifer I, Lemery D, Bignon YJ. Systemic diffusion including germ cells after 
plasmidic in utero gene transfer in the rat. Fetal Diagnosis and Therapy 2002; (17): 157- 
162.
Garrett DJ, Larson JE, Dunn D, Marrero L, Cohen JC. In utero recombinant adeno- 
associated virus gene transfer in mice, rats, and primates. BMC Biotechnology 2003;
(3): 16.
Geipel A, Berg C, Germer U, Krapp M, Kohl M, Gembruch U. Mucopolysaccharidosis 
VII (Sly disease) as a cause o f increased nuchal translucency and non-immune fetal 
hydrops: study o f a family and technical approach to prenatal diagnosis in early and late 
pregnancy. Prenatal Diagnosis 2002; (22): 493-495.
Gerdts V, Tsang C, Griebel PJ, Babiuk LA. DNA vaccination in utero: a new approach 
to induce protective immunity in the newborn. Vaccine 2004; (22): 1717-1727.
Ghezzi F, Raio L, Di Naro E, Franchi M, Balestreri D, D'Addario V. Nomogram o f 
Wharton's jelly as depicted in the sonographic cross section o f  the umbilical cord. 
Ultrasound in Obstetrics and Gynaecology 2001; (18): 121-125.
Gill P, Jeffreys AJ, Werrett DJ. Forensic application o f  DNA 'fingerprints'. Nature 
1985; (318): 577-579.
Golbus MS, Cunningham N, Goldberg JD, Anderson R, Filly R, Callen P. Selective 
termination o f multiple gestations. American Journal o f  Medical Genetics 1988a; (31): 
339-348.
Golbus MS, Simpson TJ, Koresawa M, Appelman Z, Alpers CE. The prenatal 
determination o f glucose-6-phosphatase activity by fetal liver biopsy. Prenatal 
Diagnosis 1988b; (8): 401-404.
352
REFERENCES
Golden JA, Zitz JC, McFadden K, Cepko CL. Cell migration in the developing chick 
diencephalon. Development 1997; (124): 3525-3533.
Goldstein I, Reece EA, Yarkoni S, Wan M, Green JL, Hobbins JC. Growth o f the fetal 
stomach in normal pregnancies. Obstetrics and Gynaecology 1987; (70): 641-644.
Gordon JW. Adenovirus gene transfer vector toxicity to mouse embryos: implications 
for human IVF. Human Reproduction 2002; (17): 2380-2387.
Graham FL, Smiley J, Russell WC, Naim R. Characteristics o f  a human cell line 
transformed by DNA from human adenovirus type 5. Journal o f  General Virology 1977;
(36): 59-74.
Greenwood PL, Slepetis RM, Hermanson JW, Bell AW. An ultrasound-guided 
procedure to administer a label o f  DNA synthesis into fetal sheep. Reproduction, 
Fertility and Devevelopment 1999; (11): 303-307.
Gregory LG, Harbottle RP, Lawrence L, Knapton HJ, Themis M, Coutelle C. 
Enhancement o f adenovirus-mediated gene transfer to the airways by DEAE dextran 
and sodium caprate in vivo. Molecular Therapy 2002; (7): 19-26.
Gregory LG, Waddington SN, Holder MV, Mitrophanous KA, Buckley SMK, Mosley 
K.L, Bigger BW, Ellard FM, Walmsley LE, Lawrence L, A l-A llaf F, Kingsman S, 
Coutelle C, Themis M. Highly efficient EIAV-mediated in utero gene transfer and 
expression in the major muscle groups affected by Duchenne muscular dystrophy. Gene 
Therapy 2004; (11): 1117-1125.
Griffin D. The normal fetus. In: Ultrasound in obstetrics and gynaecology. 
(Eds.Dewbury K, Meire H, Cosgrove D, Farrant P). London: Churchill Livingstone, 
2002; 2nd: 189-212.
Grubb BR, Pickles RJ, Ye H, Tankaskas JR, Vick RN, Engelhardt JF, Wilson JM, 
Johnson LG, Boucher RC. Inefficient gene transfer by adenovirus vector to cystic 
fibrosis airway epithelia o f mice and humans. Nature 1994; (371): 802-806.
Gulbis B, Jauniaux E, Cotton F, Stordeur P. Protein and enzyme patterns in the fluid 
cavities o f the first trimester gestational sac: relevance to the absorptive role o f 
secondary yolk sac. Molecular Human Reproduction 1998; (4): 857-862.
Gunnarsson GO, Gudmundsson S, Hokegard K, Stale H, Kjellmer I, Hafstrom O, 
Marsal K. Cerebral Doppler blood flow velocimetry and central hemodynamics in the 
ovine fetus during hypoxemia-acidaemia. Journal o f Perinatal Medicine 1998; (26): 
107-114.
Hamilton TE. Adenoviral-mediated gene transfer to murine small intestine is more 
efficient in neonates than adults. Journal o f  Pediatric Surgery 1997; (32): 373-377.
Hardy KJ, Hoffman NE, Mihaly G, Sewell RB, Smallwood RA. Bile acid metabolism 
in fetal sheep; perinatal changes in the bile acid pool. Journal o f  Physiology 1980;
(309): 1-11.
353
REFERENCES
Harman CR, Bowman JM, Manning FA, Menticoglou SM. Intrauterine transfusion - 
intraperitoneal versus intravascular approach: a case control comparison. American 
Journal o f Obstetrics and Gynecology 1990; (162): 1053-1059.
Harris A. Towards an ovine model o f cystic fibrosis. Human Molecular Genetics 1997; 
(6): 2191-2194.
Harrison MR, Albanese CT, Hawgood SB, Farmer DL, Farrell JA, Sandberg PL, Filly 
RA. Fetoscopic temporary tracheal occlusion by means o f  detachable balloon for 
congenital diaphragmatic hernia. American Journal o f Obstetrics and Gynecology 2001; 
(185): 730-733.
Harrison MR, Keller RL, Hawgood SB, Kitterman JA, Sandberg PL, Farmer DL, Lee 
H, Filly RA, Farrell JA, Albanese CT. A randomised trial o f  fetal endoscopic tracheal 
occlusion for severe fetal congenital diaphragmatic hernia. New England Journal o f 
Medicine 2003; (349): 1916-1924.
Harrison MR, Mychaliska GB, Albanese CT, Jennings RW, Farrell JA, Hawgood S, 
Sandberg P, Levine AH, Lobo E, Filly RA. Correction o f congenital diaphragmatic 
hernia in utero IX: fetuses with poor prognosis (liver herniation and low lung-to-head 
ratio) can be saved by fetoscopic temporary tracheal occlusion. Journal o f Pediatric 
Surgery 1998; (33): 1017-1022.
Harvey BG, HackettNR, El-Sawy T, Rosengart TK, Hirschowitz EA, Lieberman MD, 
Lesser ML, Crystal RG. Variability o f human systemic humoral immune responses to 
adenovirus gene transfer vectors administered to different organs. Journal o f  Virology 
1999; (73): 6729-6742.
Hatzoglou M, Moorman A, Lamers W. Persistent expression o f  genes transferred in the 
fetal rat liver via retroviruses. Somatic Cell and Molecular Genetics 1995; (21): 265- 
278.
Hay JG, McElvaney NG, Herena J, Crystal RG. Modification o f nasal epithelial 
potential differences o f individuals with cystic fibrosis consequent to local 
administration o f a normal CFTR cDNA adenovirus gene transfer vector. Human Gene 
Therapy 1995; (6): 1487-1496.
Hayashi M, Sakai T, Hasegawa Y, Nishikawahara T, Tomioka H, Iida A, Shimizu N, 
Tomita M, Awazu S. Physiological mechanism for enhancement o f paracellular drug 
transport. Journal o f  Controlled Release 1999; (62): 141-148.
Haynes BF, Martin ME, Kay HH, Kurtzberg J. Early events in human T cell ontogeny. 
Journal o f Experimental Medicine 1988; (168): 1061-1080.
Hendrickx AG, Peterson PE. Perspectives on the use o f the baboon in embryology and 
teratology research. Human Reproduction Update 1997; (3): 575-592.
Hermens WT, Verhaagen J. Adenoviral vector-mediated gene expression in the nervous 
system o f immunocompetent Wistar and T cell-deficient nude rats: preferential survival 
o f transduced astroglial cells in nude rats. Human Gene Therapy 1997; (8): 1049-1063.
354
REFERENCES
Hermens WTJMC, Giger RJ, Holtmaat AJGD, Dijkhuizen PA, Houweling DA, 
Verhaagen J. Transient gene transfer to neurons and glia: Analysis o f adenoviral vector 
performance in the CNS and PNS. Journal o f Neuroscience Methods 1997; (71): 85-98.
Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, High KA. Stable 
gene transfer and expression o f human blood coagulation factor IX after intramuscular 
injection o f recombinant adeno-associated virus. Proceedings o f the National Academy 
o f Science o f America 1997; (94): 5804-5809.
Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, Burton M, 
Bellinger DA, Read MS, Brinkhous DM, Podsakoff GM, Nichols TC, Kurtzman GJ, 
High KA. Long-term correction o f canine hemophilia B by gene transfer o f blood 
coagulation factor IX mediated by adeno-associated viral vector. Nature Medicine 1999; 
(5): 56-63.
Higashida RT, Halbach VV, Dowd CF, Barnwell SL, Hieshima GB. Intracranial 
aneurysms: interventional neurovascular treatment with detachable balloons—results in 
215 cases. Radiology 1991; (178): 663-670.
Hill RR, de Bruyn G. Changes in lectin-binding patterns during late fetal development 
o f the rat colon. Acta Anatomica 1991; (141): 245-250.
Holzinger A, Trapnell BC, Weaver TE, Whitsett JA, Iwamoto HS. Intraamniotic 
administration o f an adenoviral vector for gene transfer to fetal sheep and mouse tissues. 
Pediatric Research 1995; (38): 844-850.
Honda T, Saitoh H, Masuko M, Katagiri-Abe T, Tominaga K, Kozakai I, Kobayashi K, 
Kumanishi T, Watanabe YG, Odani S, Kuwano R. The coxsackievirus-adenovirus 
receptor protein as a cell adhesion molecule in the developing mouse brain. Molecular 
Brain Research 2000; (77): 19-28.
Horn HM, Tidman MJ. The clinical spectrum o f dystrophic epidermolysis bullosa. 
British Journal o f  Dermatology 2002; (146): 267-274.
Howard JG, Michie D. Induction o f transplantation immunity in the newborn mouse. 
Transplant Bulletin 1962; (29): 1-6.
Huard J, Feero WG, Watkins SC, Hoffman EP, Rosenblatt DJ, Glorioso JC. The basal 
lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature 
muscle fibers. Journal o f Virology 1996; (70): 8117-8123.
Hubeau C, Puchelle E, Gaillard D. Distinct pattern o f  immune cell population in the 
lung o f  human fetuses with cystic fibrosis. Journal o f Allergy and Clinical Immunology 
2001; (108): 524-529.
Hutchins B, Sajjadi N, Seaver S, Shepherd A, Bauer SR, Simek S, Carson K, Aguilar- 
Cordova E. Working toward an adenoviral vector testing standard. Molecular Therapy 
2000; (2): 532-534.
355
REFERENCES
Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE, Gooi HC, 
Goddard CA, Hannavy K, Smyth SE, Egan JJ, Sorgi FL, Huang L, Cuthbert AW, Evans 
MJ, Colledge WH, Higgins CF, Webb AK, Gill DR. Repeat administration o f 
DNA/liposomes to the nasal epithelium o f patients with cystic fibrosis. Gene Therapy 
2000; (7): 1156-1165.
Inoue M, Tokusumi Y, Ban H, Kanaya T, Tokusumi T, Nagai Y, Iida A, Hawegawa M. 
Nontransmissible virus-like particle formation by F-deficient Sendai virus is 
temperature sensitive and reduced by mutations in M and HN proteins. Journal o f 
Virology 2003; (77): 3238-3246.
Iwamoto HS, Trapnell BC, McConnell CJ, Daugherty C, Whitsett JA. Pulmonary 
inflammation associated with repeated, prenatal exposure to an E l, E3-deleted 
adenoviral vector in sheep. Gene Therapy 1999; (6): 98-106.
Jauniaux E, Gulbis B. Fluid compartments o f the embryonic environment. Human 
Reproduction Update 2000; (6): 268-278.
Jauniaux E, Gulbis B, Gerloo E. Free amino acids in human fetal liver and fluids at 12 - 
17 weeks o f gestation. Human Reproduction 1999a; (14): 1638-1641.
Jauniaux E, Jurkovic D, Gulbis B. Coelocentesis. In: Ultrasound and endoscopic 
surgery in obstetrics and gynaecology. (Eds.Timmerman D, Deprest J, Bourne T). 
Springer, 2003; 316-323.
Jauniaux E, Watson A, Ozturk O, Quick D, Burton GJ. In vivo measurement o f 
intrauterine gases and acid-base values early in human pregnancy. Human Reproduction 
1999b; (14): 2901-2904.
Jerebtsova M, Batshaw ML, Ye X. Humoral immune response to recombinant 
adenovirus and adeno-associated virus after in utero administration o f  viral vectors in 
mice. Pediatric Research 2002; (52): 95-104.
Jobe AH, Polk DH, Ervin MG, Padbury JF, Rebello CM, Ikegami M. Preterm 
betamethasone treatment o f fetal sheep: outcome after term delivery. Journal o f Society 
for Gynecological Investigation 1996; (3): 250-258.
John HA. Variable efficiency o f retroviral-mediated gene transfer into early-passage 
cultures o f fetal lamb epithelial, mesenchymal, and neuroectodermal tissues. Human 
Gene Therapy 1994; (5): 283-293.
Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC. Efficiency o f 
gene transfer for restoration o f normal airway epithelial function in cystic fibrosis. 
Nature Genetics 1992; (2): 21-25.
Jones CPJ, Jauniaux E. Ultrastructure o f the matemo-embryonic interface in the first 
trimester o f pregnancy. Micron 1995; (26): 145-173.
Joubert DM. A study o f prenatal growth and development in the sheep. Journal o f 
Agricultural Science 1956; (47): 382-427.
Jubb KVF, Kennedy PC, Palmer N. Pathology o f domestic animals. Academic Press 
Limited, London 1993.
356
REFERENCES
Juengst ET. What next for human gene therapy? British Medical Journal 2003; (326): 
1410-1411.
Jurkovic D, Jauniaux E, Campbell S, Pandya P, Cardy DL, Nicolaides KH. 
Coelocentesis: a new technique for early prenatal diagnosis. Lancet 1993; (341): 1623- 
1624.
Kaiser J. Side effects sideline hemophilia trial. Science 2004; (304): 1424-1425.
Kajiwara K, Byrnes AP, Ohmoto Y, Charlton HM, Wood MJ, Wood KJ. Humoral 
immune responses to adenovirus vectors in the brain. Journal o f Neuroimmunology 
2000; (103): 8-15.
Kalache KD, Nishina H, Ojutiku D, Hanson MA. Visualisation and measurement o f 
tracheal diameter in the sheep fetus: an ultrasound study with stereomicroscopic 
correlation. Fetal Diagnosis and Therapy 2001; (16): 342-345.
KSlin N, Claass A, Sommer M, Puchelle E, TUmmler B. DF508 CFTR protein 
expression in tissues from patients with cystic fibrosis. Journal o f Clinical Investigation 
1999; (103): 1379-1389.
Kamata Y, Tanabe A, Kanaji A, Kosuga M, Fukuhara Y, Li XK, Suzuki S, Yamada M, 
Azuma N, Okuyama T. Long-term normalization in the central nervous system, ocular 
manifestations, and skeletal deformities by a single systemic adenovirus injection into 
neonatal mice with mucopolysaccharidosis VII. Gene Therapy 2003; (10): 406-414.
Kamps WA, Cooper MD. Development o f lymphocyte populations identified by 
monoclonal antibodies in human fetuses. Journal o f  Clinical Immunology 1984; (4): 36- 
39.
Kaneko JJ, Harvey JW, Bruss M. Clinical biochemistry o f domestic animals. Academic 
Press, San Diego 1997.
Kaplan JM, Pennington SE, St.George JA, Woodworth LA, Fasbender A, Marshal J, 
Cheng SH, Wadsworth SC, Gregory RJ, Smith AE. Potentiation o f gene transfer to the 
mouse lung by complexes o f  adenovirus vector and polycations improves therapeutic 
potential. Human Gene Therapy 1998; (9): 1469-1479.
Kay MA, Landen CN, Rothenberg SR, Taylor LA, Leland F, Wiehle S, Fang B, 
Bellinger D, Finegold M, Thompson AR, Read M, Brinkhous KM, Woo SLC. In vivo 
hepatic gene therapy: Complete albeit transient correction o f  factor IX deficiency in 
hemophilia B dogs. Proceedings o f the National Academy o f Science o f America 1994; 
(91): 2353-2357.
Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew 
AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High 
KA. Evidence for gene transfer and expression o f factor IX in haemophilia B patients 
treated with an AAV vector. Nature Genetics 2000; (24): 257-261.
Kay MA, Rothenberg SR, Landen CN, Bellinger DA, Leland F, Toman C, Finegold M, 
Thompson AR, Read MS, Brinkhous KM, Woo SLC. In vivo gene therapy o f 
hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 1993; 
(262): 117-119.
357
REFERENCES
Kelly EJ, Brownlee KG. When is the fetus first capable o f gastric acid, intrinsic factor 
and gastrin secretion? Biology o f the Neonate 1993; (63): 153-156.
Kelly RW, Newnham JP. Estimation o f gestational age in Merino ewes by ultrasound 
measurement o f fetal head size. Australian Journal o f Agricultural Research 1989; (40): 
1293-1299.
Kelly RW, Newnham JP, Johnson T, Speijers EJ. An ultrasound technique to measure 
placental growth in ewes. Australian Journal o f Agricultural Research 1987; (38): 757- 
764.
Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL, Hu PC, Leigh MW, 
Engelhardt JF, Edwards LJ, Jones KR, Grossman M, Wilson JM, Johnson LG, Boucher 
RC. A controlled study o f adenoviral-vector-mediated gene transfer in the nasal 
epithelium o f patients with cystic fibrosis. New England Journal o f Medicine 1995; 
(333): 823-831.
Kobinger GP, Weiner DJ, Yu QC, Wilson JM. Filovirus-pseudotyped lentiviral vector 
can efficiently and stably transduce airway epithelia in vivo. Nature Biotechnology 
2001; (19): 225-230.
Kohl T, Strumper D, Witteler R, Merschhoff G, Alexiene R, Callenbeck C, Asfour B, 
Reckers J, Aryee S, Vahlhaus C, Vogt J, Van Aken H, Scheld HH. Fetoscopic direct 
fetal cardiac access in sheep. Circulation 2000; (102): 1602-1604.
Kohl T, Sharland G, Allan L D, Gembruch U, Chaoui R, Lopes L M, Zielinsky P, Huhta 
J, Silverman N H. World experience o f percutaneous ultrasound-guided balloon 
valvuloplasty in human fetuses with severe aortic valve obstruction. [Review] [14 refs]. 
American Journal o f Cardiology 2000a; (85): 1230-1233.
Kohl T, Sharland G, Allan L D, Gembruch U, Chaoui R, Lopes L M, Zielinsky P, Huhta 
J, Silverman N H. World experience o f percutaneous ultrasound-guided balloon 
valvuloplasty in human fetuses with severe aortic valve obstruction. [Review] [14 refs]. 
American Journal o f Cardiology 2000b; (85): 1230-1233.
Kubo S, Mitani K. A new hybrid system capable o f efficient lentiviral vector production 
and stable gene transfer mediated by a single helper-dependent adenoviral vector. 
Journal o f Virology 2003; (77): 2964-2971.
Kutteh WH, Rainey WE, Beutler B, Carr BR. Tumor necrosis factor-alpha and 
interleukin-1 beta production by human fetal Kupffer cells. American Journal o f 
Obstetrics and Gynecology 1991; (165): 112-120.
Lai L, Davison BB, Veazey RS, Fisher KJ, Baskin GB. A preliminary evaluation o f 
recombinant adeno-associated virus biodistribution in rhesus monkeys after intrahepatic 
inoculation in utero. Human Gene Therapy 2002; (13): 2027-2039.
Larsen JF, Jacobsen B, Holm HH, Pedersen JF, Mantoni M. Intrauterine injection o f 
vitamin K before the delivery during anticoagulant therapy o f  the mother. Acta 
Obstetricia et Gynecologica Scandinavica 1978; (57): 227-230.
358
REFERENCES
Larson JE, Delcarpio JB, Farberman MM, Morrow SL, Cohen JC. CFTR modulates 
lung secretory cell proliferation and differentiation. American Journal o f Physiology 
2000a; (279): L333-L341.
Larson JE, Morrow SL, Delcarpio JB, Bohm RP, Ratterree MS, Blanchard JL, Cohen 
JC. Gene transfer into the fetal primate: evidence for the secretion o f transgene product. 
Molecular Therapy 2000b; (2): 631-639.
Larson JE, Morrow SL, Happel L, Sharp JF, Cohen JC. Reversal o f cystic fibrosis 
phenotype in mice by gene therapy in utero. Lancet 1997; (349): 619-620.
Latshaw WK. Veterinary Developmental Biology. B C Decker Inc, Toronto 1987.
Laurema A, Vanamo K, Heikkila A, Riekkinen M, Heinonen S, Yla-Herttuala S. Fetal 
membranes act as a barrier for adenoviruses: Gene transfer into exocoelomic cavity o f 
rat fetuses does not affect cells in the fetus. American Journal o f Obstetrics and 
Gynecology 2004; (190): 264-267.
Le LP, Everts M, Dmitriev IP, Davydova JG, Yamamoto M, Curiel DT. Fluorescently 
labeled adenovirus with pIX-EGFP for vector detection. Molecular Imaging 2004; (3): 
105-116.
Leach CL, Greenspan JS, Rubenstein SD, Shaffer TH, Wolfson MR, Jackson JC, 
DeLemos R, Fuhrman BP. Partial liquid ventilation with perflubron in premature infants 
with severe respiratory distress syndrome. New England Journal o f Medicine 1996; 
(335): 761-767.
Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999; (401): 
517-518.
Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AB, Deans R, Marshak 
DR, Flake AW. Human mesenchymal stem cells engraft and demonstrate site-specific 
differentiation after in utero transplantation in sheep. Nature Medicine 2000; (6): 1282- 
1286.
Liley AW. Intrauterine transfusion o f the foetus in haemolytic disease. British Medical 
Journal 1963; (2): 1107-1109.
Lim F-Y, Martin BG, Sena-Esteves M, Radu A, Crombleholme TM. Adeno-associated 
virus (AAV)-mediated fetal gene transfer in respiratory epithelium and submucosal 
gland cells in human fetal tracheal organ culture. Journal o f Pediatric Surgery 2002; 
(37): 1051-1057.
Lin Q, Cunningham LA, Epstein LG, Pechan PA, Short MP, Fleet C, Bohn MC. Human 
fetal astrocytes as an ex vivo gene therapy vehicle for delivering biologically active 
nerve growth factor. Human Gene Therapy 1997; (8): 331-339.
Lindmark T, Kimura Y, Artursson P. Absorption enhancement through intracellular 
regulation o f  tight junction permeability by medium chain fatty acids in Caco-2 cells. 
The Journal o f  Pharmacology and Experimental Therapeutics 1998; (284): 362-369.
359
REFERENCES
Lindmark T, Soderholm JD, Olaison G, Alvan G, Ocklind G, Artursson P. Mechanism 
o f absorption enhancement in humans after rectal administration o f ampicillin in 
suppositories containing sodium caprate. Pharmaceutical Research 1997; (14): 930-935.
Lipshutz GS, Contag C, Andriole S, Gaensler K. Gene expression in the central nervous 
system after in utero, intracranial delivery o f adenoviral or adeno-associated viral 
vectors. Molecular Therapy 2001a; (3): S306-S307.
Lipshutz GS, Flebbe-Rehwaldt L, Gaensler KML. Adenovirus-mediated gene transfer 
in the midgestation fetal mouse. Journal o f Surgical Research 1999a; (84): 150-156.
Lipshutz GS, Flebbe-Rehwaldt L, Gaensler KML. Adenovirus-mediated gene transfer 
to the peritoneum and hepatic parenchyma o f fetal mice in utero. Surgery 1999b; (126): 
171-177.
Lipshutz GS, Flebbe-Rehwaldt L, Gaensler KML. Reexpression following 
readministration o f an adenoviral vector in adult mice after initial in utero adenoviral 
administration. Molecular Therapy 2000; (2): 374-380.
Lipshutz GS, Gruber CA, Cao Y, Hardy J, Contag CH, Gaensler KML. In utero 
delivery o f adeno-associated viral vectors: intraperitoneal gene transfer produces long­
term expression. Molecular Therapy 2001b; (3): 284-292.
Lipshutz GS, Sarkar R, Flebbe-Rehwaldt L, Kazazian H, Gaensler KML. Short-term 
correction o f factor VIII deficiency in a murine model o f hemophilia A after delivery of 
adenovirus murine factor VIII in utero. Proceedings o f the National Academy o f 
Science o f America 1999c; (96): 13324-13329.
Lipshutz GS, Titre D, Brindle M, Bisconte AR, Contag CH, Gaensler KM. Comparison 
o f gene expression after intraperitoneal delivery o f AAV2 or AAV5 in utero. Molecular 
Therapy 2003; (8): 90-98.
Liu SL, Halbert CL, Miller AD. Jaagsiekte sheep retrovirus envelope efficiently 
pseudotypes human immunodeficiency virus type 1-based lentiviral vectors. Journal o f 
Virology 2004; (78): 2642-2647.
Ljubic A, Cvetkovic M, Sulovic V, Radunovic N, Antonovic O, Vukolic D, Popovic B, 
Petkovic S. New technique for artificial lung maturation. Direct intramuscular fetal 
corticosteroid therapy. Clinical and Experimental Obstetrics and Gynecology 1999; 
(26): 16-19.
Lofqvist T, Nilsson EM, Bemtorp E, Pettersson H. Haemophilia prophylaxis in young 
patients—a long-term follow-up. Journal o f Internal Medicine 1997; (241): 395-400.
Loser P, Jennings GS, Strauss M, Sandig V. Reactivation o f the previously silenced 
cytomegalovirus major immediate-early promoter in the mouse liver: involvement o f 
NFkB. Journal o f Virology 1998; (72): 180-190.
Lovell KL, Sprecher DJ, Ames NK, Jones MZ. Development and efficacy o f ultrasound 
guided fetal aspiration techniques in prenatal diagnosis o f caprine p-mannosidosis. 
Theriogenology 1995; (44): 517-527.
360
REFERENCES
Lozier JN, Yankaskas JR, Ramsey WJ, Chen L, Berschneider H, Morgan RA. Gut 
epithelial cells as targets for gene therapy o f hemophilia. Human Gene Therapy 1997; 
(8): 1481-1490.
Lusher JM. Inhibitors in young boys with haemophilia. Baillieres Best Practice & 
Research Clinical Haematology 2000; (13): 457-468.
Luskin MB, Pearlman AL, Sanes JR. Cell lineage in the cerebral cortex o f the mouse 
studied in vivo and in vitro with a recombinant retrovirus.Cell lineage in the cerebral 
cortex o f the mouse studied in vivo and in vitro with a recombinant retrovirus. Neuron 
1988; (1): 635-647.
Lutzko C, Omori F, Abrams-Ogg AC, Shull R, Li L, Lau K, Ruedy C, Nanji S, Gartley 
C, Dobson H, Foster R, Kruth S, Dube ID. Gene therapy for canine alpha-L-iduronidase 
deficiency: in utero adoptive transfer o f genetically corrected hematopoietic progenitors 
results in engraftment but not amelioration o f disease. Human Gene Therapy 1999; (10): 
1521-1532.
Mackay CR, Maddox JF, Brandon MR. Thymocyte subpopulations during early fetal 
development in sheep. Journal o f Immunology 1986; (136): 1592-1599.
Mackenzie IZ, Maclean DA. Pure fetal blood from the umbilical cord obtained at 
fetoscopy: experience with 125 consecutive cases. American Journal o f Obstetrics and 
Gynecology 1980; (138): 1214-1218.
MacKenzie TC, Kobinger GP, Kootstra NA, Radu A, Sena-Esteves M, Bouchard S, 
Wilson JM, Verma IM, Flake AW. Efficient transduction o f liver and muscle after in 
utero injection o f  lentiviral vectors with different pseudotypes. Molecular Therapy 
2002; (6): 349-358.
Maizel JV, White DO, Scharff MD. The polypeptides o f adenovirus. I. Evidence for 
multiple protein components in the virion and a comparison o f  types 2, 7A, and 12. 
Virology 1968; (36): 1 15-125.
Manning FA, Harrison MR, Rodeck C. Catheter shunts for fetal hydronephrosis and 
hydrocephalus. Report o f the International Fetal Surgery Registry. New England 
Journal o f Medicine 1986; (315): 336-340.
Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni 
MV, Thompson A, Ozelo M, Couto LB, Leonard DGB, Johnson FA, McClelland A, 
Scallan C, Skarsgard E, Flake AW, Kay MA, High KA, Glader B. AAV-mediated 
factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 
2003; (101): 2963-2972.
Martino S, Emiliani C, Tancini B. Absence o f metabolic cross-correction in Tay-Sachs 
cells: implications for gene therapy. Journal o f Biological Chemistry 2002; (277): 
20177-20184.
Masaki I, Yonemitsu Y, Komori K, Ueno H, Nakashima Y, Nakagawa K, Fukumura M, 
Kato A, Hasan MK, Nagai Y, Sugimachi K, Hasegawa M, Sueishi K. Recombinant 
Sendai virus-mediated gene transfer to vasculature: a new class o f efficient gene transfer 
vector to the vascular system. FASEB Journal 2001; (15): 1294-1296.
361
REFERENCES
Mason CA, Bigras JL, O'Blenes SB, Zhou B, McIntyre B, Nakamura N, Kaneda Y, 
Rabinovitch M. Gene transfer in utero biologically engineers a patent ductus arteriosus 
in lambs by arresting fibronectin-dependent neointimal formation. Nature Medicine 
1999; (5): 176-182.
Maxwell DJ, Johnson P, Hurley P, Neales K, Allan L, Knott P. Fetal blood sampling 
and pregnancy loss in relation to indication. British Journal o f  Obstetrics & 
Gynaecology 1991; (98): 892-897.
Mazarakis ND, Azzouz M, Rohll JB, Ellard FM, Wilkes FJ, Olsen AL, Carter EE, 
Barber RD, Baban DF, Kingsman SM, Kingsman A, O'Malley K, Mitrophanous K. 
Rabies virus glycoprotein pseudotyping o f lentiviral vectors enables retrograde axonal 
transport and access to the nervous system after peripheral delivery. Human Molecular 
Genetics 2001;(10): 2109-2121.
McCandless SE, Brunger JW, Cassidy SB. The burden o f genetic disease on inpatient 
care in a children's hospital. American Journal o f Human Genetics 2004; (74): 121-127.
McClure S, McCullagh P, Parsonson IM, McPhee DA, Della-Porta AJ, Orsini A. 
Maturation o f immunological reactivity in the fetal lamb infected with Adabane virus. 
Journal o f Comparative Pathology 1988; (99): 133-143.
McConnell MJ, Imperiale MJ. Biology o f adenovirus and it use as a vector for gene 
therapy. Human Gene Therapy 2004; (15): 1022-1033.
McCormack J E, Martineau D, DePolo N, Maifert S, Akbarian L, Townsend K, Lee W, 
Irwin M, Sajjadi N, Jolly D J, Warner J. Anti-vector immunoglobulin induced by 
retroviral vectors. Human Gene Therapy 1997; (8): 1263-1273.
McCray PB. Spontaneous contractility o f human fetal airway smooth muscle. Am J 
Respir Cell Mol Biol 1993; (8): 573-580.
McCray PB, Armstrong K, Zabner J, Miller DW, Koretzky GA, Couture L, Robillard 
JE, Smith AE, Welsh MJ. Adenoviral-mediated gene transfer to fetal pulmonary 
epithelia in vitro and in vivo. Journal o f Clinical Investigation 1995; (95): 2620-2632.
McCullagh P. Immunological tolerance o f sheep to skin allografts. Transplantation 
1988; (46): 280-285.
McCullagh P. Inability o f  fetal skin to induce allograft tolerance in fetal lambs. 
Immunology 1989; (67): 489-495.
McEwan GT, Jepson MA, Hirst BH, Simmons NL. Polycation-induced enhancement o f 
epithelial paracellular permeability is independent o f tight junctional characteristics. 
Biochimica et Biophysica Acta 1993; (1148): 51-60.
Meertens L, Zhao Y, Rosic-Kablar S, Li L, Chan K, Dobson H, Gartley C, Lutzko C, 
Hopwood J, Kohn D, Kruth S, Hough MR, Dube ID. In utero injection o f alpha-L- 
iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection o f 
multiple tissues and neonatal gene expression. Human Gene Therapy 2002; (13): 1809- 
1820.
362
REFERENCES
Meyer DJ, Harvey JW. Evaluation o f hepatobiliary system and skeletal muscle and lipid 
disorders. In: (Eds.Meyer DJ, Harvey JW). Philadelphia: W B Saunders Company,
1998;157-186.
Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in 
cells that are actively replicating at the time o f infection. Molecular and Cellular 
Biology 1990; (10): 4239-4242.
Mitchell M, Jerebtsova M, Batshaw ML, Newman K, Ye X. Long-term gene transfer to 
mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors. 
Gene Therapy 2000; (7): 1986-1992.
Mitchell RM. Attempts to induce tolerance o f renal homografts in sheep by intra- 
embryonic injection o f spleen cells. Transplant Bulletin 1959; (6): 424-426.
Mitrophanous K, Yoon S, Rohll J, Patil D, Wilkes F, Kim V, Kingsman S, Kingsman A, 
Mazarakis N. Stable gene transfer to the nervous system using a non-primate lentiviral 
vector. Gene Therapy 1999; (6): 1808-1818.
Miyasaka M, Morris B. The ontogeny o f the lymphoid system and immune 
responsiveness in sheep. Progress in Veterinary Microbiology and Immunology 1988;
(4): 21-55.
Miyoshi H, Verma IM, Takahashi M, Gage F, Verma EM. Development o f a self- 
inactivating lentivirus vector. Journal o f Virology 1998; (72): 8150-8157.
Mollgard K, Balslev Y, Lauritzen B, Saunders NR. Cell junctions and membrane 
specializations in the ventricular zone (germinal matrix) o f the developing sheep brain: 
a CSF-brain barrier. Journal o f Neurocytology 1987; (16): 433-444.
Mollgard K, Saunders JM. The development o f the human blood-brain and blood-CSF 
barriers. Neuropathology and Applied Neurobiology 1986; (12): 337-358.
Moore NW, Rowson LEA. Attempts to induce tissue tolerance in sheep. Research in 
Veterinary Science 1961; (2): 1.
Morral N, O'Neal WK, Rice K, Leland MM, Piedra PA, Aguilar-Cordova E, Carey KD, 
Beaudet AL, Langston C. Lethal toxicity, severe endothelial injury, and a threshold 
effect with high doses o f an adenoviral vector in baboons. Human Gene Therapy 2002;
(13): 143-154.
Morris B. The ontogeny and comportment o f lymphoid cells in fetal and neonatal sheep. 
Immunological Reviews 1986; (91): 219-233.
Morris B, Miyasaka M. Immunology o f the sheep. Editiones Roche, Basle, Switzerland 
1985.
Moss IR, Scarpelli EM. Stimulatory effect o f theophylline on regulation o f fetal 
breathing movements. Pediatric Research 1981; (15): 870-873.
Moss TJM, Newnham JP, Willett KE, Kramer BW, Jobe AH, Ikegami M. Early 
gestational intra-amniotic endotoxin. American Journal o f Respiratory and Critical Care 
Medicine 2002; (165): 805-811.
363
REFERENCES
Muench MO, Rae J, Barcena A, Leemhuis T, Farrell J, Humeau L, Maxwell-Wiggins 
JR, Capper J, Mychaliska GB, Albanese CT, Martin T, Tsukamoto A, Curnutte JT, 
Harrison MR. Transplantation o f a fetus with paternal Thy-1(+)CD34(+) cells for 
chronic granulomatous disease. Bone Marrow Transplant 2001; (27): 355-364.
Muldoon LL, Nilaver G, Kroll RA, Pagel MA, Breakefield XO, Chiocca EA, Davidson 
BL, Weissleder R, Neuwelt EA. Comparison o f intracerebral inoculation and osmotic 
blood-brain barrier disruption for delivery o f adenovirus, herpesvirus, and iron oxide 
particles to normal rat brain. American Journal o f  Pathology 1995; (147): 1840-1851.
Muruve DA, Barnes MJ, Stillman IE, Libermann TA. Adenoviral gene therapy leads to 
rapid induction o f multiple chemokines and acute neutrophil-dependent hepatic injury 
in vivo. Human Gene Therapy 1999; (10): 965-976.
Nagata S, Koyanagi T, Fukushima S, Akazawa K, Nakano H. Change in the three- 
dimensional shape o f the stomach in the developing human fetus. Early Human 
Development 1994; (37): 27-38.
Naito M, Hasegawa G, Takahashi K. Development, differentiation and maturation o f 
Kupffer cells. Microscopy Research and Technique 1997; (39): 350-364.
Nakatani T, Ohtani O, Tanaka S. Lymphatic stomata in the murine diaphragmatic 
peritoneum: the timing o f their appearance and a map o f their distribution. Anatomical 
Record 1996; (244): 529-539.
Nalbantoglu J, Larochelle N, W olf E, Karpati G, Kochmuller H, Holland PC. Muscle- 
specific overexpression o f the adenovirus primary receptor CAR overcomes low 
efficiency o f gene transfer to mature skeletal muscle. Journal o f  Virology 2001; (75): 
4276-4282.
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In 
vivo gene delivery and stable transduction o f nondividing cells by a lentiviral vector. 
Science 1996; (272): 263-267.
Neiderhuber JE, Shermeta D, Turcotte JG, Pikas PW. Kidney transplantation in the 
foetal lamb. Transplantation 1971; (12): 161-166.
Nettleton PF, Entrican G. Ruminant pestiviruses. British Veteminary Journal 1995; 
(151): 615-642.
Newnham JP, Kelly RW. Ultrasound for research with fetal sheep. In: Obstetric 
Ultrasound I. (Eds.Neilson JP, Chambers SE). Oxford Medical Publications, 1993; 203- 
222 .
Newnham JP, Kelly RW, Boyne P, Reid SE. Ultrasound guided blood sampling from 
fetal sheep. Australian Journal o f Agricultural Research 1989; (40): 401-407.
Newnham JP, Polk DH, Kelly RW, Padbury JF, Evans SF, Idegami M, Jobe AH. 
Catecholamine response to ultrasonographically guided percutaneous blood sampling in 
fetal sheep. American Journal o f Obstetrics and Gynecology 1994; (171): 465.
364
REFERENCES
Nicolaides KH, Soothill PW, Rodeck C, Campbell S. Ultrasound-guided sampling o f 
umbilical cord and placental blood to assess fetal well-being. Lancet 1986; (i): 1065- 
1067.
Nicolaides K H, Rodeck C H. Fetal blood sampling. [Review] [117 refs]. Baillieres 
Clinical Obstetrics & Gynaecology 1987; (1): 623-648.
Nicolaidis P, Nicolini U, Fisk NM, Tannirandom Y, Nasrat H, Rodeck C. Fetal blood 
sampling from the intrahepatic vein for rapid karyotyping in the second and third 
trimesters. British Journal o f Radiology 1991; (64): 505-509.
Nicolini U, Kochenour NK, Greco P, Letsky E, Rodeck C. When to perform the next 
intra-uterine transfusion in patients with Rh allo-immunization: combined intravascular 
and intraperitoneal transfusion allows longer intervals. Fetal Therapy 1989; (4): 14-20.
Nicolini U, Nicolaidis P, Fisk NM, Tannirandom Y, Rodeck C. Fetal blood sampling 
from the intrahepatic vein: analysis o f safety and clinical experience with 214 
procedures. Obstetrics and Gynaecology 1990; (76): 47-53.
Noden DM, De Lahunta A. Respiratory system and partitioning o f  body cavities. In:
The embryology o f domestic animals. Williams & Wilkins, 1985; 279-291.
Noia G, Pierelli L, Bonnano G, Monego G, Perillo A, Rutella S, Cavaliere AF, Straface 
G, Fortunato G, Cesari E, Scambia G, Terzano M, Iannace E, Zelano G, Michetti F, 
Leone G, Mancuso S. The intracoelomic route: a new approach for in utero human cord 
blood stem cell transplantation. Fetal Diagnosis and Therapy 2004; (19): 13-22.
Nugent CE, Hayashi RH, Rubin J. Prenatal treatment o f type 1 congenital cystic 
adenomatoid malformation by intrauterine fetal thoracocentesis. Journal o f  Clinical 
Ultrasound 1989; (17): 675-677.
Olsson M, Campbell K, Turnbull DH. Specification o f  mouse telencephalic and mid­
hindbrain progenitors following heterotopic ultrasound-guided embryonic 
transplantation. Neuron 1997; (19): 761-772.
Olver RE, Schneeburger EE, Walters DV. Epithelial solute permeability, ion transport 
and tight junction morphology in the developing lung o f the fetal lamb. Journal o f 
Physiology 1981; (315): 395-412.
Orlandi F, Damiani G, Jakil C, Lauricella S, Bertolino O, Maggio A. The risks o f early 
cordocentesis (12-21 weeks): analysis o f  500 procedures. Prenatal Diagnosis 1990; (10): 
425-428.
Owen RD. Immunological consequences o f vascular anastomoses between bovine 
twins. Science 1945; (102): 400-401.
Pack RJ, Al-Ugaily LH, Morris G. The cells o f the tracheobronchial epithelium o f the 
mouse: a quantitative light and electron microscope study. Journal o f Anatomy 1981; 
(132): 71-84.
Pahal GS, Jauniaux E, Kinnon C, Thrasher AJ, Rodeck C. Normal development o f 
human fetal hematopoiesis between eight and seventeen weeks' gestation. American 
Journal o f Obstetrics and Gynecology 2000; (183): 1029-1034.
365
REFERENCES
Palmer TD, Rosman GJ, Osborne WRA, Miller D. Genetically modified skin fibroblasts 
persist long after transplantation but gradually inactivate introduced genes. Proceedings 
o f the National Academy o f Science o f America 1991; (88): 1330-1334.
Papadopulos NA, Dumitrascu I, Ordonez JL, Decaluwe H, Lerut TE, Barki G, Deprest 
JA. Fetoscopy in the pregnant rabbit at midgestation. Fetal Diagnosis and Therapy 
1999; (14): 118-121.
Papaioannou VE. In utero manipulations. In: Postimplantation Mammalian Embryos. A 
Practical Approach. (Eds.Copp AJ, Cockroft DL). Oxford: JRL Press, 1990; 61-80.
Parulekar S. Sonography o f normal fetal bowel. Journal o f Ultrasound in Medicine 
1991; (10): 211-220.
Passini MA, Watson DJ, Vite CH, Landsburg DJ, Feigenbaum AL, Wolfe JH. 
Intraventricular brain injection o f adeno-associated virus type 1 (AAV1) in neonatal 
mice results in complementary patterns o f neuronal transduction to AAV2 and total 
long-term correction o f storage lesions in the brains o f beta-glucuronidase-deficient 
mice. Journal o f Virology 2003; (77): 7034-7040.
Passini MA, Wolfe JH. Widespread gene delivery and structure-specific patterns o f 
expression in the brain after intraventricular injections o f  neonatal mice with an adeno- 
associated virus vector. Journal o f Virology 2001; (75): 12382-12392.
Patrick JE, Dalton KJ, Dawes GS. Breathing patterns before death in fetal lambs. 
American Journal o f  Obstetrics and Gynecology 1976; (125): 73-78.
Peault B, Tavian M. Hematopoietic stem cell emergence in the human embryo and 
fetus. Annals o f New York Academy o f Science 2003; (996): 132-140.
Peebles DM, Wyatt JS. Synergy between antenatal exposure to infection and 
intrapartum events in causation o f perinatal brain injury at term. British Journal o f 
Obstetrics & Gynaecology 2002; (109): 737-739.
Phillips J H, Hori T, Nagler A, Bhat N, Spits H, Lanier LL. Ontogeny o f human natural 
killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic 
CD3 epsilon,delta proteins. Journal o f Experimental Medicine 1992; (175): 1055-1066.
Piedrahita JA. Targeted modification o f the domestic animal genome. Theriogenology 
2000; (53): 105-116.
Pitt BR, Schwarz MA, Pilewski JM, Nakayama D, Mueller GM, Robbins PD, Watkins 
SA, Albertine KH, Bland RD. Retrovirus-mediated gene transfer in lungs o f  living fetal 
sheep. Gene Therapy 1995; (2): 344-350.
Polak JM, Van Noorden S. Introduction to immunocytochemistry. Bios Scientific 
Publishers Limited, Oxford 1997.
Polak-Charcon S, Shoham J, Ben-Shaul Y. Tight junctions in epithelial cells o f human 
fetal hindgut, normal colon, and colon adenocarcinoma. Journal o f the National Cancer 
Institute 1980; (65): 53-62.
366
REFERENCES
Polakowska RR, Piacentini M, Bartlett R, Goldsmith LA, Haake AR. Apoptosis in 
human skin development: morphogenesis, periderm, and stem cells. Developmental 
Dynamics 1994; (199): 176-188.
Ponder BA, Schmidt GH, Wildinson MM, Wood MJ, Monk M, Reid A. Derivation o f 
mouse intestinal crypts from single progenitor cells. Nature 1985; (313): 689-691.
Ponder KP, Melniczek JR, Xu L, Weil MA, O’Malley TM, O'Donnell PA, Knox VW, 
Aguirre GD, Mazrier H, Ellinwood NM, Sleeper M, Maguire AM, Volk SW, Mango 
RL, Zweigle J, Wolfe JH, Haskins ME. Therapeutic neonatal hepatic gene therapy in 
mucopolysaccharidosis VII dogs. Proceedings o f the National Academy o f Science o f 
America 2002; (99): 13102-13107.
Porada CD, Tran N, Eglitis M, Moen RC, Troutman L, Flake AW, Zhao Y, Anderson 
WF, Zanjani ED. In utero gene therapy: transfer and long-term expression o f the 
bacterial neox gene in sheep after direct injection o f retroviral vectors into preimmune 
fetuses. Human Gene Therapy 1998; (9): 1571-1585.
Pretorius DH, Gosink BB, Clautice-Engle T, Leopold GR, Minnick CM. Sonographic 
evaluation o f the fetal stomach: significance o f nonvisualization. American Journal o f 
Roentgenology 1988; (151): 987-989.
Pringle KC. Human fetal lung development and related animal models. Clinical 
Obstetrics and Gynecology 1986; (29): 502-513.
Ramsdell F, Fowlkes B. Maintenance o f in vivo tolerance by persistence o f antigen. 
Science 1992; (257): 1130-1134.
Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ, Furth EE, Propert KJ, 
Robinson MB, Magosin S, Simoes H, Speicher L, Hughes J, Tazelaar J, Wivel NA, 
Wilson JM, Batshaw ML. A pilot study o f in vivo liver-directed gene transfer with an 
adenoviral vector in partial ornithine transcarbamylase deficiency. Human Gene 
Therapy 2002; (13): 163-175.
Recombinant DNA Advisory Committee. Prenatal gene transfer; Scientific, medical, 
and ethical issues. Human Gene Therapy 2000; (11): 1211-1229.
Reynaud CA, Garcia C, Hein WR, Weill JC. Hypermutation generating the sheep 
immunoglobulin repertoire is an antigen-independent process. Cell 1995; (80): 115-125.
Reynolds LP, Redmer DA. Utero-placental vascular development and placental 
function. Journal o f Animal Science 20021; (73): 1839-1851.
Richardson B, Korkola S, Asano H, Challis J, Polk D, Fraser M. Regional blood flow 
and the endocrine response to sustained hypoxemia in the preterm ovine fetus. Pediatric 
Research 1996; (40): 337-343.
Riley RL. Neonatal immune response. In: Encyclopedia o f Immunology. (Eds.Delves 
PJ, Roitt IM). London: Academic Press, 1998; 1818-1821.
Rodeck CH, Deans A. Red cell alloimmunisation. In: Fetal medicine: basic science and 
clinical practice. (Eds.Rodeck CH, Whittle MJ). London: Churchill Livingstone, 1999; 
785-804.
367
REFERENCES
Rodeck CH, Deans A. Fetal blood transfusion. In: Ultrasound and fetal therapy. 
(Eds.Evans MI, Rodeck CH). New York: The Parthenon Publishing Group, 2001; 19- 
29.
Rodeck CH, Patrick AD, Pembrey ME, Tzannatos C, Whitfield AE. Fetal liver biopsy 
for prenatal diagnosis o f ornithine carbamyl transferase deficiency. Lancet 1982; (2): 
297-300.
Rohll JB, Mitrophanous KA, Martin-Rendon E, Ellard FM, Radcliffe PA, Mazarakis 
ND, Kingsman SM. Design, production, safety, evaluation and clinical applications o f 
nonprimate lentiviral vectors. Methods in Enzymology 2003; (346).
Ross J, Jurkovic D, Nicolaides KH. Coelocentesis: a study o f short-term safety. Prenatal 
Diagnosis 1997; (17): 913-917.
Ross MG, Nijland MJ. Development o f ingestive behavior. American Journal o f 
Physiology 1998; (274): R879-R893.
Russel DW, Berger MS, Miller AD. The effects o f  human serum and cerebrospinal fluid 
on retroviral vectors and packaging cell lines. Human Gene Therapy 1995; (6): 635-641.
Sadler TW. Langman's medical embryology. Williams & Wilkins, Baltimore, Maryland 
USA 1990.
Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in 
immunological tolerance to self and non-self. Nature Immunology 2005; (6): 345-352.
Sandberg J, Lau C, Jacomino M. Improving access to intestinal stem cells as a step 
toward intestinal gene transfer. Human Gene Therapy 1994; (10): 13-18.
Santolaya-Forgas J, Vengalil S, Kushwaha A, Bieniarz A, Fortman J. Assessment o f the 
risk o f  fetal loss after the coelocentesis procedure using a baboon model. Fetal 
Diagnosis and Therapy 1998; (13): 257-260.
Sase M, Lee JJ, Ross MG, Buchmiller-Crair TL. Effect o f hypoxia on fetal rabbit 
gastrointestinal motility. Journal o f Surgical Research 2002; (99): 347-351.
Sase M, Tamura H, Ueda K, Kato H. Sonographic evaluation o f antepartum 
development o f fetal gastric motility. Ultrasound in Obstetrics and Gynaecology 1999;
(13): 323-326.
Saunders NR, Knott GW, Dziegielewska KM. Barriers in the immature brain. Cellular 
and Molecular Neurobiology 2000; (20): 29-40.
Sawyer M, Moe J, Osbum BI. Ontogeny o f immunity and leukocytes in the ovine fetus 
and elevation o f immunoglobulins related to congenital infection. American Journal o f  
Veterinary Research 1978; (39): 643-648.
Schachtner SK, Buck CA, Bergelson JM, Baldwin HS. Temporally regulated expression 
patterns following in utero adenovirus-mediated gene transfer. Gene Therapy 1996; (6): 
1249-1257.
368
REFERENCES
Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, Graham FL, 
Beaudet AL, Kochanek S. Genomic DNA transfer with a high-capacity adenovirus 
vector results in improved in vivo gene expression and decreased toxicity. Nature 
Genetics 1998; (18): 180-183.
Schinkel PG, Ferguson KA. Skin transplantation in the foetal lamb. Australian Journal 
o f  Biological Science 1953; (6): 533.
Schittny JC, Miserocchi G, Sparrow MP. Spontaneous peristaltic airway contractions 
propel lung liquid through the bronchial tree o f intact and fetal lung explants. Am J 
Respir Cell Mol Biol 2000; (23): 11-18.
Schneider H, Adebakin S, Themis M, Cook T, Douar A-M, Pavirani A, Coutelle C. 
Therapeutic plasma concentrations o f human factor IX in mice after gene delivery into 
the amniotic cavity: a model for the prenatal treatment o f haemophilia B. Journal o f 
Gene Medicine 1999; (1): 424-432.
Schneider H, Coutelle C. In utero gene therapy: The case for. Nature Medicine 1999;
(5): 256-257.
Schneider H, Miihle C, Douar A-M, Waddington S, Jiang Q-J, von der Mark K,
Coutelle C, Rascher W. Sustained delivery o f therapeutic concentrations o f human 
clotting factor IX - a comparison o f adenoviral and AAV vectors administered in utero . 
Journal o f Gene Medicine 2002; (4): 46-53.
Schwartz RH. Natural regulatory T cells and self-tolerance. Nature Immunology 2005;
(6): 327-330.
Sekhon HS, Larson JE. In utero gene transfer into the pulmonary epithelium. Nature 
Medicine 1995; (1): 1201-1203.
Senoo M, Matsubara Y, Fujii K, Nagasaki Y, Hiratsuka M, Kure S, Uehara S, Okamura 
K, Yajima A, Narisawa K. Adenovirus-mediated in utero gene transfer in mice and 
guinea pigs: tissue distribution o f recombinant adenovirus determined by quantitative 
TaqMan-polymerase chain reaction assay. Molecular Genetics and Metabolism 2000; 
(69): 269-276.
Shaffer TH, Wolfson MR, Clark LC. Liquid ventilation. Pediatric Pulmonology 1992;
(14): 102-109.
Shao G, Backstrom KC, Huang Q, Sferra T. Gastric acid neutralization and protease 
inhibition improves oral recombinant adeno-associated virus mediated gene delivery to 
the intestines. Molecular Therapy 2003; (7): S389-S390.
Shao XJ, Ohtani O, Saitoh M, Ohtani Y. Development o f diaphragmatic lymphatics: the 
process o f their direct connection to the peritoneal cavity. Archives o f Histology and 
Cytology 1998; (61): 137-149.
Sherman DJ, Ervin MG, Ross MG. Fetal gastrointestinal composition: implications for 
water and electrolyte absorption. Reproduction, Fertility and Devevelopment 1996; (8): 
323-326.
369
REFERENCES
Shields LE, Bryant EM, Easterling TR, Andrews RG. Fetal liver cell transplantation for 
the creation o f lymphohematopoietic chimerism in fetal baboons. American Journal o f 
Obstetrics and Gynecology 1995; (173): 1157-1160.
Shiotani A, Fukumura M, Maeda M, Flou X, Inoue M, Kanamori T, Komaba S, 
Washizawa K, Fujikawa S, Yamamoto T, Kadono C, Watabe K, Fukuda H, Saito K, 
Sakai Y, Nagai Y, Kanzaki J, Hasegawa M. Skeletal muscle regeneration after insulin­
like growth factor 1 gene transfer by recombinant Sendai virus vector. Gene Therapy 
2001; (8): 1043-1050.
Shulkes A, Chick P, Hardy KJ, Robinson P, Trahair J. Ontogeny o f gastric acidity in the 
ovine fetus. Journal o f  Developmental Physiology 1985; (7): 195-206.
Silverstein AM, Prendergast RA, Kraner KL. Fetal response to antigenic stimulus IV. 
Rejection o f skin homografts by the fetal lamb. Journal o f Experimental Medicine 1964; 
(119): 955-964.
Silverstein AM, Thorbecke GJ, Kraner KL, Lukes RJ. Fetal response to antigenic 
stimulus. III. gamma-globulin production in normal and stimulated fetal lambs. Journal 
o f Immunology 1963a; (91): 384-395.
Silverstein AM, Uhr JW, Lukes RJ. Fetal response to antigenic stimulus II. Antibody 
production by the fetal lamb. Journal o f Experimental Medicine 1963b; (117): 799-812.
Skarsgard ED, Meuli M, VanderWall KJ, Bealer JF, Adzick NS, Harrison MR. Fetal 
endoscopic tracheal occlusion ('Fetendo-PLUG') for congenital diaphragmatic hernia. 
Journal o f Pediatric Surgery 1996; (31): 1335-1338.
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, 
Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement o f  protein using 
bicinchoninic acid. Annals o f  Biochemistry 1985; (150): 76-85.
Smith T, Christianson K, Moss R, Bailey D. Structural and biochemical differentiation 
o f the guinea-pig colon during foetal development. Cell Tissue Res 1985; (242): 197- 
209.
Smolich JJ, Stratford BF, Maloney JE, Ritchie BC. New features in the development o f 
the submucosal gland o f the respiratory tract. Journal or Anatomy 1978; (127): 223-238.
Snowdon C, Green JM. Preimplantation diagnosis and other reproductive options: 
attitudes o f male and female carriers o f recessive disorders. Human Reproduction 1997; 
(12): 341-350.
Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin H-F, Stafford DW, Patel S, 
Thompson AR, Nichols T, Read MS, Brinkhous DM, Kay MA. Correction o f 
hemophilia B in canine and murine models using recombinant adeno-associated viral 
vectors. Nature Medicine 1999; (5): 64-70.
Soucie JM, Nuss R, Evatt B, Abdelhak A, Cowan L, Jill H, Kolakoski M, Wilber N. 
Mortality among males with hemophilia: relations with source o f medical care. The 
Hemophilia Surveillance System Project Investigators. Blood 2000; (96): 437-442.
370
REFERENCES
Stewart PH, Hayakawa EM. Interendothelial junctional changes underlie the 
developmental 'tightening' o f the blood-brain barrier. Dev Brain Res 1987; (32): 271- 
281.
Stonestreet BS, Patlak CS, Pettigrew KD, Reilly CB, Cserr HF. Ontogeny o f blood- 
brain barrier function in ovine fetuses, lambs, and adults. American Journal o f 
Physiology 1996; (271): R1594-R1601.
Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Widespread long-term 
gene transfer to mouse skeletal muscles and heart. Journal o f Clinical Investigation 
1992; (90): 626-630.
Strong TV, Boehm K, Collins FS. Localization o f cystic fibrosis transmembrane 
conductance regulator mRNA in the human gastrointestinal tract by in situ 
hybridization. Journal o f Clinical Investigation 1994; (93): 347-354.
Sturgiss SN, Wright C, Davison JM, Robson SC. Fetal hepatic necrosis following blood 
sampling from the intrahepatic vein. Prenatal Diagnosis 1996; (16): 866-869.
Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn JA, Rossier B, Boucher RC. 
CFTR as a cAMP-dependent regulator o f sodium channels. Science 1995; (269): 847- 
850.
Sun J, Hayward C, Shinde R, Christenson R, Ford SP, Butler JE. Antibody repertoire 
development in fetal and neonatal piglets. I. Four VH genes account for 80 percent of 
VH usage during 84 days o f fetal life. Journal o f Immunology 1998; (161): 5070-5078.
Surbek D, Tercanli S, Holzgreve W. In utero stem cell and gene therapy: gaining early 
access to the fetus. Fetal Diagnosis and Therapy 1997; (12): 107.
Surbek DV, Tercanli S, Holzgreve W. Transabdominal first trimester embryofetoscopy 
as a potential approach to early in utero stem cell transplantation and gene therapy. 
Ultrasound in Obstetrics and Gynaecology 2000; (15): 302-307.
Sutherland RJ, Deol HS, Hood PJ. Changes in plasma bile acids, plasma amino acids, 
and hepatic enzyme pools as indices o f  functional impairment in liver-damaged sheep. 
Veterinary Clinical Pathology 1992; (21): 51-55.
Sylvester KG, Yang EY, Cass DL, Crombleholme TM, Scott Adzick N. Fetoscopic 
gene therapy for congenital lung disease. Journal o f Pediatric Surgery 1997; (7): 964- 
969.
Tabor A, Philip J, Madsen M, Bang J, Obel EB, Norgaard-Pedersen B. Randomised 
controlled trial o f genetic amniocentesis in 4606 low-risk women. Lancet 1986; (i): 
1287-1293.
Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J, Fawell SE. 
Sequestration o f adenoviral vector by Kupffer cells leads to a nonlinear dose response 
o f transduction in liver. Molecular Therapy 2001; (3): 28-35.
Tarantal AF. Interventional ultrasound in pregnant macaques: embryonic/fetal 
applications. Journal o f Medical Primatology 1990; (19): 47-58.
371
REFERENCES
Tarantal AF, Chu F, O'Brien WD, Hendrickx AG. Sonographic heat generation in vivo 
in the gravid long-tailed macaque (Macaca fascicularis). Journal o f Ultrasound in 
Medicine 1993; (12): 285-295.
Tarantal AF, Lee Cl, Ekert JE, McDonald R, Kohn DB, Plopper CG, Case SS, Bunnell 
BA. Lentiviral vector gene transfer into fetal rhesus monkeys (Macaca mulatta): lung- 
targeting approaches. Molecular Therapy 2001a; (4): 614-621.
Tarantal AF, Lee Cl, Ekert JE, O'Rourke JP, McDonald RJ, Plopper CG, Permenter M, 
Kohn DB, Bunnell BA. Lentiviral vector gene transfer efficiency using fetal routes o f 
administration in Rhesus monkeys. Molecular Therapy 2001b; (3): S I29.
Tarantal AF, O'Rourke JP, Case SS, Newbound GC, Li J, Lee Cl, Baskin CR, Kohn 
DB, Bunnell BA. Rhesus monkey model for fetal gene transfer: studies with retroviral- 
based vector systems. Molecular Therapy 2001c; (3): 128-138.
Tavian M, Coulombel L, Luton D, Clemente HS, Dieterlen LF, Peault B. Aorta- 
associated CD34+ hematopoietic cells in the early human embryo. Blood 1996; (87): 
67-72.
Tavian M, Hallais MF, Peault B. Emergence o f intraembryonic hematopoietic 
precursors in the pre-liver human embryo. Development 1999; (126): 793-803.
Taylor PM. Anaesthesia in sheep and goats. In: Sheep and goat practice. (Eds.Melling 
M, Alder M). London: W B Saunders Company Ltd, 1991; 99-116.
Tebbutt SJ, Harris A, Hill DF. An ovine CFTR variant as a putative cystic fibrosis 
causing mutation. Journal o f Medical Genetics 1996; (33): 623-624.
Thakur A, Lansford R, Thakur V, Narone JN, Atkinson JB, Buchmiller-Crair T, Fraser 
SE. Gene transfer to the embryo: strategies for the delivery and expression o f proteins at 
48 to 56 hours post-fertilization. Journal o f Pediatric Surgery 2001; (36): 1304-1307.
Themis M, Forbes SJ, Chan L, Cooper RG, Etheridge CJ, Miller AD, Hodgson HJ, 
Coutelle C. Enhanced in vitro and in vivo gene delivery using cationic agent complexed 
retrovirus vectors. Gene Therapy 1998; (5): 1180-1186.
Themis M, Schneider H, Kiserud T, Cook T, Adebakin S, Jezzard S, Forbes S, Hanson 
M, Pavirani A, Rodeck C, Coutelle C. Successful expression o f p-galactosidase and 
factor IX transgenes in fetal and neonatal sheep after ultrasound-guided percutaneous 
adenovirus vector administration into the umbilical vein. Gene Therapy 1999; (6): 
1239-1248.
Thurlbeck WM, Benjamin B, Reid L. Development and distribution o f mucous glands 
in the fetal human trachea. British Journal o f Diseases o f the Chest 1961; (55): 54-64.
Thyagarajan B, Olivares EC, Hollis RP, Ginsburg DS, Calos MP. Site specific genomic 
integration in mammalian cells mediated by phage (J)C31 integrase. Molecular and 
Cellular Biology 2001; (21): 3926-3934.
Tongsong T, Wanapirak C, Kunavikatikul C, Sirirchotiyakul S, Piyamongkol W, 
Chanprapaph P. Cordocentesis at 16-24 weeks o f gestation: experience o f 1,320 cases. 
Prenatal Diagnosis 2000; (20): 224-228.
372
REFERENCES
Toubas PL, Silverman NH, Heymann MA, Rudolph AM. Cardiovascular effects o f 
acute hemorrhage in fetal lambs. American Journal o f Physiology 1981; (240): H45- 
H48.
Touraine J L. Induction o f transplantation tolerance in humans using stem cell 
transplants prenatally or postnatally. Transplantation Proceedings 1999; (31): 2735- 
2737.
Tran ND, Porada CD, Almeida-Porada G, Glimp HA, Anderson WF, Zanjani ED. 
Induction o f stable prenatal tolerance to p-galactosidase by in utero gene transfer into 
preimmune sheep fetuses. Blood 2001; (97): 3417-3423.
Tran ND, Porada CD, Zhao Y, Almeida-Porada G, Anderson WF, Zanjani ED. In utero 
transfer and expression o f  exogenous genes in sheep. Experimental Hematology 2000; 
(28): 17-30.
Trapnell BC, Chu CS, Paakko PK, Banks TC, Yoshimura K, Ferrans VJ, Chernick MS, 
Crystal RG. Expression o f the cystic fibrosis transmembrane conductance regulator 
gene in the respiratory tract o f normal individuals and individuals with cystic fibrosis. 
Proceedings o f the National Academy o f Science o f America 1991; (88): 6565-6569.
Trezise AE, Buchwald M. In vivo cell-specific expression o f the cystic fibrosis 
transmembrane conductance regulator. Nature 1991; (353): 434-437.
Trezise AE, Chambers JA, Wardle CJ, Gould S, Harris A. Expression o f the cystic 
fibrosis gene in human foetal tissues. Human Molecular Genetics 1993; (2): 212-218.
Trier J S, Moxey PC. Morphogenesis o f the small intestine during fetal development. 
Ciba Foundation Symposium 1979; (70): 3-29.
Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Therapy 
2000; (7): 20-23.
Van den Veyver IB, Ni J, Bowles N, Carpenter RJ, Weiner CP, Yankowitz J, Moise KJ, 
Henderson J, Towbin JA. Detection o f intrauterine viral infection using the polymerase 
chain reaction. Molecular Genetics and Metabolism 1998; (63): 85-95.
van Esseveldt KE, Hermens WT, Verhaagen J, Boer GJ. Transgene expression in rat 
fetal brain grafts is maintained for 7 months after ex vivo adenoviral vector-mediated 
gene transfer. Neuroscience Letters 1998; (240): 116-120.
van Esseveldt KE, Liu R, Hermens WT, Verhaagen J, Boer GJ. Adenoviral vector- 
mediated gene transfer and neurotransplantation: possibilities and limitations in grafting 
o f the fetal rat suprachiasmatic nucleus. Journal o f Neuroscience Methods 1997; (71): 
113-123.
van Zalen-Sprock RM, van Vugt JM, van Geijn HP. First and early second trimester 
diagnosis o f  anomalies o f  the central nervous system. Journal o f  Ultrasound in Medicine 
1995; (14): 603-610.
Vaughan JI, Rodeck CH. Interventional procedures. In: Ultrasound in Obstetrics and 
Gynaecology. (Eds.Dewbury K, Meire H, Cosgrove D, Farrant P). London: Churchill 
Livingstone, 2001; 557-606.
373
REFERENCES
Verma KB. Development o f mucosa o f  the human ileum. Journal o f Anatomy 1979; 
(128): 512-521.
Vincent MC, Trapnell BC, Baughman RP, Wert SE, Whitsett JA, Iwamoto HS. 
Adenovirus-mediated gene transfer to the respiratory tract o f fetal sheep in utero.
Human Gene Therapy 1995; (6): 1019-1028.
Virgintino D, Errede M, Robertson D, Capobianco C, Girolamo F, Vimercati A,
Bertossi M, Roncali L. Immunolocalization o f tight junction proteins in the adult and 
developing human brain. Histochemistry and Cell Biology 2004; (122): 51-59.
Waddington SN, Buckley SMK, Berloehr C, Bossow S, Ungerechts G, Cook T,
Gregory L, Rahim A, Themis M, Neubert WJ, Coutelle C, Lauer UM, Bitzer M. 
Reduced toxicity o f F-deficient Sendai virus vector in the mouse fetus. Gene Therapy 
2004a; (11): 599-608.
Waddington SN, Buckley SMK, Cook T, Gregory L, Rahim A, Nivsarkar M, Themis 
M, Bemloehr C, Neubert WJ, Lauer UM, Coutelle C, Bitzer M. Fetal gene delivery 
using first and second generation Sendai virus. Molecular Therapy 7, S4. 2003a.
R ef Type: Abstract
Waddington SN, Buckley SMK, Nivsarkar M, Jezzard S, Schneider H, Dahse T, 
Dallman MJ, Kemball-Cook G, Miah M, Tucker N, Dallman MJ, Themis M, Coutelle 
C. In utero gene transfer o f human factor IX to fetal mice can induce postnatal tolerance 
o f the exogenous clotting factor. Blood 2003b; (101): 1359-1366.
Waddington SN, Mitrophanous KA, Ellard F, Buckley SMK, Nivsarkar M, Lawrence L, 
Cook HT, Al-AUaf F, Bigger B, Kingsman S, Coutelle C, Themis M. Long-term 
transgene expression by administration o f a lentivirus-based vector to the fetal 
circulation o f  immuno-competent mice. Gene Therapy 2003c; (10): 1234-1240.
Waddington SN, Nivsarkar MS, Mistry AR, Buckley SM, Kemball-Cook G, Mosley 
KL, Mitrophanous K, Radcliffe P, Holder MV, Brittan M, Georgiadis A, Al-Allaf F, 
Bigger BW, Gregory LG, Cook HT, Ali RR, Thrasher A, Tuddenham EG, Themis M, 
Coutelle C. Permanent phenotypic correction o f Hemophilia B in immunocompetent 
mice by prenatal gene therapy. Blood 2004b; (104): 2714-2721.
Wagner JA, Nepomuceno IB, Shah N, Messner AH, Moran ML, Norbash AM, Moss 
RB, Wine JJ, Gardner P. Maxillary sinusitis as a surrogate model for CF gene therapy 
clinical trials in patients with antrostomies. Journal o f  Gene Medicine 1999; (1): 13-21.
Wales RG, Murdoch RN. Changes in the composition o f sheep fetal fluids during early 
pregnancy. Journal o f Reproduction and Fertility 1973; (33): 197-205.
Walsh C, Cepko CL. Clonally related cortical cells show several migration patterns. 
Science 1988; (241): 1342-1345.
Walters RW, Grunst T, Bergelson JM, Finberg RW, Welsh MJ, Zabner J. Basolateral 
localization o f  fiber receptors limits adenovirus infection from the apical surface o f 
airway epithelia. Journal o f Biological Chemistry 1999; (274): 10219-10226.
374
REFERENCES
Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin 
genes effectively ameliorates muscular dystrophy in mdx mouse model. Proceedings o f 
the National Academy o f Science o f America 2000; (97): 13714-13719.
Wang G, Slepushkin V, Zabner J, Keshavjee S, Johnston JC, Sauter SL, Jolly DJ, 
Dubensky TW, Davidson BL, McCray PB. Feline immunodeficiency virus vectors 
persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. 
Journal o f  Clinical Investigation 1999; (104): R55-R62.
Wang G, Williamson R, Mueller G, Thomas P, Davidson BL, McCray Jr PB. 
Ultrasound-guided gene therapy to hepatocytes in utero. Fetal Diagnosis and Therapy 
1998; (13): 197-205.
Waszak P, Franco-Montoya M, Jacob M, Deprez I, Levame M, Lafuma C, Harf A, 
Delacourt C. Effect o f intratracheal adenoviral vector administration on lung 
development in newborn rats. Human Gene Therapy 2002; (13): 1873-1885.
Watt BR, Anderson GA, Campbell IP. A comparison o f six methods used for detecting 
pregnancy in sheep. Australian Veterinary Journal 1984; (61): 377-382.
Watts D H, Luthy D A, Benedetti T J, Cyr D R, Easterling T R, Hickok D. 
Intraperitoneal fetal transfusion under direct ultrasound guidance. Obstetrics and 
Gynaecology 1988; (71): 84-88.
Wee LY, Fisk NM. The twin-twin transfusion syndrome. Seminars in Neonatology 
2002; (7): 187-202.
Weiner, Okamura K. Diagnostic fetal blood sampling technique-related losses. Fetal 
Diagnosis and Therapy 1996; (11): 169-175.
Weiner CP, Wenstrom KD, Sipes SL, Williamson RA. Risk factors for cordocentesis 
and fetal intravascular transfusion. American Journal o f Obstetrics and Gynecology 
1991; (165): 1020-1025.
Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, 
Rosenbloom BE, Scott CR, Wappner RS, Zimran A. Effectiveness o f enzyme 
replacement therapy in 1028 patients with Type I Gaucher disease after 2 to 5 years o f 
treatment: a report from the Gaucher registry. American Journal o f Medicine 2002; 
(113): 112-119.
Weiss DJ, Baskin GB, Shean MK, Blanchard JL, Kolls JK. Use o f perflubron to 
enhance lung gene expression: safety and initial efficacy studies in non-human primates. 
Molecular Therapy 2002a; (5): 8.
Weiss DJ, Beckett T, Bonneau L, Young J, Kolls JK, Wang G. Transient increase in 
lung epithelial tight junction permeability: an additional mechanism for enhancement o f 
lung transgene expression by perfluorochemical liquids. Molecular Therapy 2003; (8): 
927-935.
Weiss DJ, Bonneau L, Liggitt D. Use o f perfluorochemical liquid allows earlier 
detection o f gene expression and use o f less vector in normal lung and enhances gene 
expression in acutely injured lung. Molecular Therapy 2001; (3): 734-745.
375
REFERENCES
Weiss DJ, Mutlu GM, Bonneau L, Mendez M, Wang Y, Dumasius V, Factor P. 
Comparison o f surfactant and perfluorochemical liquid enhanced adenovirus-mediated 
gene transfer in normal rat lung. Molecular Therapy 2002b; (6): 43-49.
Weiss DJ, Strandjord TP, Jackson JC, Clark JG, Liggitt D. Perfluorochemical liquid- 
enhanced adenoviral vector distribution and expression in lungs o f spontaneously 
breathing rodents. Experimental Lung Research 1999; (25): 317-333.
Wells D, Delhanty JD. Preimplantation genetic diagnosis: applications for molecular 
medicine. Trends in Molecular Medicine 2001; (7): 23-30.
Welsh RJ, Cooper NR, Jensen FC, Oldstone MB. Human serum lyses RNA tumor 
viruses. Nature 1975; (257): 612-614.
Wenstrom KD, Andrews WW, Bowles NE, Towbin JA, Hauth JC, Goldenberg JL. 
Intrauterine viral infection at the time o f second trimester genetic amniocentesis. 
Obstetrics and Gynaecology 1998; (92): 420-424.
West HJ. Changes in the concentrations o f bile acids in the plasma o f sheep with liver 
damage. Research in Veterinary Science 1987; (43): 243-248.
Westbrook C A, Chmura S J, Arenas R B, Kim S Y, Otto G. Human APC gene 
expression in rodent colonic epithelium in vivo using liposomal gene delivery. Human 
Molecular Genetics 1994; (3): 2005-2010.
Westgren M, Ek S, Bui T, Jansson B, Kjaeldgaard A, Markling L, Nennesmo I, Seiger 
A, Sarby B, ThornstrOm S, Ringden O. Tissue distribution o f  transplanted fetal liver 
cells in the human fetal recipient. American Journal o f Obstetrics and Gynecology 
1997; (176): 49-53.
Westgren M, Ringden O, Bartmann P, Bui T, Lindton B, Mattson J, Uzunel M, 
Zetterquist H, Hansmann M. Prenatal T-cell reconstitution after in utero transplantation 
with fetal liver cells in a patient with X-linked severe combined immunodeficiency. 
American Journal o f Obstetrics and Gynecology 2002; (187): 475-482.
Westgren M, Selbing A, Stangenberg M. Fetal intracardiac transfusion in patients with 
severe rhesus isoimmunization. British Medical Journal 1988; (296): 885-889.
Westlake VJ, Jolly RD, Boyd RJ. Hematopoietic cell transplantation in fetal lambs with 
ceroid-lipofuscinosis. American Journal o f Medical Genetics 1995; (57): 365-368.
Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha 
v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; (73): 
309-319.
Willet KE, Jobe AH, Ikegami M, Kovar J, Sly PD. Lung morphometry after repetitive 
antenatal glucocorticoid treatment in preterm sheep. American Journal o f  Respiratory 
and Critical Care Medicine 2001; (163): 1437-1443.
Williams SH, Sahota V, Palmai-Pallag T, Tebbutt SJ, Walker J, Harris A. Evaluation o f 
gene targeting by homologous recombination in ovine somatic cells. Molecular 
Reproduction and Development 2003; (66): 115-125.
376
REFERENCES
Wilson JM, Wivel NA. Report on the potential use o f gene therapy in utero. Gene 
Therapy Advisory Committee. Human Gene Therapy 1999; (10): 689-692.
Winton D J, Ponder B A. Stem-cell organization in mouse small intestine. Proceedings 
Biological Sciences 1990; (241): 13-18.
Wlodek ME, Challis JR, Patrick J. Urethral and urachal urine output to the amniotic and 
allantoic sacs in fetal sheep. Journal o f Developmental Physiology 1988; (10): 309-319.
Wolberg A, Stafford D, Erie D. Human factor IX binds to specific sites on the 
collagenous domain o f collagen IV. Journal o f Biology 1997; (272): 16717-16720.
Wolfensohn S, Lloyd M. Larger domestic species. In: Handbook o f laboratory animal 
management and welfare. Oxford: Blackwell Science, 1998; 257-277.
Wooding FB. Current topic: the synepitheliochorial placenta o f  ruminants: binucleate 
cell fusions and hormone production. Placenta 1992; (13): 101-113.
Wraith JE. Lysosomal disorders. Seminars in Neonatology 2002; (7): 75-83.
Wu Y, Liu J, Woo S, Finegold MJ, Brandt ML. Prenatal orogastric gene delivery results 
in transduction o f the small bowel in the fetal rabbit. Fetal Diagnosis and Therapy 1999;
(14): 323-327.
Xu L, Gao C, Sands MS, Cai SR, Nichols TC, Bellinger DA, Raymer RA, 
McCorquodale S, Ponder KP. Neonatal or hepatocyte growth factor-potentiated adult 
gene therapy with a retroviral vector results in therapeutic levels o f canine factor IX for 
hemophilia B. Blood 2003; (101): 3924-3932.
Yang EY, Cass DL, Sylvester KG, Wilson JM, Adzick NS. Fetal gene therapy: efficacy, 
toxicity, and immunologic effects o f  early gestation recombinant adenovirus. Journal o f 
Pediatric Surgery 1999; (34): 235-241.
Yang Y, Nunes FA, Berenesi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to 
viral antigens limits El-deleted adenoviruses for gene therapy. Proceedings o f the 
National Academy o f Science o f America 1994; (91): 4407-4411.
Yang Y, Wilson JM. Clearance o f adenovirus-infected hepatocytes by MHC class 1- 
restricted CD4+ CTLs in vivo. Journal o f  Immunology 1995; (155): 2564-2570.
Yang E Y, Kim H B, Shaaban A F, Milner R, Adzick N S, Flake. Persistent postnatal 
transgene expression in both muscle and liver after fetal injection o f recombinant 
adenovirus. Journal o f Pediatric Surgery 1999a; (34): 766-772.
Yang E Y, Kim H B, Shaaban A F, Milner R, Adzick N S, Flake. Persistent postnatal 
transgene expression in both muscle and liver after fetal injection o f recombinant 
adenovirus. Journal o f Pediatric Surgery 1999b; (34): 766-772.
Yonemitsu Y, Kitson C, Ferrari S, Farley R, Griesenbach U, Judd D, Steel R, Scheid P, 
Zhu J, Jeffery PK, Kato A, Hasan MK, Nagai Y, Masaki I, Fukumura M, Hasegawa M, 
Geddes DM, Alton EW. Efficient gene transfer to airway epithelium using recombinant 
Sendai virus. Nature Biotechnology 2000; (18): 970-973.
377
REFERENCES
Young AJ, Holzgreve W, Dudler L, Schoeberlein A, Surbek DV. Engraftment o f human 
cord blood-derived stem cells in preimmune ovine fetuses after ultrasound-guided in 
utero transplantation. American Journal o f Obstetrics and Gynecology 2003; (189): 
698-701.
Young PP, Fantz CR, Sands MS. VEGF disrupts the neonatal blood-brain barrier and 
increases life span after non-ablative BMT in a murine model o f congenital 
neurodegeneration caused by a lysosomal enzyme deficiency. Experimental Neurology 
2004; (188): 104-114.
Younger JG, Taqi AS, Till GO, Hirschl RB. Partial liquid ventilation protects lung 
during resuscitation from shock. Journal o f Applied Physiology 1997; (83): 1666-1670.
Zabner J, Couture L, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus- 
mediated gene transfer transiently corrects the chloride transport defect in nasal 
epithelia o f  patients with cystic fibrosis. Cell 1993; (75): 207-216.
Zanjani ED, Pallavicini MG, Ascensao JL, Flake AW, Langlois RG, Reitsma M, 
MacKintosh FR, Stutes D, Harrison MR, Tavassoli M. Engraftment and long-term 
expression o f  human fetal hemopoietic stem cells in sheep following transplantation in 
utero. Journal o f Clinical Investigation 1992; (89): 1178-1188.
Zepeda ML, Chinoy MR, Wilson JM. Characterization o f stem cells in human airway 
capable o f reconstituting a fully differentiated bronchial epithelium. Somatic Cell and 
Molecular Genetics 1995; (21): 61-73.
Zhang H-G, Xie J, Xu L, Yang P, Xu X, Sun S, Wang Y, Curiel DT, Hsu H-C, Mountz 
JD. Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product 
expression in the liver. Journal o f Virology 2002; (76): 5692-5699.
Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M, Joshi B, Tazelaar J, Wilson JM. 
Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic 
cells and macrophages. Molecular Therapy 2001; (3): 697-707.
Zimmer EZ, Chao CR, Abramovich G, Timor-Tritisch IE. Fetal stomach measurements: 
not reproducible by the same observer. Journal o f Ultrasound in Medicine 1992; (11): 
663-665.
Zuckerman JB, Robinson CB, McCoy KS, Shell R, Sferra TJ, Chirmule N, Magosin 
SA, Propert KJ, Brown-Parr EC, Hughes JV, Tazelaar J, Baker C, Goldman MJ, Wilson 
JM. A Phase 1 study o f  adenovirus-mediated transfer o f the human cystic fibrosis 
transmembrane conductance regulator gene to a lung segment o f individuals with cystic 
fibrosis. Human Gene Therapy 1999; (10): 2973-2985.
378
